Malaysia Pharmaceutical

MINISTRY OF HEALTH MEDICINES FORMULARY - 2/2015
No. Generic Name MDC Category Indication(s) Dosage
Antiretroviral combination therapy

ADULTS & ADOLESCENT (>
of HIV infection in adults and
12 years of age):
adolescents from 12 years of age
Abacavir Recommended dose is one
with the following criteria:
Sulphate 600 mg J05AR02964T tablet once daily. Not to be
1 A* i)Patients unsuitable or failed other
and Lamivudine 1001XX used in adults or
HAART treatment; ii)Patients who
300 mg Tablet adolescents weigh less than
are at high risk of renal impairment
40kg. CHILDREN : Not
iii)Patients with osteoporosis or at
recommended
high risk of bone loss
Only for treatment of: i) Non insulin
dependent diabetes mellitus
(NIDDM) when diet therapy is
Initially 50 mg daily,
insufficient; ii) Non insulin
Acarbose 50 mg A10BF01000 increase to 3 times daily up
2 A/KK dependent diabetes mellitus
Tablet T1001XX to 100 mg 3 times daily.
(NIDDM) in combination with
Max 200 mg 3 times daily
existing conventional oral therapy
where glycaemic control is
inadequate
Reduction of intraocular pressure 250mg 1-4 times a day, the
Acetazolamide S01EC01000T in open-angle glaucoma, secondary dosage being titrated
3 B
250 mg Tablet 1001XX glaucoma and peri-operatively in according to patient
angle-closure glaucoma response
Reduction of intra-ocular pressure Adult : 250-1000mg per
Acetazolamide S01EC01000P in open-angle glaucoma, secondary 24hours, usually in divided
4 B
500 mg Injection 4001XX glaucoma and peri-operatively in doses for amounts over
angle-closure glaucoma 250mg daily
Diluted with dextrose 5%
and infused IV. Initial, 150
mg/kg IV in 200 ml over 60
Acetylcysteine
V03AB23520 minutes, then 50 mg/kg IV
5 200 mg/ml A* Antidote for paracetamol poisoning
P3001XX in 500 ml over 4 hours,
Injection
followed by 100 mg/kg IV in
1000 ml over 16 hours. Total
dose: 300mg/kg in 20 hour
Acetylsalicylic Prevention of myocardial infarct,
Acid 100 mg, B01AC06259 stroke, vascular occlusion and deep
6 B 1 tablet daily
Glycine 45 mg T1001XX vein thrombosis. Transient
Tablet ischaemic attacks
300 - 900 mg every 4 - 6
Acetylsalicylic
N02BA01000 hours as required. Max 4 g
7 Acid 300 mg C Mild to moderate pain
T4001XX daily. Use in children not
Soluble Tablet
recommended
1 / 371

ADULT: initially 25-30 mg
daily for 2-4 weeks, then
adjusted according to
i) Severe form of psoriasis including response, usually within
erythrodermic psoriasis and local range 25-50 mg daily for
or generalized pustular psoriasis. further 6-8 weeks (max: 75
ii) Severe disorders of mg daily). In disorders of
Acitretin 10 mg D05BB02000
8 A* keratinization, such as -congenital keratinization, maintenance
Capsule C1001XX
ichthyosis -pityriasis rubra pilaris - therapy of less than
Darier's disease -other disorders of 20mg/day and should not
keratinization which may be exceed 50mg/day CHILD:
resistant to other therapies 0.5mg/kg daily occasionally
up to 1 mg/kg daily to a
max. 35 mg daily for limited
periods
ADULT: initially 25-30 mg
daily for 2-4 weeks, then
i) Severe form of psoriasis including response, usually within
erythrodermic psoriasis and local range 25-50 mg daily for
or generalized pustular psoriasis. further 6-8 weeks (max: 75
ii) Severe disorders of mg daily). In disorders of
Acitretin 25 mg D05BB02000
9 A* keratinization, such as -congenital keratinization, maintenance
Capsule C1002XX
ichthyosis -pityriasis rubra pilaris - therapy of less than
Darier's disease -other disorders of 20mg/day and should not
keratinization which may be exceed 50mg/day CHILD:
resistant to other therapies 0.5mg/kg daily occasionally
up to 1 mg/kg daily to a
max. 35 mg daily for limited
periods
Acriflavine 0.1% D08AA03000 Infected skin, lesions, cuts, Apply undiluted three times
10 C+
Lotion L6001XX abrasions, wounds and burns. daily to the affected part.
i) ADULT: 500 mcg IV daily
for max of 5 days. CHILD: 1.5
mg/m2 once every 3 weeks
Actinomycin D
(if weight less than 10 kg, 50
(Dactinomycin) L01DA01110 i) For solid tumours ii) Gestational
11 A mcg/kg) ii) 500 mcg IV on
500 mcg/ml P4001XX trophoblastic disease
Days 2, 4, 6, 8, 10, repeat
Injection
every 7 - 10 days or 500 mcg
IV bolus on Days 1 and 2,
repeat every 15 days
2 / 371
i) ADULT: initially 400 mg 5

i) Mucocutaneous Herpes Simplex
times daily for 7 - 14 days.
infection in immunocompromised
CHILD less than 2 years: 200
and AIDS patients ii) Primary and
mg 4 times daily, CHILD
recurrent Varicella Zoster infection
more than 2 years: 400 mg 4
in immunocompromised and AIDS
times daily ii), iii) and iv)
patients iii) Severe Kaposi Varicella
ADULT: 200 - 400 mg 4
Eruption (Eczema herpeticum) iv)
times daily. CHILD: less than
Severe primary HSV infections (eg.
2 years, half adult dose;
Neonatal herpes, encephalitis,
Acyclovir 200 mg J05AB01000T more than 2 years, adult
12 A/KK eczema herpeticum, genital herpes,
Tablet 1001XX dose v) ADULT: 800 mg 5
gingival stomatitis, vaginal delivery
times daily for 7 days vi)
with maternal vulva herpes) v)
ADULT: 20 mg/kg
Severe and complicated varicella
(maximum: 800 mg) four
infection (eg. Encephalitis, purpura
times daily for 5 days, CHILD
fulminans) vi) Severe zoster
6 years: 800 mg four times
infection in paediatrics (eg.
daily. CHILD less than 2
Encephalitis, purpura fulminans,
years; 400mg 4 times daily,
immunocompromised patients and
more than 2 years; 800mg 4
facial, sacral and motor zoster)
times daily
i) Mucocutaneous Herpes Simplex i) ADULT: initially 400 mg 5
infection in immunocompromised times daily for 7 - 14 days.
and AIDS patients ii) Primary and CHILD less than 2 years: 200
recurrent Varicella Zoster infection mg 4 times daily, CHILD
in immunocompromised and AIDS more than 2 years: 400 mg 4
patients iii) Severe Kaposi Varicella times daily ii), iii) and iv)
Eruption (Eczema herpeticum) iv) ADULT: 200 - 400 mg 4
Severe primary HSV infections (eg. times daily. CHILD: less than
Neonatal herpes, encephalitis, 2 years, half adult dose;
Acyclovir 200
J05AB01000L eczema herpeticum, genital herpes, more than 2 years, adult
13 mg/5 ml A*
8001XX gingival stomatitis, vaginal delivery dose. v) ADULT: 800 mg 5
Suspension
with maternal vulva herpes) v) times daily for 7 days vi)
Severe and complicated varicella ADULT: 20 mg/kg
infection (eg. Encephalitis, purpura (maximum: 800 mg) four
fulminans) vi) Severe zoster times daily for 5 days, CHILD
infection in paediatrics 6 years: 800 mg four times
(eg.Encephalitis, purpura daily. CHILD: less than 2
fulminans, immunocompromised years; 400mg 4 times daily,
patients and facial, sacral and more than 2 years; 800 mg 4
motor zoster) times daily
3 / 371

ADULT: 5 mg/kg by IV
infusion 8 hourly for 5 days,
doubled to 10mg/kg every 8
hourly in varicella-zoster in
the immunocompromised
and in simplex encephalitis
(usually given for at least 10
days in encephalitis;
possibly for 14 - 21 days).
NEONATE & INFANT up to 3
months with disseminated
Treatment and prophylaxis of herpes simplex: 20mg/kg
herpes simplex in every 8 hourly for 14 days
Acyclovir 250 mg J05AB01000P
14 A* immunocompromised, severe (21 days in CNS
Injection 4001XX
initial genital herpes and Varicella - involvement), varicella-
Zoster zoster 10-20mg/kg every 8
hourly usually for 7 days.
CHILD, 3 months - 12 years:
Herpes simplex or Varicella
Zoster: 250 mg/m2 8 hourly
for 5 days, doubled to 500
mg/m2 8 hourly for
varicella-zoster in the
immunocompromised and
in simplex encephalitis
(usually given for 10 days in
encephalitis)
Apply 1 cm 5 times daily.
Acyclovir 3% Eye S01AD03000 Only for the treatment of herpes
15 A* Continue for at least 3 days
Ointment G5101XX simplex keratitis
after healing
Herpes simplex infections of the
Acyclovir 5% D06BB03000 skin, including initial and recurrent Apply every 4 hours for 5 -
16 A*
Cream G1001XX labial and genital herpes simplex 10 days
infections
4 / 371
i) ADULT: initially 400 mg 5

i) Mucocutaneous Herpes Simplex
times daily for 7 - 14 days.
infection in immunocompromised
CHILD less than 2 years: 200
and AIDS patients ii) Primary and
mg 4 times daily, CHILD
recurrent Varicella Zoster infection
more than 2 years: 400 mg 4
in immunocompromised and AIDS
times daily ii), iii) and iv)
patients iii) Severe Kaposi Varicella
ADULT: 200 - 400 mg 4
Eruption (Eczema herpeticum) iv)
times daily. CHILD: less than
Severe primary HSV infections (eg.
2 years, half adult dose;
Neonatal herpes, encephalitis,
Acyclovir 800 mg J05AB01000T more than 2 years, adult
17 A/KK eczema herpeticum, genital herpes,
Tablet 1002XX dose v) ADULT: 800 mg 5
gingival stomatitis, vaginal delivery
times daily for 7 days vi)
with maternal vulva herpes) v)
ADULT: 20 mg/kg
Severe and complicated varicella
(maximum: 800 mg) four
infection (eg. Encephalitis, purpura
times daily for 5 days, CHILD
fulminans) vi) Severe zoster
6 years: 800 mg four times
infection in paediatrics (eg.
daily. CHILD less than 2
Encephalitis, purpura fulminans,
years; 400mg 4 times daily,
immunocompromised patients and
more than 2 years; 800mg 4
facial, sacral and motor zoster)
times daily
5 / 371

i) Third line treatment of: - Severe
rheumatoid arthritis - Psoriatic
arthritis - Ankylosing spondylitis
after failure of conventional
DMARDs or other biologics. ii)
Treatment of adults with moderate
i) Severe rheumatoid
to severe chronic plaque psoriasis
arthritis, Psoriatic arthritis,
who have not responded to, have
Ankylosing spondylitis :
contraindication or are unable to
Subcutaneous 40 mg every
tolerate phototherapy and/or
other week ii)Chronic
systemic therapies including
plaque psoriasis : Initial, 80
acitretin, methotreaxate and
mg SC, followed by 40 mg SC
cyclosporine. iii) Crohn's Disease -
every other week starting
a) For treatment of moderately to
one week after the initial
severely active Crohn’s Disease in
dose. iii) & iv) Crohn’s
adult patients who have
Adalimumab 40 L04AB04000 disease & Ulcerative colitis:
18 A* inadequate response to
mg Injection P5001XX 160mg at week 0 (dose can
conventional therapy;
be administered as four
b) For treatment of moderately to
injections in one day or as
severely active Crohn’s Disease in
two injections per day for
adult patients who have lost
two consecutive days) and
response to or are intolerant to
80mg at week 2. After
infliximab. iv) Ulcerative Colitis -
induction treatment, the
For treatment of moderately to
recommended maintenance
severely active ulcerative colitis in
dose is 40mg every other
adult patients who have had an
week via subcutaneous
inadequate response to
injection.
conventional therapy including
corticosteroids and 6-
mercaptopurine or azathioprine, or
who are intolerant to or have
medical contraindications for such
therapies
Acne vulgaris where comedones,
papules and pustules predominate Apply once daily to the
Adapalene 0.1% D10AD03000
19 A* in those sensitive to benzoyl affected areas after washing
Cream G1001XX
peroxide or topical tretinoin [third at bedtime
line treatment]
Acne vulgaris where comedones,
papules and pustules predominate Apply once daily to the
Adapalene 0.1% D10AD03000
20 A* in those sensitive to benzoyl affected areas after washing
Gel G3001XX
peroxide or topical tretinoin [third at bedtime
line treatment]
6 / 371
i) Treatment of chronic HBeAg

positive and HBeAg negative
hepatitis B infection in adults with
Adult (18-65 years): 10mg
compensated liver function
Once Daily Renal Dose
(lamivudine should be tried first) ii)
Adjustment : 10mg every
Adefovir Dipivoxil J05AF08000T Lamivudine-resistant chronic
21 A* 48hours (30-49ml/min);
10 mg Tablet 1001XX hepatitis B virus infection with
10mg every 72hours (10-
either compensated or
29ml/min); 10mg every 7
decompensated hepatitis function
days (Hemodialysis)
(only by hepatologist and
gastroenterologist for approved
indications)
ADULT: Initially: 3 mg given
as a rapid IV bolus (over 2
seconds). Second dose: If
the first dose does not result
in elimination of the
supraventricular tachycardia
Rapid conversion of paroxysmal with in 1 or 2 minutes, 6 mg
Adenosine C01EB10000
22 B supraventricular tachycardia to should be given also as a
3mg/ml Injection P3001XX
sinus rhythm rapid IV bolus. Third dose: If
the second dose does not
result in elimination of the
supraventicular tachycardia
within 1-2 minutes, 12 mg
should be given also as a
rapid IV bolus
Adrenaline Acid 1 mg by intravenous
(Epinephrine) C01CA24123 injection repeated every 3-5
23 B Cardiopulmonary resuscitation
Tartrate 1 mg/ml P3001XX minutes according to
Injection response
The recommended dose is
Agomelatine 25 N06AX22000 25mg once daily at bedtime,
24 A* Major depression
mg Tablet T1001XX maybe increased to 50mg
once daily at bedtime.
i)Child 12-24months: 200mg
as a single dose ii) Adult &
Child above 2 years: 400mg
i) Single or mixed infestations of
Albendazole 200 P02CA03000 as a single dose for 3
25 C+ intestinal parasites ii) Strongyloides
mg Tablet T1001XX consecutive days; Child 12 -
infection
24months: 200mg as a
single dose for 3
consecutive days
7 / 371

i)Child 12-24months: 200mg
as a single dose ii) Adult &
Child above 2 years: 400mg
Albendazole 200 i) Single or mixed infestations of
P02CA03000 as a single dose for 3
26 mg/5 ml C+ intestinal parasites ii) Strongyloides
L8001XX consecutive days; Child 12 -
Suspension infection
24months: 200mg as a
single dose for 3
consecutive days
Alcohol 70% D08AX08000 Apply to the skin undiluted
27 C+ Use as antiseptic and disinfectant
Solution L9901XX or when needed
1 tablet once weekly
[70mg/5600 IU]. Patient
should receive supplemental
Osteoporosis in post menopausal calcium or vitamin D, if
women with a history of vertebral dietary vitamin D
fracture and whom oestrogen inadequate. The tablet
replacement therapy is should be taken at least half
contraindicated. Review treatment an hour before the first
Alendronate after 2 years and if there is positive food, beverage, or
Sodium 70 mg response, treatment may be medication of the day with
M05BB03972
28 and A* continued up to 5 years and then plain water only. To
T1002XX
Cholecalciferol re-evaluate. Treatment should be facilitate delivery to
5600 IU Tablet stopped if there is no positive stomach and thus reduce
response after 5 years. Otherwise, the potential for esophageal
patient needs to be given drug irritation, it should only be
holiday for 1 to 2 years and then swallowed upon arising for
continue treatment shall the the day with a full glass of
benefit outweigh the risk. water and patient should
not lie down for at least 30
minutes and until after their
first food of the day.
Osteoporosis in post menopausal
women with a history of vertebral
fracture and whom oestrogen
70 mg once weekly. Swallow
replacement therapy is
the tablet whole with a full
contraindicated. Review treatment
glass of plain water only on
after 2 years and if there is positive
an empty stomach at least
Alendronate response, treatment may be
M05BA04520 30 minutes before breakfast
29 Sodium 70 mg A* continued up to 5 years and then
T1001XX (and any other oral
Tablet re-evaluate. Treatment should be
medication); stand or sit
stopped if there is no positive
upright for at least 30
response after 5 years. Otherwise,
minutes and do not lie down
patient needs to be given drug
until after eating breakfast
holiday for 1 to 2 years and then
continue treatment shall the
benefit outweigh the risk.
8 / 371

i) Renal osteodystrophy in patients
Initial dose ADULT and
on haemodialysis
CHILD above 20kg body
ii) Hypoparathyroidism and
weight: 1 mcg daily; CHILD
Alfacalcidol 0.25 A11CC03000 pseudohypoparathyroidism
30 A/KK under 20kg body weight:
mcg Capsule C1001XX iii) Adjunct to the management of
0.05mcg/kg/day.
tertiary hyperparathyroidism
Maintenance dose : 0.25
iv) Rickets and osteomalacia
mcg to 2 mcg daily
v) Osteoporosis
Initial dose ADULT and
on haemodialysis
CHILD above 20kg body
weight: 1 mcg daily; CHILD
Alfacalcidol 1 A11CC03000 pseudohypoparathyroidism
31 A/KK under 20kg body weight:
mcg Capsule C1002XX iii) Adjunct to the management of
0.05mcg/kg/day.
Maintenance dose : 0.25
mcg to 2 mcg daily
v) Osteoporosis
on haemodialysis
Alfacalcidol 2 A11CC03000 pseudohypoparathyroidism
32 A* NEONATES : 0.1 mcg/kg/day
mcg/ml Drops D5001XX iii) Adjunct to the management of
v) Osteoporosis
Treatment of: i) Renal
osteodystrophy in patients on Adult: Initially, 1 mcg daily.
haemodialysis Maintenance: 0.25-1 mcg
ii) Hypoparathyroidism and daily. Child: Premature
Alfacalcidol 2 A11CC03000
33 A* pseudohypoparathyroidism infants and neonates: 0.05-
mcg/ml Injection P3001XX
iii) Adjunct to the management of 0.1 mcg/kg daily; <20 kg:
tertiary hyperparathyroidism 0.05 mcg/kg daily. Elderly:
iv) Rickets and osteomalacia 0.5 mcg daily.
v) Osteoporosis
Initial dose: 20 - 40 mcg/kg.
For use as short acting narcotic
Alfentanil HCl 0.5 N01AH02110 Supplemental dose: 15
34 A* analgesic in short procedures and
mg/ml Injection P3001XX mcg/kg or infusion 0.5 - 1.0
day-care surgical procedures
mcg/kg/min
Treatment of functional symptoms
Alfuzosin HCl 10 G04CA01110
35 A* related with benign prostatic 10 mg once a day pre bed
mg Tablet T1001XX
hypertrophy (BPH)
9 / 371

20 mg/kg of body weight
administered once every 2
weeks as an intravenous
infusion. Monitoring It is
suggested that patients be
monitored periodically for
IgG antibody formation.
Patients who experience
Infusion-associated
Alglucosidase reactions suggestive of
A16AB07000
36 alfa 5 mg/ml A* Infantile-onset Pompe disease hypersensitivity may be
P4001XX
Injection tested for IgE antibodies to
alglucosidase alfa. Treated
patients who experience a
decrease in benefit despite
continued treatment with
Alglucosidase Alfa, in whom
antibodies are suspected to
play a role, may be tested
for neutralization of enzyme
uptake or activity.
To be diluted with an equal
Alkaline Nasal R01A000999
37 B To remove nasal plug volume of warm water
Douche L5001XX
before use
i) Frequent and disabling attacks of
gouty arthritis (3 or more
attacks/year). ii) Clinical or
radiographic signs of erosive gouty
Initial dose: 100-300 mg
arthritis. iii) The presence of
Allopurinol 100 M04AA01000 daily. Maintenance: 300-600
38 A/KK tophaceous deposits. iii) Urate
mg Tablet T1002XX mg daily. Maximum: 900 mg
nephropathy. iv) Urate
daily
nephrolithiasis. v) Impending
cytotoxic chemotherapy or
radiotherapy for lymphoma or
leukaemia
i) Frequent and disabling attacks of
gouty arthritis (3 or more
attacks/year). ii) Clinical or
radiographic signs of erosive gouty
Initial dose: 100-300 mg
arthritis. iii) The presence of
Allopurinol 300 M04AA01000 daily. Maintenance: 300-600
39 A/KK tophaceous deposits. iii) Urate
mg Tablet T1001XX mg daily. Maximum: 900 mg
nephropathy. iv) Urate
daily
nephrolithiasis. v) Impending
cytotoxic chemotherapy or
radiotherapy for lymphoma or
leukaemia
10 / 371

Induction: 45 mg/m2 daily
for 30 - 90 days.
Maintenance: 45 mg/m2
All-Trans Retinoic
L01XX14000C daily for 2 weeks every 3
40 Acid 10 mg A* Acute promyelocytic leukaemia
1001XX months. Renal/or hepatic
Capsule
insufficiency: 25mg/m2 daily
for 30-90 days. Refer to
protocols
0.25 - 0.5 mg 3 times daily
(elderly or debilitated 0.25
Alprazolam 0.25 N05BA12000 mg 2-3 times daily),
41 A/KK Anxiety disorders
mg Tablet T1001XX increased if necessary to a
total dose of 3 mg/day. Not
recommended for children
Alprazolam 0.5 N05BA12000 mg 2-3 times daily),
42 A Anxiety disorders
mg Tablet T1002XX increased if necessary to a
Alprazolam 1 mg N05BA12000 mg 2-3 times daily),
43 A Anxiety disorders
Tablet T1003XX increased if necessary to a
0.05 - 0.1 mcg/kg/min by
For treatment of congenital heart
Alprostadil 500 C01EA01000 continuous IV infusion, then
44 A* diseases which are ductus
mcg/ml Injection P3001XX decreased to lowest
arteriosus dependent
effective dose
0.9 mg/kg (maximum of 90
mg) infused over 60 minutes
with 10% of the total dose
administered as an initial
intravenous bolus.
Treatment must be started
Alteplase 50 mg B01AD02000 Thrombolytic treatment of acute
45 A* as early as possible within
per vial Injection P4001XX ischaemic stroke.
4.5 hours after onset of
stroke symptoms and after
exclusion of intracranial
haemorrhage by
appropriate imaging
technique.
Aluminium 600 mg- 1.2 g 4 times daily
A02AB01250
46 Hydroxide 600 A Dyspepsia, hyperphosphataemia and at bedtime or as
T1001XX
mg Tablet required
11 / 371

Initial dose: 100 mg daily
and is increased to 100 mg
twice daily (not later than 4
Amantadine HCl N04BB01110
47 B Parkinson's disease p.m.) after a week. Elderly
100 mg Capsule C1001XX
over 65 years: less than 100
mg or 100 mg at intervals of
more than 1 day
ADULT: (IM or IV): 15
mg/kg/day 8 - 12 hourly for
7 - 10 days. Maximum: 1.5
g/day. CHILD: 15 mg/kg/day
Amikacin 125 J01GB06183P Infections due to susceptible 8 - 12 hourly. Maximum: 1.5
48 A
mg/ml Injection 3003XX organisms g/day. Neonates: Initial
loading dose of 10 mg/kg
followed by 7.5 mg/kg/day
12 hourly. Maximum
15mg/kg/day
ADULT: (IM or IV): 15
mg/kg/day 8 - 12 hourly for
7 - 10 days. Maximum: 1.5
g/day. CHILD: 15 mg/kg/day
Amikacin
J01GB06183P Infections due to susceptible 8 - 12 hourly. Maximum: 1.5
49 250mg/ml A
3002XX organisms g/day. Neonates: Initial
Injection
loading dose of 10 mg/kg
followed by 7.5 mg/kg/day
12 hourly. Maximum
15mg/kg/day
i) Initially 1 - 2 tab daily
Amiloride HCl 5
i) Diuretic as an adjunct to the adjusted according to
mg & C03EA01900
50 B management of oedematous states response. Max: 4 tabs daily.
Hydrochlorothiaz T1001XX
ii) Hypertension ii) 1 -2 tabs daily as a single
ide 50 mg Tablet
or divided dose
Dose to be individualized.
ADULT usually 500-2000 ml
Amino Acids B05BA01910 Source of amino acids in patients
51 A by IV. ADULT usual
Injection P3001XX needing IV nutrition
requirement for amino acid:
1-2 g/kg/day
Amino Acids with Source of amino acids and Dose to be individualized.
B05BA10910
52 Electrolytes A electrolytes in patients needing IV ADULT usual requirement
P3002XX
Injection nutrition for amino acid 1-2 g/kg/day
Amino Acids with Dose to be individualized.
Source of amino acids,
Glucose with B05BA10910 ADULT usual requirement
53 A carbohydrate and electrolytes in
Electrolytes P3003XX for amino acid 1-2 g/kg/day,
patients needing IV nutrition
Injection carbohydrate 4-6 g/kg/day
12 / 371

Dose to be individualized.
ADULT: 500 - 2000 ml daily
Amino Acids,
Source of amino acids, given by IV. ADULT usual
Glucose and Lipid B05BA10910
54 A carbohydrate, lipid and electrolytes requirement for amino acid
with Electrolytes P3001XX
in patients needing IV nutrition 1-2 g/kg/ day, carbohydrate
Injection
4-6 g/kg/day, lipid 2-3
g/kg/day
Adult: Loading dose: 5
mg/kg (ideal body weight)
or 250-500 mg (25 mg/ml)
by slow injection or infusion
over 20-30 min.
Aminophylline 25 R03DA05000 Reversible airways obstruction, Maintenance infusion dose:
55 B
mg/ml Injection P3001XX acute severe brochospasm 0.5 mg/kg/hr. Max rate: 25
mg/min. Child: Loading
dose: same as adult dose.
Maintenance dose: 6 mth-9
yr: 1 mg/kg/hr and 10-16 yr:
0.8 mg/kg/hr.
200 mg 3 times daily for 1
week, then reduced to 200
mg twice daily for another
Amiodarone 200 C01BD01110
56 A* Arrhythmias week. Maintenance dose,
mg Tablet T1001XX
usually 200 mg daily or the
minimum required to
control the arrhythmia
Initial infusion of 5mg/kg via
large venous access over 20-
120 minutes with ECG
Amiodarone 50 C01BD01110 Arrhythmias when other drugs are monitoring; subsequent
57 A*
mg/ml Injection P3001XX contraindicated or ineffective infusion given if necessary
according to response up to
a maximum of 1.2 g in 24
hours
Predominantly negative
Treatment of psychoses, episodes: 50-300 mg once
particularly acute or chronic daily adjusted according to
schizophrenia disorders the patient’s response.
characterized by positive Mixed episodes with
symptoms(e.g. delusion, positive and negative
Amisulpride 100 N05AL05000
58 A* hallucinations, thought disorders) symptoms: 400-800 mg/day
mg Tablet T1001XX
and/or negative symptoms(e.g. in 2 divided doses adjusted
blunted emotions, emotional and according to the patient’s
social withdrawal) including when response. Should be taken
the negative symptoms on an empty stomach
predominate (Preferably taken before
meals)
13 / 371

Predominantly negative
Treatment of psychoses, episodes: 50-300 mg once
particularly acute or chronic daily adjusted according to
schizophrenia disorders the patient’s response.
characterized by positive Mixed episodes with
symptoms(e.g. delusion, positive and negative
Amisulpride 400 N05AL05000
59 A* hallucinations, thought disorders) symptoms: 400-800 mg/day
mg Tablet T1002XX
and/or negative symptoms(e.g. in 2 divided doses adjusted
blunted emotions, emotional and according to the patient’s
social withdrawal) including when response. Should be taken
the negative symptoms on an empty stomach
predominate (Preferably taken before
meals)
Initially 25mg 3 times a day.
Maintenance: 25-100mg
daily in divided doses.
Hospitalized patient:
100mg/day &gradually
Amitriptyline HCl N06AA09110
60 B Depression increase to 200-300mg/day.
25 mg Tablet T1001XX
ADOLESCENT and ELDERLY:
initially 20-30mg/day in
divided doses w/ gradual
increments. CHILD under 16
years are not recommended
Doses range from
amlodipine besylate 5
mg/valsartan 160 mg to
Essential hypertension in patients
Amlodipine 10 mg/valsartan 320 mg
C09DB01935 whose blood pressure is not
61 mg and Valsartan A/KK ORALLY once daily, with
T1003XX adequately controlled by
160 mg Tablet dose titration occurring
monotherapy
every 1 to 2 weeks if
necessary. MAX amlodipine
besylate 10 mg/valsartan
320 mg
Amlodipine 10 C08CA01000 5 mg once daily. Max: 10 mg
62 B Hypertension
mg Tablet T1002XX once daily
Doses range from
mg/valsartan 160 mg to
Essential hypertension in patients
Amlodipine 5 mg mg/valsartan 320 mg
C09DB01935 whose blood pressure is not
63 and Valsartan A/KK ORALLY once daily, with
T1002XX adequately controlled by
160 mg Tablet dose titration occurring
monotherapy
every 1 to 2 weeks if
necessary. MAX amlodipine
besylate 10 mg/valsartan
320 mg
14 / 371

Amlodipine 5 mg C08CA01000 5 mg once daily. Max: 10 mg
64 B Hypertension
Tablet T1001XX once daily
One tablet daily i) A patient
whose blood pressure is not
adequately controlled on
dual therapy with
amlodipine
besylate/valsartan/HCTZ. ii)
For convenience, patients
receiving valsartan,
amlodipine and HCTZ from
seperate tablets may be
switched to amlodipine
besylate/valsartan/HCTZ
Amlodipine Treatment of essential
containing the same
besylate 10mg, hypertension. This fixed
C09DX01941 component dosses. Dosage
65 valsartan 160mg, A/KK combination drug is not indicated
T1001XX may be increased after 2
hydrochlorothiazi for the initial therapy of
weeks. The maximum
de 12.5mg tablet hypertension.
antihypertensive effect of
amlodipine
besylate/valsartan/HCTZ is
reached within 2 weeks of
change in dose. The
maximum recommended
dose of amlodipine
10/320/25 mg. It can be
taken with or without food.
It is recommended to take it
with some water.
15 / 371

dual therapy with
amlodipine
besylate/valsartan/HCTZ
containing the same
besylate 10mg, hypertension. This fixed
C09DX01941 component dosses. Dosage
66 valsartan 160mg, A/KK combination drug is not indicated
T1002XX may be increased after 2
hydrochlorothiazi for the initial therapy of
weeks. The maximum
de 25mg tablet hypertension.
antihypertensive effect of
amlodipine
change in dose. The
maximum recommended
dose of amlodipine
10/320/25 mg. It can be
with some water.
16 / 371

dual therapy with
amlodipine
Amlodipine besylate/valsartan/HCTZ
Treatment of essential
besylate containing the same
hypertension. This fixed
5mg,valsartan C09DX01941 component dosses. Dosage
67 A/KK combination drug is not indicated
160mg,hydrochlo T1004XX may be increased after 2
for the initial therapy of
rothiazide weeks. The maximum
hypertension.
12.5mg tablet antihypertensive effect of
amlodipine
change in dose. The
maximum recommended
dose of amlodipine
10/320/25 mg. It can be
with some water.
Amlodipine 5mg/losartan
50mg OR amlodipine
5mg/losartan 100mg orally
once daily. MAXIMUM
DOSE: amlodipine
5mg/losartan 100mg. No
dosage adjustment in mild
renal impairment. Not
Camsylate 5 mg hypertension in adults patients
C09DB06935 recommended in moderate
68 and Losartan A/KK whose blood pressure is not
T1002XX to severe renal impairment
Potassium 100 adequately controlled on either
or in patients on dialysis.
mg Tablet monotherapy
Not recommended in
patients who require lower
dose of losartan (25mg). Not
recommended in patients <
18 years as safety and
efficacy is not established in
this group
17 / 371

Amlodipine 5mg/losartan
50mg OR amlodipine
5mg/losartan 100mg orally
once daily. MAXIMUM
DOSE: amlodipine
5mg/losartan 100mg. No
dosage adjustment in mild
renal impairment. Not
Camsylate 5 mg hypertension in adults patients
C09DB06935 recommended in moderate
69 and Losartan A/KK whose blood pressure is not
T1001XX to severe renal impairment
Potassium 50 mg adequately controlled on either
or in patients on dialysis.
Tablet monotherapy
Not recommended in
patients who require lower
dose of losartan (25mg). Not
recommended in patients <
18 years as safety and
efficacy is not established in
this group
Adults, the elderly and
Ammonium children over 12 years: 10-
Bicarbonate, R05CA04900 20ml, repeated after 4 hours
70 C Cough
Tincture Ipecac, L2101XX if required. Not more than 4
etc Mixture doses to be taken in any 24
hours.
Apply to affected nail once
or sometimes twice a week
after filling and cleansing,
Amorolfine 5 % D01AE16110
71 A* Fungal nail infections allow to dry, treat finger nail
Nail Lacquer L5001XX
for 6 months, toe nail for 9 -
12 months (review at
intervals of 3 months)
Mild to Moderate infection:
25mg/kg/day (based on
Amoxicillin & Amoxicillin dose) in 2
J01CR02961F Infections caused by susceptible
72 Clavulanate 228 A/KK divided dose. Severe
2102XX organisms
mg/5 ml Syrup infection: 45mg/kg/day
(based on Amoxicillin dose)
in 2 divided dose
CHILD less than 3 months:
Infections caused by susceptible
30mg/kg 12 hourly. 3
Amoxicillin 1 g & organisms. Respiratory tract, skin,
J01CR02961P months - 12 years: 30mg/kg
73 Clavulanate 200 A soft tissue, GUT infection,
4002XX 6 - 8 hourly. ADULT: 1.2 g by
mg Injection septicaemia, peritonitis, post-
IV or intermittent infusion 6
operative infection & osteomyelitis
- 8 hourly
ADULT: 250 - 500 mg 3
Amoxicillin 250 J01CA04012C times daily. CHILD: 20 - 40
74 B strains of gram positive and gram
mg Capsule 1001XX mg/kg/day in divided doses
negative organisms
8 hourly
18 / 371

Infections due to beta-lactamase
producing strain where amoxicillin
ADULT & CHILD more than
Amoxicillin 500 alone is not appropriate.
J01CR02961T 12 years: Mild to moderate
75 mg & Clavulanate A/KK Respiratory tract, skin, soft tissue,
1002XX infections: 625 mg twice
125 mg Tablet GUT infection, septicaemia,
daily.
peritonitis, post-operative infection
& osteomyelitis
Infections caused by susceptible CHILD less than 3 months:
Amoxicillin 500 organisms. Respiratory tract, skin, 30mg/kg 12 hourly. 3
mg and J01CR02961P soft tissue, GUT infection, months - 12 years: 30 mg/kg
76 A
Clavulanate 100 4001XX septicaemia, peritonitis, post- 6 - 8 hourly. ADULT: 1.2 g by
mg Injection operative infection and IV or intermittent infusion 6
osteomyelitis - 8 hourly
ADULT: 250 - 500 mg 3
Amoxicillin 500 J01CA04012C times daily. CHILD: 20 - 40
77 B strains of gram positive and gram
mg Capsule 1002XX mg/kg/day in divided doses
negative organisms
8 hourly
CHILD less than 10 years:
Amoxicillin Infections caused by susceptible 125 - 250 mg 8 hourly.
J01CA04012F
78 Trihydrate 125 B strains of gram positive and gram CHILD less than 20 kg: 20 -
1001XX
mg/5 ml Syrup negative organisms 40 mg/kg/day in 3 - 4
divided doses
Amphotericin B S01A000801
79 A Fungal infection of the cornea 1 drop hourly or 2 hourly
0.15% Eye Drops D2002XX
Amphotericin B S01A000801
80 A Fungal infection of the cornea 1 drop hourly or 2 hourly
ADULT: 0.25 mg/kg/day by
IV infusion. Gradually
increase if tolerated to 1
Amphotericin B J02AA01801P mg/kg/day. Maximum in
81 A Systemic fungal infections
50 mg Injection 4001XX severe cases: 1.5 mg/kg
daily or on alternate days.
For neonates, lower doses
are recommended
Ampicillin
ADULT: (1-) 2-6g daily
Sodium &
CHILDREN: (25-) 50-
Sulbactam J01CR01961F Treatment of susceptible bacterial
82 A 100mg/kg daily PREMATURE
Sodium 250 2101XX infections
AND NEWBORNS: 25-
mg/5 ml
50mg/kg daily
Suspension
Ampicillin ADULT: 375-750mg twice
Sodium & daily CHILDREN AND
J01CR01961T Treatment of susceptible bacterial
83 Sulbactam A/KK INFANTS: 25-50mg/kg/day
1001XX infections
Sodium 375 mg in 2 divided doses, if ≥ 30kg
Tablet use an adult dose
19 / 371

ADULT: 1.5 - 12 g/day in
divided doses 6 - 8 hourly.
Maximum: 4 g Sulbactam.
Ampicillin CHILD: 150-300 mg/kg/day 6
Sodium 1g & - 8 hourly. Prophylaxis of
J01CR01961P Treatment of susceptible bacterial
84 Sulbactam A surgical infections: 1.5 - 3 g
4002XX infections
Sodium 500mg at induction of anaesthesia.
Injection May be repeated 6 - 8
hourly. NEONATES: First
week of life, 75mg/kg/day in
divided doses every 12 hour
ADULT: 1.5 - 12 g/day in
divided doses 6 - 8 hourly.
Ampicillin Maximum: 4 g Sulbactam
Sodium 500 mg per day. CHILD: 150-
J01CR01961P Treatment of susceptible bacterial
85 & Sulbactam A 300mg/kg/day 6 - 8 hourly.
4001XX infections
Sodium 250 mg Prophylaxis: 1.5 -3 g at
Injection induction of anaesthesia.
May be repeated 6 - 8
hourly
250 - 500 mg IM/IV every 4 -
6 hours. Maximum: 400
mg/kg/day. Meningitis: 2 g 6
Ampicillin Treatment of susceptible bacterial
J01CA01520P hourly. CHILD: 150
86 Sodium 500 mg B infections (non beta-lactamase-
4001XX mg/kg/daily IV in divided
Injection producing organisms); meningitis
doses. Usual children dose
less than 10 years, half adult
dose
CHILD: 50 - 100 mg/kg/day 4
Ampicillin
Treatment of susceptible bacterial times daily. Under 1 year:
Trihydrate 125 J01CA01012F
87 B infections (non beta-lactamase- 62.5 - 125 mg 4 times daily,
mg/5 ml 2101XX
producing organisms) 1 - 10 years: 125 - 250 mg 4
Suspension
times daily
Treatment of hormone responsive
Anastrozole 1 mg L02BG03000 metastatic or locally advanced
88 A* 1 mg daily
Tablet T1001XX breast cancer after failure of
tamoxifen
Loading dose of 200 mg on
Treatment of invasive candidiasis,
day 1, then 100 mg once
Anidulafungin J02AX06000P including candidemia in adults
89 A* daily thereafter for at least
100mg Injection 3001XX when intolerance or resistance to
14 days after the last
Amphotericin B or Fluconazole
positive culture.
Antazoline HCl, ADULT: Instill 1 drop, 3 - 4
Hay fever, conjunctivitis, allergic
Tetrahydrozoline times daily, into the lower
S01GA52110 conjunctivitis, vernal
90 HCl and A/KK eyelid. CHILD 2 - 12 years :
D2001XX keratoconjunctivitis and
Benzalkonium Instill 1 drop daily or twice
eczematosa
Cloride Eye Drops daily
20 / 371

50 - 100 mcg within 72
Anti RhD Gamma
Prevention of Rh(D) sensitisation by hours after incompatible
Globulin 250
J06BB01000P IM injection to rhesus-negative blood transfusion: 25 mcg
91 mcg/2 ml B
3001XX woman after delivery of rhesus- (125 units) per ml
Injection (500
positive infant transfused blood, up to
units=100 mcg)
1000 mcg
i) To be used when conventional
anti-rejection therapy is not
successful ii) Treatment of aplastic
anaemia not responding to
oxymethalone after 3 months, in
10 - 30 mg/kg body weight
which there is persistent
Antilymphocyte/ daily. Slow IV infusion (over
pancytopenia with repeated
Antithymocyte at least 4 hours) diluted in
L04AA03000 attacks of septicaemia and
92 Immunoglobulin A* 250 - 500 ml Normal Saline.
P3001XX bleeding. iii) Severe aplastic
(from Horse) For Graft versus host
anaemia with the following
Injection disease treatment:40
parameters: a) Granulocyte less
mg/kg/day
than 0.5x109/L b) Platelet less than
20x109/L c) Reticulocyte less than
20x109/L iv) As a conditioning
regime prior to transplant. v) Graft-
versus-host disease treatment
Antirabies
20 iu/kg; half by IM and half
Immunoglobulin J06BB05000P
93 B Treatment of rabies, post-exposure by infiltration around the
(Human) 300 3001XX
wound
iu/2ml
i)1.0 - 1.5 mg/kg/day for 2 -
i)Prophylaxis of acute graft 9 days after transplantation
rejection ii)Treatment of acute of a kidney, pancreas or
Antithymocyte graft rejection iii)Prophylaxis of liver, for 2 - 5 days after
Immunoglobulin L04AA04000 acute and chronic graft versus host heart transplantation ii)1.5
94 A*
(from rabbit) P3001XX disease iv)Treatment of steroid- mg/kg/day for 3 - 14 days
Injection resistant, acute graft versus host iii)2.5 - 5.0 mg/kg/day for 4
disease v)Treatment of aplastic days iv)2.5 - 5.0 mg/kg/day
anemia for 5 days v)2.5 - 3.5
mg/kg/day for 5 days
Initial dose of 100ml of
reconstituted antivenene
given by slow intravenous
infusion (2ml/min).
Treatment of patients who exhibit Subsequent dose can be
Antivenene J06AA03000P manifestations of systemic given every 12 hours
95 B
Cobra Injection 3002XX envenoming following a bite by according to the clinical
Cobra (Naja kaouthia). symptoms. As product may
differ from batches and
manufacturer, it is strongly
recommended to refer to
the product insert on dosing
21 / 371

recommendation.
Initial dose of 30ml of
reconstituted antivenene
given by slow intravenous
infusion (2ml/min).
Treatment of patients who exhibit Subsequent dose can be
manifestations of systemic given every 6 hours
Antivenene Pit J06AA03000P
96 B envenoming following a bite by according to the clinical
Viper Injection 3001XX
Malayan Pit Viper (Calloselasma symptoms. As product may
rhodostoma). differ from batches and
manufacturer, it is strongly
recommended to refer to
the product insert on dosing
recommendation.
Antivenene Treatment of patients who exhibit 1000 units by IV infusion
Serum (Sea J06AA03000P manifestations of systemic over 1/2 to 1 hour. In severe
97 B
snake) 1000 units 3003XX envenoming following a bite by sea cases 3000 -10000 units may
Injection snake. be required
Recommended initial dose is
20ml by intravenous
Treatment of patients who exhibit infusion. The injection
manifestations of systemic should be given very slowly
Antivenene
envenoming following a bite by as 5 minutes by direct slow
Serum Snake J06AA03000P
98 B Indian Cobra (Naja naja),Common intravenous route or 1hour
polyvalent 3004XX
Krait (Bungarus caeruleus), by infusion. If symptoms
Injection
Russell's Viper (Daboia russelli) and continue, further doses are
Saw-scaled Viper (Echis carinatus) administered as required
until symptoms completely
disappear
In combination with other 125 mg 1 hour prior to
antiemetic agents for prevention of chemotherapy on Day 1. To
Aprepitant 125 A04AD12000 delayed nausea and vomiting be given as part of a 3-day
99 A*
mg Capsule C1002XX associated with initial and repeat regimen that includes a
course of highly emetogenic corticosteroid and a 5-HT3
chemotherapy antagonist
In combination with other 80 mg once daily in the
antiemetic agents for prevention of morning on Days 2 and Day
Aprepitant 80 mg A04AD12000 delayed nausea and vomiting 3. To be given as part of a 3-
100 A*
Capsule C1001XX associated with initial and repeat day regimen that includes a
course of highly emetogenic corticosteroid & a 5-HT3
chemotherapy antagonist
22 / 371

All patients should receive a
1 ml IV test dose at least 10
minutes prior to loading
dose. Initially 2 million KIU
Aprotinin 10,000 B02AB01000 Only for Open Heart Surgery bolus followed by 2 million
101 A*
KIU/ml Injection P3001XX (extracorporeal circulation) KIU in heart-lung machine
followed by a slow infusion
of 500,000 KIU/hr until end
of surgery. CHILD: 20,000
KIU/kg/day
D02AX00000 As a soap or apply to the
102 Aqueous Cream C+ Dry skin
G1001XX skin as an emollient cream
Schizophrenia: 10 or 15
i) Treatment of acute episodes of
mg/day. Maintenance dose:
schizophrenia and for maintenance
15 mg/day. Bipolar mania:
Aripiprazole N05AX12000 of clinical improvement during
103 A* Starting dose: 15 or 30
10mg Tablet T1001XX continuation therapy. ii) Treatment
mg/day. Dose adjustment
of acute manic episodes associated
should occur at intervals of
with bipolar I disorder
not less than 24 hour
Schizophrenia: 10 or 15
i) Treatment of acute episodes of
mg/day. Maintenance dose:
schizophrenia and for maintenance
15 mg/day. Bipolar mania:
Aripiprazole N05AX12000 of clinical improvement during
104 A* Starting dose: 15 or 30
15mg Tablet T1002XX continuation therapy. ii) Treatment
mg/day. Dose adjustment
of acute manic episodes associated
should occur at intervals of
with bipolar I disorder
not less than 24 hour
Induction: 0.15 mg/kg/day
IV until bone marrow
remission. Total induction
dose ≤ 60 doses.
Relapsed acute promyelocytic Consolidation : 0.15
Arsenic Trioxide L01XX27550P leukaemia (APML). To be mg/kg/day IV for 25 doses in
105 A*
1 mg/ml Injection 3001XX prescribed by consultant 5 weeks (5 days per week,
haematologist only followed by 2 days
interruption; treatment
should begin 3-6 weeks
after completion of
induction therapy).
23 / 371

ADULT and CHILD over 12
years weighing over 35 kg :
4 tablets as a single dose at
the time of initial diagnosis,
again 4 tablets after 8 hours
and then 4 tablets twice
Artemether
daily (morning and evening)
20mg + P01BE52981 Acute uncomplicated falciparum
106 B on each of the following two
Lumefantrine T1001XX malaria
days (total course comprises
120mg
24 tablets). INFANT and
CHILD weighing 5 kg to less
than 35 kg : A 6 dose
regimen with 1 to 3 tablets
per dose, depending on
bodyweight
Weight 5-8kg, Age 6-11
months, Dose: One tablet
25/55mg OD x 3 days
Weight : 9-17kg, Age 1-6
Treatment of acute uncomplicated
Artesunate 100 years, Dose : Two tablet
Plasmodium falciparummalaria,
mg and P01BF02000T 25/55mg OD x 3 days
107 A resulting either from P. falciparum
Mefloquine HCI 1002XX Weight :18-29kg, Age 7-12
mono-infection or mixed infection
220 mg Tablet years, Dose :One tablet
with P. vivax.
100/220mg OD x 3 days
Weight ≥30kg, Age ≥13
years, Dose:Two tablet
Weight 5-8kg, Age 6-11
months, Dose: One tablet
25/55mg OD x 3 days
Weight : 9-17kg, Age 1-6
Treatment of acute uncomplicated
Artesunate 25 years, Dose : Two tablet
Plasmodium falciparummalaria,
mg and P01BF02000T 25/55mg OD x 3 days
108 A resulting either from P. falciparum
Mefloquine HCI 1001XX Weight :18-29kg, Age 7-12
mono-infection or mixed infection
55 mg Tablet years, Dose :One tablet
with P. vivax.
Weight ≥30kg, Age ≥13
years, Dose:Two tablet
24 / 371

2.4mg of artesunate/kg
body weight, by intravenous
(IV) or intramuscular (IM)
injection, at 0, 12 and 24
hours, then once daily until
oral treatment can be
substituted. For adults and
Treatment of severe malaria
Artesunate 60 P01BE03000 children with severe malaria
109 A caused by Plasmodium falciparum
mg Injection P3001XX or who are unable to
in adults and children
tolerate oral medicines,
artesunate 2.4 mg/kg body
weight IV or IM given on
admission (time = 0), then at
12 hrs and 24 hrs, then once
a day for 5-7 days is the
recommended treatment.
ADULT: 100-250 mg once or
twice daily CHILD: 100 mg
Ascorbic Acid 100 A11GA01000
110 C+ Vitamin C deficiency three times daily for one
mg Tablet T1002XX
week followed by 100mg
daily until symptoms abate.
ADULT: 100-250 mg once or
twice daily CHILD: 100 mg
Ascorbic Acid 500 A11GA01000
111 C+ Vitamin C deficiency three times daily for one
mg Tablet T1003XX
week followed by 100mg
daily until symptoms abate.
Therapeutic: Not less than
Ascorbic Acid 500 A11GA01000 For prevention and treatment of
112 B 250 mg daily in divided
mg/2 ml Injection P3001XX scurvy
doses
Hypertension and
Hypertension, angina pectoris, arrythmias; 50 - 100 mg
Atenolol 100 mg C07AB03000
113 B myocardial infarction and daily, Angina; 100 mg daily,
Tablet T1002XX
arrhythmias Myocardial infarction;
individualised
Hypertension and
Hypertension, angina pectoris, arrythmias; 50 - 100 mg
Atenolol 50 mg C07AB03000
114 B myocardial infarction and daily, Angina; 100 mg daily,
Tablet T1001XX
arrhythmias Myocardial infarction;
individualised
25 / 371

CHILD and ADOLESCENTS up
to 70 kg: Initially 0.5
mg/kg/day for at least 7
Attention deficit hyperactivity
days then increased
disorder (ADHD) in children 6 years
according to response.
and older who do not respond to
Maintenance: 1.2
Atomoxetine HCl N06BA09110 methylphenidate or who have
115 A* mg/kg/day. ADULTS and
10 mg Capsule C1001XX intolerable effects or have tics.
ADOLESCENTS more than 70
Diagnosis should be made
kg: Initially 40 mg/day for at
according to DSM IV criteria or the
least 7 days then increased
guidelines in ICD-10
Maintenance: 80 mg/day.
Max 100 mg/ day
days then increased
Maintenance: 1.2
Max 100 mg/ day
days then increased
Maintenance: 1.2
Max 100 mg/ day
26 / 371

days then increased
Maintenance: 1.2
Max 100 mg/ day
days then increased
Maintenance: 1.2
60mg Capsule C1005XX intolerable effects or have tics.
Max 100 mg/ day
Hypercholesterolaemia and
Atorvastatin 20 C10AA05000 coronary heart disease intolerant 10 mg once daily.
120 A/KK
mg Tablet T1002XX or not responsive to other forms of Maximum: 80 mg daily
therapy
121 A/KK
therapy
122 A/KK
therapy
27 / 371

Initial intravenous bolus
dose of 6.75mg (using
7.5mg/ml solution for
injection). Immediately
To delay imminent preterm birth in followed by a continuous
pregnant women with i) Regular high dose infusion (loading
uterine contractions of at least 30 infusion 300 mcg/min using
seconds duration at a rate of ≥ 4 7.5mg/ml concentrate for
Atosiban 7.5 G02CX01122 per 30 minutes ii) A cervical dilation solution for infusion) during
123 A*
mg/ml Injection P3001XX of 1 to 3 cm (0 - 3 nulliparas) and three hours, followed by
effacement of ≥ 50% iii) Age ≥ 18 lower infusion of
years iv) A gestational age from 28 100mcg/min up to 45 hours.
until 33 completed weeks v) A Duration of treatment
normal foetal heart rate. should not exceed 48 hours.
Total dose given during a full
course should not exceed
330mg of the active
substance.
Adult & childn >2 mth 0.3-
0.6 mg/kg IV. Endotracheal
intubation dose: 0.5-0.6
Atracurium Muscle relaxant in general mg/kg. Supplementary dose:
Besylate 10 mg M03AC04197 anaesthesia, Endotracheal 0.1-0.2 mg/kg as required.
124 A*
/ml in 2.5 ml P3001XX intubation, Aid controlled Continuous infusion rates of
Injection ventilation. 0.3-0.6 mg/kg/hr to
maintain neuromuscular
block during long surgical
procedure.
Adult & childn >2 mth 0.3-
0.6 mg/kg IV. Endotracheal
intubation dose: 0.5-0.6
Atracurium Muscle relaxant in general mg/kg. Supplementary dose:
Besylate 10 mg M03AC04197 anaesthesia, Endotracheal 0.1-0.2 mg/kg as required.
125 A*
/ml in 5 ml P3002XX intubation, Aid controlled Continuous infusion rates of
Injection ventilation. 0.3-0.6 mg/kg/hr to
maintain neuromuscular
block during long surgical
procedure.
Atropine
Sulphate 0.3%,
Cocaine HCl Subconjunctival injection to dilate
S01F000183P
126 1.7%, Adrenaline A pupils resistant to topical 1 - 2 drops
3001XX
Acid Tartrate mydriatics
0.03% Mydriatic
Injection
28 / 371

PREOPERATIVE MYDRIASIS :
one drop of a 1% solution
supplemented with one
Determination of refraction, drop of 2.5 or 10%
Atropine
S01FA01183 strabismus, iritis and iridocyclitis, phenylephrine prior to
127 Sulphate 1% Eye B
D2001XX after extra or intracapsular surgery. ANTERIOR UVEITIS
Drops
extraction of lens or POSTOPERATIVE
MYDRIASIS : one drop of a
1% or 2% solution up to 3
times a day
i) Adult: 300-600 mcg IM/SC
30-60 minutes before
anaesthesia. Alternatively,
300-600 mcg IV immediately
before induction of
anaesthesia. Child: >20 kg:
300-600 mcg; 12-16 kg: 300
mcg; 7-9 kg: 200 mcg; >3 kg:
100 mcg. Doses to be given
via IM/SC admin 30-60
minutes before
anaesthesia.ii) Adult: 500
i) Reduce vagal inhibition,salivary mcg every 3-5 minutes.
and bronchiol secretion in Total: 3 mg. Max Dosage:
anaesthesia ii) Reversal of 0.04 mg/kg body weight.iii)
Atropine excessive bradycardia iii) Reversal Adult 0.6-1.2 mg before or
A03BA01183
128 Sulphate 1mg/ml B of effect of competitive muscle with anticholinesterase iv)
P3001XX
Injection relaxants iv) Overdosage with other Adult: 0.6-1 mg IV/IM/SC,
compounds having muscarinic repeated every 2 hr. v)
action v) Organophosphate Adult: 2 mg IV/IM, every 10-
poisoning 30 minutes until muscarinic
effects disappear or
atropine toxicity appears. In
severe cases, dose can be
given as often as every 5
minutes. In moderate to
severe poisoning, a state of
atropinisation is maintained
for at least 2 days and
continued for as long as
symptoms are present.
Child: 20mcg/kg given every
5-10 minutes.
29 / 371

Recommended starting dose
for the first treatment cycle,
for all patients regardless of
First line therapy for intermediate-
Azacitidine baseline haematology
2 and high risk MDS, CMMOL with
Powder for laboratory values, is
L01BC07000P 10-29% blasts with no transplant
129 suspension for A* 75mg/m2 of body surface
4001XX option and elderly AML with 20-
injection area. Injected
30% blasts and multiline age
100mg/vial subcutaneously. Daily for 7
dysplasia.
days, followed by a rest
period of 21 days (28 day
treatment cycle)
i) Adult: 1-5 mg/kg/day.
Adjust dose according to
clinical response and
haematological tolerance.
Dose may also be given via
IV administration. ii) Adult:
1-3 mg/kg/day. Discontinue
i) Prophylaxis of rejection in organ treatment if there is no
Azathioprine 50 L04AX01000T and tissue transplant ii) Auto- improvement after 12 week.
130 A
mg Tablet 1001XX immune diseases iii) Rheumatoid iii) Adult: Initially, 1
arthritis mg/kg/day given in 1-2
divided doses for 6-8 week,
may increase by 0.5 mg/kg
every 4 week until response
or up to 2.5 mg/kg/day.
Maintenance: Reduce dose
gradually to achieve the
lowest effective dose.
Apply twice daily (sensitive
Azelaic Acid 20% D10AX03000 skin, once daily for 1st
131 A* Acne vulgaris
Cream G1001XX week). Treatment should
not exceed 6 months
CHILD 36 - 45 kg: 400 mg, 26
- 35 kg: 300mg, 15 - 25 kg
200 mg, less than 15 kg: 10
Azithromycin 200 Treatment of complicated
J01FA10011F mg/kg. To be taken daily for
132 mg/5 ml A* respiratory tract infections not
1001XX 3 days or to be taken as a
Granules responding to standard macrolides
single dose on day 1, then
half the daily dose on days 2
-5
30 / 371
i) Treatment of complicated
respiratory tract infection not
responding to standard macrolides
ii) Adult treatment of
i) 500 mg daily for 3 days ii)
Azithromycin 250 J01FA10011T uncomplicated genital infections
133 A* 1 g as a single dose iii) 1 g
mg Tablet 1001XX due to Chlamydia trichomatis or
weekly
susceptible Neisseria gonorrhoea
iii) Prophylaxis against
Mycobacterium avium complex in
patients with advanced HIV
500 mg IV as a single daily
dose for a minimum of two
Azithromycin 500 J01FA10011P Only for treatment of severe days followed by 500 mg
134 A*
mg Injection 4001XX atypical pneumonia oral dose as a single daily
dose to complete a 7 - 10
days course
ADULT: 400 mg twice daily.
Infections caused by ampicillin- Severe infection: 800 mg
Bacampicillin 400 J01CA06000T
135 B sensitive gram positive& gram twice daily. CHILD more
mg Tablet 1001XX
negative microorganisms than 25 kg: 12.5 - 25 mg/kg
12 hourly
ADULT: 5 mg 3 times daily.
Max: 80 mg daily. CHILD:
Baclofen 10 mg M03BX01000
136 B Spasticity of the skeletal muscle 0.75 - 2 mg/kg daily (more
Tablet T1001XX
than 10 years, maximum:
2.5 mg/kg daily)
Balanced Salt B05CB10907
137 A For irrigation during ocular surgery Irrigate as directed
Solution L5001XX
Balanced Salt
Solution PLUS
For irrigation during intraocular
(fortified with
B05CB10905 surgery especially in patients with
138 sodium A Irrigate as directed
L5001XX poor cornea endothelium and
bicarbonate,
poorly controlled diabetes
glucose &
glutathione)
i) Up to 150 ml of a 50% -
200% suspension orally ii)
For x-ray examination of the
Barium Sulphate V08BA01183 Up to 300 ml of a 30% -
139 B alimentary tract: i) Oesophagus ii)
Suspension L8001XX 200% suspension orally iii)
Stomach and duodenum iii) Colon
Up to 2 liter of a 30% - 200%
suspension orally
ADULT & CHILD 2 years and
above & 35 kg or more: 20
Prophylaxis of acute organ mg /dose. 2 years or more
Basiliximab 20 L04AC02000
140 A* rejection in de novo renal but less than 35kg: 10
mg Injection P3001XX
transplantation. mg/dose. First dose given
within 2 hours before start
of transplantation and
31 / 371

second dose 4th day after
transplant
81 mg intravesically once
weekly for 6 weeks,
L03AX03000
141 BCG 81 mg/3 ml A* Superficial bladder cancer followed by treatments at 3,
P3001XX
6, 12, 18, and 24 months
after initial treatment
BCG Vaccine 0.1 ml by intradermal
J07AN01000
142 Freeze-Dried C+ For the prevention of tuberculosis injection. INFANT under 12
P4001XX
Injection months: 0.05 ml
Adults: The usual
maintenance dose is one to
two inhalations (200-400
mcg) twice daily. If needed,
the dose can be increased
Beclomethasone Prophylaxis of asthma especially if up to 1600 mcg/day divided
R03BA01133
143 Dipropionate 100 B not fully controlled by in two to four doses :
A2101XX
mcg/dose Inhaler bronchodilators Children 6-12 years old: One
inhalation (200 mcg) two
times daily and dose may be
increased up to 800
mcg/day in divided two to
four doses if necessary.
Regular treatment of asthma
where use of a combination Dose recommended for
Beclomethasone
product (inhaled corticosteroid and patients 18 years and above.
dipropionate
long-acting beta2 agonist) is One or two inhalations
100mcg and
appropriate in: i. Patients not twice daily. The maximum
formoterol
R03AK07986 adequately controlled with inhaled daily dose is 4 inhalations
144 fumarate A/KK
A2101XX corticosteroids and ‘as needed’ daily. No need to adjust
dehydrate 6mcg
inhaled short-acting beta2 agonist dose in elderly patients.
pressurized
or ii. Patients already adequately There are no data available
inhalation
controlled on both inhaled for use in patients with
solution
corticosteroids and long-acting hepatic or renal impairment.
beta2-agonists
ADULT: 1 - 2 puff twice
daily. May increase to 2 puff
Beclomethasone Prophylaxis of asthma especially if
R03BA01133 2 - 4 times daily CHILD: 1
145 Dipropionate 200 A/KK not fully controlled by
A2102XX puff twice daily. May
mcg/dose Inhaler bronchodilators
increase to 1 puff 2 - 4 times
daily
32 / 371

years: Apply 100 mcg (2
sprays) into each nostril
twice daily or 50 mcg (1
Beclomethasone
Prophylaxis and treatment of spray) into each nostril 3 - 4
Dipropionate 50 R01AD01133
146 A/KK perennial and seasonal allergic times/day. Maximum 400
mcg/dose Nasal A4101XX
rhinitis and vasomotor rhinitis mcg daily (8 sprays). When
Spray
symptoms controlled,
reduce dose to 50 mcg (1
spray) into each nostril
twice daily
Wash and dry baby's
bottom. Apply by spreading
Benzalkonium D08AJ01000 Prevention and treatment of nappy the cream evenly paying
147 B
0.01% Cream G1001XX rash particular attention to the
fold of the skin, after every
nappy change
Benzalkonium
Low level disinfectant suitable for Cleaning purposes: Dilute 1
Chloride V07AV00100
148 C general cleaning and disinfection of in 10. Disinfection, use
Disinfectant L9908XX
hard surface undiluted
Solution
i) Treatment of mild to moderately
Benzathine i) ADULT: 1.2 mega units IM
J01CE08702P severe infections due to Penicillin
149 Penicillin 2.4 MIU B ii) For syphillis: 2.4 mega
4001XX G-sensitive organisms ii) Treatment
(1.8 g) Injection units weekly for 1 - 3 weeks
of syphillis
ADULT: Initially 1 mg daily,
increase gradually.
Benzhexol 2 mg N04AA01110 i) Parkinson's disease ii) Drug
150 B Maintenance: 5 - 15 mg
Tablet T1001XX induced parkinsonism iii) Dystonias
daily in 3 - 4 divided doses.
(Max 15mg/day)
Benzoic Acid
Compound Half D01AE12952 Apply sparingly to affected
151 C Tinea infections of the skin
Strength (Paed) G5001XX area once or twice daily
Ointment
Benzoic Acid
D01AE12952 Tinea infections of thickened skin Apply sparingly to affected
152 Compound C
G5002XX of palms and soles area once or twice daily
Ointment
Apply undiluted to the skin 1
Benzoin or 2 times daily. Duration of
D08AX00000 Infected skin, lesions, cuts,
153 Compound C therapy, may be weeks to
L5001XX abrasions, wounds and burns
Tincture months depending on the
infection being treated
Apply 1-2 times daily
Benzoyl Peroxide D10AE01241
154 B Mild to moderate acne vulgaris preferably after washing
10% Gel G3002XX
with soap and water
Benzoyl Peroxide D10AE01241 Apply 1-2 times daily
155 B Mild to moderate acne vulgaris
5% Gel G3001XX preferably after washing
33 / 371

with soap and water
Used as a 30 seconds gargle

or rinse, undiluted. ADULT
Benzydamine HCl A01AD02110 For relief of painful condition of the 15 ml. CHILD less 12 years 5-
156 B
0.15% Solution M2001XX oral cavity 15 ml. Uninterrupted
treatment should not be
more than 7 days
ADULTS and CHILDREN
OVER 12 YEARS: 2-4 sprays
(1-2mg) directly onto the
sore/inflamed area and
Temporary relief of painful swallow gently. Repeat
conditions of the mouth and throat every 1 1/2 to 3 hours as
including tonsillitis, sore throat, necessary. CHILDREN 6-12
Benzydamine radiation mucositis, aphthous YEARS: 2 sprays (1mg)
Hydrochloride A01AD02110 ulcers, pharyngitis, swelling, directly onto sore/ inflamed
157 A*
3.0 mg/ml throat A4201XX redness, inflammatory conditions, area and swallow gently.
spray post-orosurgical and periodontal Repeat every 11/2 to 3
procedures. (For pediatric and hours as necessary.
otorhinolaringology use. Restrict to CHILDREN UNDER 6 YEARS:
patients who are not able to gargle) Not recommended.
Uninterrupted treatment
should not exceed seven
days, unless under medical
supervision
After bath, apply over the
whole body, neck down and
leave on for 24 hours then
wash off. Reapply for
Benzyl Benzoate
P03AX01252 Scabies and pediculosis, for child another 24 hours, the first
158 12.5 % Emulsion C
L2001XX under 2 years repeat application should be
(Child)
within 5 days of the initial
application, a third
application may be required
in some cases
After bath, apply over the
whole body, neck down and
leave on for 24 hours then
wash off. Reapply for
Benzyl Benzoate
P03AX01000 another 24 hours, the first
159 25 % Emulsion C+ Scabies and pediculosis
L2002XX repeat application should be
(Adult)
within 5 days of the initial
application, a third
application may be required
in some cases
34 / 371

i) Adult: 600mg - 3600mg (1
- 6 mega units) daily, divided
into 4 to 6 doses. Higher
doses (24 mega units) in
divided doses may be given
in serious infections such as
meningitis. Child 1 month to
Benzylpenicillin 1
J01CE01702P i) Infections caused by susceptible 12 years old: 100mg/kg/day
160 mega unit (600 B
4001XX organisms ii) Infective endocarditis in 4 divided doses, not
mg) Injection
exceeding 4g/day; Infants 1
-4 weeks: 75mg/kg/day in 3
divided doses; Newborn
Infants: 50mg/kg/day in 2
divided doses ii)7.2 to 12g
(12 - 20 mega units) maybe
given daily in divided doses
Benzylpenicillin 1-2 drops every 15 minutes
S01AA14702
161 10,000 units/ml B Eye infection or accordingly to needs of
D2002XX
Eye Drops the patient
Benzylpenicillin
1-2 drops every 15 minutes
2,500 units/ml S01AA14702
162 B Eye infection or accordingly to needs of
(1.5 mg/ml) Eye D2001XX
the patient
Drops
i) ADULT: 600 - 1200 mg IM
4 times daily, increased if
necessary in more serious
Benzylpenicillin 5
J01CE01702P i) Infections caused by susceptible infections. CHILD: 50 - 100
163 mega units (3 g) B
4002XX organisms ii) Infective endocarditis mg/kg body weight daily IV
Injection
in 2 - 4 divided doses ii)
ADULT: 7.2 g daily by slow IV
infusion in 6 divided doses
Treatment of newborn baby with 100 mg/kg (4 ml/kg) body
Beractant birth weight of 700 g or greater weight intratracheally up to
Intratracheal undergoing mechanical ventilation 4 doses in 1st 48 hr. Doses
R07AA02000
164 Suspension (200 A* for respiratory distress syndrome, should not be given more
L8001XX
mg phospholipids whose heart rate and arterial frequently than 6 hrly. To be
in 8 ml vial) oxygenation are continuously administered as soon as
monitored possible.
Given in doses of 8 to 16 mg
Betahistine orally 3 times daily (total 24
N07CA01110 Vertigo, tinnitus and hearing loss
165 Dihydrochloride A/KK to 48 mg/day) preferably
T1002XX associated with Meniere's disease
16 mg Tablet with food. CHILD not
recommended
Betahistine
N07CA01110 Vertigo, tinnitus and hearing loss 24-48mg in divided doses
166 Dihydrochloride A*
T1003XX associated with Meniere's disease daily
24 mg Tablet
35 / 371

Given in doses of 8 to 16 mg
Betahistine orally 3 times daily (total 24
N07CA01110 Vertigo, tinnitus and hearing loss
167 Dihydrochloride A/KK to 48 mg/day) preferably
T1001XX associated with Meniere's disease
8 mg Tablet with food. CHILD not
recommended
Suppression of inflammatory and 0.5 - 9 mg daily in divided
Betamethasone H02AB01000 allergic disorders, congenital doses. CHILD: 0.5 - 7.5
168 A
0.5 mg Tablet T1001XX adrenal hyperplasia, cerebral mg/m2/day divided every 6
oedema - 12 hours
Apply sparingly to affected
Betamethasone
D07AC01256 Eczemas, prurigo nodularis, limited area 2 - 3 times daily then
169 17-Valerate 0.01- B
G1001XX psoriasis in appropriate in sites reduced to once daily when
0.05% Cream
improvement occurs
Betamethasone
D07AC01256 Eczema, prurigo nodularis, limited area 2 - 3 times daily then
170 17-Valerate 0.01- B
G5001XX psoriasis in appropriate in sites reduced to once daily when
0.05% Ointment
improvement occurs
Betamethasone Eczemas, prurigo nodularis,
D07AC01256 area 2 - 3 times daily then
171 17-Valerate 0.1% A psoriasis (excluding widespread
G1002XX reduced to once daily when
Cream plaque psoriasis)
improvement occurs
Betamethasone Eczema, prurigo nodularis, psoriasis
D07AC01256 area 2-3 times daily then
172 17-Valerate 0.1% A (excluding widespread plaque
G5002XX reduced to once daily when
Ointment psoriasis)
improvement occurs
Betamethasone
Apply 2 - 3 drops every 2 - 3
Disodium S03BA03162 Non-infected inflammatory
173 B hours, reduce frequency
Phoshate 0.1% D1001XX conditions
when relief obtained
Ear Drops
Betamethasone
Apply 2 - 3 drops every 2 - 3
174 B hours, reduce frequency
Phoshate 0.5% D1002XX conditions
Ear Drops
Betamethasone
1 - 2 drops every 1 - 2 hours
175 A until controlled then reduce
Phosphate 0.1% D2001XX conditions of the eyes
frequency
Eye Drops
Betamethasone
Disodium S01BA06162 Non-infected inflammatory 2 - 4 times daily or at night
176 A
Phosphate 0.1% G5101XX conditions of the eyes when used with eye drops
Eye Ointment
Betamethasone
Disodium
Apply 2 - 3 drops 3 - 4 times
Phosphate and S03CA06991
177 B Allergic dermatosis in the ear daily, reduce frequency
Neomycin D1001XX
Sulphate 0.5%
Ear Drops
36 / 371

Betamethasone
Disodium
Phosphate and S01CA05991 Infected inflammatory conditions
178 A 2 - 3 drops every 2 - 3 hours
Neomycin D2001XX of the eyes
Sulphate Eye
Drops
Usual intravenous doses are
Pre-operative and in serious up to 9 mg/day of the
Betamethasone trauma or illness, shock, as sodium phosphate salt only.
Sodium H02AB01162 adjunctive therapy in rheumatoid CHILD: IM: 0.5 - 7.7 mg
179 B
Phosphate 4 P3001XX disorders, ocular, dermatologic and base/m2/day divided every
mg/ml Injection respiratory allergic and 6 - 12 hours. ADOLESCENT
inflammatory states and ADULT, IM: 0.6 - 9 mg
divided every 12 - 24 hours
Betaxolol 0.25% S01ED02110 Chronic open-angle glaucoma, One to two drops in the
180 A
Eye Suspension D2001XX ocular hypertension affected eye(s) twice daily
50 mg once daily (morning
or evening), with or without
food. Take on the same time
each day. Adult: When used
Advanced prostate cancer in
Bicalutamide 50 L02BB03000T with gonadorelin analogue:
181 A* combination with LHRH analogue
mg Tablet 1001XX Usual dose: 50 mg once
therapy or surgical castration.
daily. May be started with
or at least 3 days before
starting gonadorelin
analogue therapy.
Lowering of intraocular pressure in
patients with open-angle glaucoma
Bimatoprost and ocular hypertension who are
0.03% S01EE03000 intolerant of other intraocular 1 drop in affected eye(s)
182 A*
Ophthalmic D2001XX pressure lowering medications or once daily at evening
Solution insufficiently responsive to another
intraocular pressure lowering
medication
i) ADULT and CHILD over 10
years: 10 mg, CHILD less
i) Constipation ii) Bowel than 10 years 5 mg insert
Bisacodyl 10 mg A06AB02000
183 C preparation for radiological rectally ii) ADULT 10-20 mg,
Suppository S2002XX
procedures and surgery CHILD over 4 years 5 mg the
following morning before
procedures insert rectally
years: 10 mg, CHILD less
i) Constipation ii) Bowel than 10 years 5 mg insert
184 C preparation for radiological rectally ii) ADULT 10-20 mg,
Suppository S2001XX
procedures and surgery CHILD over 4 years 5 mg the
following morning before
procedures insert rectally
37 / 371

years 5-10 mg, CHILD 4-10
years 5 mg. To be taken at
i) Constipation ii) Bowel night for effect on the
185 C preparation for radiological following morning ii) ADULT
Tablet T1001XX
procedures and surgery 10-20 mg the night before
procedures, CHILD over 4
years 5 mg the night before
procedures
Bismuth As a mild antiseptic for wounds and
Subnitrate, abscesses. Sterile gauze
R01AX30984 As directed for local
186 Iodoform and B impregnated with paste for packing
G6001XX application
Liquid Paraffin cavities after otorhinological
Paste surgery
Bisoprolol Treatment of stable moderate to
C07AB07000 1.25 mg once daily to 5 - 10
187 Fumarate 2.5 mg B severe congestive cardiac failure in
T1001XX mg daily
Tablet addition to ACEI's and diuretics
Bisoprolol Treatment of stable moderate to
C07AB07000 1.25 mg once daily to 5 - 10
188 Fumarate 5 mg B severe congestive cardiac failure in
T1002XX mg daily
Tablet addition to ACEI's and diuretics
15 - 30 mg weekly in divided
doses or 10 - 20 mg/m2
Squamous cell carcinoma, germ cell once or twice weekly or 10
tumours, lymphomas. Routes: SC, mg/m2 slow bolus in 15
Bleomycin HCl 15 L01DC01110
189 A IM, IV (either as bolus or as minutes D1 and D15. Total
infusion over 24 hours), intra- dosage:should not exceed
arterial, intra-pleural 300 mg. CHILD: 10 - 15
mg/m2 over 6 hours every 3
- 4 weeks
Boric Acid with
S02AA03000 3 drops instilled into
190 Spirit 2% w/v Ear C Perforated eardrum
D1001XX affected ear 3 - 4 times daily
Drops
i) Treatment of multiple myeloma
1.3 mg/ m2/dose given as IV
in patient who have received at
bolus injection twice weekly
least one prior therapy. ii) For use
for two weeks (days 1, 4, 8,
in combination with conventional
Bortezomib 3.5 L01XX32000P and 11) followed by a 10-
191 A* therapy for the treatment of
mg Injection 3001XX day rest period (days 12-21).
previously untreated multiple
At least 3 days should elapse
myeloma patients who are not
between consecutive doses
eligible for haematopoietic stem
of bortezomib
cell transplantation.
38 / 371

For the treatment of pulmonary
arterial hypertension (PAH) in
patients with WHO Class III or IV
Initially 62.5 mg bd for 4
symptoms, to improve exercise
Bosentan 125 mg C02KX01000 weeks, then increase to the
192 A* ability and decrease the rate of
tablet T1001XX maintenance dose of 125
clinical worsening (To be used by
mg bd
those who are trained and
specialized in treating and
managing PAH)
Brimonidine Lowering of intraocular pressure in
S01EA05123 1 drop in the affected eye(s)
193 Tartrate 0.15% A* patients with open-angle glaucoma
D2001XX 3 times daily
Ophthalmic or ocular hypertension
Adult: Initially, 6-18 mg daily
in divided doses. Doses up
Bromazepam 3 N05BA08000
194 A Anxiety disorders to 60 mg daily have been
mg Tablet T1002XX
used. Elderly: Max initial
dose: 3 mg daily
Secretolytic therapy in acute and
4 to 8 mg SC, IM or IV 2 - 3
Bromhexine HCl chronic bronchopulmonary
R05CB02110 times daily (maximum
195 4 mg/2 ml A diseases associated with abnormal
P3001XX 24mg/ day). Elderly: Max
Injection mucous secretion and impaired
initial dose: 3 mg daily.
mucous transport
1) Adults: 10 ml three times
Secretolytic therapy in acute and a day. Can increase up to 15
chronic bronchopulmonary ml four times a day.
Bromhexine HCl R05CB02110
196 B diseases associated with abnormal 2)Children 5 to 12 years : 5
4 mg/5 ml Elixir L1001XX
mucous secretion and impaired ml four times a day
mucous transport 3)Children 2 to 5 years: 5 ml
two times a day
Secretolytic therapy in acute and ADULT and CHILD more than
chronic bronchopulmonary 12 years : 8 mg 3 times
Bromhexine HCl R05CB02110
197 B diseases associated with abnormal daily, 6 - 12 years : 4 mg 3
8 mg Tablet T1001XX
mucous secretion and impaired times daily, 2 - 6 years : 4
mucous transport mg 2 times daily
i) Initially 1 - 1.25 mg at
bedtime increased
gradually, usual dose: 7.5
mg daily in divided doses.
Bromocriptine
G02CB01196 i) Hypogonadism or Galactorrhoea Max 30 mg daily ii) 1.25 - 2.5
198 Mesilate 10 mg A/KK
T1003XX ii) Acromegaly mg at bedtime for 3 days
Tablet
and may be increased by
1.25 - 2.5 mg every 3 - 7
days up to 30 mg a day in
divided doses
39 / 371

bedtime increased
Bromocriptine
199 Mesilate 2.5 mg A/KK
Tablet
1.25 - 2.5 mg every 3 - 7
divided doses
bedtime increased
Bromocriptine
200 Mesilate 5 mg A/KK
Tablet
1.25 - 2.5 mg every 3 - 7
divided doses
ADULT: Initially 1 - 2 mg
Budesonide 1 Maintenance treatment of asthma
twice daily. CHILD 3 months
mg/2 ml R03BA02000 as prophylactic therapy especially if
201 B - 12 years of age : 500 mcg -
Nebuliser A3002XX not fully controlled by
1 mg. Maintenance dose :
Solution bronchodilators
half of the above doses
ADULT: 200 - 1600 mcg daily
in 2 - 4 divided doses.
Maintenance treatment of asthma Maintenance with twice
Budesonide 100 R03BA02000 as prophylactic therapy especially if daily dosing. CHILD more
202 B
mcg/dose Inhaler A2101XX not fully controlled by than 7 years 200 - 800 mcg,
bronchodilators 2 - 7 years 200 - 400 mcg. To
be taken orally in 2 - 4
divided doses
40 / 371

Asthma Maintenance
therapy Adult ≥18 yr 160
mcg to 320 mcg bd. Some
patients may require up to a
max of 640 mcg bd.
Adolescent 12-17 yr 160
mcg to 320 mcg bd. Childn
6-11 yr 160 mcg bd, <6 yr
Not recommended.
Maintenance & relief Adult
≥18 yr 320 mcg/day either
as 160 mcg bd or 320 mcg
either morning or evening.
For some patients a
maintenance dose of 320
i) Regular treatment of asthma
mcg bd may be appropriate.
where use of a combination
Patients should take 160mcg
(inhaled corticosteroid & long-
additional inhalation as
acting β2-agonist) is appropriate. ii)
Budesonide 160 needed in response to
Symptomatic treatment of patients
mcg and R03AKO7989 symptoms. If symptoms
203 A/KK with severe COPD (FEV1<50%
Formoterol 4.5 A2101XX persist after a few minutes,
predicted normal) & a history of
mcg Inhalation an additional inhalation
repeated exacerbations, who have
should be taken. Not more
significant symptoms despite
than 960 mcg should be
regular therapy with long-acting
taken on any single
bronchodilators.
occasion. A total daily dose
of more than 1280 mcg is
not normally needed;
however a total daily dose
of up to 1920 mcg could be
used for a limited period.
Patients using more than
1280 mcg daily should seek
medical advice, should be
reassessed & their
maintenance therapy
reconsidered. Childn &
adolescent <18 yr Not
recommended. COPD Adult
≥18 yr 320 mcg bd.
ADULT: 200 - 1600 mcg daily
Maintenance treatment of asthma Maintenance with twice
Budesonide 200
R03BA02000 as prophylactic therapy especially if daily dosing. CHILD more
204 mcg/dose B
A2102XX not fully controlled by than 7 years 200 - 800 mcg,
Inhalation
bronchodilators 2 - 7 years 200 - 400 mcg. To
be taken orally in 2 - 4
divided doses
41 / 371

Asthma; Maintenance
therapy: Adult ≥18 yr 160
mcg to 320 mcg bd. Some
patients may require up to a
max of 640 mcg bd.
Adolescent 12-17 yr 160
mcg to 320 mcg bd. Childn
6-11 yr 160 mcg bd, <6 yr
Not recommended.
Maintenance & relief: Adult
≥18 yr 320 mcg/day either
as 160 mcg bd or 320 mcg
either morning or evening.
For some patients a
i) Regular treatment of asthma mcg bd may be appropriate.
where use of a combination Patients should take 160mcg
(inhaled corticosteroid & long- additional inhalation as
acting β2-agonist) is appropriate. ii) needed in response to
Budesonide 320
Symptomatic treatment of patients symptoms. If symptoms
mcg and R03AK07989
205 A/KK with severe COPD (FEV1<50% persist after a few minutes,
Formoterol 9 A2102XX
predicted normal) & a history of an additional inhalation
mcg Inhalation
repeated exacerbations, who have should be taken. Not more
significant symptoms despite than 960 mcg should be
regular therapy with long-acting taken on any single
bronchodilators. occasion. A total daily dose
of more than 1280 mcg is
not normally needed,
however a total daily dose
of up to 1920 mcg could be
used for a limited period.
Patients using more than
1280 mcg daily should seek
medical advice, should be
reassessed & their
maintenance therapy
reconsidered. Children &
adolescent less than 18 yr:
Not recommended. COPD;
Adult more than or equal to
18 yr: 320 mcg bd.
ADULT: Initially 1 - 2 mg
Budesonide 500 Maintenance treatment of asthma
twice daily. CHILD 3 months
mcg/2 ml R03BA02000 as prophylactic therapy especially if
206 B - 12 years of age : 500 mcg -
Nebuliser A3001XX not fully controlled by
1 mg. Maintenance dose :
Solution bronchodilators
half of the above doses
42 / 371

ADULT and CHILD 6 years
and older. Rhinitis: 2 spray
Budesonide into each nostril once daily
R01AD05000 Seasonal allergic, perennial rhinitis
207 64mcg Nasal A in the morning or 1 spray
A4103XX and nasal polyposis
Spray into each nostril twice daily.
Nasal polyps : 2 spray twice
daily
IV injection: 1 - 2 mg
Bumetanide 0.5 C03CA02000 Oedema used in furosemide repeated after 20 mins. IV
208 A*
mg/ml Injection P3001XX allergic patient infusion: 2 - 5 mg over 30 -
60 mins
1 mg in the early evening.
Bumetanide 1 mg C03CA02000 Oedema used in furosemide
209 A* Up to 5 mg daily in severe
Tablet T1001XX allergic patient
cases
Bupivacaine Infuse at 6 - 15 ml/hour. Not
N01BB01110 Epidural analgesia for
210 0.125% Epidural A to exceed 2 mg/kg in a
P3004XX postoperative pain relief.
Injection single dose.
Bupivacaine 0.5 ADULT: 2 - 4 ml. Not to
N01BB01110
211 % Heavy A Used for spinal anaesthesia exceed 2 mg/kg in a single
P3003XX
Injection dose
Regional nerve block or
epidural block: 15 - 30 ml.
For peripheral sympathetic nerve Nerve block of finger or toe:
Bupivacaine 0.5 N01BB01110 and epidural (excluding caudal) 2 - 6 ml. Maximum: 2 mg/kg
212 B
% Injection P3002XX anaesthesia and obstetrics body weight in any 4 hours
anaesthesia period, equivalent to 25 - 30
ml in adults of average
weight
Bupivacaine 0.5 10 - 40 ml (0.25 %) or
% with maximum : 2 mg/kg body
N01BB51975 Regional nerve block or epidural
213 Adrenaline B weight in any 4 hours
P3001XX block.
1:200,000 period, equivalent to 25 - 30
Injection ml of 0.5% solution
Once weekly transdermal
patch/for hospital use only.
Patient aged 18 years and
over. Initial dose: 5mcg/hr
Treatment of non-malignant pain
For elderly: Renal
of moderate intensity when an
impairment. No special dose
Buprenorphine opioid is necessary for obtaining
adjustments necessary in
10mcg/hr N02AE01110 adequate analgesia. Not suitable
214 A* patients with renal
transdermal M7001XX for the treatment of acute pain.
impairment Hepatic
patch Restrictions: For elderly patients or
impairment Patients with
patients with
hepatic insufficiency should
comorbidities/difficult to swallow
be carefully monitored
during the treatment with
buprenorphine patch.
Alternate therapy should be
43 / 371

considered. Patch should be
used with cautions in severe
hepatic impairment patient
Once weekly transdermal

patch/for hospital use only.
Patient aged 18 years and
over. Initial dose: 5mcg/hr
For elderly: Renal
Treatment of non-malignant pain impairment. No special dose
of moderate intensity when an adjustments necessary in
Buprenorphine opioid is necessary for obtaining patients with renal
5mcg/hr N02AE01110 adequate analgesia. Not suitable impairment Hepatic
215 A*
transdermal M7003XX for the treatment of acute pain. impairment Patients with
patch Restrictions: For elderly patients or hepatic insufficiency should
patients with co - be carefully monitored
morbidities/difficult to swallow during the treatment with
buprenorphine patch.
Alternate therapy should be
considered. Patch should be
used with cautions in severe
hepatic impairment patient
i) ADULT: Initial: 2 - 4 mg
daily. Maintenance: 0.5 - 2
mg daily. Stop when white
blood cell less than 20 x
i) Chronic myeloid leukaemia (CML) 109/L. CHILD: 60 mcg/kg
and other myeloproliferative body weight daily ii) CHILD:
Busulfan 2 mg L01AB01000
216 A diseases ii) Haemopoietic stem cell Induction 60 mcg/kg body
Tablet T1001XX
transplant (HSCT)- refer to specific weight daily (maximum 4
protocols mg) if leucocytes more than
20,000/mm3 and platelets
more than 100,000/mm3.
Maintenance 10 - 30mcg/kg
(maximum 2 mg daily)
For use in combination with
0.8 mg/kg of ideal body
cyclophosphamide as a
weight or actual body
conditioning regimen prior to
weight, whichever is lower
allogeneic hematopoietic stem cell
via central venous catheter
transplantation (HSCT) for chronic
as a 2-hour infusion on the
Busulfan 6 mg/ml L01AB01000 myelogenous leukemia in selected
217 A* basis of every 6 hours for 4
Injection P3001XX cases with high risk of liver toxicity
days, for a total of 16 doses.
and intolerance to oral busulfan. To
For obese or severely obese
be prescribed by paediatric
patients, IV Busulfan should
oncologist and consultant
be administered based on
haematologist trained in transplant
adjusted ideal body weight
only.
44 / 371

i) 0.5mg per week given in 1
or 2 (one-helf of one 0.5mg
i) Treatment of
tablet) doses per week ii)
hyperprolactinaemic disorders
Cabergoline 0.5 G02CB03000 HIV mothers only: Prevent
218 A* ii) Prevention of puerperal lactation
mg Tablet T1001XX lactation 2 tab first day after
and suppression of lactation in HIV
delivery. Interruption of
infected mothers only
laction : 0.25mg 12 hourly
for 2 days
Soothes and relieves nappy rashes,
D04AX00000 prickly heat, minor skin irritations, Apply to the affected area
219 Calamine Cream C+
G1001XX insect bites and sunburn, Pruritic as required, 1-3 times daily
skin conditions.
Apply to the skin as required
D04AX00000 prickly heat, minor skin irritations,
220 Calamine Lotion C+ and allow to dry, 1-3 times
L8001XX insect bites and sunburn, Pruritic
daily
skin conditions.
Calamine with Apply to the skin as required
D04AX00952 prickly heat, minor skin irritations,
221 0.25 - 0.5% C and allow to dry, 1 - 3 times
L6001XX insect bites and sunburn, Pruritic
Menthol Lotion daily
skin conditions.
Calamine with
D04AX00952 Apply to the affected area
222 0.5% Phenol C For use as a mild astringent
G1001XX as required
Cream
Calamine with 2 - Apply to the skin as required
D04AX00952
223 6% Precipitated C Acne vulgaris and allow to dry, 1 - 3 times
L6002XX
Sulphur Lotion daily
ADULT Apply to the affected
skin lesions twice daily.
Maintenance therapy may
be achieved with less
frequent application. The
Calcipotriol 50 D05AX02000 Only for the treatment of Psoriasis
224 A* weekly dose should not
mcg/g Cream G1001XX Vulgaris
exceed 100 g. CHILD over 6
years, apply twice daily. 6-
12 years maximum 50gm
weekly, over 12 years
maximum 75gm weekly
ADULT Apply to the affected
skin lesions twice daily.
Maintenance therapy may
be achieved with less
Calcipotriol 50 D05AX02000 Only for the treatment of Psoriasis
225 A* frequent application. The
mcg/g Ointment G5001XX Vulgaris
weekly dose should not
exceed 100 g. CHILD over 6
years, apply twice daily. 6-
12 years maximum 50gm
45 / 371

weekly, over 12 years
maximum 75gm weekly
Calcipotriol 50
D05AX02000 Only for the treatment of Psoriasis Apply to scalp twice daily.
226 mcg/ml Scalp A*
L9901XX Vulgaris Maximum 60 mL weekly.
Solution
Calcipotriol
Apply once daily up to 4
Hydrate 50
weeks with maximum
mcg/g & D05AX52952
227 A* Resistant plaque psoriasis weekly dose of 100g and
Betamethasone G5001XX
maximum treatment area
Dipropionate 0.5
30% of body surface
mg/g Ointment
Should be applied to
affected areas once daily.
The recommended
Calcipotriol treatment period is 4 weeks
monohydrate 50 for scalp areas and 8 weeks
Topical treatment of scalp and non-
mcg/g and D05AX52952 for non-scalp areas. The
228 A* scalp plaque psoriasis vulgaris in
Betamethasone G3001XX body surface area treated
adults
dipropionate 0.5 with calcipotriol containing
mg/g Gel products should not exceed
30% and maximum dose
should not exceed 15g or
100g/ week
5-10 IU per kg body weight
in 500mL physiological
Calcitonin saline daily by i.v. infusion
(synthetic H05BA01000 over at least 6 hours or by
229 A* Acute hypercalcaemia
Salmon) 100 IU P3002XX slow i.v. injection in 2-4
Injection divided doses spread over
the day. Renal impairment:
Dosage adjustment needed.
Calcitonin
(Synthetic H05BA01000
230 A* Osteoporosis 200 units daily
Salmon) 200 IU A4101XX
Nasal Spray
5-10 IU per kg body weight
in 500mL physiological
Calcitonin saline daily by i.v. infusion
(Synthetic H05BA01000 over at least 6 hours or by
231 A* Acute hypercalcaemia
Salmon) 50 IU P3001XX slow i.v. injection in 2-4
Injection divided doses spread over
the day. Renal impairment:
Dosage adjustment needed.
46 / 371

i) 0.25 mcg 2 times daily;
ii) Initial dose 0.25 mcg. In
patients with normal or only
i)Established postmenopausal
slightly reduced serum
osteoporosis ii) Renal
calcium levels, doses of 0.25
osteodystrophy in patients on
Calcitriol 0.25 A11CC04000 mcg every other day is
232 A/KK haemodialysis
mcg Capsule C1001XX sufficient; iii) 0.25 mcg/day
iii)Hypoparathyroidism and rickets
given in the morning; iv)
iv)Secondary hyperparathyroidism
ADULT and CHILD 3 years
in renal failure
and older : Initially 0.25
mcg/ml. CHILD less than 3
years : 10 to 15 ng/kg/day "
Initially dose, depending on
Management of hypocalcaemia
severity, 1 mcg (0.02 mg/kg)
Calcitriol 1 A11CC04000 and/or secondary
233 A* to 2 mcg 3 times weekly,
mcg/ml Injection P3001XX hyperparathyroidism in patients
approximately every other
undergoing chronic renal dialysis
day
Initially dose, depending on
Management of hypocalcaemia
severity, 1 mg (0.02 mg/kg)
Calcitriol 2 A11CC04000 and/or secondary
234 A* to 2 mg 3 times weekly,
mcg/ml Injection P3002XX hyperparathyroidism in patients
approximately every other
undergoing chronic renal dialysis
day
ADULT: Typical oral doses of
calcium carbonate range
from about 3gm to 7gm
daily in divided dose. US
National Foundation suggest
i) Elemental calcium
Calcium the calcium-based
A12AA04121 supplementation ii) Phosphate
235 Carbonate 500 A/KK phosphate binder should
C1001XX binder in chronic renal failure
mg Capsule not exceed 1.5gm daily in
patients
those with kidney failure.
CHILD (12-18 years old):
1.25gm 3 or 4 times daily
with or before meals and
adjusted as necessary.
To be used only for elemental
Calcium
A12AA04121 calcium supplementation and Initial 2.5 g daily and
236 Carbonate 500 A/KK
T1001XX phosphate binding activity in increased up to 17 g daily
mg Tablet
patients with chronic renal failure
Calcium Chloride The maximum infusion rate
Dihydrate, depends on the needs of the
Sodium Chloride, Replacement of extracellular fluid patient in fluid replacement
Magnesium B05BB01905 losses in the case of isotonic and electrolytes, patient’s
237 A
Chloride P6002XX dehydration, where acidosis is weight, clinical condition,
Hexahydrate, present or imminent. and biological status. Adults,
Sodium Acetate elderly, adolescents:500ml-
Trihydrate,Potass 3L/24hr. Babies, children:
47 / 371

ium Chloride, 20ml to 100ml/kg/24 hr.
and Malic Acid
Solution
IM (Lead encephalopathy):
1000 mg/m (2)/day IM in
divided equal doses 8 to 12
hours apart, for 5 days.
Therapy is interrupted for 2
to 4 days, and followed by
an additional 5-day course
Calcium
of therapy, if indicated. Do
Disodium V03AB03999
238 A Lead Poisoning not exceed the
Edetate 200 mg P3001XX
recommended daily dosage.
Injection
IV: 1000 mg/m (2)/day
administered IV over 8 to 12
hours for 5 days. Therapy is
interrupted for 2 to 4 days,
and followed by an
additional 5-day course of
therapy, if indicated.
i) 1-2 g (2.25-4.5 mmol).
CHILD 50 mg/kg ii) ADULT 1g
Calcium i)Acute hypocalcaemia (2.2 mmol) by slow IV
A12AA03000
239 Gluconate 10% B ii)Hypocalcaemic tetany iii)Cardiac injection followed by
P3001XX
Injection resuscitation continuous infusion of 4 g
(8.8 mmol) daily iii) IV or
intracardiac injection, 10 ml
For prophylaxis of calcium
Calcium Lactate A12AA05125 ADULT 1-5 g daily in divided
240 C deficiency and treatment of chronic
300 mg Tablet T1001XX doses
hypocalcaemia
15 - 30g daily in 2-3 divided
Calcium
doses. Each dose should be
Polystyrene V03AE01999 Hyperkalemia resulting from acute
241 A suspended in 30 - 50ml of
Sulphonate F2101XX or chronic renal failure
water and administered
Powder
orally
i) Metastatic breast cancer in i) & ii) 1250 mg/m2 twice
elderly and poor performance daily (morning and evening)
status patients and refractory to for 2 weeks, every 21 days.
taxanes. ii) Metastatic colon iii) Recommended for a total
cancer, first line in elderly and poor of 24 weeks (8 cycles of 2
Capecitabine 150 L01BC06000T performance status patients. iii) weeks of drug
242 A*
mg Tablet 1002XX Colon cancer, adjuvant therapy for administration and 1 week
stage III (Duke's Stage C) following rest period. Iv) In
surgery. iv) First line treatment of combination with platinum
patients with advanced gastric on day 1, give capecitabine
cancer in combination with a 1250 mg/m2 twice daily for
platinum-based regimen 14 days. Repeated every 3
48 / 371

weeks for 8 cycles or
optimum number of cycles
i) & ii) 1250 mg/m2 twice
daily (morning and evening)
i)Metastatic breast cancer in
for 2 weeks, every 21 days
elderly and poor performance
iii) Recommended for a total
status patients and refractory to
of 24 weeks (8 cycles of 2
taxanes ii) Metastatic colon cancer,
weeks of drug
first line in elderly and poor
administration and 1 week
Capecitabine 500 L01BC06000T performance status patients iii)
243 A* rest period iv) In
mg Tablet 1001XX Colon cancer, adjuvant therapy for
combination with a
stage III (Duke's Stage C) following
platinum on day 1, give
surgery iv) First line treatment of
capecitabine 1250 mg/m2
patients with advanced gastric
twice daily for 14 days.
cancer in combination with a
Repeated every 3 weeks for
platinum-based regimen
8 cycles or optimum number
of cycles
i) Initially 12.5 mg twice
daily. Maintenance: 25-50
mg 2 - 3 times daily, may be
increased to maximum 450
mg/day in divided doses ii)
Initially 6.25 - 12.5 mg 3
times daily, increase after
i) Hypertension ii) Congestive heart several days to 25 - 50 mg 3
Captopril 25 mg C09AA01000
244 B failure iii) Post-myocardial times daily iii) Start 3 days
Tablet T1002XX
infarction iv) Diabetic nephropathy after MI Initially 6.25 mg
daily, gradually increased to
37.5 mg daily in divided
doses. May increase after
several week to 150 mg/day
in divided doses if needed
and tolerated iv)75 - 100 mg
daily in divided dose.
Carbachol 0.01% Instill no more than 0.5 ml
S01EB02100 For intraocular use for miosis
245 Intraocular A gently into the anterior
D2001XX during surgery
Solution chamber
49 / 371

ADULT: Initially, 100-200 mg
once or twice daily gradually
increased by increments of
100-200 mg every 2 week.
Maintenance: 0.8-1.2 g daily
in divided doses. CHILD: 10-
Carbamazepine
N03AF01000 15 years: 0.6-1 g daily; 5-10
246 100 mg/5 ml (2% A Epilepsy
L9001XX years: 400-600 mg daily; 1-5
w/v) Syrup
years: 200-400 mg daily; less
than or equal to 1 year: 100-
200 mg daily. Alternatively,
10-20 mg/kg body weight
daily in divided doses. Max:
Adult: 1.6 g daily
ADULT: Initial, 200 mg twice
daily for the first week, may
increase dosage by 200
mg/day at weekly intervals
until optimal response is
Carbamazepine N03AF01000 obtained. Maximum 1.6
247 A Epilepsy
200 mg CR Tablet T5001XX g/day. CHILD: usual
maximum dosage 1000
mg/day in children 12-15
years of age, 1200 mg/day
in patients above 15 years of
age
i) ADULT: 100 - 200 mg 1 - 3
times daily increased
gradually to usual dose of
0.8 - 1.2 g daily in divided
doses. CHILD: Up to 1 year:
100 - 200 mg daily; 1 - 5 yrs:
200 - 400 mg daily; 5 - 10
years: 400 - 600 mg daily; 10
- 15 years: 0.6 - 1 g daily ii)
The initial dosage of 200 to
Carbamazepine N03AF01000
248 B i) Epilepsy ii) Trigeminal neuralgia 400mg should be slowly
raised daily until freedom
from pain is achieved
(normally at 200mg 3 to 4
times daily). The dosage
should then be gradually
reduced to the lowest
possible maintenance level.
In elderly patients, an initial
dose of 100mg twice daily is
recommended.
50 / 371

ADULT: Initial, 200 mg twice
daily for the first week, may
increase dosage by 200
mg/day at weekly intervals
until optimal response is
Carbamazepine N03AF01000 obtained. Maximum 1.6
249 A Epilepsy
400 mg CR Tablet T5002XX g/day. CHILD: usual
maximum dosage 1000
mg/day in children 12-15
years of age, 1200 mg/day
in patients above 15 years of
age
Apply sparingly and rub into
Carbamide Contact irritant dermatitis, infantile
D02AE01000 affected area 2 - 3 times
250 (Urea) 10 % B eczemas, acute and chronic allergic
G1001XX daily and when required
Cream eczemas, icthyosis, hyperkeratotic
after cleansing skin
A single IV dose of 100mcg
(1ml) is adminitered by
bolus injection, slowly over
Prevention of uterine atony and 1minute, only when delivery
Carbetocin 100 H01BB03000 postpartum hemorrhage following of the infant has been
251 A*
mcg/ ml Injection P2001XX elective cesarean section under completed by caesarean
epidural or spinal anaesthesia section under epidural or
spinal anaesthesia, before
or after delivery of the
placenta.
ADULT: Initially, 10-60mg
daily in divided doses given
8 hourly. Maintenance: 5 to
Carbimazole 5 H03BB01000 20mg daily. CHILDREN > 6
252 B Hyperthyroidism
mg Tablet T1001XX years: Initially 15mg daily in
divided doses. CHILDREN 1-6
years: Initially 7.5mg daily in
divided doses
360 - 400 mg/m2 BSA, by IV
infusion over 15 mins to 1
hour on Day 1 every 4
weeks. Alternatively,
prescription may be based
on Area Under Curve (AUC)
Adult solid tumours, paediatric
Carboplatin 150 L01XA02000 calculations. CHILD: 500-600
253 A* tumours. Salvage therapy for
mg Injection P4001XX mg/m2 over 1 hour once
lymphoma
every 3 weeks. Salvage
regimes in lymphomas -
refer to specific protocols.
Starting dose in renal
impairment, please refer to
product insert.
51 / 371

360 - 400 mg/m2 BSA, by IV
infusion over 15 mins to 1
hour on Day 1 every 4
weeks. Alternatively,
prescription may be based
on Area Under Curve (AUC)
Adult solid tumours, paediatric
Carboplatin 450 L01XA02000 calculations. CHILD: 500-600
254 A* tumours. Salvage therapy for
mg Injection P4002XX mg/m2 over 1 hour once
lymphoma
every 3 weeks. Salvage
regimes in lymphomas -
refer to specific protocols.
Starting dose in renal
impairment, please refer to
product insert.
Initially 250 mcg deep IM
Carboprost
inj. The dose may be
Tromethamine G02AD04999 Postpartum haemorrhage
255 A* repeated at intervals of 15-
250 mcg P3001XX refractory to oxytocin
90 min if necessary. Max
Injection
total dose: 2 mg.
Dilute 20 ml to 1 L of Ringer
Cardioplegia
solution (cooled to 2-8 °C
solution
prior to use). Initial rapid
containing
instillation into aortic root at
Potassium For myocardial
B05XA16934 300 ml/m² body surface
256 Chloride, A* preservation(prevent myocardial
P3001XX area/min for 3 minutes.
Magnesium damage) during cardiac surgery
Should myocardial activity
chloride &
persist or recur instill at
Procaine HCl
300ml/m² body surface
Injection
area/min for 2 minutes
3.125 mg twice daily for 2
weeks, then 6.25 mg twice
daily for 2 weeks, then 12.5
Treatment of stable moderate to mg twice daily for 2 weeks
Carvedilol 25 mg C07AG02000
257 A/KK severe congestive cardiac failure in then 25 mg twice daily
Tablet T1002XX
addition to ACEI's and diuretics (titrated up to the highest
tolerated level). Max: <85
kg: 25 mg bid; >85 kg: 50 mg
bid.
3.125 mg twice daily for 2
weeks, then 6.25 mg twice
daily for 2 weeks, then 12.5
Treatment of stable moderate to mg twice daily for 2 weeks
Carvedilol 6.25 C07AG02000
258 A/KK severe congestive cardiac failure in then 25 mg twice daily
mg Tablet T1001XX
addition to ACEI's and diuretics (titrated up to the highest
tolerated level). Max: <85
kg: 25 mg bid; >85 kg: 50 mg
bid.
52 / 371

i) Confirmed systemic fungal
infection in patients who are
refractory or intolerant to other
fungal therapies. ii) For pediatric i) Invasive aspergillosis &
patient (12 month and older) for invasive candidiasis: ADULT:
the following indications : a) Initially, 70 mg infused over
Empirical therapy for presumed 1 hour followed by
fungal infections in febrile, subsequent doses of 50
Caspofungin neutropenic patients b) Treatment mg/day. Oesophageal
J02AX04122P
259 Acetate 50 mg A* of invasive candidiasis, including candidiasis: ADULT: 50 mg
4001XX
Injection candidemia and the following by slow IV infusion over
Candida infections ; intra- approximately 1 hour ii) For
abdominal abscesses, peritonitis all indications, a loading
and pleural space infections c) dose of 70mg/m2 on D1
Treatment of esophageal followed by maintenance
candidiasis d) Treatment of invasive dose of 50mg/m2 od.
Aspergillosis in patients who are
refractory to or intolerant of others
therapy (eg : Amphotericin B)
i) Invasive aspergillosis &
invasive candidiasis: ADULT:
For adult and pediatric patient (12 Initially, 70 mg infused over
month and older) for the following 1 hour followed by
indications: a) Treatment of subsequent doses of 50
invasive candidiasis, including mg/day. Oesophageal
candidemia and the following candidiasis: ADULT: 50 mg
Candida infections ; intra- by slow IV infusion over
Caspofungin
J02AX04122P abdominal abscesses, peritonitis approximately 1 hour daily
260 Acetate 70 mg A*
4002XX and pleural space infections b) ii) Child (12months to 17
Injection
Treatment of invasive Aspergillosis years) : For all indication) A
in patients who are refractory to or single 70mg/m2 loading
intolerant of others therapy (eg : dose (not to exceed an
Amphotericin B) c) Treatment of actual dose of 70mg) by
esophageal candidiasis (need to slow IV infusion over 1hour;
follow the current indications) followed by 50mg/m2 (not
to exceed an actual dose of
70mg)
Infections caused by susceptible CHILD :> 1 mth: 20 mg/kg
organisms including Staphylococcus daily in 3 divided doses,
Cefaclor 125 aureus and H. influenzae, increased to 40 mg/kg daily
J01DC04000F
261 mg/5 ml A treatment of sinusitis and if necessary, <1 yr: 62.5 mg
2101XX
Suspension infections involving the respiratory tid, 1-5 yr: 125 mg tid, >5 yr:
tract, skin and skin structure, bone 250 mg tid. Maximum: 1 g
and joint, and urinary tract daily
i) Adult pharyngitis, tonsillitis, i) 375 mg twice daily ii) 375
Cefaclor 375 mg J01DC04010T
262 A skin& soft tissue infections ii) mg or 500 mg twice daily iii)
MR Tablet 5001XX
Bronchitis iii) Pneumonia iv) Lower 750mg twice daily iv) 375mg
53 / 371

UTI twice daily or 500 mg once
daily
ADULT: 250 mg 3 times daily
for 10 days. For severe
Infections caused by susceptible infections, double the
organisms including Staphylococcus dosage. Maximum: 4 g daily.
aureus and H. influenzae, CHILD :> 1 mth: 20 mg/kg
Cefaclor 500 mg J01DC04000C
263 A treatment of sinusitis and daily in 3 divided doses,
Capsule 1002XX
infections involving the respiratory increased to 40 mg/kg daily
tract, skin and skin structure, bone if necessary, <1 yr: 62.5 mg
and joint, and urinary tract tid, 1-5 yr: 125 mg tid, >5 yr:
250 mg tid. Maximum: 1 g
daily
ADULT: Uncomplicated
infections: 500 - 1000 mg 2 -
3 times daily. Moderately
Infection caused by cefazolin-
severe and severe
sensitive microorganism, infection
infections: 500 - 1000 mg 3 -
of the respiratory tract, urogenital
Cefazolin Sodium J01DB04520P 4 times daily. Severe life-
264 A tract, skin and soft tissue, bile duct,
1 g Injection 3001XX threatening infections: 1 -
bones and joint, endocarditis,
1.5 g 4 times daily. Rarely,
systemic septic infection, peri-
dose up to 12 g daily.
operative/ surgical prophylaxis
CHILDREN >1 month: 25-
50mg/kg/day in 3-4 divided
dose
ADULT: 1 - 2 g twice daily for
Febrile neutropenia, septicaemia, most infections. For severe
lower respiratory tract infection, infections including febrile
Cefepime 1 g J01DE01110P
265 A* urinary tract infection, skin and skin neutropenia: 2 g 3 times
Injection 4002XX
structure infections, gynaecologic daily. CHILD:2 mth - 16 yr:
and intra-abdominal infections ≤40 kg: 50 mg/kg every 8-12
hr for 7-10 days
ADULT: 1 - 2 g twice daily for
Febrile neutropenia, septicaemia, most infections. For severe
lower respiratory tract infection, infections including febrile
Cefepime 500 mg J01DE01110P
266 A* urinary tract infection, skin and skin neutropenia: 2 g 3 times
Injection 4001XX
structure infections, gynaecologic daily. CHILD: 2 mth - 16 yr:
and intra-abdominal infections ≤40 kg: 50 mg/kg every 8-12
hr for 7-10 days
ADULT: 1 - 2 g twice daily IM
or IV. By IV, adult dose may
be doubled. Maximum: 16 g
Cefoperazone daily in divided doses. CHILD
J01DD12520 Infections due to gram-negative
267 Sodium 1 g A & INFANT: 50 - 200
P4002XX bacteria
Injection mg/kg/day in 2 - 4 divided
doses. NEONATE less than 8
days: 50 - 200 mg/kg/day 12
hourly
54 / 371

268 Sodium 2 g A & INFANT: 50 - 200
P4003XX bacteria
hourly
ADULT: 1 - 2 g twice daily. In
severe or refractory
infections the daily dosage
of sulbactam/cefoperazone
Cefoperazone i) Treatment of infections due to
may be increased up to 8g
Sodium 500 mg multi-drug resistance pathogens
J01DD62000 (4g cefopreazone activity)
269 & Sulbactam A producing B-lactamase ii)
P4001XX CHILD: 40 - 80 mg/kg/day in
Sodium 500 mg Treatment of infections caused by
2 to 4 equally divided doses;
Injection Acinetobacter species
in serious or refractory
infections, may increase to
160mg/kg/d in 2 - 4 equally
divided doses.
270 Sodium 500 mg A & INFANT: 50 - 200
P4001XX bacteria
hourly
ADULT: 1 g 12 hourly (up to
Cefotaxime 1 g J01DD01520 Infections due to gram-negative 12 g/day in severe cases).
271 A
Injection P4002XX bacteria CHILD: 50 - 180 mg/kg/day
in 4 - 6 divided doses
ADULT: 1 g 12 hourly (up to
Cefotaxime 500 J01DD01520 Infections due to gram-negative 12 g/day in severe cases).
272 A
mg Injection P4001XX bacteria CHILD: 50 - 180 mg/kg/day
600mg administered every
12 hours by intravenous
Ceftaroline Treatment of complicated skin and
infusion over 60 minutes for
Fosamil 600mg soft tissue infections (cSSTI) in
5-14 days. Dose adjustment
Powder for J01D102000P adults Restriction: Restricted for
273 A* in renal impairment: - CrCl >
concentrate for 4001XX only complicated SSTI in patients
30 to ≤50 ml/min : 400mg
solution for who are unable to tolerate or not
every 12 hours - CrCl <
infusion responding to vancomycin.
30ml/min is not
recommended
55 / 371

ADULT: 1 g 8 hourly or 2 g
12 hourly. In severe
Ceftazidime 1 g J01DD02520 Severe gram negative bacterial
274 A infections: 2 g 8 hourly.
Injection P4003XX infections
CHILD: 25 - 150 mg/kg/day
Ceftazidime 2 g J01DD02520 Severe gram negative bacterial
Injection P4004XX infections
Ceftazidime 250 J01DD02520 Severe gram negative bacterial
mg Injection P4001XX infections
Ceftazidime 500 J01DD02520 Severe gram negative bacterial
mg Injection P4002XX infections
i) 250 mg by deep IM
injection ii) single IM
Ceftriaxone 0.25 J01DD04520
278 A/KK i) Gonorrhoea ii) Chancroid injection 250 mg only. For
g Injection P4001XX
severe infection up to 100
mg/kg/day
ADULT: 1 - 2 g once daily.
Severe infection: 4 g daily at
12 hour intervals. INFANT &
CHILD, 3 weeks - 12 years:
Ceftriaxone 0.5 g J01DD04520 Infections caused by susceptible
279 A daily. CHILD with body
Injection P4002XX organisms
weight 50 kg or more: adult
dose. NEONATE up to 2
weeks: 20 - 50 mg/kg body
weight daily, not to exceed
50 mg/kg
ADULT: 1 - 2 g once daily.
Severe infection: 4 g daily at
12 hour intervals. INFANT &
CHILD, 3 weeks - 12 years:
Ceftriaxone 1g J01DD04520 Infections caused by susceptible
280 A daily. CHILD with body
Injection P4003XX organisms
weight 50 kg or more: adult
dose. NEONATE up to 2
weeks: 20 - 50 mg/kg body
weight daily, not to exceed
50 mg/kg
56 / 371

ADULT: 250 mg twice daily;
Upper and lower respiratory tract,
Cefuroxime UTI: 125 mg twice daily.
J01DC02233T genito-urinary tract, skin & soft
281 Axetil 125 mg A/KK CHILD:30 mg/kg/day in 2
1001XX tissue and urinary tract infections
Tablet divided doses, up to 500 mg
(UTI)
daily
Cefuroxime
J01DC02233F Infections caused by susceptible 30 mg/kg/day in 2 divided
282 Axetil 125 mg/5 A
2101XX organisms doses, up to 500 mg daily.
ml Suspension
ADULT: 250 mg twice daily;
Upper and lower respiratory tract,
Cefuroxime UTI: 125 mg twice daily.
J01DC02233T genito-urinary tract, skin & soft
283 Axetil 250 mg A/KK CHILD:30 mg/kg/day in 2
1002XX tissue and urinary tract infections
Tablet divided doses, up to 500 mg
(UTI)
daily
ADULT: 750 mg every 6 - 8
hours as IM or IV. Severe
infections: 1.5 g every 6 - 8
Cefuroxime
J01DC02520P Infections caused by susceptible hours as IV. CHILD: 30 - 100
284 Sodium 1.5 g A
4003XX organisms, surgical prophylaxis mg/kg/day in 3 - 4 divided
Injection
doses or 2-3 divided doses
in neonates. Surgical
prophylaxis: 1.5 g IV
Cefuroxime
285 Sodium 250 mg A
Injection
Cefuroxime
286 Sodium 750 mg A
Injection
57 / 371

i) ADULTS: 200 mg once
daily. May increase to 200
mg bid, if necessary. CHILD
not recommended ii) 100mg
twice daily, increased if
necessary to 200 mg 2 times
daily; CHILD not
recommended iii) 400mg as
a single dose on first day
i) Osteoarthritis ii) Rheumatoid followed by 200mg once
Celecoxib 200 mg M01AH0100
287 A Arthritis iii) Acute pain iv) daily on subsequent days iv)
Capsule 0C1001XX
Ankylosing Spondylitis Initial, 200 mg once daily or
100 mg twice daily; if no
effect after 6 weeks, may
increase to max. 400 mg
daily in 1-2 divided doses. If
no response following 2
weeks of treatment with
400 mg/day, consider
discontinuation and
alternative treatment
i) ADULTS: 200 mg once
daily. CHILD not
recommended ii) 100 mg
twice daily, increased if
necessary to 200 mg 2 times
daily; CHILD not
recommended iii) 400 mg as
a single dose on first day
followed by 200 mg once
i) Osteoarthritis ii) Rheumatoid
Celecoxib 400 mg M01AH0100 daily on subsequent days iv)
288 A* Arthritis iii) Acute pain iv)
Capsule 0C1002XX Initial, 200 mg once daily or
Ankylosing Spondylitis
100 mg twice daily; if no
effect after 6 weeks, may
increase to max. 400 mg
daily in 1-2 divided doses. If
no response following 2
weeks of treatment with
400 mg/day, consider
discontinuation and
alternative treatment
Cephalexin Respiratory tract infections, ear,
Monohydrate J01DB01010F nose and throat infections, urinary
289 B every 6 hourly. Maximum: 4
125 mg/5 ml 2101XX tract infections, obstetric and
g daily
Syrup gynaecologic infections
58 / 371

i) 250 mg 6 hourly ii) 250 -
i) Respiratory tract infection, 500 mg 6 hourly iii) 1 - 1.5 g
Cephalexin urinary tract infection ii) 3 times daily or 4 times
J01DB01010C
290 Monohydrate B Complicated, recurrent or chronic daily. Maximum: 6 g/day
1001XX
250 mg Capsule infections, bronchitis iii) Child: 25-100 mg/kg daily in
Pneumonia divided doses. Max: 4 g
daily.
i) 250 mg 6 hourly ii) 250 -
J01DB01010T
1001XX
250 mg Tablet infections, bronchitis iii) Child: 25-100 mg/kg daily in
daily.
i) Respiratory tract infection,
i) 250 mg 6 hourly ii) 250 -
Cephalexin urinary tract infection ii)
J01DB01010C 500 mg 6 hourly iii) 1 - 1.5 g
292 Monohydrate B Complicated, recurrent or chronic
1002XX 3 times daily or 4 times
500 mg Capsule infections, bronchitis iii)
daily. Maximum: 6 g/day
Pneumonia
i) 250 mg 6 hourly ii) 250 -
J01DB01010T
1002XX
500 mg Tablet infections, bronchitis iii) Child: 25-100 mg/kg daily in
daily.
Urticaria, allergic dermatoses years: 10 mg daily or 5 mg
Cetirizine HCl 10 R06AE07110
294 A/KK (insect bites, atopic eczema), twice daily. Child 2-6 years:
mg Tablet T1001XX
perennial rhinitis, allergic rhinitis 5 mg once daily or 2.5 mg
twice daily
Cetrimide 1-2% D08AJ04000L
295 C+ As shampoo and cleansing agent Apply to affected area
Lotion. 6001XX
Given by SC 0.25 mg/day,
Prevention of premature ovulation given either in the morning
in patients undergoing a controlled beginning on the day 5 or 6
Cetrorelix 0.25 H01CC02122
296 A* ovarian stimulation, followed by of ovarian stimulation or in
oocyte pick-up and assisted the evening beginning on
reproductive techniques day 5, and continued until
ovulation induction
59 / 371

For neo-adjuvant treatment of
KRAS wild type metastatic
colorectal cancer with the aim of Administered once a week.
liver resection with the following The very first dose is 400mg
conditions: i) The primary cetuximab per m2 body
colorectal tumour has been surface area with a
resected or is potentially resected. recommended infusion
Cetuximab 5 ii)The metastatic disease is period of 120 minutes. All
L01XC06000P
297 mg/ml Solution A* confined to the liver and is subsequent weekly doses
5002XX
for Infusion unresectable iii) The patient is fit are 250mg per m2 body
enough to undergo surgery to surface area each with a
resect the primary colorectal recommended infusion
tumour and to undergo liver period of 60 minutes. The
surgery if the metastases become maximum infusion rate
resectable after treatment with must not exceed 10mg/min.
cetuximab. iv)The treatment is
limited to 16 weeks
i) ADULT 0.5-1 g given 3-4
times daily. CHILD half adult
dose. ii) Need to be
dissolved in liquid (slurry
consistency). ADULT and
CHILD over 12 years: initial
30-100 g or 1-2 g/kg; repeat
initial dose as soon as
possible or 20-50 g every 2-6
i) Diarrhoea and food poisoning ii)
Charcoal, hours. CHILD over 1-12
A07BA01000 Reduce absorption of drugs, plant,
298 Activated 250 mg C years, 25-50 g or 1-2 g/kg;
T1001XX inorganic poison and chemicals in
Tablet may repeat half the initial
poisoning cases
dose every 2-6 hour as
needed. CHILD to 1 year of
age, 1 g/kg; may repeat half
the initial dose every 2-6
hours as needed. For
maximum efficacy
administer within 1 hour
after ingestion of toxic
compound
ADULT: Acute poisoning: 50
- 100g in suspension. Severe
Charcoal,
A07BA01000 Emergency treatment of acute oral poisoning: 50 - 100g as an
299 Activated 50 g A
F1001XX poisoning and drug overdose initial dose followed by 20g
Granules
every 4 - 6 hours. CHILDREN:
1g/kg/dose
60 / 371

ADULT: 0.5 - 1 g (max 2 g)
with plenty of water at
bedtime. CHILD: Neonate:
30-50 mg/kg; up to 100
mg/kg may be used with
respiratory monitoring. 1
Chloral Hydrate
N05CC01010 mth-12 yr: 30-50 mg/kg
300 200 mg/5 ml B Preoperative sedation
L2101XX (max: 1 g); up to 100 mg/kg
Mixture
(max: 2 g) may be used; 12-
18 yr: 1-2 g. Doses to be
taken 45-60 minutes before
procedure. May be given
rectally if oral route is not
available.
General: Initial: 0.1 -0.2
mg/kg body weight daily for
4 - 8 weeks maintanance :
given either by reduced
daily dosage or intermittent
course of treatment.
Low grade lymphoma, chronic Chronic Lymphocytic
Chlorambucil 2 L01AA02000
301 A lymphocytic leukaemia. Ovarian Leukaemia: initial :
mg Tablet T1001XX
cancer 0.15mg/kg/day untill total
leukocyte count has fallen
to 10,000peruL, then
resumed treatment untill 4
weeks after the end of the
first course then continued
at a dosage 0.1mg/kg/day.
Instill 1 drop of a 0.5%
solution every 2 hr. Increase
Chloramphenicol S01AA01000 Broad spectrum antibiotic in dosage interval upon
302 C
0.5% Eye Drops D2001XX superficial eye infections improvement. To continue
treatment for at least 48 hr
after complete healing
ADULT and CHILD : Apply to
Treatment of ocular infections
the conjunctiva, a thin strip
Chloramphenicol S01AA01000 involving the conjunctiva and/or
303 C (approximately 1 cm) of
1% Eye Ointment G5101XX cornea caused by chloramphenicol
ointment every 3 hours or
susceptible organisms
more frequently
CHILD: 25 - 50 mg/kg/day in
4 divided doses. Severe
infections, premature& full-
Chloramphenicol Typhoid fever, salmonella
J01BA01126L term infants less than 2
304 125 mg/5 ml B infections, meningitis, cholera,
8001XX weeks: 25mg/kg/day in
Suspension anaerobic and rickettsial infections
divided doses. Full-term
infants more than 2 weeks:
up to 50mg/kg/day in
61 / 371

divided doses

or 50 mg/kg/day in 4 divided
Treatment of typhoid, paratyphoid
Chloramphenicol J01BA01126C doses. Maximum dose: 4
305 B fevers, bronchopneumonia and
250 mg Capsule 1001XX g/day. CHILD: 25 - 100
enteric infection
mg/kg/day in 4 divided
doses
Apply 2 - 3 drops into the
Chloramphenicol S02AA01000 Acute otitis media, otitis externa
306 C ear 2 - 3 times daily. Not to
5% w/v Ear Drops D1001XX with perforation
be used for long term
Adult:50 to 100 mg/kg/day
in 4 divided doses.
Premature and full-term
Chloramphenicol Treatment of typhoid, paratyphoid neonates: 25 mg/kg/day in 4
J01BA01520P
307 Sodium Succinate B fevers, bronchopneumonia and divided doses. Full-term
4001XX
1 g Injection enteric infection infants >2 wk: 50 mg/kg/day
in 4 divided doses. Children:
50-100 mg/kg/day in 4
divided doses
Chlorhexidine
R02AA05137 Rinse mouth with 10 ml for
308 Gluconate 0.2 % C As a gargle
M2001XX about 1 minute twice daily
Mouthwash
Skin Preparation: Use
Chlorhexidine Gluconate 2%
in Isopropyl Alcohol 70%
Chlorhexidine
and allow to dry. Catheter
Gluconate 2% in D08AC52137 Use as disinfectant in central
309 C access: Apply to catheter
Alcohol 70% L9902XX venous catheter care bundle
ports or hubs prior to
Solution
accessing the line for
administering fluids or
injections
Surgical hand disinfection:
Apply 5ml to clean hands
and forearms for 1 min.
Rinse and repeat with
Chlorhexidine another 5ml for a further 2
D08AC02137 Surgical hand scrub/disinfection,
310 Gluconate 4% C+ minutes, and then rinse and
M9901XX pre-op skin preparation
Scrub dry. General skin
disinfection: Apply
appropriate quantity to wet
area and scrub for 1 min.
Rinse thoroughly & dry
Chlorhexidine i) Preoperative skin disinfection ii)
D08AC02137 i) & iii) 1 : 10 in 70 % Alcohol
311 Gluconate 5% C+ Wounds or burns iii) Emergency
L9901XX ii) 1 : 100
Solution disinfection of instruments
62 / 371

Pre-op surgical hand
disinfection: Spread 5ml
thoroughly over both hands
and forearms, rubbing
vigorously. When dry apply
a further 5ml and repeat
Chlorhexidine
procedure. Antiseptic hand
Gluconate 5%
disinfection on the ward:
Solution 1:10 in D08AC52137 To be used undiluted for hand and
312 C+ Spread 3ml thoroughly over
70% alcohol with L9901XX skin disinfections
the hands and wrist rubbing
lanolin as
vigorously until dry.
emollient
Disinfection of patient's
skin: Prior to surgery, apply
to a sterile swab and rub
thoroughly over the
operation site for a
minimum of 2 mins
Chlorinated Lime V07AV00000
313 C Antiseptic and disinfectants Not applicable
Powder F9901XX
Chlorinated Lime
Apply to affected areas
Solution & D08A000999
314 C Wound or ulcer undiluted as a cleansing
Buffered Acetate G9901XX
agent
Solution
ADULT 600 mg base stat,
300 mg 6 - 8 hours later and
a further 300 mg on each of
Chloroquine
2 following days. CHILD 3 - 4
Phosphate 250
P01BA01162 years: 150 mg base stat, 75
315 mg Tablet (150 C Treatment of malaria - acute attack
T1001XX mg 6 hours later, then 75
mg Chloroquine
mg daily for 2 days. CHILD 5
base)
- 8 years : 300 mg stat, 150
mg 6 hours later, then 150
mg daily for 2 days
10 - 20 mg IM or SC,
Chlorpheniramin repeated if required. Not to
R06AB04253
316 e Maleate 10 B Allergic conditions exceed 40 mg in 24 hours.
P3001XX
mg/ml Injection 10 - 20 mg over 1 minute by
slow IV
CHILD 1 - 2 years : 1 mg
twice daily, 2 - 5 years : 1
Chlorpheniramin Symptomatic treatment of allergic mg every 4 - 6 hours
R06AB04253
317 e Maleate 2 C conditions responsive to (maximum 6 mg daily), 6 -
L9001XX
mg/5 ml Syrup antihistamine 12 years : 2 mg every 4 - 6
hours (maximum 12 mg
daily)
63 / 371

hours. Maximum 24 mg
daily. CHILD 1 - 2 years : 1
Chlorpheniramin Symptomatic treatment of allergic mg twice daily, 2 - 5 years :
R06AB04253
318 e Maleate 4 mg C conditions responsive to 1 mg every 4 - 6 hours
T1001XX
Tablet antihistamines (maximum 6 mg daily), 6 -
12 years : 2 mg every 4 - 6
hours (maximum 12 mg
daily)
ADULT: Initial dose - 25 mg 3
times daily according to
response up to 1 g daily.
PAEDIATRIC: Up to 5 years:
Chlorpromazine
N05AA01110 0.5 mg/kg body weight
319 HCl 100 mg B Psychosis mania and agitation
T1002XX every 4 - 6 hours (Maximum
Tablet
40 mg daily). CHILD 6 - 12
years: A third to half adult
dose (Maximum 75 mg
daily)
ADULT: Initial dose - 25 mg 3
times daily according to
response up to 1 g daily.
PAEDIATRIC: Up to 5 years:
Chlorpromazine N05AA01110 0.5 mg/kg body weight
320 B Psychosis mania and agitation
HCl 25 mg Tablet T1001XX every 4 - 6 hours (Maximum
40 mg daily). CHILD 6 - 12
years: A third to half adult
dose (Maximum 75 mg
daily)
Apply thin strip
Chlortetracycline S01AA02000 Eye infections requiring a broad (approximately 1 cm) to the
321 B
1% Eye Ointment G5101XX spectrum antibiotic conjuctiva 2 to 4 hourly or
more frequently.
Apply directly to affected
Chlortetracycline D06AA02000
322 B Bacterial skin infections area twice daily as required
1-3 % Cream G1001XX
for 1 - 2 weeks
Prophylactic ADULT: First
dose of 0.5 ml SC/IM
followed after 1 - 4 weeks
by a second dose of 1 ml.
CHILD: 1 - 5 years: 0.1 ml
J07AE01000P (1st dose), 0.3 ml (2nd
323 Cholera Vaccine B Immunisation of cholera
3001XX dose). CHILD; 5 - 10 years:
0.3 ml (1st dose), 0.5ml (2nd
dose). Booster: For optimum
long-term protection, a
booster dose is
recommended for adults
64 / 371

after 2 years. Children 2-6
years should receive a
booster dose after 6
months.
i) Hypercholesterolemia ii) Familial

Hypercholesterolemia:
hypercholesterolemia -
Adjunct: initial, 4 g orally 1-2
heterozygous iii) Generalized
Cholestyramine C10AC01000 times daily, maintenance, 8
324 A atherosclerosis iv) Diarrhoea due to
Resin 4 G M4001XX to 16 g in divided doses,
bile acid malabsorption v) Pruritus
max 24 g daily CHILD: 50 -
of skin associated with partial
150 mg/ kg 6 - 8 hourly oral
biliary obstruction
Choline Salicylate
For relief of the pain and
8.7%,
N02BA03900 discomfort in mouth ulcers and
325 Cetylkonium B Apply to area 4 times daily
G3001XX sores, infant teething and denture
Chloride 0.01%
irritation
Dental Gel
i)Women undergoing
Choriogonadotro 250 mcg 24-48 hour after
superovulation prior to assisted
pin Alfa 250 the last administration of an
G03GA01000 reproductive techniques such as in-
326 mcg/0.5 ml A* FSH or hMG preparation,
P5001XX vitro fertilization (IVF)
Injection in when optimal stimulation of
ii)Anovulatory or oligo-ovulatory
Prefilled Syringe follicular growth is achieved.
women
i) & ii)Induction of ovulation:
5000 - 10,000 units one day
Chorionic i)Treatment of infertile women to following last dose of
Gonadotrophin G03GA01000 induce ovulation ii) As a luteal menotropin. Up to 3 repeat
327 A*
Human (HCG) P4001XX support in controlled ovarian injections of 5000 units each
5000 IU Injection hyperstimulation cycles may be given within the
following 9 days to prevent
insufficiency corpus luteum
For adults and adolescents
over 12 years of age with
Prophylactic treatment of asthma
mild to moderate asthma is
Ciclesonide R03BA08000 in adults, adolescents and children
328 A* 160 to 640mcg per day:
160mcg Inhaler A2101XX over 6 years (follow current
severe asthma dose may be
indication) Not meant for 6 yo)
increased to 1280mcg per
day.
65 / 371

i & ii) Initially 12.5 - 15
mg/kg/day, beginning on
the day before transplant.
Maintenance approx 12.5
mg/kg/day for 3 - 6 months
before being tapered off to
zero by 1 year of
transplantation iii) 3
Only for: i) Patients in whom donor
doses for first 6 weeks. May
specific transplantation cannot be
increased gradually to
carried out and in young children to
maximum 5 mg/kg.
minimise side-effects of steroids ii)
Treatment withdrawn if no
Follow-up cases of bone marrow
response after 3 months iv)
transplant iii) Patients with severe
ADULT: 5 mg/kg/day in 2
rheumatoid arthritis not
divided doses. CHILD: 6
responding to other second line
Ciclosporin 100 L04AD01000 mg/kg/day in 2 divided
329 A* drugs iv) Patients with idiopathic
mg Capsule C1002XX doses. Patients with
nephrotic syndrome who are
permitted levels of kidney
steroid toxic or poor response to
failure, the starting dose
cyclophosphamide v) Severe
must not more than 2.5
aplastic anemia, pure red cell
mg/kg/day v) 12 mg/kg/day.
aplasia vi) Cases of recalcitrant
vi) 2.5 mg/kg/day in 2
psoriasis and atopic eczema vii)
divided doses increasing if
Treatment of chronic ocular
there is no improvement
inflammatory disorders/uveitis
after 4 weeks by 0.5 -1
mg/kg/month up to
maximum 5 mg/kg/day vii) 5
doses, may increase to 7
mg/kg/day in resistant
cases. Maintenance: Less
than 5 mg/kg/day especially
during remission
66 / 371

zero by 1 year of
Only for : i) Patients in whom donor
maximum 5 mg/kg.
Ciclosporin 100 Rheumatoid arthritis not
L04AD01000 response after 3 months iv)
330 mg/ml Drink A* responding to other second line
L5002XX ADULT: 5 mg/kg/day in 2
Solution drugs iv) Patients with idiopathic
doses. Patients with
aplastic anaemia, pure red cell
psoriasis and atopic eczema
mg/kg/day v) 12 mg/kg/day
mg/kg/month up to
maximum 5 mg/kg/day
67 / 371

zero by 1 year of
Only for: i) Patients in whom donor
maximum 5 mg/kg.
response after 3 months iv)
ADULT: 5 mg/kg/day in 2
rheumatoid arthritis not
responding to other second line
Ciclosporin 25 L04AD01000 mg/kg/day in 2 divided
331 A* drugs iv) Patients with idiopathic
mg Capsule C1001XX doses. Patients with
aplastic anemia, pure red cell
mg/kg/day v) 12 mg/kg/day
psoriasis and atopic eczema vii)
Treatment of chronic ocular
inflammatory disorders/uveitis
mg/kg/month up to
maximum 5 mg/kg/day vii) 5
doses, may increase to 7
mg/kg/day in resistant
cases. Maintenance: Less
than 5 mg/kg/day especially
during remission
i) 3 - 5 mg/kg/day until
tolerate orally ii) 2 - 3
Ciclosporin 50 L04AD01000 i) Post bone marrow transplant ii)
332 A* mg/kg/day for recipients
mg/ml Injection P3001XX Solid organ transplant
who are unable to take
orally
Improvement of the maximal and
pain-free walking distances in
Cilostazol 100 mg B01AC00000 patients with intermittent
333 A* 100 mg twice daily
Tablet T1002XX claudication, who do not have rest
pain and who do not have evidence
of peripheral tissue necrosis.
68 / 371

Cimicifuga
Traditionally used for the relief of
Racemosa HG03WA500
334 A hot flushes, sweating, restlessness 20 mg twice daily
Rhizome Extract 1T1001XX
associated with menopause
20 mg Tablet
Cinnarizine 25 N07CA02000
335 B Vestibular disorders One tablet 3 times daily
mg Tablet T1001XX
ADULT: the dosage range is
100-400mg twice daily
Gonorrhoea: 100mg single
dose Upper and Lower
Urinary Tract Infection:
Ciprofloxacin 100 100mg bd Upper and Lower
J01MA02125 Treatment of infections due to
336 mg/50 ml A Respiratory Tract Infection:
P3001XX susceptible bacterial strains
Injection 200mg bd-400mg twice
daily Cystic Fibrosis with
psuedomonal Lower RTI:
400mg bd Others: 200-
400mg bd inhalation
Anthrax: 400mg bd
Suggest to rephrase ADULT:
the dosage range is 100-
400mg twice daily
Gonorrhoea: 100mg single
dose Upper and Lower
Urinary Tract Infection:
Ciprofloxacin 200
J01MA02125 Treatment of infections due to 100mg bd Upper and Lower
337 mg/100 ml A
P3002XX susceptible bacterial strains Respiratory Tract Infection:
Injection
200mg bd-400mg twice
daily Cystic Fibrosis with
psuedomonal Lower RTI:
400mg bd Others: 200-
400mg bd inhalation
Anthrax: 400mg bd
ADULT: 125-750 mg twice
Ciprofloxacin 250 J01MA02110 Treatment of infections due to
338 A daily. Acute gonorrhoea: a
mg Tablet T1001XX susceptible bacterial strains
single dose of 250 mg
ADULT: 125-750 mg twice
Ciprofloxacin 500 J01MA02110 Treatment of infections due to
339 A daily. Acute gonorrhoea: a
mg Tablet T1002XX susceptible bacterial strains
single dose of 250 mg
69 / 371

i) 2 drops every 15 minutes
for the first 6 hours, then 2
drops every 30 minutes for
the rest of the first day.
Second day: 2 drops every
hour. Subsequent days (3rd
Treatment of bacterial infections - 14th day): 2 drops every 4
Ciprofloxacin HCl
S01AX13110 caused by susceptible strains in i) hours. Treatment may be
340 0.3% Ophthalmic A*
D2001XX corneal ulcers ii) bacterial continued after 14 days if
Solution
conjunctivitis corneal re-epithelialization
has not occurred ii) 1 - 2
drops every 2 hours into the
conjunctival sac while
awake for 2 days and 1-2
drops every 4 hours while
awake for the next 5 days
Administered as bolus
intravenous injection. May
As an adjunct to general be administered as infusion
anaesthesia to facilitate in ICU patients at a rate of
Cisatracurium endotracheal intubation, to provide 3mcg/kg/min. Adult dose: a)
M03AC11197
341 Besylate 2 mg/ml A* skeletal muscle relaxation during Induction: 0.15mg/kg over
P3001XX
Injection surgery and to facilitate mechanical 5-10 secs, b) Maintenance:
ventilation. Restricted to patients 0.03 mg/kg. Children 2-12
with lung problem such as asthma. years: a) Induction: 0.1
mg/kg over 5-10 secs, b)
Maintenance: 0.02 mg/kg
Germ cell tumours: 20
mg/m2 daily for 5 days
every 3 weeks for 3 - 4
courses. Ovarian tumours:
75 mg/m2 once every 3
weeks as part of
combination therapy with
paclitaxel or 50-60mg/m2 IV
once every 3 weeks as a
Germ cell tumours, ovarian single agent. Baseline
Cisplatin 10 mg L01XA01000
342 A tumours, adult solid tumours, creatinine clearance,
Injection P3001XX
lymphomas pretreatment hydration and
forced diuresis are
mandatory. CHILD:
100mg/m2 over 6 hours
once every 3 weeks.
Lymphomas: Refer to
protocols CHILD: 100mg/m2
over 6 hours once every 3
weeks. Lymphomas: Refer
to protocols
70 / 371

Germ cell tumours: 20
mg/m2 daily for 5 days
every 3 weeks for 3 - 4
courses. Ovarian tumours:
75 mg/m2 once every 3
weeks as part of
combination therapy or 100
mg/m2 IV once every 3
weeks as a single agent.
Germ cell tumours, ovarian
Cisplatin 50 mg L01XA01000 Baseline creatinine
343 A tumours, adult solid tumours,
Injection P3002XX clearance, pretreatment
lymphomas
hydration and forced
diuresis are mandatory.
CHILD: 100mg/m2 over 6
hours once every 3 weeks.
Lymphomas: Refer to
protocols CHILD: 100mg/m2
over 6 hours once every 3
weeks. Lymphomas: Refer
to protocols
CHILD: 8 - 12 years: 30 - 40
kg 10 mL, 4 - 8 years: 20 - 29
kg 7.5 mL, 2 - 4 years: 12 -
Clarithromycin Treatment of complicated
J01FA09000F 19 kg 5 mL, 1 - 2 years: 8 -
344 125 mg/5 ml A* respiratory tract infections not
1001XX 11 kg 2.5 mL, less than 8 kg:
Granules responding to standard macrolides
7.5 mg/kg. To be given twice
daily. Maximum dose:
1g/day
Only for i) treatment of
i) 250 - 500 mg twice daily.
complicated respiratory tract
Clarithromycin J01FA09000T Up to 6 - 14 days ii) 500 mg
345 A* infection not responding to
250 mg Tablet 1001XX twice daily with omeprazole
standard macrolides ii) eradication
& amoxicillin. Up to 2 weeks
of Helicobacter pylori infection
Susceptible infections Adult:
500 mg bid for 2-5 days.
Dose to be infused over 60
minutes in a 0.2% solution;
revert to oral therapy
Only for treatment of complicated whenever possible. Child: 1
Clarithromycin J01FA09000P
346 A* respiratory tract infection not mth-12 yr: 7.5 mg/kg every
500 mg Injection 3001XX
responding to standard macrolides 12 hr. Dose to be given via
infusion into proximal vein.
Dosage Recommendation
CrCl (ml/min)<30 : Half the
dosage or double dosing
interval
71 / 371

i) ADULT: 150 - 300 mg
every 6 hours; up to 450 mg
every 6 hours in severe
i) Skin and soft tissue infections, infections; Max: 1.8g/day
bone& joint infections ii) Cerebral CHILD: 3 - 6 mg/kg every 6
toxoplasmosis iii) Children less than hours. Children weighing
Clindamycin HCl J01FF01110C
347 A* 8 years old: Treatment and <10 kg should receive at
300 mg Capsule 1001XX
prophylaxis of malaria in least 37.5 mg every 8 hr. ii)
combination with quinine, as an 600 mg 6 hourly for 6 weeks
alternative to doxycycline iii) 10mg/kg twice a day, in
combination with quinine.
The combination to be given
for 7 days
i) ADULT: 0.6 - 2.7 g daily (in
2 - 4 divided doses); up to
4.8 g daily; CHILD over 1
month, 20 - 40 mg/kg/day
Clindamycin i) Skin and soft tissue infections,
J01FF01162P or 350 mg/m2/day in 3 - 4
348 Phosphate 150 A* bone & joint infections ii) Cerebral
3001XX divided doses ii) 1200 mg
mg/ml Injection toxoplasmosis
every 6 hours for 3 weeks
followed by 300 mg orally
every 6 hours for another 3
weeks
The initial dose in adults and
adolescents >15 yr should
be low (5 to15mg daily), if
necessary, increased
gradually to a maximum
As adjunctive therapy in patients daily dose of about 80mg.
Clobazam 10 mg N05BA09000 with epilepsy not adequately Doses of up to 30mg may be
349 A*
tablet T1001XX stabilised with their basic taken as a single dose in the
medication. evening. The initial dose in
children from 3 to15 yr is
normally 5mg. A
maintenance dose of 0.3 to
1.0mg/kg body weight daily
is usually sufficient.
Apply sparingly once or
twice daily, changing to
Short term treatment only of more
lower potency therapy as
resistant dermatoses eg. psoriasis,
soon as condition is
Clobetasol recalcitrant eczemas, lichen planus,
D07AD01133 controlled. For mild to
350 Propionate A discoid lupus erythematosus and
G1001XX moderate use maximum for
0.05% Cream other conditions which do not
2 weeks. For moderate to
respond satisfactorily to less potent
severe maximum duration 4
steroids
consecutive weeks. Max: 50
g/week
72 / 371

Apply sparingly once or
twice daily, changing to
Short term treatment only of more
lower potency therapy as
resistant dermatoses eg. psoriasis,
soon as condition is
Clobetasol recalcitrant eczemas, lichen planus,
D07AD01133 controlled. For mild to
351 Propionate A discoid lupus erythematosus and
G5001XX moderate use maximum for
0.05% Ointment other conditions which do not
2 weeks. For moderate to
respond satisfactorily to less potent
severe maximum duration 4
steroids
consecutive weeks. Max:50
g/week
Clobetasone Apply up to four times daily
D07AB01255
352 Butyrate 0.05% A/KK Eczema and dermatitis of all types until condition improves,
G1001XX
Cream then reduce frequency
Clobetasone Apply up to four times daily
D07AB01255
353 Butyrate 0.05% A Eczema and dermatitis of all types until condition improves,
G5001XX
Ointment then reduce frequency
Clodronate 800 M05BA02011 Treatment of hypercalcaemia due 2 tablets in single or two
354 A*
mg Tablet T1011XX to malignancy divided doses
i) ADULT: 100 mg each other
day or 50 mg daily with
100mg Dapsone & 300mg
once a month with 600mg
rifampicin under
supervision. Maximum: 200
mg/day. CHILD: 10-14 yr:
i) Previously untreated leprosy 50mg clofazimine on
Clofazimine 100 J04BA01000C patients ii) Leprosy patients alternate days with 50mg
355 B
mg Capsule 1002XX resistant to sulphones iii) dapsone & 150 mg
Suppression of lepra reactions clofazimine with 450 mg
rifampicin once a
month.Maximum: 100
mg/day. ii) 100 mg daily iii)
200-300mg usually effective.
Treatment with minimum
suppression dose continued
for at least 6 months
73 / 371

i) ADULT: 100 mg each other
day or 50 mg daily with
100mg Dapsone & 300mg
once a month with 600mg
rifampicin under
supervision. Maximum: 200
mg/day. CHILD: 10-14 yr:
i) Previously untreated leprosy 50mg clofazimine on
Clofazimine 50 J04BA01000C patients ii) Leprosy patients alternate days with 50mg
356 B
mg Capsule 1001XX resistant to sulphones iii) dapsone & 150 mg
Suppression of lepra reactions clofazimine with 450 mg
rifampicin once a
month.Maximum: 100
mg/day. ii) 100 mg daily iii)
200-300mg usually effective.
Treatment with minimum
suppression dose continued
for at least 6 months
50 mg daily from 2nd - 6th
or 5th - 9th day of menstrual
cycle. Increase dose
gradually by increments of
50 mg if there is no
response until a dosage of
Clomiphene
G03GB02136 200 mg daily is achieved
357 Citrate 50mg A Anovulatory infertility
T1001XX (starting as early as 30 days
Tablet
afer the previous course).
Further treatment may not
be recommended if
pregnancy has not occurred
after a total of 6 treatment
cycles.
Initially 10 mg daily,
increased gradually as
necessary to 30 - 150 mg
daily in divided doses or as a
single dose at bedtime; max
250 mg daily. ELDERLY
initially 10 mg daily
Clomipramine N06AA04110 Depression, obsessive-compulsive increased carefully over
358 A
HCI 25 mg Tablet T1001XX disorder. approximately 10 days to 30
- 75 mg daily; Child: ≥10 yr:
Initially, 25 mg daily
increased gradually over 2
wk. Max: 3 mg/kg/day or
100 mg daily, whichever is
smaller. Give in divided
doses. Once titrated, dose
74 / 371

may be given as a single
dose at bedtime.
i) & ii) ADULT: Initial dose
should not exceed
1.5mg/day divided into 3
doses, may be increased in
increments of 0.5mg every 3
days until seizures are
controlled. Maintenance
dose: 3-6mg/day.
Maximum: 20mg/day. CHILD
up to 10 years: initial dose
Clonazepam 0.5 N03AE01000 i) Epilepsy ii) Non-epileptic 0.01-0.03 mg/kg/day in 2-3
359 B
mg Tablet T1001XX myoclonus divided doses, increased by
no more than 0.25-0.5mg
every third day, maximum
0.2mg/kg/day. CHILD 10-16
years: initial dose 1-
1.5mg/day in 2-3 divided
dose, may be increased by
0.25-0.5mg every third day
until individual maintenance
dose of 3-6mg/day is
reached.
i) & ii) ADULT: Initial dose
should not exceed
1.5mg/day divided into 3
doses, may be increased in
increments of 0.5mg every 3
days until seizures are
controlled. Maintenance
dose: 3-6mg/day.
Maximum: 20mg/day. CHILD
up to 10 years: initial dose
Clonazepam 2 N03AE01000 i) Epilepsy ii) Non-epileptic 0.01-0.03 mg/kg/day in 2-3
360 B
mg Tablet T1002XX myoclonus divided doses, increased by
no more than 0.25-0.5mg
every third day, maximum
0.2mg/kg/day. CHILD 10-16
years: initial dose 1-
1.5mg/day in 2-3 divided
dose, may be increased by
0.25-0.5mg every third day
until individual maintenance
dose of 3-6mg/day is
reached.
75 / 371

Rapid detoxification in 4-5
days (use with naltrexone):
6 mcg/kg ORALLY divided in
3 doses 6 to 8 hours apart
the first day, increasing to
11 mcg/kg divided in 3
Clonidine HCl N02CX02110 Rapid opiod detoxification
361 A doses given day two,
0.025 mg Tablet T1001XX combination use with naltrexone
tapering to 0.6 mcg/kg the
third day. Rapid opioid
detoxification for 7 days (
use with naltrexone) : 0.1 to
0.2 mg every 4 hours as
needed
Prevention of myocardial infarct,
stroke or established peripheral
Clopidogrel 75 B01AC04192 arterial disease. As second/third
362 A* 75 mg once daily
mg Tablet T1001XX line treatment in patients who are
sensitive to acetylsalicylic acid &
intolerant to ticlopidine
Clostridium i) Focal dystonias ii) Hemifacial
M03AX01000 20 - 200 units 3 months
363 Botulinum Toxin A* spasm iii) Spasticity including
P4001XX once
Type A 100 units cerebral palsy
Initially 20 U/kg divided
Clostridium between both calf muscles.
Botulinum Type May be titrated 10-30 U/kg
A toxin i) Focal dystonias ii) Hemifacial up to max of not >1000
M03AX01000
364 haemagglutinin A* spasm iii) Spasticity including U/patient. Should only be
P4003XX
complex 300 cerebral palsy used in children > 2 years of
units/vial powder age. Repeat injections given
for injection not less than 3 months from
previous injection.
Initially 20 U/kg divided
Clostridium
between both calf muscles.
botulinum Type
May be titrated 10-30 U/kg
A toxin
i) Focal dystonias ii) Hemifacial up to max of not >1000
haemagglutinin M03AX01000
365 A* spasm iii) Spasticity including U/patient. Should only be
complex P4002XX
cerebral palsy used in children > 2 years of
500U/vial
age. Repeat injections given
powder for
not less than 3 months from
injection
previous injection.
Rub in gently onto affected
and surrounding skin 2 or 3
Cutaneous candidiasis, Tinea
Clotrimazole 1% D01AC01000 times daily continuing for
366 B corporis, Tinea cruris, Tinea pedis
Cream G1001XX about 2 weeks beyond the
and Tinea versicolor
dissapearance of all
symptoms
76 / 371

Otomycosis; concomitant therapy
Clotrimazole 1% S02AA00000 4 to 5 drops 3 to 4 times
367 B with antibiotics and corticosteroid
Ear Drop D1002XX daily
ear drops
Apply gently onto affected
Cutaneous candidiasis, tinea
Clotrimazole 1% D01AC01000 and surrounding skin area 2
368 A orporis, tinea cruris, tinea pedis
Solution L6001XX or 3 times daily continuing
and tinea versicolor
for 2-4 weeks
Clotrimazole 200 200 mg once daily,
G01AF02000
369 mg Vaginal B Vaginal candidiasis preferably at bedtime for
S1002XX
Tablet three consecutive days
Clotrimazole 500
G01AF02000 500 mg as a single one-time
370 mg Vaginal B Vaginal candidiasis
S1003XX dose
Tablet
Cloxacillin
Treatment of susceptible bacterial
Sodium 125 J01CF02520L Child: 50-100 mg/kg in
371 B infections, notably penicillinase-
mg/5 ml 8001XX divided doses every 6 hr
producing staphylococci
Suspension
ADULT: 250 - 500 mg every
Cloxacillin Treatment of susceptible bacterial
J01CF02520C 6 hours. Child: 50-100
372 Sodium 250 mg B infections, notably penicillinase-
1001XX mg/kg in divided doses
Capsule producing staphylococci
every 6 hr.
ADULT: 250 to 500 mg every
6 hours depending on type
J01CF02520P and severity of infection.
4001XX CHILD less than 20 kg: 25 to
Injection producing staphylococci infections
50 mg/kg/day in equally
divided doses every 6 hours
J01CF02520C 6 hours. Child: 50-100
1002XX mg/kg in divided doses
Capsule producing staphylococci
every 6 hr.
ADULT: 250 to 500 mg every
6 hours depending on type
J01CF02520P and severity of infection.
4002XX CHILD less than 20 kg: 25 to
Injection producing staphylococci infections
50 mg/kg/day in equally
divided doses every 6 hours
Initial dose: 12.5 mg (once
or twice) daily, increase
Clozapine 100 mg N05AH02000 Treatment of resistant slowly in steps of 25 - 50 mg
376 A
Tablet T1002XX schizophrenia up to 300 mg daily within 2 -
3 weeks. Maximum 900
mg/day
77 / 371

Initial dose: 12.5 mg (once
or twice) daily, increase
Clozapine 25 mg N05AH02000 Treatment of resistant slowly in steps of 25 - 50 mg
377 A
Tablet T1001XX schizophrenia up to 300 mg daily within 2 -
3 weeks. Maximum 900
mg/day
Coal Tar 1- 6 % in
Dandruff, seborrhoeic dermatitis,
Betamethasone D05AA00946 Apply to the affected areas
378 B atopic dermatitis, eczema and
17 - Valerate G5003XX sparingly 1-2 times daily
psoriasis
0.01 % Ointment
atopic dermatitis, eczema and
Apply sparingly to the
psoriasis. Used as a mild astringent
Coal Tar 1-9% D05AA00000 affected area 1-3 times daily
379 B for the skin, as a soothing and
Ointment G5001XX starting with low strength
protective application in eczema
preparations
and as a protective to slight
excoriation
Coal Tar 20% D05AA00000
380 B atopic dermatitis, eczema and Use 100 ml in a bath
Solution L5201XX
psoriasis
Coal Tar and
Salicylic Acid Dandruff, seborrhoeic dermatitis,
D05AA00946
381 (various B atopic dermatitis, eczema and Apply to the affected areas
G5002XX
concentrations) psoriasis
Ointment
Coal Tar with
Salicylic Acid Dandruff, seborrhoeic dermatitis,
D05AA00000 Apply to the affected areas
382 (various B atopic dermatitis, eczema and
L5202XX or as in product leaflet
concentrations) psoriasis
Solution
Maximum total dose
To produce local anaesthesia or recommended for
Cocaine 10% N01BC01110 vasoconstriction during endoscopic application to the nasal
383 B
Solution L5001XX nasal surgery, turbinectomy mucosa in healthy adult is
septoplasty, polypectomy etc 1.5 to 2 mg/kg of a 10%
cocaine solution
Cocois Co. D05AA00946 Scalp psoriasis and severe Rub a small amount into the
384 B
Ointment G5001XX seborrhoeic dermatitis scalp gently
78 / 371

i) Initial dose, 0.5-1.2 mg,
and then 0.5-0.6 mg every
hour until relief of pain is
obtained or vomiting or
i) Acute gout and prophylaxis of diarrhoea occurs
recurrent gout. ii) Leucocytoclastic (Maximum: 8 mg). The
Vasculitis either cutaneous or course should not be
Colchicine 0.5 mg M04AC01000 systemic involvement, Behcet's repeated within 3 days.
385 B
Tablet T1001XX syndrome, Urticarial vasculitis, Prevention of attacks during
Systemic sclerosis, Sweet's initial treatment with
syndrome and severe recalcitrant allopurinol or uricosuric
aphthous stomatitis drugs: 0.5 mg 1-3 times
daily. ii) 0.5 mg 1-3 times
daily depends on disease
and severity, up to a
maximum of 3 mg/day
Eradication therapy for
Colloidal Bismuth
A02BX05136 Helicobacter Pylori in combination 240 mg twice daily for 1-2
386 Subcitrate 120 A
T1001XX with antibiotics and antisecretory weeks
mg Tablet
drugs
Compound
Replacement of extracellular losses 100-1000 ml by IV or
Sodium Lactate B05XA30125
387 C of fluid and electrolytes, as an according to the needs of
(Hartmanns P6001XX
alkaliniser agent the patient
Solution)
i) Osteoporosis associated with
oestrogen deficiency ii) Female i) 0.3 - 0.625 mg daily ii) 0.3-
Conjugated
G03CA57000 hypoestrogenism iii) Vasomotor 1.25mg daily for 3weeks,
388 estrogens 0.3 mg A
T1003XX symptoms associated with then off for 1 week iii) & iv)
Tablet
oestrogen deficiency iv)atrophic 0.3mg-1.25mg daily
vaginitis and urethritis
Management of moderate to
Conjugated severe vasomotor symptoms
Estrogens 0.625 associated with menopause,
mg & G03FA12295 prevention and management of
389 A 1 tablet daily
Medroxyprogest T1002XX postmenopausal osteoporosis,
erone Acetate atropic vaginitis and atropic
2.5 mg Tablet urethritis in post menopausal
woman with intact uterus
i) Osteoporosis associated with
oestrogen deficiency ii) Female i) 0.3 - 0.625 mg daily ii) 0.3-
Conjugated
G03CA57000 hypoestrogenism iii) Vasomotor 1.25mg daily for 3weeks,
390 Oestrogens 0.625 A
T1001XX symptoms associated with then off for 1 week iii) & iv)
mg Tablet
oestrogen deficiency iv)atrophic 0.3mg-1.25mg daily
vaginitis and urethritis
79 / 371

Intravaginally or topically
0.5-2g daily, depending on
severity of condition.
Administration should be
cyclic, with 3 weeks on
conjugated estrogens and
one week off. Estrogens
should be used for the
Conjugated
G03CA57000 Atrophic vaginitis and post shortest duration possible
391 Oestrogens 0.625 A
G1001XX menopausal atrophic urethritis when treating atrophic
mg/g Cream
vaginitis. Every 3 to 6
months attempts should be
made to taper or
discontinue therapy and
conjugated estrogens
should be titrated to give
the lowest possible dosage
to control symptoms
Continuous
Ambulatory
Peritoneal
Dialysis (CAPD) For chronic renal diseases requiring
Solution B05DB00908 dialysis and acute therapy- Dose depending on clinical
392 B
containing 2.3% H2504XX resistance renal failure eg. prior to cases
glucose (Calcium transfer to a dialysis centre
1.75mmol/L) &
(Calcium
1.25mmol/L)
Continuous
Ambulatory For chronic renal diseases requiring
Peritoneal B05DB00908 dialysis and acute therapy- Dose depending on clinical
393 B
Dialysis Solution H2501XX resistance renal failure eg. prior to cases
containing 1.5% transfer to a dialysis centre
Dextrose
Continuous
394 B
Dextrose
Continuous
395 B
Dextrose
80 / 371

One unit intrauterine device
to be inserted into the
uterine cavity on the last
Copper 250 mm2
G02BA02000 day of the menstrual flow or
396 Intrauterine B Intrauterine contraception
M9001XX in the first days afterwards.
Device
It is advised that the
Multiload Cu 250 devices
are replaced every 3 years
One unit intrauterine device
to be inserted into the
uterine cavity on the last
Copper 375 mm2
G02BA02000 day of the menstrual flow or
397 Intrauterine B Contraception
M9002XX in the first days afterwards.
Device
It is advised that the
Multiload Cu 375 devices
are replaced every 5 years
The tip of the crystal should
Copper Sulphate D08A000183 be moistened by dipping in
398 C Wounds
Crystal F9901XX water and applied carefully
to the lesion
Controlled Ovarian Stimulation Women with Body Weight
(COS) in combination with a GnRH ≤60 kg: A single dose of 100
Corifollitropin antagonist for the development of mcg should be
Alfa multiple follicles in woman administered. Women with
G03GA09000
399 100mcg/0.5ml A* participating in an Assisted Body Weight >60 kg: A
P5001XX
solution for Reproductive Technology (ART) single dose of 150 mcg
injection program Restriction: As second line should be administered.
treatment alternative to other Details : Refer to Product
recombinant FSH Information
Controlled Ovarian Stimulation Women with Body Weight
(COS) in combination with a GnRH ≤60 kg: A single dose of 100
Corifollitropin antagonist for the development of mcg should be
Alfa multiple follicles in woman administered. Women with
G03GA09000
400 150mcg/0.5ml A* participating in an Assisted Body Weight >60 kg: A
P5002XX
solution for Reproductive Technology (ART) single dose of 150 mcg
injection program Restriction: As second line should be administered.
treatment alternative to other Details : Refer to Product
recombinant FSH Information
20-30 mg/m2 daily. Doses
Cortisone For salt losing congenital adrenal may be divided with two-
H02AB10122
401 Acetate 5 mg B hyperplasia in newborn and thirds in the morning and
T1002XX
Tablet paediatric patients one-third late in the
afternoon
81 / 371

i) and iii) Massage into
affected area until the
medication is completely
absorbed. Repeat as
Crotamiton 10 % P03A000000 i) Pruritus ii) Scabies iii) Insect bite needed. Apply 2 or 3 times
402 A/KK
Cream G1001XX reactions daily ii) Apply to the whole
body from below the chin.
2nd application is applied 24
hr later. May need to use
once daily for up to 5 days.
i) Prophylaxis of anaemia:
250-1000 mcg IM every
month ii) Uncomplicated
pernicious anaemia or
Vitamin B12 malabsorption:
Initial 100 mcg daily for 5-10
days followed by 100-200
i) Prophylaxis of anaemia ii) mcg monthly until complete
Cyanocobalamin B03BA01000
403 B Uncomplicated pernicious anaemia remission is achieved.
0.1 mg Injection P3001XX
or Vitamin B12 malabsorption Maintenance: up to 1000
mcg monthly. CHILD 30-50
mcg daily for 2 or more
weeks (to a total dose of 1-
5mg). Maintenance: 100
mcg monthly to sustain
remission OR AS
PRESCRIBED.
i) Prophylaxis of anaemia:
250-1000 mcg IM every
month ii) Uncomplicated
pernicious anaemia or
Vitamin B12 malabsorption:
i) Prophylaxis of anaemia
Initial 100 mcg daily for 5-10
associated with Vitamin B12
Cyanocobalamin B03BA01000 days followed by 100-200
404 B deficiency ii) Uncomplicated
1 mg Injection P3002XX mcg monthly until complete
pernicious anaemia or Vitamin B12
remission is achieved.
malabsorption
Maintenance: up to 1000
mcg monthly. CHILD 30-50
mcg daily for 2 or more
weeks (to a total dose of 1-
5mg). OR AS PRESCRIBED.
ADULT 50-150 mcg daily.
Cyanocobalamin B03BA01000 Vitamin B12 deficiency of dietary
405 B CHILD 50-105 mcg daily in 1-
50 mcg Tablet T1002XX origin
3 divided doses
Cyclopentolate 1 drop every 5 - 10 minutes;
0.2% with S01GA55990 not exceeding three times
406 A Dilating agent for premature babies
Phenylephrine D2001XX to produce rapid mydriasis.
1% Eye Drops Observe infants closely for
82 / 371

at least 30 minutes
1 drop of solution in eye(s);

may repeat after 5 to 10
minutes if needed. INFANT :
Single instillation of 1 drop
of 0.5% solution in the eye;
Cyclopentolate S01FA04000 apply pressure to
407 A Mydriasis and cycloplegia
0.5% Eye Drops D2001XX nasolacrimal sac for 2 to 3
minutes; observe infant
closely for at least 30
minutes for signs or
symptoms of systemic
absorption
ADULT: 1 drop of solution in
eye(s); may repeat after 5-
10 minutes if needed.
CHILD: 1 drop of solution in
eye(s); may repeat after 5-
Cyclopentolate S01FA04000 10 minutes if needed. Pre-
408 A Mydriasis and cycloplegia
1% Eye Drops D2002XX treatment on the day prior
to examination is usually not
necessary. If desirable, 1 or
2 drops may be instilled the
evening prior to
examination.
83 / 371

i) ADULT: 600 - 750 mg/m2
IV once every 3 weeks as
part of combination regime.
CHILD: Dose variable
depending on disease and
protocol. Range 600 mg/m2
to 2 g/m2 infusion over 1
hour to 6 hours (lower doses
can be given as bolus). Care
with pre and post-hydration.
Mesna to be given with
doses more than 1 g/m2.
Higher doses are used in
haematopoetic stem cell
i) Solid tumours (adult and
transplant-refer to specific
paediatric), leukaemia, non-
protocols ii) 750 mg/m2 BSA
Hodgkin's lymphoma, multiple
monthly for 18 months iii)
myeloma ii) Severe lupus nephritis
750 mg/m2 BSA monthly for
Cyclophosphami L01AA01000 (Class III and IV) iii) Other systemic
409 A 6 months. Dose can be
de 1 g Injection P4002XX vasculitis iv) Systemic lupus
adjusted up to 1,000 mg/m2
erythematosus, rheumatoid
BSA to achieve adequate
arthritis, polyarteritis nodosa,
leucocyte suppression iv)
wegener granulomatosis v)
500 - 1000 mg intravenously
Pemphigus vulgaris
(Regime varies according to
indication). Starting dose
may be given fortnightly
then at monthly intervals
followed by 3 monthly
intervals v) 500 mg infusion
on the 2nd day of the
dexamethasone-
cyclophosphamide pulsed
regime, the cycle is
repeated every 4 weeks up
to 6 cycles or till remission
followed by oral
cyclophosphamide
84 / 371

i) ADULT: 600 - 750 mg/m2
IV once every 3 weeks as
part of combination regime.
CHILD: Dose variable
depending on disease and
protocol. Range 600 mg/m2
to 2 g/m2 infusion over 1
hour to 6 hours (lower doses
can be given as bolus). Care
with pre and post-hydration.
Mesna to be given with
doses more than 1 g/m2.
Higher doses are used in
haematopoetic stem cell
i) Solid tumours (adult and
transplant-refer to specific
paediatric), leukaemia, non-
protocols ii) 750 mg/m2 BSA
Hodgkin's lymphoma, multiple
monthly for 18 months iii)
myeloma ii) Severe lupus nephritis
Cyclophosphami 750 mg/m2 BSA monthly for
L01AA01000 (Class III and IV) iii) Other systemic
410 de 200 mg A 6 months. Dose can be
P4001XX vasculitis iv) Systemic lupus
Injection adjusted up to 1,000 mg/m2
erythematosus, rheumatoid
BSA to achieve adequate
arthritis, polyarteritis nodosa,
leucocyte suppression iv)
wegener granulomatosis v)
500 - 1000 mg intravenously
Pemphigus vulgaris
(Regime varies according to
indication). Starting dose
may be given fortnightly
then at monthly intervals
followed by 3 monthly
intervals v) 500 mg infusion
on the 2nd day of the
dexamethasone-
cyclophosphamide pulsed
regime, the cycle is
repeated every 4 weeks up
to 6 cycles or till remission
followed by oral
cyclophosphamide
85 / 371
i) Solid tumours, leukaemia, i) ADULT: 50 - 100 mg/day.

lymphoma, autoimmune disorders, Monitor full blood count
autoimmune bullous diseases, (FBC), liver function, urine
connective tissue disease, microscopy and renal
pyoderma gangrenosum ii) For function. CHILD, up to 1
Cyclophosphami L01AA01000 severe lupus nephritis (Class III & year: 10 - 20 mg daily, 1 - 5
411 A
de 50 mg Tablet T1001XX IV), systemic vasculitis and steroid years: 30 - 50 mg daily, 6 -
resistant/dependent nephrotic 12 years: 50 - 100 mg daily
syndrome iii) Systemic lupus ii) 2 mg/kg/day for 3 - 4
erythematosus (SLE), rheumatoid months iii) 1 - 1.5
arthritis, polyarteritis nodosa, mg/kg/day orally in divided
wegener granulomatosis doses
ADULT: Initial: 250 mg every

12 hours for 14 days, then
administer 0.5 - 1 g daily in 2
Multi-Drug Resistance Tuberculosis divided doses for 18 - 24
Cycloserine 250 J04AB01000C
412 A* treatment failure. (For respiratory months (maximum daily
mg Capsule 1001XX
physicians) dose: 1 g). CHILD: 2-12 yr: 5
mg/kg bid; 12-18 yr: 250 mg
bid for 2 wk then adjusted
to a max dose of 1 g daily
To increase tear production in
patients whose tear production is
presumed to be suppressed due to
Cyclosporine ocular inflammation associated 1 drop twice a day in each
S01XA18000
413 Ophthalmic A* with keratoconjunctivitis sicca. eye approximately 12 hours
D2001XX
Emulsion 0.05% Increased tear production was not apart.
seen in patients currently taking
anti inflammatory drugs or using
punctal plugs.
1 tablet daily for 21 days on
the first day of the cycle,
Cyproterone followed by 7 tab free days.
Acetate 2 mg & G03HB01954 Androgen dependent diseases in Starting on day 2 to 5 is
414 A*
Ethinyloestradiol T1001XX women allowed, but during the first
0.035 mg Tablet cycle a barrier method is
recommended for the first
7days of tablet taking.
i) After orchidectomy, 100
mg once daily or twice daily
ii) If used together with
Cyproterone
G03HA01122 LHRH agonists, the initial
415 Acetate 50 mg A* Carcinoma of prostate
T1001XX dose is 100 mg twice daily
Tablet
for 5 to 7 days before the
start of LHRH agonist, then
100 mg twice daily for 3 to 4
86 / 371

weeks together with the
LHRH agonist
Standard doses 100 - 200
mg/m2 daily over 5 - 10
days. Higher doses for
i) Central nervous system intensification/consolidation
lymphoma ii) Meningeal leukemia : 1000 - 3000 mg/m2 daily
iii) Non Hodgkin's Lymphoma iv) over 3 - 5 days, depending
High dose cytarabine as on specific protocols. CHILD:
conditioning to cytoreduce the Dose variable depending on
disease before stem cell transplant disease and protocol. Range
Cytarabine 1 g L01BC01000P
416 A for relapsed or refractory leukemia from 100 mg/m2 to 3 g/m2
Injection 4004XX
v) As salvage for acute lymphocytic twice daily. May be given as
leukemia vi) As salvage for acute SC, IV bolus or infusion.
myeloid leukemia vii) As palliative Intrathecal dose: Less than 1
chemotherapy in elderly acute year: 15 mg, 1 - 2 years: 20
myeloid leukemia/ myelodysplastic mg, 2 - 3 years: 25 mg, more
syndrome than 3 years: 30 mg.
(ENSURE THAT
PREPARATION IS SUITABLE
FOR INTRATHECAL USE)
iii) Non Hodgkin's Lymphoma iv) over 3 - 5 days, depending
Cytarabine 100 L01BC01000P
mg Injection 4002XX
(ENSURE THAT
87 / 371

iii) Non Hodgkin's Lymphoma iv) over 3 - 5 days depending
Cytarabine 500 L01BC01000P
mg Injection 4003XX
(ENSURE THAT
i) Following total knee
replacement: Initially ADULT
110mg (ELDERLY, 75 mg)
within 1- 4 hours after
surgery, then 220 mg
(ELDERLY, 150 mg) once
daily thereafter for 6-10
days Following total hip
110 mg (ELDERLY, 75 mg)
i) Prevention of venous
thromboembolic events in patients
who have undergone total knee
Dabigatran daily thereafter for 28-35
B01AE07999 replacement or total hip
419 Etexilate 110 mg A* days ii) Recommended daily
C1002XX replacement surgery ii) Reduction
Capsule dose is 300mg taken orally
of the risk of stroke and systemic
as 150mg hard capsule
embolism in patients with non-
twice daily. Therapy should
valvular atrial fibrillation (AF)
be continued lifelong.
Patients aged 80 years and
above should be treated
with a dose of 220mg daily ,
taken orally as one 110mg
capsule twice daily. Special
patient population for Renal
Impairment : Renal function
should be assessed by
calculating the creatinine
clearance (CrCl) prior to
88 / 371

initiation of treatment with
Dabigatran to exclude
patients for treatment with
severe renal impairment
(i.e. CrCl < 30 ml/min)
Following total knee

110 mg (ELDERLY, 75 mg)
Prevention of venous (ELDERLY, 150 mg) once
Dabigatran thromboembolic events in patients daily thereafter for 6-10
B01AE07999
420 Etexilate 75 mg A* who have undergone total knee days Following total hip
C1001XX
Capsule replacement or total hip replacement: Initially ADULT
replacement surgery 110 mg (ELDERLY, 75 mg)
daily thereafter for 28-35
days
Recommended daily dose is
300mg taken orally as
150mg hard capsule twice
daily. Therapy should be
continued lifelong. Patients
aged 80 years and above
should be treated with a
dose of 220mg daily , taken
orally as one 110mg capsule
Dabigatran Reduction of the risk of stroke and
B01AE07999 twice daily. Special patient
421 Etexilate150 mg A* systemic embolism in patients with
C1003XX population for Renal
Capsule non-valvular atrial fibrillation (AF)
Impairment : Renal function
should be assessed by
calculating the creatinine
clearance (CrCl) prior to
initiation of treatment with
Dabigatran to exclude
patients for treatment with
severe renal impairment
(i.e. CrCl < 30 ml/min).
i) Malignant melanoma, sarcomas, i) 250 mg/m2 for 5 days,
Dacarbazine 100 L01AX04000 neuroblastomas and other may be repeated every 3
422 A*
mg Injection P4001XX childhood solid tumours ii) weeks ii) 375 mg/m2 IV
Hodgkin's Disease every 2 weeks
89 / 371

i)200 - 800 mg daily for max
i)Endometriosis and gynaecomastia of 9 months ii)200 mg daily
Danazol 100 mg G03XA01000
423 A/KK ii)Menorrhagia iii)Prophylaxis of for 12 weeks ii)400 mg daily.
Capsule C1001XX
hereditary angioedema Reduce to 200 mg daily after
2 months attack free period
i)200 - 800 mg daily for max
i)Endometriosis and gynaecomastia of 9 months ii)200 mg daily
Danazol 200 mg G03XA01000
424 A/KK ii)Menorrhagia iii)Prophylaxis of for 12 weeks ii)400 mg daily.
Capsule C1002XX
hereditary angioedema Reduce to 200 mg daily after
2 months attack free period
i) ADULT: 6 - 10 mg/kg
weekly/ 1.4mg/kg daily
Dapsone 100 mg J04BA02000T i)Leprosy ii) Dermatitis (around 50 - 100 mg daily).
425 B
Tablet 1001XX herpetiformis CHILD: 1 - 2 mg/kg/day.
Maximum: 100 mg/day ii)
ADULT: 50 - 300 mg daily
i) 45 - 60 mg/m2 IV daily for
3 - 5 days ii) 25 - 45 mg/m2
once a week for first 4
weeks during induction
phase. Caution: Total
cumulative dose of
daunorubicin and
doxorubicin must not
i) Acute myeloblastic leukaemia
Daunorubicin HCl L01DB02110 exceed 500 mg/m2 due to
426 A* (AML) ii) Acute lymphoblastic
20 mg Injection P4001XX risk of cardiotoxicity. CHILD:
leukemia (ALL)
30-45 mg/m2/dose infusion
over 6 hours. Schedule
depends on protocol. Need
to check cardiac function
closely by echocardiography
every cumulative dose of
100mg/m2 to max. 360
mg/m2
90 / 371

Myelodysplastic syndromes (MDS)
including: Previously treated and
15 mg/m2 by continuous IV
untreated de novo and secondary
infusion over 3 hours
MDS of all French-American-British
repeated every 8 hours for 3
subtypes (refractory anemia,
days. Repeat this treatment
refractory anemia with ringed
cycle every 6 weeks for a
sideroblasts, refractory anemia
Decitabine 50 mg L01BC08000P minimum of 4 cycles.
427 A* with excess blasts, refractory
Injection 3001XX However, complete or
anemia with excess blasts in
partial response may take
transformation, and chronic
longer than 4 cycles.
myelomonocytic leukemia) and
Treatment may be
Intermediate-1, Intermediate-2,
continued as long as there is
and High-Risk International
continued
Prognostic Scoring System (IPSS)
groups
Treatment of chronic iron overload Initial 20 mg/kg/day.
Deferasirox 125 due to blood transfusions Starting dose can also be
V03AC03000
428 mg Dispersible A* (transfusional haemosiderosis) in based on transfusion rate
T4001XX
Tablet adult and pediatric patients aged 2 and existing iron burden.
years and above Max is 30 mg/kg/day
Treatment of chronic iron overload Initial 20 mg/kg/day.
Deferasirox 500 due to blood transfusions Starting dose can also be
V03AC03000
429 mg Dispersible A* (transfusional haemosiderosis) in based on transfusion rate
T4002XX
Tablet adult and pediatric patients aged 2 and existing iron burden.
years and above Max is 30 mg/kg/day
Treatment of iron overload in
patients with thalassemia major for
25 mg/kg 3 times a day for
whom desferrioxamine therapy is
Deferiprone 500 V03AC02000 total daily dose of 75 mg/kg.
430 A* contraindicated or inadequate. Add
mg Tablet T1001XX Doses greater 100 mg/kg
on therapy to desferrioxamine for
are not recommended
thalassemia patients with cardiac
complication
A single subcutaneous
Denosumab in
injection of 60 mg
1.0 mL solution
administered once every 6
(60 mg/mL) M05BX04000
431 A* Post-Menopausal Osteoporosis. months. Patients should
Pre‐filled syringe P4001XX
receive calcium and vitamin
(subcutaneous
D supplements whilst
injection)
undergoing treatment.
91 / 371

i) 2 g by IM immediately and
5 g by mouth after gastric
lavage ii) 0.5 - 1.5 g by IM
i) Acute iron poisoning in children
injection daily iii) Diagnosis:
Desferrioxamine ii) Investigation and treatment of
5 mg per kg by slow
B haemochromatosis iii) Diagnosis
V03AC01196 intravenous infusion during
432 Methanesulphon A and treatment of aluminium
P3001XX the last hour of
ate 0.5 g toxicity in patients with renal
haemodialysis. Treatment: 5
Injection failure and dialysis iv) Chronic iron
mg per kg once a week by
toxicity or overload
slow intravenous infusion
during the last hour of
dialysis iv) 30 - 50 mg/kg
ADULT: Induction , initially
3% in oxygen or nitrous
oxide/oxygen and increased
by 0.5%-1% every 2-3
breaths or as tolerated (up
i) Induction and maintenance of to 11%), until loss of
N01AB07000 anaesthesia in adult ii) consciousness.
433 Desflurane Liquid A
L5001XX Maintenance of anaesthesia in Maintenance: 2.5%-8.5%
infants & children with or without concomitant
nitrous oxide CHILD:
maintenance, inhaled in
concentrations of 5.2%-10%
with or without concomitant
nitrous oxide
ADULT & CHILD more than
12 years : 5 mg once daily.
Desloratadine 5 R06AX27000 Allergic rhinitis and chronic
434 A* CHILD: 6-11 yr: 2.5 mg; 1-5
mg Tablet T1001XX idiopathic urticaria
yr: 1.25 mg; 6-11 mth: 1 mg.
Doses to be taken once daily
i)ADULT and CHILD : 0.1-
0.2mg 3 times daily, up to
i)Central diabetes insipidus 0.1-1.2mg daily ii) ADULT &
Desmopressin H01BA02122 ii)Primary nocturnal enuresis Child≥5 yr 0.2-0.4mg at
435 A
0.1 mg Tablet T1001XX iii)Treatment of nocturia associated night iii)Initially 0.1 mg at
with nocturnal polyuria in adult night. May be increased to
0.2 mg and then to 0.4 mg
by means of weekly increase
i)ADULT and CHILD : 0.1-
0.2mg 3 times daily, up to
i)Central diabetes insipidus 0.1-1.2mg daily ii) ADULT &
Desmopressin H01BA02122 ii)Primary nocturnal enuresis Child≥5 yr 0.2-0.4mg at
436 A
0.2 mg Tablet T1002XX iii)Treatment of nocturia associated night iii)Initially 0.1 mg at
with nocturnal polyuria in adult night. May be increased to
0.2 mg and then to 0.4 mg
by means of weekly increase
92 / 371

i) ADULT : 10 - 20 mcg 1-2
Desmopressin
H01BA02122 i) Diabetes Insipidus ii) Primary times daily. CHILD: 5 -
437 100 mcg/ml A
A4101XX nocturnal enuresis 10mcg 1-2 times daily ii) 10-
Nasal Spray
40 mcg nocte
Desmopressin
H01BA02122 ADULT : 1 - 4 mcg IV daily.
438 Acetate 4 A Diabetes insipidus
P3001XX CHILD :0.4 mcg daily
mcg/ml Injection
Tablets must be taken in the
order directed on the
package every day at about
Contraception. Only for women the same time with some
Desogestrel G03AC09000 who should not take combined oral liquid as needed. One tablet
439 A*
0.075 mg Tablet T1001XX contraceptives (COCs) eg Obese, is to be taken daily for 28
smoker, migraine, breast feeding consecutive days. Each
subsequent pack is started
immediately after finishing
the previous pack.
Desogestrel 150 One tablet daily for 21 days
mcg & G03AA09954 starting on 1st day of
440 A/KK Oral contraception
Ethinylestradiol T1002XX menses followed by 7
20 mcg Tablet tablet-free days.
1 tablet daily for 21 days,
Desogestrel 150
subsequent courses
mcg & G03AB05954
441 C+ Contraception repeated after 7 day interval
Ethinylestradiol T1001XX
(during which withdrawal
30 mcg Tablet
bleeding occurs)
Desvenlafaxine
Recommended dose is 50mg
Succinate 50 mg N06AX23999
442 A* Major depression once daily, with or without
Extended Release T5002XX
food.
Tablet
Croup, septic shock, cerebral 0.5 - 9 mg daily, depending
Dexamethasone H02AB02000 oedema and respiratory distress upon the disease being
443 A
0.5 mg Tablet T1001XX syndrome including status treated. Up to 15 mg daily in
asthmaticus severe disease
Dexamethasone
Apply 1 - 1.5 cm 3 - 4 times
and Neomycin Treatment of ocular inflammation
S01CA01990 daily, may be used
444 Sulphate and A when concurrent use of an
G5101XX adjunctively with drops at
Polymyxin B Eye antimicrobial is judged necessary
bedtime
Ointment
Dexamethasone
and Neomycin
Sulphate and Treatment of ocular inflammation 1 - 2 drops hourly for severe
S01CA01990
445 Polymyxin B A when concurrent use of an cases and 4 - 6 hourly for
D2001XX
Sulphate antimicrobial is judged necessary mild infection
Ophthalmic
Suspension
Dexamethasone S01BA01162 Acute steroid responsive
446 A 1 - 2 drops 4 - 6 times a day
Sodium D2001XX inflammatory and allergic
93 / 371

Phosphate 0.1% conditions
Eye Drops
Dexamethasone Croup, septic shock, cerebral Initially 0.5 - 9 mg IM, IV or
Sodium H02AB02162 oedema and respiratory distress infusion daily, depending
447 B
Phosphate 4 P3001XX syndrome including status upon the disease being
mg/ml Injection asthmaticus treated
Dexchlorphenira ADULT : 2 mg 3 times daily.
R06AB02253 Symptomatic treatment of allergic
448 mine Maleate 2 B CHILD : 1 - 12 years : 2 mg 3
T1001XX rhinitis and allergic dermatoses
mg Tablet times daily
CHILD 2 - 5 years : 0.5 mg
Dexchlorphenira
R06AB02253 Symptomatic treatment of allergic every 4 - 6 hours; 6 - 11
449 mine Maleate 2 B
L9001XX rhinitis years : 1 mg every 4 - 6
mg/5 ml Syrup
hours
i) Not to be infused for more
than 24 hours, 1 mcg/kg
i) Sedation of intubated and
over 10 minutes as loading
mechanically ventilated ICU
dose. Maintenance dose:
Dexmedetomidin patients. For use only by specialist
N05CM1811 0.2 - 0.7 mcg/kg/hr ii) Not to
450 e HCl 100 mcg/ml A* anaesthetist ii) For sedation of non-
0P4001XX be infused for more than 24
Injection intubated patients prior to and/or
hours, 1 mcg/kg over 10
during surgical and other
minutes as loading dose.
procedures
Maintenance dose: 0.2 - 0.7
mcg/kg/hr
Condition associated with Initially 500-1000 ml by
Dextran 40 B05AA05000 peripheral local slowing of the infusion, further doses are
451 A*
Injection P6001XX blood flow, prophylaxis of post given according to the
surgical thromboembolic disease patient's condition
For parenteral replenishment of
Dextrose 10% B05BA03000 fluid and minimal carbohydrate According to the needs of
452 B
Injection P6002XX calories as required by the clinical the patient
condition of the patient
453 B
454 B
455 B
94 / 371

456 B
V04CA02000 Use as a diagnostic agent for
457 Dextrose Powder B 75 g stat
F2101XX diabetes
i) ADULT and CHILD more
than 10 year, ORALLY: 60 -
100 ml RECTALLY, contrast
medium should be diluted
with 3-4 times its volume of
water. ORALLY: CHILD less
than 10 years,: 15- 30 ml
i) Contrast medium for the
NEWBORN, INFANT contrast
Diatrizoate radiological examination of the
Meglumine and gastrointestinal tract (primarily in
V08AA01254 with 3 times its volume of
458 Sodium A cases in which barium sulphate is
L9901XX water. RECTALLY: CHILD
Amidotrizoate contraindicated) ii) Computerised
more than 5 years, contrast
Solution tomography in abdominal region iii)
Treatment of Mecolinium ileus
with 4-5 times its volume of
water. Younger patients a
dilution with 5 times its
volume is recommended ii)
Adult, orally, 25-77 mL in
1000 mL tap water 15-30
minutes prior to imaging
i) ADULT: 2-10 mg 3-4 times
daily. CHILD 6 months and
older: 0.12 - 0.8 mg/kg daily
in divided doses, every 6-8
i) Muscle spasm of varied aetiology, hours ii) ADULT : 2 mg 3
Diazepam 2 mg N05BA01000
459 B including tetanus ii) Anxiety times daily, increased in
Tablet T1001XX
disorders severe anxiety to 15 - 30 mg
ELDERLY (or delibitated) half
adult dose. CHILD (night
terrors), 1 - 5 mg at bedtime
Status epilepticus - ADULT:
0.5 mg/kg repeated after 12
hours if necessary. CHILD
(febrile convulsions,
Diazepam 5 mg N05BA01000 Status epilepticus, skeletal muscle
460 C prolonged or recurrent): 0.5
Rectal Solution G2001XX spasm
mg/kg (maximum 10 mg),
repeated if necessary. Not
below 2 years
95 / 371

i) ADULT: 2-10 mg 3-4 times
daily. CHILD 6 months and
older: 0.12 - 0.8 mg/kg daily
in divided doses, every 6-8
i) Muscle spasm of varied aetiology, hours ii) ADULT : 2 mg 3
Diazepam 5 mg N05BA01000
461 B including tetanus ii) Anxiety times daily, increased in
Tablet T1002XX
disorders severe anxiety to 15 - 30 mg
ELDERLY (or delibitated) half
adult dose. CHILD (night
terrors), 1 - 5 mg at bedtime
i) Status epilepticus, by slow
IV: 5-10 every 10-15 minute
(rate not more than 5
mg/min), to a total dose of
30 mg, may repeat in 2 hour
if needed. Infants 30 days to
5 years, 0.05-0.3
mg/kg/dose given over 2-3
minutes, every 15-30
minutes to a total dose of 5
mg, repeat in 2-4 hours if
necessary. CHILD more than
5 years, 1 mg by slow IV,
every 2-5 minutes,
Diazepam 5 N05BA01000 i) Status epilepticus ii) Skeletal
462 B maximum 10 mg, repeat in
mg/ml Injection P3001XX muscle spasm iii) Anxiety disorders
2-4 hours if necessary ii)
Skeletal muscle spasm, by
slow IV or IM, 5-10 mg
repeated if necessary in 3-4
hours. CHILD (tetanus): 30
days - 5 years, 1-2 mg IM or
IV slowly every 3-4 hours as
needed. 5 years and above,
5-10 mg IM or IV slowly
every 3-4 hours if needed iii)
Anxiety disorders, 2-10 mg
by slow IV (not more than 5
mg/min). Repeat if
necessary every 3-4 hours
Post-traumatic inflammation of the
tendons,ligaments & joints.
Diclofenac 1% M02AA15520 Apply 3 - 4 times daily and
463 A Localised forms of soft tissue
Gel G3001XX gently rubbed in
rheumatism and degenerative
rheumatism
96 / 371

Diclofenac Suppositories are
Diclofenac Pain and inflammation in normally inserted one, two
M01AB05520
464 100mg A rheumatic disease and juvenile or three times a day up to a
S2004XX
Suppository arthritis maximum total daily dose of
150 mg.
Pain and inflammation in ADULT: 75 - 150 mg daily in
Diclofenac 12.5 M01AB05520
465 A rheumatic disease and juvenile divided doses. CHILD 1-12
mg Suppository S2001XX
arthritis years, 12.5- 25 mg daily
Pain and inflammation in ADULT: 75 - 150 mg daily in
Diclofenac 25 mg M01AB05520
466 A rheumatic disease and juvenile divided doses. CHILD 1-12
Suppository S2002XX
arthritis years, 12.5- 25 mg daily
ADULTS: Initial dose of 150
mg daily. Mild or long term:
75 - 150 mg daily in 2 to 3
divided doses after food.
Diclofenac 50 mg M01AB05520 Pain and inflammation in Maximum 200mg/day.
467 B
Tablet T1001XX rheumatic disease PAEDS more than 6 months
: 1 - 3 mg/kg body weight
Maximum 3mg/kg/day (Max
150mg/day).
ADULTS: 75 - 150 mg daily in
divided doses. Maximum
150mg/day. PAEDS more
Diclofenac Pain and inflammation in
M01AB05520 than 6 months : 1 - 3 mg/kg
468 Sodium 50 mg A rheumatic disease and juvenile
S2003XX body weight daily in divided
Suppository arthritis
doses. Maximum
3mg/kg/day (Max
150mg/day).
IM 75 mg once daily (2 times
Diclofenac daily in severe cases) for not
M01AB05520 Pain and inflammation in
469 Sodium 75 mg/3 A/KK more than 2 days. Max
P3001XX rheumatic disease
ml Injection 150mg/day. Not suitable for
children.
ADULT less than 60 kg: 125
mg twice daily or 250 mg
once daily; more than 60 kg:
400 mg once daily or 200
Didanosine 100 J05AF02000T HIV infection, in combination with
470 A* mg twice daily. CHILD: 2
mg Tablet (ddI) 1002XX other antiretrovirals
weeks to less than 3
months: 50mg/m2 twice
daily; 3-8 months:
100mg/m2 twice daily
97 / 371

Didanosine 2 g 400 mg once daily or 200
J05AF02000F HIV infection, in combination with
471 Oral Solution A* mg twice daily. CHILD: 2
2101XX other antiretrovirals
(ddI) weeks to less than 3
daily; 3-8 months:
400 mg once daily or 200
Didanosine 25 J05AF02000T HIV infection, in combination with
472 A* mg twice daily. CHILD: 2
mg Tablet (ddI) 1001XX other antiretrovirals
weeks to less than 3
daily; 3-8 months:
Didanosine 250 mg once daily; 60 kg or
J05AF02000C HIV infection, in combination with
473 mg Enteric A* greater: 400 mg once daily.
Coated Capsule Dose may varies if taken in
combination with tenofovir
Didanosine 400 mg once daily; 60 kg or
J05AF02000C HIV infection, in combination with
474 mg Enteric A* greater: 400 mg once daily.
Coated Capsule Dose may varies if taken in
combination with tenofovir
One tablet daily. Treatment
can be started on any day of
Dienogest 2mg G03DB08000 menstrual cycle. Tablets
475 A/KK Treatment of endometriosis
tablet T1001XX must be taken continously
without regard to vaginal
bleeding.
i) 1 mg/kg on the first day
and increased gradually over
3 days to 6 mg/kg daily in
i) Bancrofti filariasis, divided doses. This dosage is
Diethylcarbamazi
P02CB02136 onchocerciasis, loasis, creeping maintained for 21 days. ii)
476 ne Citrate 50 mg B
T1001XX eruption ii) Ascariasis iii) Tropical 13 mg/kg once daily for 7
Tablet
eosinophilia days. CHILD : 6 - 10 mg/kg 3
times daily for 7 days iii) 6
doses for 21 days
98 / 371

Rapid digitalisation: 0.75 -
1.5 mg in divided doses over
24 hours; less urgent
digitalisation, 250 mcg-500
mcg daily (higher dose may
be divided). Maintenance :
Heart failure , with atrial
62.5mg -500 mcg daily
Digoxin 0.25 mg C01AA05000 fibrillation, supraventricular
477 B (higher dose may be
Tablet T1001XX arrhythmias (particularly, atrial
divided) according to renal
fibrillation)
function and , in atrial
fibrillation, on heart rate
response; usual range, 125-
250 mcg daily (lower dose
may be appropriate in
elderly)
Rapid digitilisation: ADULT &
Heart failure with atrial fibrillation, CHILD over 10 years, initially
Digoxin 250 C01AA05000
478 A supraventricular arrhythmias 0.75 - 1.5 mg, followed by
mcg/ml Injection P3001XX
(particularly atrial fibrillation) 250 mcg 6 hourly until
digitilisation is complete
Rapid digitalization, give in
divided doses; PREMATURE:
20-30 mcg/kg; FULLTERM:
25-35 mcg/kg; CHILD 1-2
years : 35 to 60 mcg/kg;
CHILD 2-5 years: 30-40
mcg/kg; CHILD 5-10 years:
Heart failure, supraventricular 20- 35 mcg/kg; CHILD over
Digoxin 50 C01AA05000
479 B arrhythmias (particularly atrial 10 years: 10-15 mcg/kg. For
mcg/ml Elixir L1001XX
fibrillation) daily maintenance doses or
for gradual digitalization,
give 20% to 30% of oral
digitalizing dose for
premature infants or 25% to
35% of oral digitalizing dose
for all other pediatric
patients
Rapid digitalisation: 1-1.5
mg in divided doses over 24
hours; less urgent
digitalisation, 250 mcg-500
Heart failure, with atrial fibrillation, mcg daily (higher dose may
Digoxin 62.5 mcg C01AA05000
480 B supraventricular arrhythmias be divided). Maintenance:
Tablet T1002XX
(particularly, atrial fibrillation) 62.5 - 500 mcg dailly (higher
dose may be divided)
according to renal fuction,
and in atrial fibrillation, on
heart-response; usual range
99 / 371

:125 - 250 mcg daily (lower
doses may be appropriate in
the elderly)
ADULT: 30 - 60 mg every 4 -
Dihydrocodeine
N02AA08123 For the control of moderate to 6 hours. PAED, over 4 yrs:
481 Tartrate 30 mg B
T1001XX severe chronic pain 0.5 - 1 mg/kg body weight
Tablet
every 4-6 hours
Dihydroergocristi
ne or Co- Adjunct in elderly with mild to
C04AE01196 3-6 mg daily in divided
482 dergocrine A/KK moderate dementia, prevention of
T1001XX doses
Mesilate 1 mg migraine and vascular headache
Tablet
Treatment of angina pectoris in the
Initially 30mg tds, may
following cases: i) inadequate
increase to 60mg tds
Diltiazem HCl 30 C08DB01110 response or intolerance to beta-
483 B (elderly initially twice daily;
mg Tablet T1001XX blockers and Isosorbide Dinitrate ii)
increased if necessary to
contraindication to beta-blockers
360 mg daily.
iii) coronary artery spasm
Usual Adult & Adolescent
Dose: Antiemetic; or
Antivertigo agent ?
Intramuscular, 50 mg
repeated every four hours
as needed. Intravenous, 50
mg in 10 mL of 0.9% sodium
chloride injection,
administered slowly over a
period of at least two
minutes, repeated every
Prevention and relief of motion four hours as needed. Usual
sickness, treatment of vertigo, Pediatric Dose: Antiemetic;
Dimenhydrinate
nausea or vomiting associated with or Antivertigo agent ?
Injection N07CA00000
484 B electroshock therapy, anaesthesia Intramuscular, 1.25 mg per
10ml/vial P2001XX
and surgery; labyrinthine kg of body weight or 37.5
(50mg/ml)
disturbances and radiation mg per square meter of
sickness. body surface, every six
hours as needed, not to
exceed 300 mg per day.
Intravenous, 1.25 mg per kg
of body weight or 37.5 mg
per square meter of body
surface, in 10 ml of 0.9%
sodium chloride injection,
administered slowly over a
period of at least two
minutes, every six hours as
needed, not to exceed 300
100 / 371

mg per day.
ADULT: 50-100 mg every 4

For prevention and treatment of hours as needed. For motion
motion sickness. Also used as anti- sickness, take medicine at
emetic agent in irradiation sickness, least 30 minutes, and
postoperative vomiting, drug preferably 1-2 hours before
Dimenhydrinate N07CA00000
485 B induced nausea and vomiting, and travelling. Usual adult
Syrup 15mg/5ml L9003XX
for symptomatic treatment of prescribing limit: Up to 400
nausea and vertigo due to mg daily. CHILD: Children 6-
Meniere`s disease and other 12 years: 25-50 mg every 6-
labyrinthine disturbances. 8 hours as needed
(maximum of 150 mg daily).
ADULT: 50-100 mg every 4
hours as needed. For motion
Prevention and treatment of the sickness, take medicine at
nausea, vomiting and dizziness least 30 minutes, and
associated with motion sickness. preferably 1-2 hours before
Dimenhydrinate N07CA00000
486 B Symptomatic treatment of nausea travelling. Usual adult
Tablet 50mg T1001XX
and vertigo caused by Meniere's prescribing limit: Up to 400
disease and other vestibular mg daily. CHILD: 6-12 years:
disturbances. 25-50 mg every 6-8 hours as
needed (maximum of 150
mg daily).
By IM: 2.5 - 3 mg/kg every 4
hours for 2 days, 2 - 4 times
Poisoning by antimony, arsenic, on the third day, then 1 - 2
bismuth, gold, mercury, possibly times daily for 10 days or
Dimercaprol 50 V03AB09000
487 B thallium; adjunct (with calcium until recovery. For
mg/ml Injection P3001XX
disodium edetate) in lead ophthalmic use : instillation
poisoning of 50 mg/ml oily solution in
conjunctival sac, within 5
minutes of contamination
3 mg vaginal tablet to be
Dinoprostone inserted high into the
(Prostagladin E2) G02AD02000 posterior formix. A second 3
488 A Induction of labour
3 mg Vaginal S1001XX mg tablet may be inserted
Tablet after 6-8 hours if labour is
not established. Max 6 mg
i) Acute attack: 6 tablets
daily for the first 4 days,
Diosmin 450 mg then 4 tablets daily in 2
C05CA53931 i) Haemorrhoids ii) Chronic venous
489 and Hesperidin A/KK divided doses for 3 days and
T1001XX insufficiency
50 mg Tablet 2 tablets thereafter.
Chronic: 2 tablets daily ii) 2
tab daily with meals
101 / 371

Allergic rhinitis :1) Adults &
Children over 12 years of
age : 25 to 50 mg 3 to 4
times a day 2) Children 6 to
12 years of age: 10 mg 3 to 4
times a day 3) Children 1 to
6 years of age: 5 mg 3 to 4
times a day. Maximum daily
Diphenhydramin
dosage <300 mg (adults and
e Hydrochloride R06AA02110
490 C Cough and allergic rhinitis children) Cough and cold :
10 mg/5 ml Oral L1001XX
1)Adults: 25 mg every 4 hrs.
solution
Not to exceed 150 mg in 24
hours 2) Children (6 to
12years): 12.5 mg every 4
hours. Not to exceed 75 mg
in 24 hours 3) Children (2 to
6 years): 6.25 mg every 4
hours. Not to exceed 25 mg
in 24 hours
ADULT : 5 - 10 ml 2 - 3 times
Diphenhydramin
daily. CHILD : 2.5 - 5 ml 2 - 3
491 C Cough times daily (not to be used
14 mg/5 ml L2101XX
in children less than 2 years
Expectorant
of age)
ADULT : 5 - 10 ml 2 - 3 times
Diphenhydramin
daily. CHILD : 2.5 - 5 ml 2 - 3
492 C Cough times daily (not to be used
7 mg/5 ml L9003XX
in children less than 2 years
Expectorant
of age)
ADULT initially 4 tablet
Diphenoxylate
A07DA01922 followed by 2 tablet 4 times
493 with Atropine B Acute diarrhoea
T1001XX daily until diarrhoea is
Sulphate Tablet
controlled
Prophylactic: 2 or 3 doses by
deep SC or IM injection, 0.5
Diphtheria and
J07AM51963 Immunisation against diphtheria or 1 ml. Each second dose at
494 Tetanus Vaccine C+
P3001XX and tetanus 4 - 6 weeks then 4 - 6
Injection
months. Booster at 4 - 6
years
Therapeutic: 10,000 - 30,000
units by IM or IV. Increase to
Diphtheria
J07AF01000P 40,000 - 100,000 units in
495 Antitoxin B Diphtheria
3001XX severe cases. Doses up to
Injection
30,000 units may be given
IM
Diphtheria, Immunisation of children against
J07AG52000
496 Pertussis, C Haemophilus Type B infections, 0.5 ml given by IM
P3001XX
Tetanus and diphtheria, tetanus and pertussis
102 / 371

Conjugated
Haemophilus
Type B 10 mcg
Vaccine
Primary vaccination: 3 doses
of 0.5 ml each within the
Diphtheria,
Active immunisation against first 6 months of life.
Pertussis,
J07CA05963P diphtheria, tetanus, pertussis and Administer each dose at
497 Tetanus and C+
3001XX hepatitis B in infants from 6 weeks intervals of at least 4 weeks.
Hepatitis B
onwards A booster dose can be
Vaccine
administered in the second
year of life
By deep SC or IM injection: 3
doses each of 0.5 or 1 ml
Diphtheria,
with intervals of 6 - 8 weeks
Pertussis, J07AJ52963P Prophylactic immunisation against
498 C and 4 - 6 months
Tetanus Vaccine 3001XX diphtheria, pertussis and tetanus
respectively between the
Injection
doses. Booster 1 and 5 years
after primary immunisation
Diphtheria,
Tetanus,
Acellular
Pertussis,
Immunisation of children against
Inactivated Polio Primary : 0.5 ml by IM at 1 -
J07CA06963P Diphtheria, Tetanus, Acellular
499 Virus, C+ 2 months intervals Booster :
3001XX Pertussis, Polio and Haemophilus
Haemophilus Second year of life
Influenza Type B infection
Influenza Type B
(DTaP-IPV-HiB)
Vaccine Injection
(Single Dose)
As an adjunct to oral
75-150 mg 3 times daily to
Dipyridamole 75 B01AC07000 anticoagulation/ antiplatelet
500 B be taken 1 hour before
mg Tablet T1001XX therapy in the prophylaxis of
meals
cerebrovascular events
i) ADULT : 5 mg daily 30
minutes before breakfast.
Increase at intervals of 3 - 4
days if necessary to
i) Myasthenia gravis ii) Prevention maximum of 20 mg daily.
Distigmine
N07AA03320 and treatment of post-operative CHILD : Up to 10 mg daily
501 Bromide 5 mg A
T1001XX intestinal atony, urinary retention according to age ii) Urinary
Tablet
and neurogenic bladder retention : 5 mg daily 30
minutes before breakfast.
Neurogenic bladder : 5 mg
daily or on alternate days 30
minutes before breakfast
103 / 371

For application to skin or
Dithranol 0.1 -
D05AC01000 Short contact treatment for plaque scalp. 0.1-0.5% suitable for
502 5% in Vaseline/ A
G5001XX psoriasis and alopecia areata overnight treatment. 1-2%
Ointment
for max 1 hour.
Apply liberally and carefully
Treatment of quiescent or chronic
Dithranol 1 % in D05AC01000 to the lesions with a suitable
503 A psoriasis of the skin, scalp and
Lassars Paste G6001XX applicator. A dressing may
alopecia areata
be applied
Initial 0.5-1 mcg/kg/min by
IV, maintenance 2.5-
10mcg/kg/min.
Frequently,doses up to
Dobutamine 12.5 C01CA07110
504 A Hypotension and heart failure 20mcg/kg/min are required
for adequate hemodynamic
improvement. On rare
occasions,infusion rates up
to 40mcg/kg/min
i) 75 mg/m2 IV over 1 hour
after doxorubicin 50 mg/m2
and cyclophosphamide 500
mg/m2 every 3 weeks for 6
cycles ii) 75 mg/m2 IV over 1
hour every 3 week in
i) Adjuvant treatment of patients combination with
with high risk node-positive breast doxorubicin 50 mg/m2 iii)
cancer in combination with Administer IV over 1 hour
doxorubicin and cyclophosphamide every 3 weeks.
ii) Breast cancer, locally advanced Chemotherapy-naive
or metastatic, not previously on patients 75 mg/m2
cytotoxic therapy, in combination immediately followed by 75
with doxorubicin iii) First line mg/m2 cisplatin over 30-60
Docetaxel
L01CD02000 therapy in non small cell lung mins or carboplatin (AUC 6
505 40mg/ml A*
P3002XX cancer in stage 3- 4 and mg/mL/min) over 30-60
Injection
performance status 0-1, in minutes. Monotherapy of
combination with cisplatin iv) non small cell lung cancer
Inoperable locally advanced (NSCLC) after failure of prior
squamous cell carcinoma of head platinum-based
and neck, in combination with chemotherapy 75 mg/m2 iv)
cisplatin and 5-FU for induction 75 mg/m2 as a 1 hour
treatment v) Prostate cancer, in infusion followed by
combination with prednisolone cisplatin 75 mg/m2 over 1
hour, on day one, followed
by 5-fluorouracil as a
continuous infusion at 750
mg/m2 per day for five days.
This regimen is administered
every 3 weeks for 4 cycles.
104 / 371

Chronic dyspepsia : CHILD
2.5 mL/10 kg body weight 3
times daily and once more
in the evening if necessary.
Dosage may be doubled in
Domperidone 1
A03FA03000 Nausea, vomiting, dyspepsia, adults & childs over 1 year.
506 mg/ml B
L8001XX gastro-esophageal reflux Acute and subacute
Suspension
conditions (particularly
nausea and vomiting).
CHILD: 5 mL/10 kg
bodyweight. All to be taken
3-4 times daily
Chronic dyspepsia ADULT 10
mg 3 times daily. Acute and
Domperidone 10 A03FA03253 Nausea, vomiting, dyspepsia, subacute conditions
507 B
mg Tablet T1001XX gastro-esophageal reflux (particularly nausea and
vomiting):ADULT 20 mg 3-4
times daily
Treatment of mild to moderate
dementia in Alzheimer's disease, as 5 - 10 mg once daily at
Donepezil HCl 10 N06DA02110
508 A well as in patients with severe bedtime. Maximum 10 mg
mg Tablet T1002XX
Alzheimer's disease. [psychiatrists daily
and neurologists only]
Treatment of mild to moderate
5 - 10 mg once daily at
Donepezil HCl 5 N06DA02110 dementia in Alzheimer's disease, as
509 A bedtime. Maximum 10 mg
mg Tablet T1001XX well as in patients with severe
daily
Alzheimer's disease.
Initiated at 5mg/day (one a
day dosing), should be
maintained for at least 1
Donepezil Treatment of mild to moderate
month in order to allow the
Hydrochloride dementia in Alzheimer's disease, as
N06DA02110 earliest clinical responses
510 10mg A* well as in patients with severe
T4002XX and to allow steady state
Orodispersible Alzheimer's disease. [psychiatrists
concentration to be
Tablet and neurologists only]
achieved. The maximum
recommended daily dose is
10 mg.
Initiated at 5mg/day (one a
day dosing), should be
maintained for at least 1
Donepezil Treatment of mild to moderate
month in order to allow the
Hydrochloride dementia in Alzheimer's disease, as
N06DA02110 earliest clinical responses
511 5mg A* well as in patients with severe
T4001XX and to allow steady state
Orodispersible Alzheimer's disease. [psychiatrists
concentration to be
Tablet and neurologists only]
achieved. The maximum
recommended daily dose is
10 mg.
105 / 371

Initial dose 2-5 mcg/kg/min
with incremental changes of
5-10 mcg/kg/min at 10-15
minutes intervals until
adequate response is noted.
Dopamine HCl 40 C01CA04110
512 B Non-hypovolemic hypotension Most patients are
maintained at less than 20
mcg/kg/min. If dosage
exceeds 50 mcg/kg/min,
assess renal function
frequently
Ventilator-associated pneumonia 500mg every 8 hours as a
Doripenem (VAP) patients at risk or involving one hour infusion for 5 to 14
J01DH04000
513 Monohydrate A* multidrug resistant pathogens days according to severity,
P4001XX
500 mg Injection especially Pseudomonas site of infection and the
aeruginosa infections patient's clinical response.
Monotherapy : 1 drop 3
times daily. Adjunctive
therapy with an ophthalmic
beta-blocker : 1 drop 2
times daily. When
substituting for another
All glaucoma patients where beta- ophthalmic antiglaucoma
Dorzolamide HCl
S01EC03110 blockers are contraindicated and agent with this product,
514 2% Ophthalmic A*
D2001XX when intraocular pressure is not discontinue the other agent
Solution
well controlled by other drugs after proper dosing on one
day and start Trusopt on the
next day. If more than 1
topical ophthalmic drug is
used, the drugs should be
administered at least 10
mins apart
Initially 75 mg (ELDERLY 50-
75 mg) daily in divided
doses or single dose at
bedtime, increased
Dothiepin HCl 25 N06AA16110 gradually as necessary to
515 A Depression of any aetiology
mg Capsule C1001XX 150 mg daily (ELDERLY 75
mg may be sufficient), up to
225 mg daily in some
circumstances. CHILD is not
recommended
106 / 371

Initially 75 mg (ELDERLY 50-
75 mg) daily in divided
doses or single dose at
bedtime, increased
Dothiepin HCl 75 N06AA16110 gradually as necessary to
516 A Depression of any aetiology
mg Tablet T1001XX 150 mg daily (ELDERLY 75
mg may be sufficient), up to
225 mg daily in some
circumstances. CHILD is not
recommended
Doxazosin
C02CA04196 4 mg once daily to
517 Mesilate 4 mg CR A* Benign Prostatic Hyperplasia
T5001XX maximum 8mg/day
Tablet
i) 30 - 75 mg/m2 IV as a
single dose at 21 day
intervals ii) 25 - 45 mg/m2
once a week for the first 4
weeks during induction or
re-induction phase (refer to
specific protocol. Caution:
Total cumulative dose of
i) Solid tumours, leukaemia, non- doxorubicin must not
Doxorubicin HCl L01DB01110 Hodgkin's lymphoma ii) Leukaemia exceed 550 mg/m2 due to
518 A
10 mg Injection P4001XX (ALL induction) iii) Multiple risk of cardiotoxicity. CHILD:
myeloma 30 mg/m2/dose over 6 - 24
hours for 1 - 2 days. Need to
check cardiac function
100 mg/m2 to maximum
360 mg/m2 iii) 9 mg/m2
over 24 hours infusion for 4
days at monthly intervals
107 / 371

i) 30 - 75 mg/m2 IV as a
single dose at 21 day
intervals ii) 25 - 45 mg/m2
once a week for the first 4
weeks during induction or
re-induction phase (refer to
specific protocol. Caution:
Total cumulative dose of
i) Solid tumours, leukaemia, non- doxorubicin must not
Doxorubicin HCl L01DB01110 Hodgkin's lymphoma ii) Leukaemia exceed 550 mg/m2 due to
519 A
50 mg Injection P4002XX (ALL induction) iii) Multiple risk of cardiotoxicity. CHILD:
myeloma 30 mg/m2/dose over 6 - 24
hours for 1 - 2 days. Need to
check cardiac function
100 mg/m2 to maximum
360 mg/m2 iii) 9 mg/m2
over 24 hours infusion for 4
days at monthly intervals
ADULT: 200 mg on the first
Doxycycline 100 J01AA02000C Infections due to susceptible day followed by 100 mg
520 B
mg Capsule 1001XX organisms daily. Severe infections: 200
mg daily
ADULT: 200 mg on the first
Doxycycline 100 J01AA02000T Infections due to susceptible day followed by 100 mg
521 B
mg Tablet 1001XX organisms daily. Severe infections: 200
mg daily
i) Heavy metal poisoning:
900mg-1800mg daily.
i) Treatment of severe lead
Duration of treatment is
poisoning, it is used as adjunctive
dictated by the urinary
treatment following initial
heavy metal excretion.
treatment with another chelating
Simultaneous oral vitamin
D-Penicillamine M01CC01000 agent. May also be used as sole
522 A B6 replacement with at least
0.25 g Capsule C1001XX therapy in the treatment of
40mg daily is essential ii)
asymptomatic patients with
Wilson's disease: 0.25g -
moderately elevated blood
1.5g daily on an incremental
concentrations ii) Wilson's Disease:
basis. Maximal daily dose:
to aid in elimination of copper ions
2g. Maintenance dose:
0.75g - 1g daily
ADULT: 60 mg once daily up
to a maximum dose of
Duloxetine 30 mg N06AX21110 Major depressive disorder, diabetic 120mg/day (in divided
523 A*
Capsule C1001XX peripheral neuropathic pain doses) CHILD and
ADOLESCENT under 18 years
not recommended
108 / 371

ADULT: 60 mg once daily up
to a maximum dose of
Duloxetine 60 mg N06AX21110 Major depression, diabetic 120mg/day (in divided
524 A*
Capsule C1002XX peripheral neuropathic pain doses) CHILD and
not recommended
Dutasteride 0.5 G04CB02000 Benign prostatic hyperplasia in men
525 A* 0.5 mg daily
mg Capsule C1001XX with an enlarged prostate gland
Combination therapy for the
Dutasteride treatment of moderate to severe
0.5mg and G04CA52953 symptoms of BPH with: i) Large
526 A* One capsule daily
Tamsulosin C1001XX prostate (>30g) ii) Poor risk or not
0.4mg Capsule fit for surgery iii)Those who are
awaiting their turn for surgery
i) 10 mg bd from day 5 - 25
of cycle ii) 10 mg bd - tds
from day 5 - 25 of the cycle
or continuously iii) To arrest
i) Dysmenorrhoea ii) Endometriosis bleeding :10 mg bd with an
iii) Dysfunctional uterine bleeding oestrogen once daily for 5 -
(to arrest and to prevent bleeding) 7 days, To prevent bleeding :
Dydrogesterone G03DB01110 iv) Threatened abortion v) Habitual 10 mg bd with an oestrogen
527 A/KK
10 mg Tablet T1001XX abortion vi) Post menopausal once daily from day 11 - 25
complaints (hormone replacement of the cycle iv) 40 mg at
therapy in combination with once, then 10mg 8hrly until
oestrogen) symptoms remit v) 10 mg bd
until 20th week of
pregnancy vi) 10-20 mg daily
during last 12-14 days of
each cycle
i) Intravenous injection on
over several minutes, 500 -
700 mcg/kg (after or with
atropine sulphate 600 mcg)
Edrophonium i) For reversal of neuromuscular
N07AA00100 ii) Intravenous injection 2
528 Chloride 10 B block ii) Diagnosis of myasthenia
P3001XX mg followed by 8 mg if no
mg/ml Injection gravis
response occurs within 30
seconds. CHILD: 20 mcg
followed by 80 mcg/kg after
30 seconds
109 / 371

ADULT: 600 mg once daily.
ADOLESCENT & CHILD less
than 17 years, more than 40
kg: 600 mg once daily, 32.5 -
less than 40 kg: 400 mg
once daily, 25 - less than
Combination therapy for HIV 32.5 kg: 350 mg once daily,
Efavirenz 100 mg J05AG03000 infections with a protease inhibitor 20 - less than 25 kg: 300 mg
529 A*
Capsule C1002XX and or Nucleoside Reverse once daily, 15 - less than 20
Transcriptase Inhibitors (NRTIs) kg: 250 mg once daily, 13 -
once daily. No studies in
children less than 3 years or
less than 13 kg. Formulation
unsuitable for children less
than 40 kg
530 A*
than 40 kg
531 A*
than 40 kg
110 / 371

Efavirenz 600 mg J05AG03000T infections with a protease inhibitor 20 - less than 25 kg: 300 mg
532 A/KK
Tablet 1001XX and or Nucleoside Reverse once daily, 15 - less than 20
than 40 kg
Individualised dosage based
on the patient's platelet
Short term use in idiopathic count. Adult Initially 50 mg
Eltrombopag
thrombocytopenic purpura once daily. East Asian
Olamine 25 mg B02BX05999
533 A* patients as bridging therapy for patient 25 mg once daily.
Film-coated T1001XX
splenectomy or surgery and in Then, adjust dose to
Tablet
cases of severe bleeding. maintain platelet count
≥50,000/microliter. Max: 75
mg daily.
Emulsificants D02AC00952
534 C Xerosis and ichthyosis Use as a soap and emollient
Ointment G5001XX
i) Initially 5 mg daily,
(ELDERLY 2.5 mg once daily),
usual maintenance dose 10 -
20 mg daily. Maximum: 40
Enalapril 10 mg C09AA02253 i) Hypertension ii) Congestive heart mg/day in 1 - 2 divided
535 B
Tablet T1002XX failure doses ii) Initially 2.5 mg
daily, usual maintenance
dose 20 mg daily in 1 - 2
divided doses; maximum: 40
mg/day
536 B
mg/day
111 / 371

537 B
mg/day
i) Prophylaxis fo DVT
especially in surgical
patients: moderate risk, 20
mg SC approximately 2
hours before surgery then
20 mg every 24 hours for
minimum 7 - 10 days, high
risk (eg orthopaedic surgery,
i) Prevention of Deep Vein medical patients, 40mg
Thrombosis(DVT) especially in every 24 hours for at least 6
Enoxaparin
B01AB05520 perioperative and high risk surgical days until patient ambulant,
538 Sodium 20 mg A*
P5001XX cases ii) Treatment of DVT iii) max 14 days. ii) Treatment
Injection
Unstable angina and non Q wave of DVT or pulmonary
Myocardial Infarction embolism, 1.5 mg/kg every
24 hours, usually for 5 days
and until adequate oral
anticoagulation established.
iii) Unstable angina and non-
ST-segment-elevation
myocardial infarction 1
mg/kg every 12 hours,
usually for 2 - 8 days
112 / 371

i) Prophylaxis for DVT
Enoxaparin
539 Sodium 40 mg A*
Injection
i) Prophylaxis fo DVT
Enoxaparin
540 Sodium 60 mg A*
Injection
113 / 371

Parkinson's Disease. An adjunct to
200 mg to be taken with
standard levodopa/benserazide or
each daily dose of
levodopa/carbidopa for use in
Entacapone 200 N04BX02000 levodopa/dopa-
541 A patients with parkinson's disease
mg Tablet T1001XX decarboxylase inhibitor.
and end of dose motor
Max 2g daily. May be taken
fluctuations, who cannot be
with or without food
stabilised on those combinations
0.5-1mg once daily. Renal
First line treatment of Chronic Dose Adjustment: 0.5-1mg
Hepatitis B in patients who satisfy every 48hours (30-
Entecavir 0.5 mg J05AF10000T
542 A* the criteria for treatment and 49ml/min); 0.5-1mg every
Tablet 1001XX
require long-term therapy or have 72hours (10-29ml/min);
a very high baseline viral load 0.5mg-1mg every 5-7 days
(<10ml/min; HD or CAPD).
Myotonic symptoms associated
Eperisone HCl 50 M03BX09110 with cervical syndrome,
543 A 50 mg 3 times daily
mg Tablet T1001XX periarthritis of shoulder and
lumbago spastic paralysis
Ephedrine 0.5% R01AA03110 Decongestion of the upper 2 drops 3 times daily.
544 A/KK
w/v Nasal Drops D6001XX respiratory tract Maximum use for 1 week
By IM, SC or IV. Severe,
acute bronchospasm : 12.5-
25 mg. Further dosage
should be determine by
patient response. When
used as a pressor agent :
Treatment of bronchial spasm in ADULT 25 - 50 mg SC/IM. If
asthma, adjunct to correct necessary, a second IM dose
Ephedrine HCl 30 R03CA02110
545 B haemodynamic imbalances and of 50 mg or an IV dose of 25
treat hypotension in epidural and mg may be given. Direct IV
spinal anaesthesia injection, 10 - 25 mg may be
given slowly. Maximum
parenteral ADULT dose : 150
mg in 24 hours. CHILD : 3
mg/kg or 100 mg/m2 SC or
IV daily, in 4 - 6 divided
doses
i) 75 - 90mg/m2 body area
injected IV in 3 - 5 min,
repeated at 21 day
intervals.Higher doses up to
Breast cancer, Non-Hodgkin's
135mg/m2 as single agent
Epirubicin 10 mg L01DB03110 lymphoma, Leukaemia (ALL
546 A* and 120mg/m2 as
Injection P4001XX induction), gastric cancer, ovarian
combination (effective in
cancer
treatment of breast cancer)
CHILD: 50 mg/m2 over 6
hours. Schedule depends on
protocol.
114 / 371

i) 75 - 90mg/m2 body area
injected IV in 3 - 5 min,
repeated at 21 day
intervals.Higher doses up to
Breast cancer, Non-Hodgkin's
135mg/m2 as single agent
Epirubicin 50 mg L01DB03110 lymphoma, Leukaemia (ALL
547 A* and 120mg/m2 as
Injection P4002XX induction), gastric cancer, ovarian
combination (effective in
cancer
treatment of breast cancer)
CHILD: 50 mg/m2 over 6
hours. Schedule depends on
protocol.
i) As monotherapy for maintenance 150 mg taken at least one
treatment in patients with locally hour before or two hours
advanced or metastatic non-small after the ingestion of food
cell lung cancer (NSCLC) with stable once daily. Reduce in steps
disease after 4 cycles of standard of 50 mg when necessary.
platinum-based first-line Continue treatment until
Erlotinib 100 mg L01XE03110T chemotherapy. ii) For the disease progression or
548 A*
Tablet 1003XX treatment of patients with locally unacceptable toxicity
advanced or metastatic NSCLC after occurs. May require dose
failure of at least one prior modifications when
chemotherapy regimen. Restricted coadministered with strong
to non-smoker, female, epidermal CYP3A4 inhibitors or
growth factor receptor (EGFR) inducers; or in cigarette
positive and Asian patients only smoking patients.
i) As monotherapy for maintenance 150 mg taken at least one

treatment in patients with locally hour before or two hours
advanced or metastatic non-small after the ingestion of food
cell lung cancer (NSCLC) with stable once daily. Reduce in steps
disease after 4 cycles of standard of 50 mg when necessary.
platinum-based first-line Continue treatment until
Erlotinib 150 mg L01XE03110T chemotherapy. ii) For the disease progression or
549 A*
Tablet 1002XX treatment of patients with locally unacceptable toxicity
advanced or metastatic NSCLC after occurs. May require dose
failure of at least one prior modifications when
chemotherapy regimen. Restricted coadministered with strong
to non-smoker, female, epidermal CYP3A4 inhibitors or
growth factor receptor (EGFR) inducers; or in cigarette
positive and Asian patients only. smoking patients.
i) Patient with confirm ESBL

producing gram-negative infection.
ADULT: 1 g once daily.
ii) Empiric treatment for severe
Ertapenem 1 g J01DH03520 CHILD 3 month to 12 years:
550 A* community acquired pneumonia or
Injection P4001XX 15 mg/kg twice daily. Not to
other infections when
exceed 1 g/ day
Pseudomonas aeruginosa is not
suspected.
115 / 371

Child: 30-50 mg/kg daily,
Erythromycin increased to twice the usual
Ethylsuccinate J01FA01238F Treatment of susceptible bacterial dose in severe cases. 2-8 yr:
551 B
200 mg/5 ml 2101XX infections 1 g daily in divided doses; <2
Suspension yr: 500 mg daily in divided
doses.
Adult 400 mg 6 hrly or 800
mg 12 hrly. Max: 4 g/day.
Childn 30-50 mg/kg in
Erythromycin
J01FA01238T Treatment of susceptible bacterial divided doses. Childn 2-8 yr
552 Ethylsuccinate B
1001XX infections 1 g/day in divided doses in
400 mg Tablet
severe cases. Infant & childn
≤2 yr 500 mg/day in divided
doses.
Erythromycin increased to twice the usual
Ethylsuccinate J01FA01238F Treatment of susceptible bacterial dose in severe cases. 2-8 yr:
553 B
400 mg/5 ml 2102XX infections 1 g daily in divided doses; <2
Suspension yr: 500 mg daily in divided
doses.
Only for treatment of i) certain
forms of meningitis ii) septicaemia
not responding to usual antibiotics
Erythromycin iii) mycoplasma pneumonia iv) Adult & Child: 25 - 50mg/kg
J01FA01129P
554 Lactobionate 500 A* infection with gram-positive /day infusion every 6 hours.
3001XX
mg Injection organisms (e.g. tetanus, Maximum: 4 g/day.
streptococcal infection) associated
with Penicillin allergy, only when
oral erythromycin cannot be given
increased to twice the usual
Erythromycin
J01FA01258T Infections due to susceptible dose in severe cases. 2-8 yr:
555 Stearate 250 mg B
1001XX organism 1 g daily in divided doses; <2
Tablet
yr: 500 mg daily in divided
doses.
116 / 371

i) ADULT by IV injection over
1-5 minutes, initially 50
units/kg 3 times weekly
response in step of 25
units/kg 3 times weekly at
interval of at least 4 weeks.
CHILD initially as for adult.
Maintenance, bodyweight
i) Treatment of anaemia associated
under 10 kg usually 75-150
with chronic renal failure. Dialysis
units/kg 3 times weekly,
Erythropoietin patients who are haemoglobin less
bodyweight 10-30 kg usually
Human than 8 g or exhibiting symptoms of
B03XA01000 60-150 units/kg 3 times
556 Recombinant A* anaemia although haemoglobin
P5005XX weekly, bodyweight over 30
10,000 IU/ml more than 8 g and pre-transplant
kg usually 30-100 units/kg 3
Injection cases ii) Anaemia in cancer (non-
times weekly ii) ADULT by
myeloid malignancies) with
SC injection (max. 1 ml per
concomitant chemotherapy
injection site), initially 150
increased if appropriate rise
in haemoglobin not
achieved after 4 weeks to
300 units/kg 3 times weekly.
Discontinue if inadequate
response after 4 weeks at
higher dose
B03XA01000 units/kg 3 times weekly,
P5001XX bodyweight 10-30 kg usually
1000 IU/0.5ml more than 8 g and pre-transplant
60-150 units/kg 3 times
weekly, bodyweight over 30
in haemoglobin not
117 / 371

higher dose.
558 Recombinant A anaemia although haemoglobin
in haemoglobin not
higher dose
118 / 371

in haemoglobin not
higher dose
B03XA01000 units/kg 3 times weekly,
560 Recombinant A anaemia although haemoglobin
P5004XX bodyweight 10-30 kg usually
60-150 units/kg 3 times
weekly, bodyweight over 30
in haemoglobin not
119 / 371

higher dose.
i) 10 mg once daily; may be

increased to max 20 mg
daily. ii) Panic disorder with
or without agoraphobia
:Initially 5 mg for the first
i) Major depression ii) Treatment of week, thereafter increased
Escitalopram 10 N06AB10124
561 A* panic disorder with or without to 10 mg daily. Max 20 mg
mg Tablet T1001XX
agoraphobia daily, ELDERLY initially half
the adult dose, lower
maintenance dose may be
sufficient. CHILD and
not recommended
By IV infusion usually within
Esmolol HCl 10 C07AB09110 Tachycardia and hypertension in
562 A* range of 50 - 200
mg/ml Injection P3001XX perioperative period
mcg/kg/min
i)20mg daily for 4-8 weeks
ii)40mg daily for 10 days in
Esomeprazole 20 A02BC05000 i)Gastro-oesophageal reflux disease combination with
563 A*
mg Tablet T1002XX ii)H. pylori eradication amoxicillin 1g twice daily or
clarithromycin 500mg twice
daily
i) 20- 40 mg once daily for 2-
i) Acute erosive/ ulcerative
Esomeprazole 40 A02BC05000 5 days ii) 80 mg by IV bolus
564 A* oesophagitis ii) Non -variceal upper
mg Injection P3001XX followed by 8mg/hour
gastrointestinal bleed
infusion for 72 hours
i)20mg daily for 4-8 weeks
ii)40mg daily for 10 days in
Esomeprazole 40 A02BC05000 i)Gastro-oesophageal reflux disease combination with
565 A*
mg Tablet T1001XX ii)H. pylori eradication amoxicillin 1g twice daily or
clarithromycin 500mg twice
daily
Essential
Phospholipids,
nicotinamide,
cyanocobalamine
A05BA00924 Nutritional supplement in liver Please refer to product
566 , tocopheryl, A/KK
C1001XX disorders leaflet
pyridoxine,
thiamine,
riboflavine
capsule
120 / 371

One tablet daily without pill-
Estradiol 1 mg & free interval, starting with 1
Hormone Replacement Therapy for
Estradiol 1 mg mg of Estradiol for first 14
G03FB08954 women with disorders due to
567 with A* days, followed by 1mg
T1001XX natural or surgically induced
Dydrogesterone Estradiol with 10 mg
menopause with intact uterus.
10 mg Dydrogestrone daily for the
next 14 days
Hormone replacement therapy for
Estradiol 1 mg & oestrogen deficiency symptoms in
Norethisterone G03FA01122 women more than 1 year after 1 tablet per day without
568 A*
Acetate 0.5 mg T1001XX menopause and prevention of interruption
Tablet osteoporosis in post menopausal
women
One tablet daily, taken
i) Hormone replacement therapy
Estradiol 1 mg continuously without
for the relief of symptoms due to
with G03FB08954 interruption. Should be used
569 A* oestrogen deficiency ii) Prevention
Dydrogesterone T1002XX only in postmenopausal
of postmenopausal osteoporosis in
5 mg Tablet women more than 12
women with a uterus
month after menopause
Estradiol Oestrogen replacement therapy - 1 mg daily continuously or
G03CA03256
570 Valerate 1 mg A* only those who cannot tolerate 21 day regimen with 1 week
T1002XX
Tablet Premarin of tablet free interval
Estradiol Pre and post menopausal Start on the 5th day of
Valerate 2 mg syndrome, primary and secondary menstrual cycle - 1 tab daily
and Norgestrel amenorrhea, menstrual for 21 days then stop for 7
G03FB01953
571 500 mcg with B irregularities. Deficiency symptoms days. If patient forgets dose
T1001XX
Estradiol after oophorectomy or radiological at usual time, it should be
Valerate 2 mg castration for noncarcinomatous taken within following 12
Tablet disease hours
121 / 371

Adult & geriatric dose:
Rheumatoid arthritis,
psoriatic arthritis, ankylosing
spondylitis; 50 mg SC once-
i) Moderately to severe rheumatoid
weekly for once-weekly
arthritis as monotherapy or in
dosing or 25 mg SC twice
combination with methotrexate in
weekly (individual doses
patients with inadequate response
should be separated by 72
to methotrexate alone. ii) Active
to 96 hours) for twice-
polyarticular-course juvenile
weekly dosing. Plaque
idiopathic arthritis in children 2-17
psoriasis; Initial: 50 mg SC
years with inadequate response to,
twice weekly, 72 to 96 hours
or who have proved intolerant of
apart; maintain initial dose
methotrexate. iii) Psoriatic arthritis
Etanercept 25 mg L04AA11000 for 3 months (starting doses
572 A* as monotherapy or in combination
Injection P4001XX of 25 or 50 mg once weekly
with methotrexate in patient’s
have also been used
successfully). Maintenance
methotrexate alone. iv)Active
dose: 50 mg SC once weekly.
ankylosing spondylitis in adults
Paediatric dose (2 to 17
v)Moderate to severe plaque
years): Juvenile idiopathic
psoriasis who failed to respond to,
arthritis; 0.8 mg/kg (max. 25
or who have a contraindication to,
mg/dose) SC once weekly
or are intolerant to other systemic
for once-weekly dosing or
therapy including cyclosporine,
0.4 mg/kg (max. 25
methotrexate or PUVA
mg/dose) SC twice weekly
(individual doses should be
separated by 72 to 96 hours)
for twice-weekly dosing.
122 / 371

Adult & geriatric dose:
Rheumatoid arthritis,
psoriatic arthritis, ankylosing
spondylitis; 50 mg SC once-
i) Moderately to severe rheumatoid
weekly for once-weekly
arthritis as monotherapy or in
dosing or 25 mg SC twice
combination with methotrexate in
weekly (individual doses
patients with inadequate response
should be separated by 72
to methotrexate alone. ii) Active
to 96 hours) for twice-
polyarticular-course juvenile
weekly dosing. Plaque
idiopathic arthritis in children 2-17
psoriasis; Initial: 50 mg SC
years with inadequate response to,
twice weekly, 72 to 96 hours
or who have proved intolerant of
apart; maintain initial dose
methotrexate. iii) Psoriatic arthritis
Etanercept 50 mg L04AB01000 for 3 months (starting doses
573 A* as monotherapy or in combination
Injection P4002XX of 25 or 50 mg once weekly
with methotrexate in patients
have also been used
successfully). Maintenance
methotrexate alone. iv) Active
dose: 50 mg SC once weekly.
ankylosing spondylitis in adults v)
Paediatric dose (2 to 17
Moderate to severe plaque
years): Juvenile idiopathic
psoriasis who failed to respond to,
arthritis; 0.8 mg/kg (max. 25
or who have a contraindication to,
mg/dose) SC once weekly
or are intolerant to other systemic
for once-weekly dosing or
therapy including cyclosporine,
0.4 mg/kg (max. 25
methotrexate or PUVA
mg/dose) SC twice weekly
(individual doses should be
separated by 72 to 96 hours)
for twice-weekly dosing.
Adult: 15-25mg/kg daily
(max 1200mg) or 50mg/kg
Ethambutol HCl J04AK02110T
574 B Tuberculosis biweekly (max2000mg).
200 mg Tablet 1001XX
Children: 15-25mg/kg daily
or 50 mg/kg twice weekly.
Ethambutol HCl J04AK02110T
575 B Tuberculosis biweekly (max2000mg).
Children: 15-25mg/kg daily
or 50 mg/kg twice weekly.
N01AA01000 To remove adhesive plaster from Dose depending on the
576 Ether Solvent C
L9901XX the skin route and procedure
i)Oral contraception ii)Treatment of
acne vulgaris in women seeking
Ethinylestradiol oral contraception. iii) Treatment 1 tab daily for 28
20 mcg & G03AA12954 of symptoms of premenstrual consecutive days starting on
577 A*
Drospirenone 3 T1002XX dysphoric disorder (PMDD) in 1st day of menstrual
mg Tablet women who choose to use an oral bleeding.
contraceptive as their method of
contraception.
123 / 371

1 tablet to be taken daily for
Ethinylestradiol 21 executive days starting
20 mcg & G03AA10954 on the first day of menses.
578 A/KK Oral contraception
Gestodene 75 T1001XX Each subsequent pack is
mcg Tablet started after a 7 days tablet
free interval.
i)Prevention of pregnancy
ii)Treatment of moderate acne
Ethinylestradiol vulgaris not controlled by Beginning on day 1 of cycle,
20 mcg & G03AA07954 conventional therapy (e.g topical 1 tablet daily for 21 days
579 A/KK
Levonorgestrel T1002XX preparations and oral antibiotics) in followed by 7 tablet-free
100 mcg Tablet post-menarchal, premenopausal days.
women more than or 14 years who
accept contraception.
As second-line therapy in the ADULT: 15-20mg/kg daily, in
treatment of Multi Drug Resistant divided doses if necessary;
Tuberculosis only in combination maximum dose 1g/day.
Ethionamide 250 J04AD03000T
580 A* with other efficacious agents and CHILD: 10-20mg/kg in 2-3
mg Tablet 1001XX
only when therapy with isoniazid, divided doses or
rifampicin, or other first-line agents 15mg/kg/24hrs as a single
has failed. daily dose.
ADULT: Initially, 500 mg
daily. Increased by 250 mg
at intervals of 4-7 days to
usual dose of 1-1.5 g daily.
Maximum: Up to 2 g, under
strict supervision. CHILD:
Greater than or equal to 6
Ethosuximide
N03AD01000 years: Same as adult dose;
581 250 mg/5 ml B Absence seizures
L9001XX less than 6 years: Initially,
Syrup
250 mg daily. Increased
gradually to usual dose of 20
mg/kg daily. Maximum:
Children greater than or
equal to 6 years: Same as
adult dose; less than 6
years: Up to 1 g
For minor surgical procedures
including lancing boils, incision and Spray to affected area at a
Ethyl Chloride N01BX01000
582 C drainage of small abscesses, pain distance of about 30cm until
100ml Spray A4001XX
due to athletic injuries and pain a fine white film is produced
due to injection administration
124 / 371

Adult: 300mcg/kg given
slowly over 30-60 seconds
into a large vein in the arm.
Etomidate 20 Induction of general anaesthesia
N01AX07000 Child: Up to 30% more than
583 mg/10 mg A* for haemodynamically unstable
P3001XX the standard adult dose.
Injection patients
Elderly: 150-200 mcg/kg,
subsequently adjusted
according to effects.
A single implant inserted
subdermally and can be left
in place for three years. The
Etonogestrel 68 G03AC08000
584 A/KK Contraception implant can be removed at
mg Implant P1001XX
any time but not later than
three years after the date of
insertion.
i) CHILD: 60-120 mg/m2/day
by IV for 3 - 5 days every 3 -
6 weeks depending on
i) For treatment of children with protocols ii) Maintenance or
solid tumours, juvenile palliative chemotherapy for
myelomonocytic leukemia (JMML) elderly acute myeloid
Etoposide 100 L01CB01000P and Langerhan cell histiocytosis ii) leukemia, consolidation
585 A*
mg/5 ml Injection 3001XX Leukaemia, lymphoma iii) therapy for acute
Testicular cancer, lung cancer, lymphoblastic leukemia,
gestational trophoblastic disease, stem cell mobilization (Refer
gastric cancer, sarcoma to protocol) iii) 100 mg/m2
by IV every other day for 3
doses repeated every 3-4
weeks
Normal adult dose is 175mg-
200mg daily for 5
consecutive days orally,
followed by recession
(withdrawal) interval of 3
Etoposide 50mg L01CB01000 Treatment of small cell lung cancer
586 A* weeks. Repeat
capsule C1003XX and malignant lymphomas
administration as necessary.
Increase or reduce dose as
appropriate, according to
the particular disease or
symptoms.
i) OA: 60 mg once daily. RA:
90 mg once daily ii & iii)
i)Acute and chronic treatment of
Acute gouty arthritis and
signs and symptoms of
Etoricoxib 120 M01AH0500 acute pain: 120 mg once
587 A* osteoarthritis (OA) and rheumatoid
mg Tablet 0T1002XX daily (Given the exposure to
arthritis (RA) ii)Acute gouty arthritis
COX-2 inhibitors, doctors
iii)Acute pain
are advised to use the
lowest effective dose for the
125 / 371

shortest possible duration of
treatment)

acute pain: 120 mg once
Etoricoxib 60 mg M01AH0500 daily (Given the exposure to
Tablet 0T1003XX COX-2 inhibitors, doctors
iii)Acute pain
treatment)
acute pain: 120 mg once
Etoricoxib 90 mg M01AH0500 daily (Given the exposure to
Tablet 0T1001XX COX-2 inhibitors, doctors
iii)Acute pain
treatment)
An initial dose regimen of
Indicated for the prophylaxis of 0.75 mg b.i.d., which is
organ rejection in adult patients at recommended for the
low to moderate immunological general kidney and heart
Everolimus L04AA18000
590 A* risk receiving an allogeneic renal or transplant population. The
0.25mg tablet T1001XX
cardiac transplant in combination daily dose of everolimus
with ciclosporin for microemulsion should always be given
and corticosteroids. orally in two divided doses
(b.i.d.).
An initial dose regimen of
Indicated for the prophylaxis of 0.75 mg b.i.d., which is
organ rejection in adult patients at recommended for the
low to moderate immunological general kidney and heart
Everolimus L04AA18000
591 A* risk receiving an allogeneic renal or transplant population. The
0.75mg tablet T1003XX
cardiac transplant in combination daily dose of everolimus
with ciclosporin for microemulsion should always be given
and corticosteroids. orally in two divided doses
(b.i.d.).
126 / 371

Treatment of post-menopausal
women with advanced breast
Exemestane 25 L02BG06000 cancer whose disease has
592 A* 25 mg once daily
mg Tablet T1001XX progressed following tamoxifen
and non-steroidal aromatase
inhibitors
Ezetimibe 10 mg
C10BA02000 Usual starting dose: 10/20
593 & Simvastatin 20 A* Primary hypercholesterolemia
T1001XX mg/day
mg Tablet
i) Co-administration with statins for
patients who have chronic heart
disease or are chronic heart disease
equivalent or familial 10 mg once daily. Not
Ezetimibe 10 mg C10AX09000
594 A* hypercholesterolaemia with target recommended for children
Tablet T1001XX
LDL-C not achieved by maximum less than 10 years old
dose of statins ii) Monotherapy in
patients with documented
biochemical intolerance to statins
Dose varies according to the
patient and the
circumstances of the
bleeding. i) Mild
haemorrhage: initial dose of
30 units/kg body weight. ii)
Prevention and control of bleeding
Factor IX B02BD04000 Moderate haemorrhage:
595 A in patients with factor IX deficiency
Injection P9901XX initial dose of 50 units/kg iii)
due to haemophilia B
Major
haemorrhage/surgery: Initial
dose of 75 - 100 units/kg.
Half of these doses may be
repeated after 18-24 hrs if
necessary.
127 / 371

Amount and frequency of
administration should be
calculated on an individual
patient basis. Individual
dosage requirements can
only be identified on the
basis of regular
i) Treatment and perioperative determinations of the
prophylaxis of bleeding in acquired individual plasma levels of
deficiency of the prothrombin the coagulation factors of
complex coagulation factors, such interest or on the global
as deficiency caused by treatment tests of the prothrombin
with vitamin K antagonists, or in complex levels (INR, Quick's
Factor IX, Factor
case of overdose of vitamin K test) and a continuous
II, Factor VII and
B02BD01000 antagonists, when rapid correction monitoring of the clinical
596 Factor X In A*
P4001XX of the deficiency is required. ii) condition of the patient. An
Combination
Treatment and perioperative approximate calculation is
Injection
prophylaxis of bleeding in as follows: Required dose
congenital deficiency of any of the (IU) = body weight (kg) x
vitamin K dependent coagulation desired factor rise (IU/dl or
factors only if purified specific % of normal) x reciprocal of
coagulation factor product is not the estimated recovery, i.e.
available. Factor II = 53 Factor VII = 59
Factor IX = 77 Factor X = 56
As product may differ from
one to another, it is strongly
advised to refer to the
manufacturer (product
insert) in regards to dosing
calculation.
Initially 4.5 KIU (90 mcg)/kg
body weight IV bolus over 2-
5 minutes, followed by 3-6
KIU (60-120 mcg)/kg body
Treatment of bleeding episodes
Factor VIIa weight depending on type &
and prevention of excessive
(Recombinant) severity of haemorrhage or
bleeding in connection with surgery
eptacog alfa B02BD08000 surgery performed. Dosing
597 A* in patients with inherited or
(activated) 100 P4005XX interval: initially 2-3 hour to
acquired haemophilia with
KIU (2 mg) obtain haemostasis and
inhibitors to coagulation factors VIII
Injection until clinically improved. If
or IX
continued therapy is
needed, dose interval can
be increased successively to
every 4, 6, 8 or 12 hours
128 / 371

Initially 4.5 KIU (90 mcg)/kg
body weight IV bolus over 2-
5 minutes, followed by 3-6
KIU (60-120 mcg)/kg body
Treatment of bleeding episodes
Factor VIIa weight depending on type &
and prevention of excessive
(Recombinant) severity of haemorrhage or
bleeding in connection with surgery
eptacog alfa B02BD08000 surgery performed. Dosing
598 A* in patients with inherited or
(activated) 50 P4004XX interval: initially 2-3 hour to
acquired haemophilia with
KIU (1 mg) obtain haemostasis and
inhibitors to coagulation factors VIII
Injection until clinically improved. If
or IX
continued therapy is
needed, dose interval can
be increased successively to
every 4, 6, 8 or 12 hours
i. Von Willebrand Disease:
Spontaneous Bleeding
Episodes: Initially, factor VIII
12.5-25 IU/kg and ristocetin
cofactor 25-50 IU/kg
followed by factor VIII 12.5
IU/kg and ristocetin cofactor
25 IU/kg subsequently every
12-24 hrs. Minor Surgery:
Factor VIII 30 IU/kg and
ristocetin cofactor 60 IU/kg
daily. Major Surgery:
i)The treatment and prophylaxis of Initially, factor VIII 30-40
haemorrhage or surgical bleeding IU/kg and ristocetin cofactor
Factor VIII in Von Willebrand Disease (VWD) 60-80 IU/kg followed by
(Human blood when 1-deamino-8-D-arginine factor VIII 15-30 IU/kg and
coagulation B02BD06000 vasopressin (desmopressin, ristocetin cofactor 30-60
599 A*
factor) & Von P4002XX DDAVP) treatment alone is IU/kg subsequently every
Willebrand factor ineffective or contraindicated. 12-24 hrs. Prophylaxis:
Injection ii)The treatment and prophylaxis of Factor VIII 12.5-20 IU/kg and
bleeding associated with factor VIII ristocetin cofactor 25-40
deficiency due to haemophilia A. IU/kg 3 times weekly. ii.
Hemophilia A therapy:
Minor haemorrage: 10-15
IU/kg every 12-24 hours.
Moderate to severe
haemorrhage: 15-40 IU/kg
every 8 to 24 hours. Minor
surgery: Loading dose 20-30
IU/kg, maintenance dose
15-30 IU/kg. Major surgery:
Loading dose 40-50 IU/kg,
maintenance dose 10-40
IU/kg. Prophylaxis: 25-40
129 / 371

IU/kg three times weekly As
product may differ from one
to another, it is strongly
advised to refer to the
manufacturer (product
insert) in regards to dosing
calculation.
The dosage and duration of
treatment should be
individualised and taking
i)Control and prevention of into account the severity of
bleeding episodes in adults and factor VIII deficiency,
children (0-16 years) with location and extent of
hemophilia A. ii)Surgical bleeding and patient's
prophylaxis in adults and children clinical condition. Dose can
Factor VIII
with hemophilia A. iii)Routine be calculated by using: i.
(Recombinant) B02BD02000
600 A* prophylactic treatment to reduce Required dose (IU) = body
Octocog Alfa 250 P4001XX
the frequency of bleeding episodes weight (kg) x desired factor
IU Injection
and the risk of joint damage in VIII rise (IU/dl or % of
children with no pre-existing joint normal) x 0.5 (IU/kg) or ii.
damage. Not indicated fot the Expected factor VIII rise (%
treatment of von willebrand's of normal) = 2 x (dose
disease. administered)/ bodyweight
(kg) Dose administered
should be titrated to
patient's clinical response
The dosage and duration of
treatment should be
individualised and taking
i)Control and prevention of into account the severity of
bleeding episodes in adults and factor VIII deficiency,
children (0-16 years) with location and extent of
hemophilia A. ii)Surgical bleeding and patient's
prophylaxis in adults and children clinical condition. Dose can
Factor VIII
with hemophilia A. iii)Routine be calculated by using: i.
(Recombinant) B02BD02000
601 A* prophylactic treatment to reduce Required dose (IU) = body
Octocog Alfa 500 P4002XX
the frequency of bleeding episodes weight (kg) x desired factor
IU Injection
and the risk of joint damage in VIII rise (IU/dl or % of
children with no pre-existing joint normal) x 0.5 (IU/kg) or ii.
damage. Not indicated for the Expected factor VIII rise (%
treatment of von willebrand's of normal) = 2 x (dose
disease. administered)/ bodyweight
(kg) Dose administered
patient's clinical response.
130 / 371

i) Treatment and prophylaxis of
hemorrhages in hemophilia A and B
patients with inhibitors. ii)
Treatment and prophylaxis of
hemorrhages in non-hemophilic
patients who have developed As a general guideline, a
inhibitors to Factors VIII, IX and XI. dose of 50 to 100IU/kg body
Factor VIII
iii) Treatment of patients with weight is recommended, not
Inhibitor B02BD03000
602 A acquired inhibitors to Factors X and exceeding an individual dose
Bypassing P4001XX
XIII. iv) In the combination with of 100IU/kg bw and a
Activity Injection
Factor VIII concentrate for a long- maximum daily dose of
term therapy to achieve a complete 200IU/kg bw.
and permanent elimination of the
Factor VIII inhibitor so as to allow
for regular treatment with Factor
VIII concentrate as in patients
without inhibitor.
Dose varies according to the
patient and the
circumstances of the
bleeding. i) Mild to
moderate: Usually a single
dose of 10-15units/kg. ii)
Prevention and control of bleeding More serious
Factor VIII B02BD02999 in patients with factor VIII haemorrhage/minor
603 A
Injection P9901XX deficiency due to classical surgery: Initially 15-25
haemophilia A units/kg followed by 10-15
units/kg every 8 - 12 hours if
required iii) Severe
haemorrhage/major
surgery: Initial: 40 - 50
units/kg followed by 20 - 25
units/kg every 8-12 hrs.
Dose to be individualised.
Fat Emulsion 10%
B05BA02000 Source of lipid in patients needing ADULT usual lipid
604 for IV Infusion A
P6001XX IV nutrition requirement 2-3 g/kg/day.
Injection
INFANT 0.5 - 1 g/kg/day
Fat Emulsion 20%
B05BA02000 Source of lipid in patients needing ADULT usual lipid
605 for IV Infusion A
P6002XX IV nutrition requirement 2-3 g/kg/day.
Injection
INFANT 0.5-1 g/kg/day
Initiate at 5 mg once daily.
Felodipine 10 mg C08CA02000
606 A/KK Hypertension Usual dose, 5 - 10 mg once
Tablet T1002XX
daily in the morning
Initiate at 5 mg once daily.
Felodipine 5 mg C08CA02000
607 A/KK Hypertension Usual dose, 5 - 10 mg once
Tablet T1001XX
daily in the morning
131 / 371
As second line therapy after failed

gemfibrozil in patients: i)
Hypercholesterolemia and
hypertriglyceridemia alone or
combined [type IIa,IIb,III and V
dysplipidemias] in patients
unresponsive to dietary and other
Fenofibrate 145 C10AB05000 non-pharmacological measures 145mg once daily, with or
608 A/KK
mg tablet T1002XX especially when there is evidence without food
of associated risk factors ii)
Treatment of secondary
hyperlipoproteinemias if
hyperlipoprotenemia persists
despite effective treatment of
underlying disease iii) Dyslipidemia
in Type 2 Diabetes Mellitus
years previously treated
As a second line drug in the
with a strong opioid
management of chronic severe
analgesic, initial dose based
Fentanyl cancer pain not responding to non-
on previous 24-hour opioid
12mcg/h N02AB03136 narcotic analgesic. Not to be used
609 A* requirement (consult
Transdermal M7005XX in opiod naive patients.The use is
product literature). If
Patch to be restricted to pain specialists,
necessary dose should be
palliative medicine specialists and
adjusted at 72-hour
oncologists
intervals in steps of 12-25
mcg/hr
Patients who have not
previously received a strong
opioid analgesic, initial dose,
one 25 mcg/hour patch to
be replaced after 72 hours.
Fentanyl 25 Patients who have received
management of chronic cancer
mcg/h N02AB03136 a strong opioid analgesic,
610 A* pain. The use is to be restricted to
Transdermal M7001XX initial dose based on
pain specialists, palliative medicine
Patch previous 24 hours opioid
specialists and oncologists.
requirement (oral morphine
sulphate 90 mg over 24
hours = one 25 mcg/hour
patch). Not recommended
in children.
132 / 371
Patients who have not

previously received a strong
opioid analgesic, initial dose,
one 25 mcg/hour patch to
be replaced after 72 hours.
Fentanyl 50 Patients who have received
management of chronic cancer
mcg/h N02AB03136 a strong opioid analgesic,
611 A* pain. The use is to be restricted to
Transdermal M7002XX initial dose based on
pain specialists, palliative medicine
Patch previous 24 hours opioid
specialists and oncologists
requirement (oral morphine
sulphate 90 mg over 24
hours = one 25 mcg/hour
patch). Not recommended
in children.
Dose should be
individualized according to
age, body weight, physical
status, underlying
pathological conditions and
type of surgery and
anaesthesia. ADULT:
Premedication: IM 50 - 100
mcg, 30 - 60 mins prior to
surgery. Adjunct to general
anaesthesia: Induction IV 50
- 100mcg, repeat 2 - 3 mins
Short duration analgesia during intervals until desired effect
Fentanyl Citrate pre-medication induction and is achieved. IV/IM 25 -
N01AH01136
612 50 mcg/ml A maintenance of anaesthesia, and in 50mcg in elderly and poor
P3001XX
Injection the immediate post-operative risk patients. Maintenance:
period. IV/IM 25 - 50mcg. Adjunct
to regional anaesthesia:
IM/slow IV 50 - 100mcg
when additinal analgesia is
required. Post-operatively
(recovery room): IM 50 -
100mcg for pain control,
tachypnoea and emergency
delirium. May be repeated
in 1- 2 hours as needed.
CHILD (2 - 12 years):
Induction & maintenance: 2
- 3 Mcg/kg.
Ferric
CHILD up to 1 year 5 ml, 1 -
Ammonium B03AB06136 Prevention and treatment of iron-
613 C 5 years 10 ml, taken well
Citrate 800 L2101XX deficiency anaemias
diluted with water
mg/10 ml
133 / 371

Paediatric
Mixture
Ferrous
controlled
release 500 mg, Anemia due to iron deficiency,
Vitamin B1, megaloblastic anemia where there
Vitamin B2, is an associated deficiency of
Vitamin B6, Vitamin C and Vitamin B-complex
B03AE10903
614 Vitamin B12, A/KK particularly in pregnancy. In One tablet daily
T1001XX
Vitamin C, primary health clinic, the indication
Niacinamide, is restricted to anemia due to iron
Calcium deficiency in pregnant women
Pantothenate, ONLY.
Folic Acid 800
mcg Tablet
Adult: Usual dose range: Up
to 600 mg daily. May
increase up to 1.2 g daily if
Ferrous necessary. Child: As syrup
B03AA02138 Prevention and treatment of iron-
615 Fumarate 200 mg C+ containing 140 mg(45 mg
T1001XX deficiency anaemias
Tablet iron)/5ml. Preterm neonate:
0.6-2.4 ml/kg daily; up to 6
years old: 2.5-5ml twice
daily
i) Adult: SC or IV 5
i) Reduction in the duration of
mcg/kg/day. Initiation: 24 -
neutropenia and incidence of
72 hours after
febrile neutropenia in cytotoxic
chemotherapy. Duration:
Filgrastim (G-CSF) chemotherapy for malignancy
L03AA02000 Until a clinically adequate
616 30 MU/ml A* except chronic myeloid leukemia
P3001XX neutrophil recovery is
Injection and myelodysplastic syndrome ii)
achieved (absolute
Haemopoeitic stem cell
neutrophil count of at least
transplantation (HSCT)/stem cell
1 x 109/L on 2 consecutive
harvesting
days) ii) Refer to protocol
i) ADULT: 5mcg/kg/day by
i) Reduction in the duration of
SC or IV. Initiation: 24 - 72
neutropenia and incidence of
hours after chemotherapy.
febrile neutropenia in cytotoxic
Duration: Until a clinically
Filgrastim 30 MU chemotherapy for malignancy
L03AA02000 adequate neutrophil
617 in 0.5 ml A* except chronic myeloid leukemia
P5001XX recovery is achieved
Injection and myelodysplastic syndrome ii)
(absolute neutrophil count
Haemopoeitic stem cell
of at least 1 x 109/L on 2
transplantation (HSCT)/stem cell
consecutive days) ii) Refer to
harvesting
protocol
134 / 371

5 mg a day as a single dose.
Clinical responses occur
within 12 weeks - 6 months
Finasteride 5 mg G04CB01000 Treatment and control of benign
618 A* of initiation of therapy.
Tablet T1001XX prostatic hyperplasia
Long-term administration is
recommended for maximal
response
Treatment of patients with
relapsing forms of multiple
Fingolimod L04AA27110 sclerosis to reduce the frequency of
619 A* 0.5mg orally once daily
0.5mg Capsule C1001XX clinical exacerbations and to delay
the accumulation of physical
disability
Urinary frequency and
ADULT: 200 mg 3 times
Flavoxate HCl G04BD02110 incontinence, dysuria, urgency,
620 A daily. CHILD under 12 years
100 mg Tablet T1001XX bladder spasm due to
not recommended
catheterisation
i) Sustained monomorphic Ventricular arrhythmias: 100
ventricular tachycardias ii) mg twice daily, maximum
Preexcited atrial fibrillation 400 mg/day (usually
associated with Wolff-Parkinson reserved for rapid control or
Flecainide White Syndrome iii) Reciprocating in heavily built patients),
C01BC04122
621 Acetate 100 mg A* Atrio-Ventricular tachycardias reduced after 3 - 5 days if
T1001XX
Tablet (AVT) associated with Wolff- possible. Supraventricular
Parkinson White Syndrome iv) arrhythmias: 50 mg twice
Supraventricular tachycardias due daily, increased if required
to Intra-Atrio Ventricular Nodul to maximum of 150 mg
Reentry twice daily
135 / 371

i) Oropharyngeal
candidiasis: 50 - 100 mg
daily for 7 - 14 days
(Maximum 14 days) except
in severely
immunocompromised
patients, treatment can be
continued for longer
i) Oropharyngeal candidiasis,
periods. Atrophic oral
atrophic oral candidiasis associated
candidiasis associated with
with dentures, other candidal
dentures: 50 mg daily for 14
infections of mucosa ii) Tinea pedis,
days. Other candidal
corporis, cruris, versicolor and
infections of mucosa: 50 -
dermal candidiasis iii) Invasive
100 mg daily for 14 - 30
candidal & cryptococcal infections
days. CHILD: 3 - 6 mg/kg on
(including meningitis) iv)
first day then 3 mg/kg daily
Prevention of relapse of
Fluconazole 100 J02AC01000C (every 72 hours in NEONATE
622 A cryptococcal meningitis in AIDS
mg Capsule 1002XX up to 2 weeks old, every 48
patients after completion of
hours in NEONATE 2 - 4
primary therapy v) Prevention of
weeks old) ii) 50 mg daily for
fungal infections in
2 - 4 weeks, maximum 6
immunocompromised patients
weeks iii) 400 mg initially
considered at risk as a
then 200 - 400 mg daily for 6
consequence of HIV infections or
- 8 weeks. CHILD: 6 - 12
neutropenia following cytotoxic
mg/kg daily (every 72 hours
chemotherapy, radiotherapy or
in NEONATE up to 2 weeks
bone marrow transplant
old, every 48 hours in
NEONATE 2 -4 weeks old) iv)
100 - 200 mg daily v) 50 -
400 mg daily. CHILD: 3 - 12
NEONATE 2 - 4 weeks old)
136 / 371

i) 50 - 100 mg daily for 7 - 14
days (Maximum 14 days)
except in severely
immunocompromised
candidal& cryptococcal infections
(every 72 hours in NEONATE
Fluconazole 2 J02AC01000P up to 2 weeks old, every 48
mg/ml Injection 9901XX hours in NEONATE 2 - 4
- 8 weeks. CHILD: 6-12
iv) 100 - 200 mg daily v) 50 -
137 / 371

i) Oropharyngeal
candidiasis: 50 - 100 mg
daily for 7 - 14 days
(Maximum 14 days) except
in severely
immunocompromised
candidal & cryptococcal infections
Fluconazole 50 J02AC01000C (every 72 hours in NEONATE
mg Capsule 1001XX up to 2 weeks old, every 48
hours in NEONATE 2 - 4
- 8 weeks. CHILD: 6 - 12
NEONATE 2 -4 weeks old) iv)
100 - 200 mg daily v) 50 -
ADULT: 100 - 200 mg/kg
Flucytosine 2.5 daily in 4 divided doses by IV
J02AX01000P Treatment of systemic fungal
625 g/250 ml A* infusion over 20 - 40
9901XX infection
Injection minutes not more than 7
days
Flucytosine 500 J02AX01000T Only for the treatment of fungal ADULT: 50 - 150 mg/kg/day
626 A*
mg Tablet 1001XX meningitis in 4 divided doses
40 mg /m2 given daily for 5
B-cell chronic lymphocytic leukemia
consecutive days every 28
who have not responded to or
Fludarabine days. Courses may be
L01BB05162T whose disease had progressed
627 Phosphate 10 mg A* repeated every 28 days,
1001XX during or after treatment with at
Tablet usually for up to 6 cycles.
least one standard alkylating-agent
Duration of treatment
containing regimen
depends on treatment
138 / 371

success and tolerability of
the drug
25 mg/m2 daily for 5
consecutive days every 28
B-cell chronic lymphocytic days. May be administered
leukaemia who have not up to the achievement of a
Fludarabine responded to or whose disease had maximal response (usually 6
L01BB05162
628 Phosphate 50 mg A* progressed during or after cycles) and then the drug
P4001XX
Injection treatment with at least one should be discontinued.
standard alkylating-agent Reduce dose by up to 50% in
containing regimen patients with mild to
moderate renal impairment
(30-70ml/min)
Adrenocorticoid
As an adjunct to glucocorticoids in insufficiency (chronic):
Fludrocortisone the management of primary ADULT 1 tablet daily. Salt-
H02AA02122
629 Acetate 0.1 mg A adrenocortical insufficiency in losing adrenogenital
T1001XX
Tablet Addison's disease and treatment of syndrome: ADULT 1 - 2
salt-losing adrenogenital syndrome tablets daily. CHILD and
INFANT 0.5 - 1 tablet daily
139 / 371

i) Initial, 0.2 mg IV over 30
seconds; if desired level of
consciousness not obtained
after an additional 30
seconds, give dose of 0.3 mg
IV over 30 seconds; further
doses of 0.5 mg IV over 30
seconds may be given at 1-
minutes intervals if needed
to maximum total dose of 3
mg; patients with only
partial response to 3 mg
may require additional slow
titration to a total dose of 5
mg; if no response 5
minutes after receiving total
dose of 5 mg, overdose is
unlikely to be
i) Diagnosis and/or management of benzodiazepine and further
benzodiazepine overdose due to treatment with flumazenil
Flumazenil 0.1 V03AB25000 self-poisoning or accidental will not help ii) 0.2 mg IV
630 B
mg/ml Injection P3001XX overdose ii) Reversal of sedation over 15 seconds; if desired
following anaesthesia with level of consciousness is not
benzodiazepine obtained after waiting 45
seconds, a second dose of
0.2 mg IV may be given and
repeated at 60-seconds
intervals as needed (up to a
maximum of 4 additional
times) to a maximum total
dose of 1 mg; most patients
respond to doses of 0.6 to 1
mg; in the event of
resedation, repeated doses
may be given at 20-minutes
intervals if needed; for
repeat treatment, no more
than 1 mg (given as 0.5
mg/minute) should be given
at any one time and no
more than 3 mg should be
given in any one hour
140 / 371

i) ADULT: 5 - 10 mg daily
preferably at night. ELDERLY
more than 65 years: 5 mg at
i) Migraine prophylaxis ii)
night. Maintenance 5-day
Flunarizine HCl 5 N07CA03110 Maintenance treatment of
631 B treatment at the same daily
mg Capsule C1001XX vestibular disturbances and of
dose ii) 5 - 10 mg at night. If
cerebral and peripheral disorders
no improvement after 1
month, discontinue
treatment
Moisten tip with tear fluid
Diagnostic fluorescein angiography from lower fornix, sterile
Fluorescein 1 mg S01JA01520
632 B or angioscopy of the fundus and of water or ophthalmic
Ophthalmic Strip M9901XX
the iris vasculature solution and gently stroke
across the conjunctiva
Fluorescein Diagnostic fluorescein angiography
S01JA01520P
633 Sodium 10% in 5 A or angioscopy of the fundus and of 500 mg IV
3001XX
ml Injection the iris vasculature
Fluorometholone 1-2 drops qds. During the
S01BA07000 Treatment of steroid responsive
634 0.1% Ophthalmic A* initial 24-48 hr, dose may be
D2001XX ocular inflammation
Suspension increased to 2 drops 2 hrly.
500 - 600 mg/m2 IV in
combination with other
cytotoxic agents, repeated
every 3 weeks or 300 - 450
mg/m2 IV slow bolus daily
Cancers of gastro-intestinal tract, for 5 days in combination
Fluorouracil 1 L01BC02000P breast and pancreas, head and with biological response
635 A*
g/20 ml Injection 4002XX neck. Ophtalmological indication: modifiers, repeated every 4
trabeculectomy weeks or 3000 - 3750
mg/m2 as a continuous
infusion over 5 days in
combination with a
platinum compound every 3
to 4 weeks
15 mg/kg (max: 1 g/day),
Fluorouracil 100 L01BC02000T may be given once weekly
636 A Colorectal cancer
mg Tablet 1001XX for maintenance. Max: 1
g/week.
141 / 371

Intravenous Infusion: 15
mg/kg bodyweight (to a
maximum of 1 g daily)
diluted in 300-500mL of 5%
glucose given over a period
of 4 hours. 12 mg/kg
bodyweight daily for 3
consecutive days. Providing
Cancers of gastro-intestinal tract,
Fluorouracil 50 there are no signs of toxic
L01BC02000P breast and pancreas, head and
637 mg / ml in 5 ml A* effects, the patient may
4001XX neck. Ophtalmological indication:
Injection then be given 6mg/kg I.V. on
trabeculectomy
the 5th, 7th and 9th days. If
after the 9th day there is
still no sign of toxicity, the
patient may be placed on
maintenance therapy.
Maintenance Therapy: 5 -
10mg/kg bodyweight by I.V.
injection once a week.
i) 20 mg once daily
increased after 3 weeks if
necessary, usual dose 20 -
60 mg (ELDERLY 20 - 40 mg)
once daily max 80 mg once
daily (ELDERLY max 60 mg
once daily). ii) Initially 20 mg
once daily increased after 2
Fluoxetine HCl 20 N06AB03110 i) Depression ii) Obsessive-
638 A weeks if necessary, usual
mg Capsule C1001XX compulsive disorder
dose 20 - 60 mg (ELDERLY 20
- 40 mg) once daily, max 80
mg (ELDERLY max 60 mg)
once daily, discontinue if no
improvement within 10
weeks. CHILD and
are not recommended
By deep IM, initial test dose
of 5-20 mg, then after at
least 7 days. 20 - 40 mg
repeated at intervals of 2 - 4
Flupenthixol weeks. Maximum 400 mg
Decanoate N05AF01135 weekly. Usual maintenance
639 B Chronic psychoses
20mg/ml P2001XX dose 50 mg every 4 weeks
lnjection to 300 mg every 2 weeks.
ELDERLY, initially quarter to
half adult dose. CHILD not
recommended. Deep IM
recommended. Not for IV
142 / 371

use.
By deep IM : Test dose 12.5

mg (6.25 mg in ELDERLY),
then after 4-7 days 12.5 mg-
Fluphenazine
N05AB02135 Long term management of 100 mg repeated at
640 Decanoate 25 B
P3001XX psychotic disorders intervals of 14-35 days,
mg/ml Injection
response. CHILD not
recommended
Flutamide 250 L02BB01000T
641 A* Metastatic prostatic carcinoma 250 mg 3 times daily
mg Tablet 1001XX
Treatment of nasal symptoms Adults/Adolescents (≥12
(rhinorrhea, nasal congestion, nasal years) : 1-2 sprays (27.5
Fluticasone
itching and sneezing) and ocular mcg/spray) in each nostril
Furoate 27.5 R01AD08139
642 A* symptoms (itching/burning, once daily. Children (2-11
mcg/dose Nasal A4101XX
tearing/watering, and redness of years) : 1-2 sprays (27.5
Spray
the eye) of seasonal and perennial mcg/spray) in each nostril
allergic rhinitis. once daily
ADULT and CHILD more than
16 years i) Mild asthma :
100 mcg - 250 mcg twice
daily ii) Moderate asthma :
250 - 500 mcg twice daily iii)
Severe asthma : 500 mcg -
1000 mcg twice daily.
Alternatively, the starting
Fluticasone dose of fluticasone
R03BA05133
643 Propionate 125 B Prophylactic treatment for asthma dipropionate may be gauged
A2101XX
mcg/dose Inhaler at half the total daily dose of
beclomethasone
dipropionate or equivalent
administered by inhalation.
CHILD 4 - 11 years, 50 mcg
twice daily (maximum 100
mcg twice daily), CHILD 1-4
years, 50-100mcg
microgram twice daily
For depression, initially 50 -
100 mg daily in the evening,
300 mg daily (over 150 mg
Fluvoxamine 100 N06AB08253
644 B Depression in divided doses); usual
mg Tablet T1002XX
maintenance dose 100 mg
daily. CHILD and
not recommended
143 / 371

For depression, initially 50 -
100 mg daily in the evening,
300 mg daily (over 150 mg
Fluvoxamine 50 N06AB08253
645 B Depressive disorder in divided doses); usual
mg Tablet T1001XX
maintenance dose 100 mg
daily. CHILD and
not recommended
i) ADULT initially 10-20mg
mg daily for 14 days or until
haematopoietic response
obtained. Daily
i) For the prevention and treatment maintenance: 2.5 mg-10mg
Folic Acid 5 mg B03BB01000 of folate deficiency states ii) For the .CHILD up to 1 year:250
646 C+
Tablet T1001XX prevention of neural tube defect in mcg/kg daily; 1 to 5
the foetus years:2.5mg/day;6-12 years:
5mg/day ii) 5 mg daily
starting before pregnancy
and continued through the
first trimester
i) Infertility treatment in i) 75 - 150 IU daily, should
anovulatory women who have commence within the first 7
been unresponsive to treatment days of the menstrual cycle
Follitropin Alpha
with clomiphene citrate ii) and increased by 37.5 IU or
(Recombinant
G03GA05000 Stimulation of follicular 75 IU at 7 or 14 days
647 Human FSH) 300 A*
P3002XX development for intra-uterine interval. Max daily dose 225
IU/0.5 ml
cycles iii) Stimulation of follicular IU ii) 150 - 225 IU daily
Injection
development in assisted commencing on days 2 or 3
reproductive technology in the of the cycle. Max daily dose
management of infertility 450 IU
i) Infertility treatment in i) 75 - 150 IU daily should
anovulatory women who have commence within the first 7
been unresponsive to treatment days of the menstrual cycle
Follitropin Alpha with clomiphene citrate ii) and increased by 37.5 IU or
(Recombinant G03GA05000 Stimulation of follicular 75 IU at 7 or 14 days
648 A*
Human FSH) 75 P3001XX development for intra-uterine interval. Max daily dose 225
IU Injection cycles iii) Stimulation of follicular IU ii) 150 - 225 IU daily
development in assisted commencing on days 2 or 3
reproductive technology in the of the cycle. Max daily dose
management of infertility 450 IU
144 / 371

Infertility treatment in anovulatory
To be individualized. Give in
women who have been
multiples of 50 IU. Starting
Follitropin Beta unresponsive to treatment with
dose can be 50 IU - 200 IU
(Recombinant G03GA06000 clomiphene citrate. Stimulation of
649 A* daily. It can be a step-up
Human FSH) 300 P3002XX follicular development for intra-
regime or a step-down,
IU Injection uterine insemination cycles and
depending on the protocol
assisted reproductive technology in
and the ovarian response
the management of infertility.
Infertility treatment in anovulatory
To be individualized. Give in
women who have been
multiples of 50 IU. Starting
Follitropin Beta unresponsive to treatment with
dose can be 50 IU - 200 IU
(Recombinant G03GA06000 clomiphene citrate. Stimulation of
650 A* daily. It can be a step-up
Human FSH) 50 P3001XX follicular development for intra-
regime or a step-down,
IU Injection uterine insemination cycles and
depending on the protocol
assisted reproductive technology in
and the ovarian response
the management of infertility.
The recommended dose to
be administered by SC
injection once daily is: 5mg
for body weight less than
50kg, 7.5mg for body weight
50 to 100kg, 10mg for body
weight greater than 100kg.
Fondaparinux
Treatment should be
Sodium 12.5 i) Treatment of acute Deep Vein
B01AX05520 continued for at least 5 days
651 mg/ml Injection A* Thrombosis (DVT). ii) Treatment of
P5002XX and until adequate oral
in Prefilled Pulmonary Embolism (PE)
anticoagulation is
Syringe
established (INR 2 to 3).
Concomitant treatment with
vitamin K antagonists should
be initiated as soon as
possible, usually within 72
hours. The usual duration of
treatment is 5 to 9 days
i) Prevention of venous i) 2.5 mg once daily given by
thromboembolic events (VTE) in SC, administered 6 hr
orthopedic surgery (e.g. hip following surgical closure
fracture, major knee or hip provided homeostasis has
replacement surgery), abdominal been established. Usual
Fondaparinux surgery in patients at risk of duration of therapy is 5 to 9
Sodium 2.5 B01AX05520 thromboembolic complication. ii) days; for hip fracture
652 A*
mg/0.5 ml P5001XX Treatment of unstable angina or patients, an extended
Injection non-ST segment elevation course of up to 24 days is
myocardial infarction [UA/NSTEMI] recommended. ii) ADULT
in patients for whom urgent more than 18 years: 2.5 mg
invasive management (PCI) is not once daily given by SC,
indicated. iii) Treatment of ST initiated as soon as possible
segment elevation myocardial after diagnosis and
145 / 371

infarction (STEMI) in patients continued for up to 8 days
managed with thrombolytics or are or until hospital discharge. If
not receiving other forms of patient needs to undergo
reperfusion therapy PCI, unfractionated heparin
to be administer as per local
practice protocol, taking
into account the patient's
bleeding risk and time of
last dose of fondaparinux.
Fondaparinux may be
restarted no earlier than 2
hr after sheath removal. iii)
ADULT more than 18 years:
2.5 mg once daily; first dose
to be given IV (directly
through an existing IV line or
as infusion in 25 or 50 ml of
0.9% saline over 1-2 min),
subsequent doses to be
given SC. Treatment to be
initiated as soon as
diagnosis is made and
continued up to a max of 8
days or until hospital
discharge, whichever comes
earlier. If patient needs to
undergo non-primary PCI,
unfractionated heparin to
be admin as per local
practice protocol, taking
into account the patient's
bleeding risk and time of
last dose of fondaparinux.
Fondaparinux may be
restarted no earlier than 3
hr after sheath removal
i) ADULT and ELDERLY : 6 -
12 mcg (1 - 2 puff) once -
Formoterol twice daily, maximum daily
Fumarate dose 8 puff. CHILD over 6
R03AC13138 i) Moderate persistent and severe
653 Dihydrate 4.5 A* years : 2 puff once - twice
A2101XX persistent asthma ii) COPD
mcg /dose daily ii) ADULT and ELDERLY
Inhaler : 2 puff once - twice daily,
maximum 4 puff once or
twice daily
146 / 371

i) ADULT and ELDERLY: 1
puff once - twice daily,
maximum daily dose 4 - 6
Formoterol
puff. CHILD over 6 years : 1
Fumarate
R03AC13138 i) Moderate persistent and severe puff once - twice daily,
654 Dihydrate 9 A*
A2102XX persistent asthma ii) COPD maximum dose : 2 puff daily
mcg/dose
ii) ADULT and ELDERLY : 1
Turbuhaler
puff, once - twice daily,
maximum dose : 2 - 4 puff
daily
Framycetin
Sulphate 0.5%,
Dexamethasone S01CA01991 Apply 2 - 3 drops 3 to 4
655 A/KK Otitis externa
0.05% and D1001XX times daily
Gramicidin
0.005% Ear Drops
Initially 20 -40 mg IM or
Frusemide 10 C03CA01000 slow IV (rate not exceeding
656 B Pulmonary oedema
mg/ml Injection P3001XX 4 mg/min). CHILD: 0.5 - 1.5
mg/kg. Max: 20 mg daily
ADULT: Initial 40 - 80 mg on
morning if required, can be
increased to a max of 1
Frusemide 40 mg C03CA01000
657 B Pulmonary oedema g/day in certain cases
Tablet T1001XX
especially in chronic renal
failure. CHILD : 1 - 3 mg/kg
daily
Adult: 100-150g every 2-4
hours. Child: 1-2g/kg. (100g
of Fuller's Earth is mixed
Fuller's Earth V03AB00000
658 C Adsorbent in pesticide poisoning with 200ml water. Repeat
Powder F2101XX
until Fuller's Earth is seen in
stool (normally between 4-6
hours)
ADULT : 1 oral or 1 nasal
inhalation 4 hourly,
Local antibiotic, anti-inflammatory
withdraw if no improvement
Fusafungine 1% R02AB03000 treatment of infectious and
659 A after 7 days. CHILD : 1 oral
Nasal Spray A4101XX inflammatory syndromes of the
or 1 nasal inhalation 6
respiratory mucosa
hourly, withdraw if no
improvement after 7 days
Treatment of infections caused by
susceptible organisms especially
Fusidate, Sodium J01XC01520T daily, skin and soft tissue
660 A* Staphylococcal infections including
250 mg Tablet 1001XX infection: 250 - 500 mg
Methicillin Resistant
twice daily
Staphylococcus aureus (MRSA)
147 / 371

1 drop in conjunctival sac 12
hourly. To be continued for
2 days after the eye appears
normal. On the first day of
Fusidic Acid 1% S01AA13000
661 A For staphylococcal infections treatment, may be applied
Eye Drops D2001XX
more frequently: 1 drop 4
hourly. Surgical prophylaxis :
1 drop every 12 hours, 24 -
48 hours before operation
Skin infections caused by
staphylococci, streptococci,
Fusidic Acid 2% D06AX01000 Apply to affected area 2 - 3
662 A corynebacterium minutissumun
Cream G1001XX times daily
and other sodium fusidate-
sensitive organisms
Inflammatory dermatosis where
bacterial infection is likely to occur Uncovered lesion- Apply 2
Fusidic Acid 2% in
eg atopic eczema, discoid eczema, to 3 times daily. Covered
Betamethasone D07CC01948
663 A/KK stasis eczema, seborrhoic lesions- Less frequent
Valerate 0.1% G1001XX
dermatitis, contact dermatitis, applications may be
Cream
lichen simplex chronicus, psoriasis, adequate
discoid lupus erythematosus
ADULT: 15 ml 3 times daily.
Treatment of infections caused by CHILD 1 - 5 years: 5 ml 3
Fusidic Acid 50
J01XC01000L staphylococcal especially times daily; 5 - 12 years: 10
664 mg/ml A*
8001XX Methicillin Resistant ml 3 times daily. INFANT : 1
Suspension
Staphylococcus aureus (MRSA) ml/kg body weight daily in 3
- 4 divided doses
diluted to 250 - 500 ml
Treatment of severe staphylococcal
infused slowly over 2 hours.
infections especially Methicillin
Fusidic Acid 500 J01XC01520P Maximum: 2 g daily. CHILD
665 A* Resistant Staphylococcus aureus
mg Injection 4001XX and INFANT : 20 mg/kg/day
(MRSA). To be used in combination
divided into 3 equal doses
therapy only
infused slowly over 2 - 4
hours
148 / 371

ADULT & CHILD > 12 yrs:
900-3600mg/day. Therapy
may be initiated by
administering 300mg TDS on
day 1, or by titrating the
dose as: 300mg once on day
1, 300mg BD on day 2,
i) Add-on therapy for intractable
300mg TDS on day 3.
partial epilepsy, refractory to
Thereafter, then dose may
standard anti-epileptic drugs ii)
be increased in 3 equally
Treatment of various types of
Gabapentin 100 N03AX12000 divided doses up to max
666 A* neuropathic pain, both peripheral
mg Tablet T1002XX 3600mg/day.CHILD 3-12 yr:
(which includes diabetic
Initially 10-15 mg/kg/day in
neuropathy, post-herpetic
3 divided dose. Effective
neuralgia, trigeminal neuralgia) in
dose: CHILD 3 to less than 5
adult more than 18 years
yrs: 40mg/kg/day in 3
divided doses, CHILD 5-12
yrs: 25-35mg/kg/day in 3
divided doses ii) ADULT:
900mg/day in 3 equally
divided doses. Max
3600mg/day
may be initiated by
administered 300mg TDS on
300mg TDS on day 3.
Thereafter, may be
increased in 3 equally
mg Capsule C1001XX 3600mg/day.CHILD 3-12 yr:
3 divided doses. Effective
adult more than 18 years
divided doses. Max
3600mg/day
149 / 371

may be initiated by
administered 300mg TDS on
300mg TDS on day 3.
Thereafter, may be
increased in 3 equally
mg Tablet T1001XX 3600mg/day.CHILD 3-12 yr:
3 divided doses. Effective
adult over 18 years
divided doses. Max
3600mg/day
i) MRI of the liver for the detection
of focal liver lesions in patients
with known or suspected primary
liver cancer (e.g. Hepatocellular i) MRI of liver: 0.05ml/kg
carcinoma) or metastatic disease; body weight. This
ii) MRI of the brain and spine corresponds to 0.1ml/kg of
where it improves the detection of the 0.5M solution ii) MRI of
lesion and provides diagnostic brain & spine: 0.1mmol/kg
Gadobenate
V08CA08996 information additional to that body weight. This
669 Dimeglumine A*
P3001XX obtained with unenhanced MRI; iii) corresponds to 0.2ml/kg of
Injection Solution
Contrast-enhanced MR- the 0.5M solution iii) MRA:
angiography where it improves the 0.1mmol/kg body weight.
diagnostic accuracy for detecting This corresponds to
clinically significant steno-occlusive 0.2ml/kg of the 0.5M
vascular disease in patients with solution
suspected or known vascular
disease of the abdominal or
peripheral arteries.
150 / 371
In adults, adolescents and children

aged 2 years and older with
diagnostic difficulty especially in
patients with renal impairment for:
i) Contrast enhancement in cranial A single intravenous
and spinal magnetic resonance injection of 0.1mmol/kg
Gadobutrol 1
V08CA09000 imaging (MRI). ii) Contrast (equivalent to 0.1 ml/kg
670 mmol/ml A*
P3001XX enhanced MRI of liver or kidneys in body weight). Max: 0.3
injection
patients with high suspicion or mmol/kg (equivalent to 0.3
evidence of having focal lesion to ml/kg body weight)
classify these lesions as benign or
malignant. iii)Contrast
enhancement in Magnetic
Resonance Angiography (CE-MRA).
The usual dose in adults,
children, and neonates is 0.2
mL/kg (0.1mmol/kg)
intravenously. For cranial
and spinal imaging, a further
dose of 0.2 mL/kg
(0.1mmol/kg) may be given
within 30 minutes if
necessary; in adults this
Gadopentetate i) Cranial and spinal magnetic second dose may be 0.4
V08CA01000
671 Dimeglumine 469 A resonance imaging ii) Whole body mL/kg (0.2mmol/kg). For
P3001XX
mg/ml magnetic resonance imaging whole body imaging in
adults and children over 2
years, a dose of 0.4 mL/kg
(0.2 mmol/kg) may be
needed in some cases to
produce adequate contrast
and in special circumstances
a dose of 0.6 mL/kg (0.3
mmol/kg) may be used in
adults
The recommended dose is
0.1mmol/kg (equivalent to
0.2 mL/kg in adults, children
Gadoterate High risk patients undergoing
and infants. In angiography,
Meglumine Magnetic Resonance Imaging for
V08CA02254 depending on the results of
672 (Gadoteric Acid) A cerebral and spinal disease,
P3001XX the examination being
0.5 mmol/ ml diseases of the vertebral column
performed, a second
Injection and other whole body pathology
injection may be
administered during the
same session if necessary
151 / 371

Gadoxetic acid
0.1ml/kg body weight
disodium 0.25 For use in adults for the
(equivalent to 25 µmol per
mmol/ml V08CA10520 enhancement of magnetic
673 A* kg body weight). Not
solution for P3001XX resonance imaging (MRI) of focal
recommended for patients
injection (10ml liver lesions
younger than 18 years
pre-filled syringe)
Gamma Benzene Apply lotion to entire body
P03AB02100
674 Hexachloride 0.1 C Scabies from neck down for 8 to 12
L6001XX
% Lotion hours, then rinse
Apply a sufficient quantity
of shampoo onto clean, dry
hair; generally 1 ounce is
sufficient, no more than 2
ounces should be used.
Gamma Benzene
Work the shampoo into hair
Hexachloride P03AB02100
675 C Head lice thoroughly and allow to
0.1% in Oil L9901XX
remain on hair for 4
Solution
minutes. Add small
quantities of water and
massage until a good lather
forms. Rinse thoroughly and
towel dry briskly
Scabies Adult: Apply a thin
layer of 1% topical
Gamma Benzene preparation onto all skin
P03AB02100
676 Hexachloride 1% A/KK Only for scabies in adult areas from the neck to toes.
G1002XX
Cream Completely wash off from
the body with warm water
after 8-12 hr.
Initial: 5 mg/kg infused over
1 hour 12 hourly for 14 - 21
Treatment of cytomegalovirus
days (CMV retinitis
(CMV) disease in
Ganciclovir treatment) or 7 - 14 days
J05AB06520P immunocompromised patients,
677 Sodium 50 mg/ A* (CMV disease prevention).
3001XX prevention of CMV disease during
ml Injection Long term maintenance: 6
immunosuppressive therapy
mg/kg daily for 5 days/week
following organ transplantation
or 5 mg/kg daily for 7
days/week
Prevention of premature luteinizing Given by SC 0.25 mg once
Ganirelix 0.25 hormone surges in women daily, starting on day 6 of
H01CC01000
678 mg/0.5 ml A* undergoing controlled ovarian ovarian stimulation and
P2001XX
Injection hyperstimulation for assisted continued until ovulation
reproduction technique induction
152 / 371
For the treatment of patients with

locally advanced or metastatic non-
small cell lung cancer (NSCLC) who
have previously failed
Gefitinib 250 mg L01XE02000T chemotherapy, and who have 250mg tablet once a day,
679 A*
tablet 1001XX activating mutation of epidermal taken with or without food
growth factor receptor (EGFR).
Restricted to non-smoker, female,
EGFR positive and Asian patients
only.
i) Alone or with cisplatin:
1000 mg/m2 day 1 & 8
every 3 weeks or 1000
i) Locally advanced or metastatic mg/m2 day 1, day 8, day 15
non-small cell lung cancer ii) Locally every 4 weeks ii) Initially
advanced or metastatic pancreatic 1000 mg/m2 weekly for 7
cancer iii) In combination with weeks followed by 1 week
carboplatin in the treatment of rest. Subsequent cycles
patients with recurrent epithelial 1000 mg/ m2 weekly for 3
ovarian carcinoma, who have weeks followed by 1 week
relapsed more than six months, rest iii) Gemcitabine 1000
Gemcitabine HCl L01BC05110P
680 A* following platinum-based therapy mg/m2 as 30 minutes IV
1 g Injection 4002XX
iv) In combination with paclitaxel infusion day 1 & 8 of each
for treatment of patients with 21-day cycle followed by
metastatic breast cancer who have carboplatin on day 1 to
relapsed following adjuvant/ attain a target AUC of 4
neoadjuvant chemotherapy. Prior mg/ml/minute iv) 1250
chemotherapy should have mg/m2 on days 1 and 8 of
included an anthracycline unless each 21-day cycle with
clinically contraindicated paclitaxel 175 mg/m2 given
as a 3-hour infusion before
gemcitabine on day 1 of
each 21-day cycle
153 / 371

i) Alone or with cisplatin:
1000 mg/m2 day 1 & 8
every 3 weeks or 1000
i) Locally advanced or metastatic mg/m2 day 1, day 8, day 15
non-small cell lung cancer ii) Locally every 4 weeks ii) Initially
advanced or metastatic pancreatic 1000 mg/m2 weekly for 7
cancer iii) In combination with weeks followed by 1 week
carboplatin in the treatment of rest. Subsequent cycles
patients with recurrent epithelial 1000 mg/ m2 weekly for 3
ovarian carcinoma, who have weeks followed by 1 week
relapsed more than six months, rest iii) Gemcitabine 1000
Gemcitabine HCl L01BC05110P
681 A* following platinum-based therapy mg/m2 as 30 minutes IV
200 mg Injection 4001XX
iv) In combination with Paclitaxel, infusion day 1 & 8 of each
for treatment of patients with 21-day cycle followed by
metastatic breast cancer who have carboplatin on day 1 to
relapsed following adjuvant/ attain a target AUC of 4
neoadjuvant chemotherapy. Prior mg/ml/minute iv) 1250
chemotherapy should have mg/m2 on days 1 and 8 of
included an anthracycline unless each 21-day cycle, with
clinically contraindicated paclitaxel 175 mg/m2 given
as a 3-hour infusion before
gemcitabine on day 1 of
each 21-day cycle
Gemeprost
Cervical dilatation: 1 pessary
(Prostagladin E1
G02AD03000 Inducing abortion in the first 3 hourly before surgery to a
682 Synthetic A
S1001XX trimester max of 5 pessaries over 24
Analogue) 1 mg
hours
Pessary
ADULT: 1200 mg/day in 2
Treatment of divided doses, 30 minutes
Gemfibrozil 300 C10AB04000
683 A/KK hyperlipoprotinaemias (TYPES IIA, before breakfast and dinner.
mg Capsule C1001XX
IIB, III, IV, V) Dose range from 0.9-1.5 g
daily
Gentamicin 0.1% D06AX07183
684 A* For localised infections Apply 2 - 3 times daily
Cream G1001XX
1 - 2 drops every 4 hours, in
Broad spectrum antibiotic in
Gentamicin 0.3% S01AA11183 severe infection dosage may
685 A/KK superficial eye infections and also
Eye Drops D2001XX be increased up to 2 drops
for Pseudomonas aeruginosa
every hour
Conjunctivitis, blepharitis,
blepharo-conjunctivitis, keratitis,
Gentamicin 0.3% S01AA11183 Apply into the conjunctival
686 A/KK keratoconjunctivitis, episcleritis,
Eye Ointment G5101XX sac 3 - 4 times daily
dacrocystitis, corneal ulcers, styes
and infected eye socket
Gentamicin 3% Broad spectrum antibiotic in
S01AA11183 Dose according to the needs
687 Fortified Eye A superficial eye infections and also
D2002XX of the patient
Drops for Pseudomonas aeruginosa
154 / 371
Treatment of chronic osteomyelitis

Gentamicin 7.5 J01GB03183P 7.5 - 22.5 mg chains to fill
688 A of post-traumatic, post-operative
mg Beads 1001XX affected cavity
or hematogenous origin
ADULT: 3 - 5 mg/kg/day 8
Gentamicin hourly IM or IV. CHILD up to
J01GB03183P Infections due to susceptible
689 Sulphate 10 B 2 weeks: 3mg/kg every 12
3002XX organisms
mg/ml Injection hours; 2 weeks - 12 years: 2
mg/kg 8 hourly
ADULT: 3 - 5 mg/kg/day 8
Gentamicin hourly IM or IV. CHILD up to
J01GB03183P Infections due to susceptible
690 Sulphate 40 B 2 weeks: 3mg/kg every 12
3003XX organisms
mg/ml Injection hours; 2 weeks - 12 years: 2
mg/kg 8 hourly
Inflammatory and allergic
Gentamicin conditions involving superficial eye
Sulphate and structures and when bacterial
Betamethasone S01CA05990 infection is present : conjunctivitis,
691 A/KK 2 drops 3 - 4 times daily
Disodium D2001XX blepharitis, keratitis, episcleritis,
Phosphate Eye dacryocystitis, hordeolum,
Drops meibomianitis, injuries involving
anterior segment of the eye
Inflammatory and allergic
Gentamicin conditions involving superficial eye
Sulphate and structures and when bacterial
Betamethasone S01CA05990 infection is present : conjunctivitis, Thin coating of ointment 3 -
692 A
Disodium G5101XX blepharitis, keratitis, episcleritis, 4 times daily
Phosphate Eye dacryocystitis, hordeolum,
Ointment meibomianitis, injuries involving
anterior segment of the eye
Range: 2.5 - 15 mg daily
(with or immediately after
Diabetes mellitus type 2.
Glibenclamide 5 A10BB01000 breakfast). Initially 2.5 mg
693 B Restriction : Use only in patient
mg Tablet T1001XX daily increasing by 2.5 mg
under 65 years old
required for metabolic
control. Max: 20mg daily.
Initially, 30mg daily at
breakfast time, may
Gliclazide 30 mg
A10BB09000 increase in successive steps
694 Modified Release B Diabetes mellitus type 2
T5002XX to 60, 90 or 120mg daily at 1
Tablet
month intervals. Max daily
dose: 120mg
Initially, 30mg daily at
breakfast time, may
Gliclazide 60 mg increase in successive steps
A10BB09000
695 Modified Release B Diabetes mellitus type 2 to 60, 90 or 120mg daily at 1
T5001XX
Tablet month intervals (except in
patients whose blood
glucose level was not
155 / 371

reduced after 2 weeks of
treatment). Max daily dose:
120mg
Initially 40-80mg daily. A
single dose should not
exceed 160mg and when
higher doses are required, a
Gliclazide 80 mg A10BB09000 twice daily split dosage is
696 B Diabetes mellitus type 2
Tablet T1001XX advised and should be
divided. Maximum daily
dose: 320mg. For elderly,
starting dose should be
40mg twice daily.
Adult, children > 20kg: 1mg
by SC, IM or IV. Children <
Glucagon 20kg : 0.5mg. If patient does
H04AA01000
697 (Lyophilised) 1 B Management of hypoglycaemia not respond within 10
P4001XX
mg/ml Injection minutes, administer IV
glucose. Repeat in 20
minutes if necessary.
20 minutes or more
immersion is recommended
for endoscopes before the
2% formulation - High level
Glutaraldehyde V07AV00000 session and between
698 A disinfection for heat sensitive
Solution 2% L9905XX patients after thorough
equipments such as endoscopes
cleaning based on
manufacturer
recommendation
A06AX01000 As a lubricant and osmotic
699 Glycerin C+ Apply to area when required
L5001XX dehydrating agent
Glycerin 25% and
A06AG20921
700 Sodium Chloride C+ Constipation 1 enema as required
G2001XX
15% Enema
0.5-1 mg sublingually may
be repeated every 5 minutes
Glyceryl
C01DA02221 Prophylaxis and treatment of until relief is obtained. Seek
701 Trinitrate 0.5 mg C
T1001XX angina and left ventricular failure physician if the pain persists
Sublingual Tablet
after a total of 3 tablets in a
15 minutes period.
Initial 5 mcg/min delivered
via infusion pump.
Subsequent titration must
Glyceryl Prophylaxis and treatment of
C01DA02221 be adjusted to clinical
702 Trinitrate 5 A angina, left ventricular failure. Not
P3001XX situation with dose
mg/ml Injection for direct IV injection.
increment becoming more
cautious as partial response
is seen.
156 / 371

At the onset of an attack,
one or two metered sprays
should be administered on
or under the tongue. A spray
maybe repeated
approximately every 5
minutes as needed. No
Glyceryl more than 3 metered sprays
Trinitrate Aerosol C01DA02221 Prophylaxis and treatment of are recommended within 15
703 B
Spray 400mcg A1001XX angina and left ventricular failure minute period. If chest pain
(metered dose) persists after a total of 3
sprays, prompt medical
attention is recommended.
Aerosol may be used
prophylactically 5 to 10
minutes before engaging in
activities that might
precipitate an acute attack
Glycine 1.5% The dosage depends on the
B05CX03000 Bladder irrigation during
704 Irrigating A extent of the procedure and
H3001XX genitourinary surgery
Solution its duration
i) Pre-op: 4mcg/kg via IM
administration 30-60 mins
before procedure.
i) To reduce secretions (respiratory
Intraoperative: 0.1 mg via IV
Glycopyrrolate tract) for certain types of surgery ii)
A03AB02320 administration, repeat at 2-
705 200 mcg/ml A* Reversal of neuromuscular block in
P3001XX 3 min intervals when
Injection patients where atropine is
needed. Max: 400mcg/dose.
contraindicated
ii) 0.2 mg by IV for each 1
mg of neostigmine or 5 mg
pyridostigmine
One capsule daily. The
recommended dose is the
inhalation of the content of
For maintenance bronchodilator
Glycopyrronium one capsule once daily using
treatment to relieve symptoms in
50mcg, inhaler. It is recommended
R03BB06320 adult patients with chronic
706 Inhalation A/KK to be administered, at the
A2001XX obstructive pulmonary disease
Powder Hard same time of the day each
(COPD). COPD diagnosis is
Capsules day. No relevant use of
confirmed by spirometry.
glycopyrronium in pediatric
population (<18 years) for
COPD.
157 / 371

i) Rheumatoid arthritis (RA): In
combination with methotrexate
(MTX), is indicated for: - The
treatment of moderate to severe
active rheumatoid arthritis in adult
patients when the response to
DMARD therapy including MTX has i) Rheumatoid arthritis
been inadequate. - The treatment 50mg given as a
of active, severe and progressive subcutaneous injection once
rheumatoid arthritis in adult a month, on the same date
Golimumab patients not previously treated each month. ii) Psoriatic
50mg (0.5ml) with MTX. ii) Psoriatic arthritis arthritis 50mg given as a
L04AB06000
707 solution for A* (PsA): Golimumab alone or in subcutaneous injection once
P5001XX
injection in a pre- combination with MTX, is indicated a month, on the same date
filled syringe for: The treatment of active each month. iii) Ankylosing
psoriatic arthritis in adult patients spondylitis 50mg given as a
when the response to previous subcutaneous injection once
DMARD therapy has been a month, on the same date
inadequate. iii) Ankylosing each month.
spondylitis (AS): Golimumab(used
alone) is indicated for: The
treatment of active ankylosing
spondylitis in adult patients when
the response to conventional
therapy has been inadequate.
Prostate
cancer,endometriosis,leiomyoma
One 10.8mg depot injected
Goserelin 10.8 uteri and assissted
L02AE03000P subcutaneously into the
708 mg Depot A reproduction,breast cancer in
2002XX anterior abdominal wall,
Injection premenopausal and
every 12 weeks.
perimenopausal women suitable
for hormonal manipulation
Prostate
cancer,endometriosis,leiomyoma
uteri and assissted
Goserelin 3.6 mg L02AE03000P 3.6 mg depot injection every
709 A reproduction,breast cancer in
Depot Injection 2001XX 28 days
premenopausal and
perimenopausal women suitable
for hormonal manipulation
ADULT 1 mg twice daily or 2
mg once daily with the first
Prevention and treatment of dose to be administered
Granisetron HCl 1 A04AA02110 nausea and vomiting associated within 1 hour prior to
710 A
mg Tablet T1001XX with chemotherapy and cytostatic therapy and can
radiotherapy be given for up to 1 week
following radiotherapy.
Maximum 9 mg/day
158 / 371

i) ADULT 1-3 mg as an IV
bolus not less than 30
seconds; maximum 9
i) Prevention and treatment of
mg/day. CHILD over 2 years;
nausea and vomiting associated
Granisetron HCl 1 A04AA02110 single dose of 10-40 mcg/kg
711 A with chemotherapy and
mg/ml Injection P3001XX as an IV infusion; maximum
radiotherapy ii) Post-operative
3 mg/day ii) ADULT 1 mg by
nausea and vomiting
slow IV injection over 30
seconds prior to induction
of anaesthesia
ADULT: 500 mg daily up to 1
g daily in divided doses, 2-8
wk in hair and skin
Griseofulvin Dermatophyte infections of the
infections, 6 mth in
(Ultramicrosize D01BA01000 skin, scalp, hair and nails, where
712 B fingernail infections and 12
125 mg = 250 mg T1001XX topical therapy has failed or
mth or more for toenail
Microsize) Tablet inappropriate
infections. CHILD: 10 mg/kg
daily in divided doses or as a
single dose
For acute renal failure, chronic
Haemodialysis
B05ZA00908 renal failure, overhydration, Dose depending on clinical
713 Concentrate with A
H1001XX intoxication, adjustment of acid- cases
Acetate
base and electrolyte balance
For acute renal failure, chronic
Haemodialysis
B05ZA00908 renal failure, overhydration, Dose depending on clinical
714 Concentrate with A
H1002XX intoxication, adjustment of acid- cases
Bicarbonate
base and electrolyte balance
Haemophilus
Influenza Type B
J07AG01000 Immunisation of infants against
715 Conjugate C 0.5 ml IM
P4001XX Haemophilus Influenzae Type B
Vaccine Injection
(Single Dose)
Adult: 0.5-5 mg bid/tid, may
increase up to 100 mg daily
in severe or resistant cases.
Usual maintenance: 3-10 mg
Haloperidol 1.5 N05AD01000
716 B Schizophrenia and other psychoses daily. Child: >3 yr: Initially,
mg Tablet T1001XX
25-50 mcg/kg daily in 2
divided doses, increased
gradually if necessary. Max:
10 mg/day.
159 / 371

Adult: 0.5-5 mg bid/tid, may
in severe or resistant cases.
Usual maintenance: 3-10 mg
Haloperidol 5 mg N05AD01000
717 B Schizophrenia and other psychoses daily. Child: >3 yr: Initially,
Tablet T1002XX
25-50 mcg/kg daily in 2
gradually if necessary. Max:
10 mg/day.
ADULT: IM or IV , 2 mg - 10
mg then every 4 - 8 hours
Haloperidol 5 N05AD01000 according to response to
718 B Acute psychoses and mania
mg/ml Injection P3001XX total maximum 18 mg daily.
Use in child is not
recommended
i) By IV injection, loading
dose of 5000 units (10,000
units in severe pulmonary
embolism) followed by
continuous infusion of 15-25
units/kg/hr. By SC injection
(for DVT) of 15,000 units
every 12 hours (laboratory
monitoring on daily basis
essential to adjust dose).
Small adult or child, lower
loading dose then, 15-25
i) Prophylaxis and treatment of units/kg/hr by IV infusion, or
venous thrombosis and pulmonary 250 units/kg every 12 hours
Heparin 1000 embolism. ii) Treatment of by SC injection. ii) As i), for
B01AB01520
719 units/ml B myocardial infarction and arterial unstable angina and acute
P3001XX
Injection embolism. iii) Prevention of clotting peripheral arterial occlusion.
in arterial and heart surgery and for iii) Prophylaxis in general
prevention of cerebral thrombosis surgery, by SC injection,
5000 units 2 hour before
surgery, then every 8-12
hours for 7 days or until
patient is ambulant, during
pregnancy (with
monitoring), 5000-10000
units every 12 hours. An
adjusted dose regimen may
be used for major
orthopaedic surgery or low
molecular weight heparin
may be selected
160 / 371

i) By IV injection, loading
dose of 5000 units (10,000
units in severe pulmonary
embolism) followed by
units/kg/hr. By SC injection
(for DVT) of 15,000 units
every 12 hours (laboratory
monitoring on daily basis
essential to adjust dose).
Small adult or child, lower
loading dose then, 15-25
i) Prophylaxis and treatment of units/kg/hr by IV infusion, or
venous thrombosis and pulmonary 250 units/kg every 12 hours
Heparin 5000 embolism. ii) Treatment of by SC injection. ii) As i), for
B01AB01520
720 units/ml B myocardial infarction and arterial unstable angina and acute
P3002XX
Injection embolism. iii) Prevention of clotting peripheral arterial occlusion.
in arterial and heart surgery and for iii) Prophylaxis in general
prevention of cerebral thrombosis surgery, by SC injection,
5000 units 2 hour before
surgery, then every 8-12
hours for 7 days or until
patient is ambulant, during
pregnancy (with
monitoring), 5000-10000
units every 12 hours. An
adjusted dose regimen may
be used for major
orthopaedic surgery or low
molecular weight heparin
may be selected
Heparin Sodium
50 units in B01AB01930 To maintain patency of peripheral Flush with 5 ml (50 units)
721 B
Sodium Chloride P3001XX venous catheters every 4 hours or as required
Injection
0.5 ml per injection. ADULT
Vaccination against hepatitis A and CHILD more than 15
Hepatitis A,
especially in those at risk of years: A single primary dose
Inactivated
J07BC02000P exposure to hepatitis A virus such followed by a booster dose
722 Vaccine 160 A
5001XX as: i) Visitors ii) Chronic hepatitis B 6 - 12 months later. CHILD 2
antigen units
and C patient iii) Those requiring - 15 years: A single primary
Injection
vaccination against hepatitis A dose followed by a booster
dose 6 - 12 months later
161 / 371

i) Adults: Recommended
Dose: 1000-2000 IU IM and
if necessary, the dose
should be increased or
repeated. Children: Inject
32-48 IU/kg of body weight,
should be administered
within 7 days after exposure
to HBsAg (preferably within
48 hrs). Neonates:
i) For post-exposure prophylaxis of
Hepatitis B Recommended Initial Dose:
hepatitis B ii) Prophylaxis against
Immunoglobulin J06BB04000P 100-200 IU. The 1st dose
723 A recurrence of hepatitis B infection
(Human) 3001XX should be administered
in chronic hepatitis B post liver
Injection within 5 days after birth
transplantation
(preferably within 48 hrs)
and booster dose should be
32-48 IU/kg body weight.
The booster dose should be
administered between 2 and
3 months after the 1st
administration. ii) Different
regimens depending on
hepatitis B virus (HBV) DNA
positivity
ADULTS over 20 years:
10mcg/dose. ADOLESCENT
11 - 19 years: 5 mcg/dose.
NEWBORN and CHILD up to
Hepatitis B J07BC01000P Immunisation against infections 10 years: 2.5 mcg/dose.
724 C+
Vaccine Injection 4001XX caused by Hepatitis B virus INFANTS born to HBsAg
positive mothers: 3 doses of
0.5 ml each. Second dose to
be given after 1 month and
booster dose after 6 months
i) Adult: Instill 1 or 2 drops
of 2% solution immediately
before the procedure,
repeat at 5-10-minute
intervals if necessary. Child:
Instill 1 drop of 2% soln
i) Mydriasis and cycloplegia for
Homatropine 2% S01FA05330 immediately before the
725 B refraction ii) Treatment of anterior
Eye Drops D2003XX procedure, repeat at 10-min
segment inflammation
intervals if necessary. ii)
Adult: Instill 1-2 drops of 2%
bd-tds up to every 3-4 hr as
needed. Child: 3 mth- 2 yr:
instill 1 drop of 0.5% soln
once daily or on alternate
162 / 371

days. >2 yr: instill 1 drop of
1% or 2% soln bd.
i) ADULT 25 g. CHILD 0.6
g/kg body weight ii)
i) Acute hypovolemic shock ii) Maximum daily dose is 2g iii)
Human Albumin B05AA01000
726 B Hypoproteinaemia iii) Neonatal 1 g/kg before exchange
Injection P3001XX
hyperbilirubinaemia transfusion. Dose is given at
rate of 1 ml of 25% solution
per minute
i) 50 mg/kg body weight
i) Hypogammaglobulinaemia and daily for 5 days, then 25 - 50
other deficiency states ii) Severe mg/kg weekly for
refractory idiopathic maintenance according to
thrombocytopenia purpura the severity of the condition
(platelet less than 20,000) with ii) 400 mg/kg daily for 5 days
Human Normal internal bleeding, particularly with a further dose of 400
J06BA02000P
727 Globulin A central nervous system iii) mg/kg as required iii)
3001XX
Injection Septicaemia in Septicaemia in
immunocompromised patients or immunocompromised
patients not responding to patients or patients not
antibiotics iv) Chronic lymphocytic responding to antibiotics iv)
leukaemia not responding to 250 mg/kg per month Dose
conventional therapy varies depending on brand
used
Human For the prevention of cervical Given by IM into deltoid
Papillomavirus J07BM02000 cancer due to papilloma virus. To region. ADULT and CHILD 10
728 C+
(Types 16, 18) P3001XX be used as part of the public health - 25 years, 3 doses of 0.5
Vaccine Injection program only mL, at 0, 1 and 6 months
Given by IM into deltoid
Human
For the prevention of cervical region or higher
Papillomavirus
J07BM01000 cancer due to papilloma virus. To anterolateral thigh. ADULT
729 (Types 6, 11, 16, C+
P3001XX be used as part of the public health and CHILD 9 - 26 years, 3
18) Vaccine
program only doses of 0.5 mL, at 0, 2 and
Injection
6 months
i) Slow IV injection, ADULT:
5-10 mg diluted with 10ml
sodium chloride 0.9%. May
Hydralazine HCl C02DB02110 be repeated after 20-30
730 B Hypertensive crisis in pregnancy
20 mg Injection P3001XX minutes if necessary. ii) IV
infusion 200-300
mcg/minutes. Maintenance
dose 50-150 mcg/minutes
163 / 371

ADULT: Diuretics; 25-200 mg
daily. Hypertension 12.5-25
mg daily CHILD: Oedema
and hypertension; Adjunct;
1 to 2 mg/kg ORALLY daily in
single or two divided doses;
Children 2-12 years old MAX
Hydrochlorothiaz C03AA03000 dose, not to exceed 100 mg
731 B Diuretic, hypertension
ide 25 mg Tablet T1001XX ORALLY daily; Infants less
than 6 months old, may
require doses up to 3 mg/kg
ORALLY daily in two divided
doses, Infants up to 2 yrs
old: MAX dose, not to
exceed 37.5 mg ORALLY
daily
ADULT: Diuretics; 25-200 mg
daily. Hypertension 12.5-25
mg daily CHILD: Oedema
and hypertension; Adjunct;
1 to 2 mg/kg ORALLY daily in
single or two divided doses;
Children 2-12 years old MAX
Hydrochlorothiaz C03AA03000 dose, not to exceed 100 mg
732 B Diuretic, hypertension
ide 50 mg Tablet T1002XX ORALLY daily; Infants less
than 6 months old, may
require doses up to 3 mg/kg
ORALLY daily in two divided
doses, Infants up to 2 yrs
old: MAX dose, not to
exceed 37.5 mg ORALLY
daily
Apply to affected part 2-3
Hydrocortisone Inflammatory and pruritic
D07CA01952 times daily (occasionally
733 1% & Neomycin B manifestations of corticosteroid
G1001XX may cause sensitisation to
0.5% Cream responsive dermatoses
Neomycin)
Inflammatory and pruritic
Hydrocortisone D07AA02000 area 2 - 3 times daily until
734 B manifestations of corticosteroid
1% Cream G1001XX condition improve, then
responsive dermatoses
reduce frequency
Inflammatory and pruritic
Hydrocortisone D07AA02000 area 2 - 3 times daily until
735 B manifestations of corticosteroid
1% Ointment G5001XX condition improve, then
responsive dermatoses
reduce frequency
164 / 371
Glucocorticoid replacement
therapy in primary or secondary ADULT: 20 - 30 mg daily in
Hydrocortisone H02AB09000
736 B adrenal insufficiencies and long divided doses. CHILD: 10 -
term management of congenital 30 mg daily in divided doses
adrenal hyperplasia in children
ADULT 100 mg 1-2
times/day for 2-3 weeks. If
Hydrocortisone A07EA02000 Adjunctive treatment for ulcerative
737 B used for longer than 3
Enema 0.1% G2001XX colitis and proctitis
weeks, taper treatment over
2-3 weeks
Initially 100 - 500 mg IV over
Hydrocortisone Conditions responsive to systemic 30 seconds to more than 10
H02AB09520
738 Sodium Succinate C or local glucocorticoid injection minutes. Dose may be
P4001XX
100 mg Injection therapy especially in emergencies repeated at intervals of 2, 4
or 6 hours
Hydrogen Instill 1 - 2 drops into the
S02AA06241
739 Peroxide 1.5% C To soften impacted ear wax ear as required (leave for a
D1001XX
Ear Drops few minutess)
Hydrogen Peroxide 6%
(=approx. 20 vol) shall be
dispensed. For cleansing
wounds: 1.5% to 6%
solution apply 2-3 times
daily or when nescessary. As
a mouthwash: rinse the
mouth for 2-3 minutes with
Hydrogen Skin disinfection, particularly 15ml of hydrogen peroxide
D08AX01241
740 Peroxide 20 C cleansing and deodorising wounds 6% diluted in half a
L9901XX
volume Solution and ulcers tumblerful of warm water 2-
3 times daily. Disinfecting
cleaned equipment:
immersion for 30 minutes in
6% solution. As ear drop for
removal of wax: hydrogen
peroxide 6% diluted with 3
parts of water preferably
just before use
i) Initially 400 mg daily in
divided dose. Maintenance :
i) SLE and mixed connective tissue 200 - 400 mg daily ii) ADULT
Hydroxychloroqu
P01BA02183 disease for skin, joint and serosa ii) : 400 - 600 mg daily.
741 ine Sulphate 200 A
T1001XX Second line therapy for acute Maintenance: 200 - 400 mg
mg Tablet
rheumatoid arthritis daily. CHILD : up to 6.5
mg/kg daily (maximum
400mg daily)
Hydroxyethyl V07AY00250 Apply sufficiently for
742 B For lubricating purpose
Cellulose Jelly G4001XX lubricating purpose
165 / 371

ADULT daily dose up to 20
ml/kg/day. Normally 500-
1500 ml. The rate of
Therapy and prophylaxis of infusion may approach 20
Hydroxyethyl
B05AA07000 hypovolaemia and shock in ml/kg/hour in acute
743 Starch 6% B
P9901XX connection with surgery trauma, haemorrhagic shock, slower
Injection
infections and burns rates in burns and septic
shock. CHILD under 10 years
do not exceed 15 ml
/kg/hour.
Hydroxyprogeste
rone Caproate G03DA03128 250 - 500 mg once weekly
744 A Habitual and threatened abortion
250 mg/ml P2001XX by IM injection
Injection
i) Intermittent therapy: 80
mg/kg orally as a single dose
every 3rd day. Continuous
therapy: 20 - 30 mg/kg
orally as a single dose dly.
Concomitant therapy with
irradiation: 80 mg/kg orally
as a single dose every 3rd
i)Solid tumours ii) Chronic day.(administration of
myelocytic leukaemia and hydroxyurea should be
myeloproliferative disease started at least 7 days
Hydroxyurea 500 L01XX05000C
745 A iii)Severe psoriasis eg. Extensive before initiation of
mg Capsule 1001XX
plaque psoriasis, erythrodermic irradiation and continued
psoriasis, pustular psoriasis -as during radiotherapy as well).
third line therapy. ii)Continuous therapy (20 -
30 mg/kg orally as a single
dose daily, therapy should
be interrupted if the white
blood cell count drops
below 2500/mm3, or the
platelet count below
100,000/mm3. iii) 500 mg
tds.
Initially 25 mg at night,
increased if necessary up to
25 mg 3-4 times daily.
Hydroxyzine HCl N05BB01110 ADULT and CHILD more than
746 A Allergic pruritus
25 mg Tablet T1001XX 10 years : 50 - 75 mg; 6 - 10
years: 25 - 50 mg; 1 - 5
years: 12.5 - 25 mg; to be
taken daily in divided doses
Hyoscine 200-600 mcg given as SC or
A04AD01330 To reduce oral secretions before
747 Hydrobromide B IM 60 minutes before
P3001XX surgery
400 mcg/ml induction of anaesthesia.
166 / 371

Injection CHILD: 15 mcg/kg
Hyoscine N- Gastrointestinal tract and genito- ADULT 40mg 4 times a day.

A03BB01320
748 Butylbromide 1 B urinary tract spasm, dyskinesia of CHILD 6-12 years old: 10mg
L5001XX
mg/ml Liquid the biliary system 3 times a day.
Hyoscine N- Gastrointestinal tract and genito- ADULT 40mg 4 times a day.
A03BB01320
749 Butylbromide 10 B urinary tract spasm, dyskinesia of CHILD 6-12 years old: 10mg
T1001XX
mg Tablet the biliary system 3 times a day.
Hyoscine N- Gastrointestinal tract and genito- 20 mg IM/IV repeated after
A03BB01320
750 Butylbromide 20 B urinary tract spasm, dyskinesia of 30 min if needed. Max: 100
P3001XX
mg/ml Injection the biliary system mg daily.
Tear deficiency, ophthalmic
Hypromellose S01XA20000 1 - 2 drops several times a
751 B lubricant; for relief of dry eyes and
0.3% Eye Drops D2002XX day
eye irritation
Hypromellose Symptomatic relief of severe dry
0.3%, Carbomer S01KA02000 eye conditions and as lens lubricant Instill 1-2 drops in affected
752 B
980 Ophthalmic G3201XX during ophthalmic diagnostic eye(s) as needed
Gel procedures
Treatment of postmenopausal
osteoporosis to reduce the risk of
fracture. Review treatment after 2
years and if there is positive
response, treatment may be
continued up to 5 years and then
Ibandronic Acid M05BA06000
753 A* re-evaluate. Treatment should be 150 mg once monthly
stopped if there is no positive
response after 5 years. Otherwise,
patient needs to be given drug
holiday for 1 to 2 years and then
continue treatment shall the
benefit outweigh the risk.
Dosage: ADULT: 200 - 400
mg 3 times daily after food,
maximum 3.2 g daily. CHILD:
Ibuprofen 200 M01AE01000 Pain and inflammation in 30-50 mg/kg body weight
754 B
mg Tablet T1001XX rheumatic disease daily in divided doses,
maximum 2.4g daily. Lowest
effective dose for the
shortest possible duration.
Ichthammol 2 - 3 drops 3 - 4 times daily
S02AA30000 Ear wick for otitis externa with
755 Glycerin 10% Ear C and in ear wick for otitis
D1001XX oedema
Drops externa
167 / 371

i) Induction phase: 12
mg/m2 IV slow bolus on
i) Acute promyelocytic leukaemia ii) Days 3, 5 and 7.
Relapse Acute myeloid leukemia Consolidation phase, month
Idarubicin 10 mg L01DB06110 (with sibling match) iii) Acute 1: 12 mg/m2 IV on Days 1
756 A*
Injection P4002XX myeloid leukemia, acute and 2. Repeat monthly for 3
lymphoblastic leukemia (salvage courses ii) 12 mg/m2 D1-3
therapy) iii) 12 mg/m2 D1-3 as part of
FLAG-IDA regimen. Children:
10mg/m2 IV daily for 3 days
i) Induction phase: 12
mg/m2 IV slow bolus on
i) Acute promyelocytic leukaemia ii) Days 3, 5 and 7.
Relapse Acute myeloid leukemia Consolidation phase, month
Idarubicin 5 mg L01DB06110 (with sibling match) iii) Acute 1: 12 mg/m2 IV on Days 1
757 A*
Injection P4001XX myeloid leukemia, acute and 2. Repeat monthly for 3
lymphoblastic leukemia (salvage courses ii) 12 mg/m2 D1-3
therapy) iii) 12 mg/m2 D1-3 as part of
FLAG-IDA regimen. Children:
10mg/m2 IV daily for 3 days
0.5 mg/kg of body weight
Idursulfase 2 A16AB09000 Hunter syndrome
758 A* administered every week as
mg/ml Injection P3001XX (Mucopolysaccharidosis II, MPS II).
an intravenous infusion.
i) 1.2 - 2.4 g/m2/day for 3 - 7
days as a 30 - 120 minutes
infusion. Alternatively, can
also be given as a single high
dose, eg. 5 g/m2 in a 24
Ifosfamide 1 g L01AA06000 i) Solid tumours ii) Leukaemia iii)
759 A* hour infusion. Cycles may be
Injection P4001XX Lymphoma
repeated every 3 - 4 weeks
ii) CHILD: 400 - 3000
mg/m2/day for 3 - 5 days
according to protocol iii)
Refer to protocols
i) ADULT: Chronic phase
i) ADULT and CHILD: Philadelphia chronic myeloid leukemia:
positive (Ph+) chronic myeloid 400 mg once daily.
leukaemia in chronic phase and in Accelerated phase or blast
early acceleration after failure of crisis chronic myeloid
Imatinib
L01XE01196T interferon therapy ii) Treatment of leukemia: 600 mg once
760 Mesylate 100 mg A*
1001XX patients with unresectable and/or daily. CHILD more than 2
Tablet
metastatic malignant years, chronic and advanced
gastrointestinal stromal tumours phase chronic myeloid
(GIST) who are positive for leukemia: 340 mg/m2 daily.
CD117/c-kit Max: 800 mg/day ii) ADULT :
400mg/day
168 / 371

i) ADULT: Chronic phase
i) ADULT and CHILD: Philadelphia chronic myeloid leukemia:
positive (Ph+) chronic myeloid 400 mg once daily.
leukaemia in chronic phase and in Accelerated phase or blast
early acceleration after failure of crisis chronic myeloid
Imatinib
L01XE01196T interferon therapy ii) Treatment of leukemia: 600 mg once
761 Mesylate 400 mg A*
1002XX patients with unresectable and/or daily. CHILD more than 2
Tablet
metastatic malignant years, chronic and advanced
gastrointestinal stromal tumours phase chronic myeloid
(GIST) who are positive for leukemia: 340 mg/m2 daily.
CD117/c-kit Max: 800 mg/day ii) ADULT :
400mg/day
Non-neuronopathic (Type 1) or
chronic neuronopathic (Type 3)
Gaucher disease and who exhibit
clinically significant non- Dosage should be
neurological manifestations of the individualized to each
disease. The non-neurological patient. Initial dosages
manifestations of Gaucher disease range from 2.5 units/kg of
Imiglucerase 400 A16AB02000
762 A* include one or more of the body weight 3 times a week
IU Injection P4002XX
following conditions: - anemia, to 60 units/kg once every 2
after exclusion of other causes, weeks. Administered by
such as iron deficiency - intravenous infusion over 1-
thrombocytopenia - bone disease, 2 hours.
after exclusion of other causes,
such as Vitamin D deficiency -
hepatomegaly or splenomegaly
Based on type or severity of
infection, susceptibility of
pathogen(s) and patient
condition including body
weight and renal function.
ADULT: 1 - 2 g/day in 3 - 4
divided doses. Maximum: 4
g/day or 50 mg/kg/day.
Severe infections caused by
Infusion rate: less than 500
Imipenem 500 susceptible pathogens especially
J01DH51961 mg dose: over 20 - 30
763 mg and Cilastatin A* useful in infections involving ESBL
P4002XX minutes, more than 500 mg:
500 mg Injection organisms. Not to be used for
dose over 40 - 60 minutes.
prophylaxis
CHILDREN: ≥ 40kg body
weight should receive adult
doses. CHILDREN AND
INFANTS: <40kg body
weight should receive
15mg/kg at six hour
intervals. The total daily
dose should not exceed 2g.
169 / 371

Initially up to 75 mg daily in
divided doses increased
gradually to 150 - 200 mg
(up to 300 mg in hospital
patients); up to 150 mg may
Imipramine HCI N06AA02110
764 B Depression be given as a single dose at
bedtime. ELDERLY initially
10 mg daily; increased
gradually to 30 - 50 mg
daily; CHILD is not
recommended
Apply to affected area at
Treatment of external genital and
Imiquimod 5 % D06BB10000 bedtime for 3 times a week
765 A* perianal warts or condyloma
w/w Cream G1001XX for up to 16 weeks; leave on
acuminata in adults
skin for 6-10 hours
Immunoglobulin Prophylaxis of tetanus: IM
Tetanus Human J06BB02000P Passive immunization against 250 units. Treatment of
766 B
250 Units/Vial 3001XX tetanus tetanus: IM 30 - 300
Injection units/kg
Maintenance bronchodilator Once-daily inhalation of the
Indacaterol
treatment of airflow obstruction in content of one 150/300
Maleate 150 mcg R03AC18253
767 A* adult patients with chronic microgram capsule.
Inhalation C9901XX
obstructive pulmonary disease Maximum dose is 300
Capsule
(COPD). microgram once-daily.
Maintenance bronchodilator Once-daily inhalation of the
Indacaterol
treatment of airflow obstruction in content of one 150/300
Maleate 300 mcg R03AC18253
768 A* adult patients with chronic microgram capsule.
Inhalation C9902XX
obstructive pulmonary disease Maximum dose is 300
Capsule
(COPD). microgram once-daily.
ADULT: 800 mg every 8
hours. CHILD
i) Post-exposure prophylaxis (PEP) (investigational): 500
among healthcare workers in high- mg/m2 every 8 hours
risk HIV occupational exposure ii) (patients with smaller body
Indinavir Sulfate J05AE02183C
769 A* For therapy as part of combination surface area (BSA) may
400 mg Capsule 1001XX
antiretroviral treatment on adult require lower doses of 300 -
HIV patients ie Highly Active Anti- 400 mg/m2 every 8 hours).
Retroviral Therapy (HAART) Dosage may vary depending
on types of combination
therapy used.
Adult: As supp: 100 mg to be
Indomethacin
M02AA23000 Pain and inflammation in inserted at night and
770 100 mg B
S2001XX rheumatic arthritis repeated in the morning if
Suppository
necessary.
50 - 200 mg daily in divided
Indomethacin 25 M01AB01000 Pain and inflammation in
771 B doses, with food. Child not
mg Capsule C1001XX rheumatic disease
recommended.
170 / 371

i) Rheumatoid arthritis:
ADULT over 18 years old: 3
mg/kg at 0, 2, 6 weeks, then
every 8 weeks; May increase
to 10 mg/kg or increase
dosing frequency to 4
i) Rheumatoid arthritis (moderate
weekly for patients with
to severe), in combination with
incomplete response.
methotrexate ii) Ankylosing
Discontinue if no response
spondylitis in patients with active
by 12 weeks of initial
disease despite treatment with
infusion or after dose
methotrexate iii) Crohn's Disease in
adjustment ii) Ankylosing
patients who have an inadequate
Infliximab 100 L04AB02000 spondylitis: ADULT over 18
772 A* response to conventional
mg Injection P4001XX years: 5 mg/kg IV over 2
therapies. iv) Fistulizing Crohn's
hour given at week 0, 2, and
Disease in patients who have an
6 then every 6-8 weeks.
conventional therapies v)
by 6 weeks of initial
Ulcerative Colitis in patients who
infusion. iii), iv) & v)5 mg/kg
have an inadequate response to
given as an intravenous
conventional therapies
infusion over a 2-hour
period followed by
additional 5 mg/kg infusion
doses at 2 and 6 weeks after
the first infusion, then every
8 weeks thereafter
Influenza Vaccine
(Inactivated,
trivalent)
Injection CHILD 6-35 months: Single
(containing 3 Prophylaxis of influenza for dose of 0.5 ml IM or deep
strains, two type J07BB02963P frontliners (KKM staff and essential SC; 3-8 years: 1-2 doses of
773 B
A subtypes, of 3001XX services personnel) and in high risk 0.5 ml IM ADULT & CHILD
which one must groups more than 9 years: Single
include pandemic dose of 0.5 ml IM
A (H1N1) and
one Type B
subtype)
Influenzae
Vaccine Prevention of influenza and
(Inactivated,Triva influenza related complications in
19 to 59 years: Single dose
lent) Type A high risk adult patients, in
of 0.1ml 9mcg/strain
(H1N1) 15 mcg, J07BB02963P particular individuals who have
774 B intradermally. ≥ 60 years:
Type A (H3N2) 15 5002XX chronic cardiovascular, pulmonary,
Single dose of 0.1ml
mcg & Type B 15 metabolic or renal disease, or who
15mcg/strain intradermally
mcg are immunocompromized and
Haemagglutinin elderly patients
Injection
171 / 371

Influenzae
Vaccine Prevention of influenza and
(Inactivated,Triva influenza related complications in
18 to 59 years: Single dose
lent) Type A high risk adult patients, in
of 0.1ml 9mcg/strain
(H1N1) 9 mcg, J07BB02963P particular individuals who have
775 B intradermally. ≥ 60 years:
Type A (H3N2) 9 5001XX chronic cardiovascular, pulmonary,
Single dose of 0.1ml
mcg & Type B 9 metabolic or renal disease, or who
15mcg/strain intradermally
mcg are immunocompromized and
Haemagglutinin elderly patients
Injection
Diabetic Type 1 and 2 in patients Dose to be individualised.
Insulin Aspart
A10AB05000 that still experienced The average daily insulin
776 100 IU/ml A*
P3001XX hypoglycaemia with use of human requirement is between 0.5
Injection
insulin to 1.0 units/kg body weight
Insulin Aspart
30% and Diabetic type 1 and 2 in patients Dose to be individualised.
Protaminated A10AD05000 that still experienced The average daily insulin
777 A/KK
Insulin Aspart P3001XX hypoglycaemia with use of human requirement is between 0.5
70% 100 U/ml insulin to 1.0 units/kg body weight
Injection
i)Type 1 Diabetes patients on basal
bolus regimen, whom experience Individualized dose given via
hypoglycemia with conventional SC once or twice daily.
Insulin Detemir insulin, to be used in combination Initiate at a dose of 10IU or
100 IU/ml with rapid or short-acting insulin. 0.1-0.2IU/kg. For twice daily
A10AE05000
778 Injection in A* ii)Type 2 Diabetes patients on oral dosing, the evening dose
P5001XX
Prefilled anti-diabetics and basal insulin can be administered either
syringe/cartridge regimen or basal bolus insulin with the evening meal, at
regimen whom experience bedtime, or 12 hours after
hypoglycemia with conventional the morning dose.
basal insulin.
years: individualised dose
Insulin Glargine
i) Diabetes mellitus type I in adults given by SC, once daily at
300IU/3ml A10AE04000
779 A/KK and child over 6 years ii) Diabetes the same time every day.
Prefilled Pen for P5001XX
mellitus type II in adult Adult patients who are
Injection
insulin naïve may be
initiated with 10IU daily.
Glulisine should be given
shortly (0-15 min) before or
soon after meals. Apidra
Insulin Glulisine
Treatment of adults, adolescents should be used in regimens
100u/ml solution
A10AB06000 and children 6 years or older with that include an intermediate
780 for injection in A*
P5001XX diabetes mellitus, where treatment or long acting insulin or
pre-filled pen
with insulin is required. basal insulin analogue and
3ml
can be used with oral
hypoglycaemic agents. The
dosage of Apidra should be
172 / 371

individually adjusted.
i) As initial therapy in children with
Type 1 diabetes ii)Type 1 diabetes
patients on basal bolus regimen,
not controlled or experience
hypoglycaemia with conventional
insulin, to be used in combination
with long-acting insulin iii)Type 2 Dose to be individualized.
Insulin Lispro 100 diabetes patients on basal bolus or The average daily insulin
IU/ml Injection in A10AB04000 premixed regimen, not controlled requirement is between 0.5
781 A*
Prefilled P5001XX or experience hypoglycaemia with to 1.0 units/kg body weight,
syringe/cartridge conventional insulin, to be used in given within 15 minutes
combination with intermediate- before meal.
acting insulin or long-acting insulin
iv)Patients with diabetes in
pregnancy with poor postprandial
control or experience
hypoglycaemia with conventional
short-acting insulin
Insulin Lispro
25% & Insulin
Patients with Type 2 diabetes Dose to be individualized.
Lispro Protamine
A10AD04000 whom experience hypoglycemia The average daily insulin
782 75% 100 IU/ml A*
P5001XX with the use of human premixed requirement is between 0.5
Injection in
insulin. to 1.0 units/kg body weight
Prefilled
syringe/cartridge
The average daily insulin
requirement is between 0.3-
Insulin
1.0 units/kg body
Recombinant
weight/day. Daily insulin
Neutral Human A10AB01000
783 B Diabetes mellitus requirement may be higher
Short Acting 100 P3001XX
in patients with insulin
IU/ml Injection in
resistance, and lower in
10ml vial
patients with residual,
endogenous insulin
production.
Insulin
1.0 units/kg body
Recombinant
Neutral Human A10AB01000
Short-acting P5001XX
100IU/ml Penfill
and Refill
endogenous insulin
production.
173 / 371

Insulin
Recombinant Dose to be individualised.
Synthetic Human The daily insulin
A10AC01000
785 Intermediate- B Diabetes mellitus requirement is usually
P3001XX
Acting 100IU/ml between 0.3 and 1.0IU/kg
in Vial for /day
Injection
Insulin
1.0 units/kg body
Recombinant
Synthetic Human A10AD01000
Premixed P3001XX
100IU/ml in Vial
for Injection
endogenous insulin
production.
Insulin dependent diabetes
Insulin mellitus, non insulin dependent
Recombinant diabetes unresponsive to Dose to be individualised.
Synthetic treatment to diet or oral The daily insulin
A10AC01000
787 Human, B hypoglycaemics, hyperkalaemia to requirement is usually
P5001XX
Intermediate- assure proper utilisation of glucose between 0.3 and 1.0IU/kg
Acting 100 IU/ml and reduce glucosuria in non /day
Penfill and Refill diabetic patients receiving
parenteral nutrition
Insulin dependent diabetes
Insulin mellitus, non insulin dependent
Recombinant diabetes unresponsive to
Synthetic treatment to diet or oral
A10AD01000 The average daily insulin
788 Human, B hypoglycaemics, hyperkalaemia to
P5001XX requirement is between 0.5-
Premixed 100 assure proper utilisation of glucose
1.0 units/kg body weight
IU/ml Penfill and and reduce glucosuria in non
Refill diabetic patients receiving
parenteral nutrition
174 / 371

i) Initial: 3 MIU SC daily. If
intolerant, 1.5 MIU daily or
3 MIU 3 times a week or 1.5
MIU 3 times a week.
Maintenance: 1.5-3 MIU SC
3 times a week ii) Patient >
18 years: 3 MIU daily (days
1-3), 6 MIU daily (days 4-6),
9 MIU daily (days 7-84) iii)
Patient > 18 years: Initially
escalating dose to 18-36
MIU SC/IM for 10-12 weeks.
For the treatment of i) Hairy cell Maintenance: up to 36 MIU
leukaemia ii) Chronic myelogenous 3 times a week iv) 2.5-5
Interferon Alfa -
L03AB04000 leukaemia iii) AIDS related Kaposi's MIU/m2 SC 3 times a week
789 2a 3 MIU A*
P3001XX Sarcoma iv) Chronic hepatitis B v) for 4-6 months. CHILD: up to
Injection
Chronic hepatitis C vi) Advanced 10 MIU/m2 BSA v)
renal cell carcinoma Monotherapy: Initial: 3 - 6
MIU SC 3 times a week for 6
months. Maintenance: 3
MIU 3 times a week for an
additional 6 months. vi) As
an adjunct to cytotoxic
chemotherapy: An
escalating dose of 3 MIU 3
times a week for 1 week,
then 9 MIU 3 times a week
for 1 week, then 18 MIU 3
times a week thereafter for
3-12 months SC
i) 2 MIU SC or IM 3 times a
week ii) Patient more than
18 years: 3 - 9 MIU 3 - 5
times a week or daily
depending on response iii)
Patient more than 18 years.
For the treatment of i) Hairy cell Initially escalating dose to
Interferon Alfa- leukaemia ii) Chronic myelogenous 18-36 MIU SC/IM for 10-12
2b 18 MIU L03AB05000 leukaemia iii) AIDS related Kaposi's weeks. Maintenance: up to
790 A
Multidose P5001XX sarcoma iv) Chronic hepatitis B v) 36 MIU 3 times weekly iv)
Injection Pen Chronic hepatitis C vi) Advanced 2.5-5 MIU/m2 SC 3 times
renal cell carcinoma weekly for 4-6 month.
CHILD: up to 10 MIU/m2
BSA v) 3 MIU for 12 months
vi) As an adjunct to cytotoxic
chemotherapy: An
escalating dose of 3 million
IU 3 times/week for 1 week,
175 / 371

then 9 million IU 3
times/week for 1 week, then
18 million IU 3 times/week
thereafter for 3-12 month
SC or IM
18 years: 3 - 9 MIU 3 - 5
Initially escalating dose to
18-36 MIU SC/IM for 10-12
weeks. Maintenance: up to
For the treatment of i) Hairy cell
36 MIU 3 times weekly iv)
Interferon Alfa- leukaemia ii) Chronic myelogenous
2.5-5 MIU/m2 SC 3 times
2b 30 MIU L03AB05000 leukaemia iii) AIDS related Kaposi's
791 A weekly for 4-6 month.
Multidose P5002XX sarcoma iv) Chronic hepatitis B v)
CHILD: up to 10 MIU/m2
Injection Pen Chronic hepatitis C vi) Advanced
renal cell carcinoma
chemotherapy: An
then 9 million IU 3
SC or IM
18 years: 3 - 9 MIU 3 - 5
Initially escalating dose to
For the treatment of i) Hairy cell 18-36 MIU SC/IM for 10-12
leukaemia ii) Chronic myelogenous weeks. Maintenance: up to
Interferon Alpha
L03AB04000 leukaemia iii) AIDS related Kaposi's 36 MIU 3 times weekly iv)
792 - 2a 4.5 MIU A*
P3002XX Sarcoma iv) Chronic hepatitis B v) 2.5-5 MIU/m2 SC 3 times
Injection
Chronic hepatitis C vi) Advanced weekly for 4-6 month.
renal cell carcinoma CHILD: up to 10 MIU/m2
chemotherapy: An
then 9 million IU 3
176 / 371

SC or IM
i) 2 MIU/m2 SC or IM 3
times a week ii) 4 - 5
MIU/m2 SC daily. Treatment
must be discontinued after
8 to 12 weeks of treatment
if at least a partial
haematological remission or
a clinically meaningful
cytoreduction has not been
achieved iii) Patient > 18
For the treatment of i) Hairy cell years : 30 MIU/m2 SC or IM
leukaemia ii) Chronic myelogenous three times a week until
Interferon Alpha
L03AB05000 leukaemia iii) AIDS related Kaposi's disease progression or
793 2b 3 MIU A*
P3001XX sarcoma iv) Chronic hepatitis B v) maximal response has been
Injection
Chronic hepatitis C vi) Advanced achieved after 16 weeks of
renal cell carcinoma treatment. iv) 5 MIU daily or
10 MIU three times a week
for 16 weeks. CHILD : 3
MIU/m2 three times a week
for the first week of therapy
followed by dose escalation
to 6 MIU/m2 (maximum of
10MIU) three times a week
SC for a total duration of 16
to 24 weeks v) 3 MIU SC or
IM 3 times a week.
i)Relapsing-remitting multiple
sclerosis (RRMS): Reduction of
frequency and degree of severity of
clinical relapses in ambulatory
patients characterized by at least
two attacks of neurological
Interferon beta -
L03AB08000 dysfunction over the preceding two 0.25 mg (8 MIU) by SC
794 1b 250mcg A*
P4001XX year period, followed by complete injection every other day
(8MIU) Injection
or incomplete recovery
ii)Secondary progressive multiple
sclerosis (SPMS):Reduction of
frequency and severity of clinical
relapses and for slowing the
progression of disease
Multiple sclerosis of the relapsing
Interferon Beta- L03AB07000
795 A* remitting type with 2 or more 22 mcg 3 times weekly
1a 22 mcg P5001XX
relapses within the last 2 years
177 / 371
Multiple sclerosis of the relapsing

Interferon Beta- L03AB07000
796 A* remitting type with 2 or more 44 mcg 3 times weekly
1a 44 mcg P5002XX
relapses within the last 2 years
Iodamide V08AA03000 According to the procedure
797 A For hysterosalpingography
Injection P3001XX and route of administration
Iodine and i) Pre-operative treatment of
H03CA00200 i) 1 ml daily in divided doses
798 Potassium Iodide B thyrotoxicosis ii) Thyrotoxicosis
L9901XX ii) 2 - 3 ml daily
Solution crisis
X-ray contrast medium for
cardioangiography, cerebral
angiography, peripheral
Iodixanol 320 mg V08AB09000 arteriography, abdominal Depending on type of
799 A
I/ml Injection P3001XX angiography, uroloraphy, examination
venography, CT enhancement,
lumbar, thoracic and cervical
myelography
X-ray contrast medium for use in
adults and children for
cardioangiography, arteriography,
urography, phlebography and CT-
enhancement. Lumbar, thoracic,
cervical myelography and
V08AB02000 computed tomography of the basal Dose depending on the
800 Iohexol Injection A
P3001XX cisterns, following subarachnoid route and procedure
injection. Arthrography, endoscopic
retrograde pancreatography
(ERCP), herniography,
hysterosalpingography, sialography
and studies of the gastrointestinal
tract
i) Neuroradiology :
myeloradiculography,
cisternography and
ventriculography ii) Angiograph :
cerebral arteriography, thoracic
For angiography and cardiac
aortography, abdominal
cases- dose depending on
aortography, angiocardiography,
the route and procedure.
Iopamidol 30.62 selective visceral arteriography,
V08AB04000 For selected vascular
801 g in 50 ml A peripheral arteriography,
P3001XX examination - bottles of 30
Injection venography, digital subtraction
ml and 100 ml; dose
angiography (DSA), DSA of cerebral
depending on the route and
arteries, DSA of peripheral arteries,
procedure
DSA of abdominal arteries iii)
Urography : intravenous urography
iv) Contrast enhancement in CT
Scanning, arthrography,
fistulography
178 / 371

Iopromide i) For angiography, urography,
300mg injection aortography and the visualization
(623 mg of V08AB05000 of body cavities ii) Contrast Dose depending on the
802 A
iopromide with P3001XX enhancement during computerized route and procedure
300 mg of iodine tomography iii) To check
per mL) functioning of a dialysis shunt
Iopromide i) For angiography, urography,
370mg injection aortography and the visualization
(769 mg of V08AB05000 of body cavities ii) Contrast Dose depending on the
803 A
iopromide with P3002XX enhancement during computerized route and procedure
370 mg of iodine tomography iii) To check
per mL) functioning of a dialysis shunt
Only for treatment of : i) Patients
with ischaemic heart disease who
develop extrasystole with
Ipratropium ADULT: 500 mcg up to 4
salbutamol or terbutaline ii)
Bromide 0.0125% times daily. CHILD 5 - 12
R03BB01320 Patients with chronic bronchitis
804 Nebulising B years : 125 - 250 mcg up to
A3001XX who have airway obstruction and
Solution (125 4 times daily, 12 years : 250
who do not respond to salbutamol
mcg/ml) - 500 mcg up to 4 times daily
or terbutaline. Reversible airways
obstruction, particularly in chronic
obstructive pulmonary disease
with ischaemic heart disease who
develop extrasystole with
Ipratropium ADULT: 500 mcg up to 4
salbutamol or terbutaline ii)
Bromide 0.025% times daily. CHILD 5 - 12
R03BB01320 Patients with chronic bronchitis
805 Nebulising B years : 125 - 250 mcg up to
A3002XX who have airway obstruction and
Solution (250 4 times daily, 12 years : 250
who do not respond to salbutamol
mcg/ml) - 500 mcg up to 4 times daily
or terbutaline. Reversible airways
obstruction, particularly in chronic
obstructive pulmonary disease
Acute attacks: 1 unit dose
vial. In severe cases not
relieved by 1 unit dose vial,
Ipratropium
Management of reversible 2 unit dose vials may
Bromide 0.5 mg R03AK04320
806 B bronchospasm associated with require, patient should
and Salbutamol A3001XX
obstructive airway diseases consult a doctor
2.5 mg per UDV
immediately. Maintenance :
1 unit dose vial 3 - 4 times
daily
179 / 371

ADULT & CHILD more than 6
years; Acute asthma 2 puffs.
Severe cases: if breathing
Management of symptoms in
has not noticeably improved
Ipratropium chronic obstructive airway
after 5 mins, 2 further puffs
Bromide 20 mcg R03AK03986 disorders with reversible
807 B may be taken. Intermittent
and Fenoterol 50 A2101XX bronchospasm such as bronchial
and long-term treatment 1-
mcg/dose Inhaler asthma and chronic bronchitis with
2 puffs for each
or without emphysema
administration, up to max 8
puffs/day (average: 1-2
puffs three times daily)
Ipratropium
ADULT and ELDERLY: 2
Bromide 20 mcg
Management of reversible inhalations 4 times daily.
and Salbutamol R03AK04320
808 B bronchospasm associated with Maximum: 12 inhalations
base 100 A1001XX
obstructive airway diseases daily. CHILD under 12 years
mcg/dose
not recommended
Inhalation
with chronic bronchitis who have 20 - 40 mcg 3 - 4 times daily.
Ipratropium
airway obstruction and who do not In the early treatment, up to
Bromide 20
R03BB01320 respond to Salbutamol or 80 mcg 3 - 4 times daily.
809 mcg/dose B
A1001XX Terbutaline ii) Patients with CHILD up to 6 years : 20 mcg
Nebuliser
ischaemic heart disease who 3 times daily, 6 - 12 years :
solution
develop extrasystole with 20 - 40 mcg 3 times daily
Salbutamol or Terbutaline
Irbesartan 150
mg and Hypertension in patients who
C09DA04000
810 Hydrochlorothiaz A/KK cannot tolerate ACE inhibitors 1 tablet daily
T1003XX
ide 12.5 mg because of cough
Tablet
Hypertension, diabetic
Irbesartan 150 C09CA04000 nephropathy (in patients who
811 A/KK 150 mg to 300 mg daily
mg Tablet T1001XX cannot tolerate ACE inhibitors
because of cough)
Irbesartan 300
mg & Hypertension in patients who
C09DA04000
T1001XX
Tablet
Hypertension, diabetic
Irbesartan 300 C09CA04000 nephropathy (in patients who
813 A/KK 150 mg to 300 mg daily
mg Tablet T1002XX cannot tolerate ACE inhibitors
because of cough)
180 / 371

In combination therapy (for
Only for patients with colorectal
previously untreated
cancer who: i) have relapsed within
patients): 180 mg/m2 once
6 months after the end of adjuvant
every 2 weeks as an IV
chemotherapy with 5-fluorouracil-
infusion over 90 mins
based regime ii) have progressive
followed by infusion with
Irinotecan HCl disease despite 5-fluorouracil
L01XX19110P folinic acid and 5-
814 Trihydrate 20 A* chemotherapy for advanced
3002XX fluorouracil. In
mg/ml Injection disease iii) good performance
monotherapy (for previously
status (WHO of 2 or less) The
treated patients): 350
treatment must be given in a
mg/m2 administered as an
tertiary oncology centre or have
intravenous infusion over 90
clearance in writing by an
minutes period once every 3
oncologist
weeks
In combination therapy (for
previously untreated
patients): 180 mg/m2 once
every 2 weeks as an IV
infusion over 90 mins
followed by infusion with
Irinotecan HCl disease despite 5-fluorouracil
L01XX19110P folinic acid and 5-
815 Trihydrate 40 A* chemotherapy for advanced
3001XX fluorouracil. In
mg/2 ml Injection disease iii) good performance
monotherapy (for previously
status (WHO of 2 or less) The
treated patients): 350
mg/m2 administered as an
intravenous infusion over 90
minutes period once every 3
oncologist
weeks
Dosage and duration of
therapy are dependent
upon the extent of iron
deficiency. Manifest iron
deficiency: 1 chewable
tablet two to three times
Iron (III)-
daily until a normalization of
hydroxide Treatment of latent and manifest
the hemoglobin value is
polymaltose iron deficiency and prevention of
B03AD04250 achieved. Afterwards the
816 complex (IPC) A/KK iron and folic acid deficiency
T2001XX therapy should be
100mg iron and before, during after pregnancy
continued with 1 chewable
0.35mg folic acid (during lactation)
tablet daily at least until the
chewable tablet
end of pregnancy to
replenish the iron stores.
Latent iron deficiency and
prevention of iron and folic
acid deficiency: 1 chewable
tablet daily
181 / 371

An initial test dose of 0.5 ml
should be given over the
desired route. For severe
Iron Dextran 50
B03AC06000 iron deficiency anaemia, 1-2
817 mg Fe/ml B Severe iron deficiency anaemia
P3001XX ml daily given by deep IM.
Injection
Dosage is individualized
according to total iron
deficit
Individualised dosage.
ADULT and ELDERLY:
Dialysis patients on erythropoietin
Cumulative dose is to be
therapy, second and third trimester
administered in single doses
pregnancy and post partum
of 100 - 200 mg of iron 2 - 3
Iron Sucrose 100 B03AC02250 anaemia patients with iron
818 A/KK times weekly depending on
mg/5 ml Injection P3001XX deficiency: i) who are not
Hb level. By IV drip infusion,
responsive to oral iron therapy ii)
slow IV injection or directly
who may be at risk of allergic
into the venous limb of the
reactions to iron dextran injection
dialyser. Total cumulative
dose: 1000 mg
i) Induction- Initiate at a
concentration of 0.5 % ii)
Maintenance- 1 - 2.5 % in
N01AB06000 i) Induction and ii) Maintenance of
819 Isoflurane Liquid B oxygen or nitrous oxide
L5001XX anaesthesia
mixture. 0.5 - 0.75 % with
oxygen and nitrous oxide for
Caesarian section
i) & ii) ADULT 5-8mg/kg daily
Isoniazid 100 mg J04AC01000T i) Tuberculosis ii)Tuberculous
820 B (Max 300mg) or 15-20mg/kg
Tablet 1001XX meningitis
biweekly (max 1200mg)
i) & ii) ADULT 5-8mg/kg daily
Isoniazid 400 mg J04AC01000T i) Tuberculosis ii)Tuberculous
821 B (Max 300mg) or 15-20mg/kg
Tablet 1002XX meningitis
biweekly (max 1200mg)
If given as IM: Initially 0.2
mg (1 ml of 1:5000
solution), followed by 0.02-1
mg depending on clinical
response. If given as SC: 0.2
mg (1 ml of 1:5000
Complete heart block (third-degree
Isoprenaline HCl solution), followed by 0.15-
C01CA02110 artrioventricular block) not
822 0.2 mg/ml B 0.2 mg depending on clinical
P3001XX responding to atropine, while
Injection response. If given as IV : 1-2
waiting for cardiac pacing
mg in 500 ml of dextrose
5%, infused at a rate of 0.5-2
ml/min while the patient's
EKG is being monitored. The
dose should be titrated to
produce the desired clinical
182 / 371

response
If given as IM: Initially 0.2

mg (1 ml of 1:5000
solution), followed by 0.02-1
mg depending on clinical
response. If given as SC: 0.2
mg (1 ml of 1:5000
Complete heart block (third-degree solution), followed by 0.15-
Isoprenaline HCl
C01CA02110 artrioventricular block) not 0.2 mg depending on clinical
823 1 mg/5 ml B
P3002XX responding to atropine, while response. If given as IV : 1-2
Injection
waiting for cardiac pacing mg in 500 ml of dextrose
5%, infused at a rate of 0.5-2
ml/min while the patient's
EKG is being monitored. The
dose should be titrated to
produce the desired clinical
response
2-10 mg/hour IV infusion
Isosorbide
C01DA08221 Treatment for angina pectoris and after dilution, higher doses
824 Dinitrate 1 A
P3001XX left ventricular failure up to 20 mg/hour may be
mg/ml Injection
required
Isosorbide i) 30 - 120 mg daily in
C01DA08221 Prophylaxis and treatment for: i)
825 Dinitrate 10 mg B divided doses ii) 40 - 160
T1001XX Angina ii) Left ventricular failure
Tablet mg, up to 240 mg if required
Isosorbide
C01DA14221 Prophylaxis and treatment of
826 Mononitrate 50 A 50 mg daily
C2001XX angina pectoris
mg SR Capsule
Initiate at 30 mg for 1st 2-4
Isosorbide-5- days to avoid headache.
C01DA14221 Prophylaxis and treatment of
827 Mononitrate 30 A Usual dose: 60 mg once
T5001XX angina pectoris
mg SR Tablet daily, may be increased to
120 mg once daily
Isosorbide-5-
C01DA14221 Prophylaxis and treatment of 60mg once daily, increase to
828 Mononitrate 60 A
T5002XX angina pectoris 120 mg daily
mg SR Tablet
183 / 371

0.5-1 mg/kg of body weight
per day (in two divided
doses) for 15 to 20 weeks;
the maximum
recommended dose is
2mg/kg of body weight per
Only for treatment of i) Severe day. After about 4 weeks,
nodulo-cystic acne ii) Acne therefore, dosage for the
Isotretinoin 10 D10BA01000
829 A* conglobata iii) Acne fulminans iv) maintenance treatment
mg Capsule C1001XX
Severe acne vulgaris failing should be adjusted within
conventional treatment. the range 0f 0.1-1mg/kg
daily to meet individual
need. Treatment usually
lasts a total of 16 weeks.
There should be an interval
of at least 8 weeks before
re-starting treatment.
0.5-1 mg/kg of body weight
per day (in two divided
doses) for 15 to 20 weeks;
the maximum
recommended dose is
2mg/kg of body weight per
Only for treatment of i) Severe
day. After about 4 weeks,
nodulo-cystic acne ii) Acne
therefore, dosage for the
Isotretinoin 20 D10BA01000 conglobata iii) Acne fulminans iv)
830 A* maintenance treatment
mg Capsule C1002XX Severe acne vulgaris failing
should be adjusted within
conventional treatment WARNING:
the range 0f 0.1-1mg/kg
THIS DRUG IS TERATOGENIC
daily to meet individual
need. Treatment usually
lasts a total of 16 weeks.
There should be an interval
of at least 8 weeks before
re-starting treatment.
Treatment of gastrointestinal
symptoms of functional, non-ulcer
dyspepsia (chronic gastritis) i.e
Itopride HCl 50 A03FA00110 50 mg 3 times daily before
831 A* sensation of bloating, early satiety,
mg Tablet T1001XX meal
upper abdominal pain or
discomfort, anorexia, heartburn,
nausea and vomiting
184 / 371

i) 200 mg daily for 1 week. If
no response after 1 week,
continue treatment for
another week ii) 100 - 200
Treatment of: i) oral and/or mg twice daily for 2 weeks.
Itraconazole 10
J02AC02000L oesophageal candidiasis ii) If no response after 2
832 mg/ml Oral A*
9901XX fluconazole resistant and/or weeks, continue treatment
Solution
oesophageal candidiasis for another 2 weeks. The
400 mg daily dose should
not be used for more than
14 days if there are no signs
of improvement
i) 200 mg once daily for 7
days ii) 100 mg daily for 15
i) Dermatomycosis including days iii) 200 mg twice daily
pityriasis versicolor ii) Oral for 7 days iv) 200mg twice
candidiasis iii) Palmar tinea manus daily for 1 week per month
Itraconazole 100 J02AC02000C
833 A/KK and plantar tinea pedis iv) for 2 months v) 200 mg
mg Capsule 1001XX
Fingernail onychomycosis v) twice daily for 1 week per
Toenail onychomycosis vi) month for 3 months vi)200
Vulvovaginal candidiasis mg morning and evening for
1 day or 200 mg once daily
for 3 days
185 / 371
i) Symptomatic treatment of
chronic stable angina pectoris in
patients with normal sinus rhythm,
who have a contraindication or
intolerance to beta blockers ii)
Treatment of coronary artery
disease. Symptomatic treatment of
coronary artery disease patients
with normal sinus rhythm. Initial dose 5 mg twice daily.
Ivabradine is indicated: - in patients May increase dose after 3-4
unable to tolerate or with a weeks to 7.5 mg twice daily
Ivabradine 5 mg C01EB17110 contraindication to the use of beta- depending on response.
834 A*
Tablet T1001XX blockers - or in combination with ELDERLY, initial dose 2.5 mg
beta-blockers in patients twice daily and titrate to a
inadequately controlled with an maximum of 7.5 mg twice
optimal beta-blocker dose and daily
whose heart rate is > 60 bpm.
Treatment of chronic heart failure.
Ivabradine is indicated in chronic
heart failure NYHA II to IV class
with sinus rhythm and whose heart
rate is ≥75bpm, in combination
with standard beta-blocker therapy
or when beta- blocker therapy is
contraindicated or not tolerated.
186 / 371
i) Symptomatic treatment of
patients with normal sinus rhythm,
who have a contraindication or
intolerance to beta blockers ii)
Treatment of coronary artery
disease. Symptomatic treatment of
coronary artery disease patients
with normal sinus rhythm. Initial dose 5 mg twice daily.
Ivabradine is indicated: - in patients May increase dose after 3-4
unable to tolerate or with a weeks to 7.5 mg twice daily
Ivabradine 7.5 C01EB17110 contraindication to the use of beta- depending on response.
835 A*
mg Tablet T1002XX blockers - or in combination with ELDERLY, initial dose 2.5 mg
beta-blockers in patients twice daily and titrate to a
inadequately controlled with an maximum of 7.5 mg twice
optimal beta-blocker dose and daily
whose heart rate is > 60 bpm.
Treatment of chronic heart failure.
Ivabradine is indicated in chronic
heart failure NYHA II to IV class
with sinus rhythm and whose heart
rate is ≥75bpm, in combination
with standard beta-blocker therapy
or when beta- blocker therapy is
contraindicated or not tolerated.
i) ADULT: 1 - 2 g daily IM in 1
i) Treatment of gonorrhoea and - 2 equally divided doses.
neonatal meningitis ii) Treatment CHILD: 30 - 50 mg/kg/day in
Kanamycin 1 g J01GB04183P of TB patients who require 1 - 2 divided doses ii)
836 A*
Injection 4001XX reserved second line drugs but ADULT: 2 g daily IM in 2
have no pre-existing renal equally divided doses twice
complications a week or 1 g once daily 3
days a week
IV Initially, 1-4.5 mg/kg IV, a
Sole anaesthetic for short dose of 2 mg/kg produces
Ketamine 10 N01AX03110 procedures or induction of anesth for 5-10 mins. IM
837 B
mg/ml Injection P3001XX anaesthesia in certain types of Initially, 6.5-13 mg/kg IM, a
patients (e.g in shock states) dose of 10 mg/kg produces
anesth for 12-25 mins.
IV Initially, 1-4.5 mg/kg IV, a
Sole anaesthetic for short dose of 2 mg/kg produces
Ketamine 50 N01AX03110 procedures or induction of anesthesia for 5-10 mins. IM
838 B
mg/ml Injection P3002XX anaesthesia in certain types of Initially, 6.5-13 mg/kg IM, a
patients (e.g in shock states) dose of 10 mg/kg produces
anesthesia for 12-25 mins.
187 / 371

Apply twice weekly for 2 - 4
Ketoconazole 2% D01AC08000
839 A/KK Resistant dandruff only weeks. Prophylaxis: Once
Shampoo L5201XX
every 1 - 2 weeks
i) 200 mg with meal once
i) Pityriasis versicolor ii) Systemic daily for 10 days ii) 200 - 400
Ketoconazole J02AB02000T
840 A/KK mycosis (other skin mycoses) iii) mg daily for 4 weeks - 6
Nail infections months iii) 200 - 400 mg
daily for 6 - 12 months.
As a short term treatment for
Ketoprofen 2.5% M02AA10000 Apply onto affected areas 2-
841 A traumatic lesions, sprains,
Gel G3001XX 4 times daily up to 10 days.
tendinitis, oedema, bruises
200mg in the morning or
Ketoprofen 200
M01AE03000 Pain and inflammation in evening. Should be taken
842 mg Slow Release A/KK
C2002XX rheumatic disease with food: Take immediately
Capsule
after meals.
Treatment of signs & symptoms of
arthritis deformans, periarthritis
Ketoprofen 30 humero-scapularis, tendinitis,
M02AA10000 Apply 1 plaster to the
843 mg Transdermal A peritendinitis, sore muscle,
M7001XX affected area twice daily
Plaster swelling, pain resulting from
trauma (eg. contusion, distorsion,
sprain).
By deep IM into gluteal
muscle, 50-100 mg every 4
Ketoprofen 50 M01AE03000 To be used only in treatment of
844 A* hours. Maximum 200 mg in
mg/ml Injection P3001XX acute inflammatory conditions
24 hours for up to 3 days.
Child not recommended
Prophylaxis and reduction of
inflammation and
i) Ocular itching due to allergic
associated symptoms
Ketorolac conjunctivitis ii) Prophylaxis and
S01BC05239 following ocular surgery: 1
845 Tromethamine A reduction of inflammation and
D2001XX drop 3 times daily starting
0.5% Eye drops associated symptoms following
24 hours pre-operatively
ocular surgery
and continuing up to 3
weeks post-operatively.
ADULT: 60mg as a single
Ketorolac dose via IM inj or 30mg as a
Short term management of
Tromethamine M01AB15239 single IV dose. Alternatively,
846 A* moderate to severe postoperative
30 mg/ml P3001XX 30mg every 6 hr via IM or IV
pain
Injection admin up to a max of 120mg
daily.
ADULT: 100 mg (50 mg in
elderly) daily with food,
increased at intervals of 14
Labetalol HCl 100 C07AG01110 Hypertension (including in
847 B days to usual dose of 200
mg Tablet T1001XX pregnancy)
mg twice daily, up to 800 mg
twice daily (3 - 4 divided
doses if higher dose). Max:
188 / 371

2.4 g daily
ADULT: 100 mg (50 mg in
elderly) daily with food,
Labetalol HCl 200 C07AG01110 Hypertension (including in days to usual dose of 200
848 B
mg Tablet T1002XX pregnancy) mg twice daily, up to 800 mg
twice daily (3 - 4 divided
doses if higher dose). Max:
2.4 g daily
ADULT: 20mg injected
slowly for at least 2 min,
followed by 40-80mg dose
Labetalol HCl 5 C07AG01110
849 B Hypertension crisis every 10 min, if necessary
upto 300 mg. Patient should
remain supine during and 3
hr after the procedure.
Atrophic vaginitis: 1 vaginal
tablet daily for 6-12 days
followed by a maintenance
dose of 1 vaginal tablet for
1-2 days per week
Restoration therapy: 1-2
vaginal tablet daily for 6-12
i)Atrophic vaginitis due to estrogen
days Administration The
deficiency during menopause and
Lactobacillus vaginal tablets should be
post-menopause, or as co-
acidophilus 100 inserted deeply into the
medication to systemic hormone
million viable G03CC06953 vagina in the evenings
850 A/KK replacement therapy ii)Restoration
cells and estriol T1001XX before bedtime. In cases of
of the Lactobacillus flora after local
0.03mg vaginal a very dry vagina, vaginal
and/or systemic treatment with
tablet tablet can be moistened
anti-infective agents or
with 1 or 2 drops of water
chemotherapeutic agents
before insertion into the
vagina. ?During
menstruation, treatment
should be interrupted and
resumed afterwards Should
not use vaginal douches or
rinses during treatment
i) ADULT 15 ml twice daily
adjusted to patient's need.
CHILD 0.5 ml/kg/dose once
Lactulose 3.35 A06AD11000 i) Constipation ii) Hepatic or twice daily ii) 30-50 ml 3-
851 C+
g/5 ml Liquid L5001XX encephalopathy 4 times daily, dose adjusted
to produce 2-3 soft stools
daily. CHILD 1 ml/kg/dose 3-
4 times daily
189 / 371

ADULT: 150 mg twice daily
or 300 mg once daily.
Lamivudine 10 INFANT under 1 month: 2
J05AF05000L HIV infection in combination with
852 mg/ml Oral A* mg/kg twice daily. CHILD 3
9901XX other antiretroviral agents
Solution month or over: 4 mg/kg
twice daily. Maximum 300
mg daily
Adult: 100 mg once daily.
For patients with
Management of chronic hepatitis B
concomitant HIV infection:
Lamivudine 100 J05AF05000T infection associated with evidence
853 A* 300 mg once daily or in 2
mg Tablet 1001XX of hepatitis B viral replication and
divided doses. Child: >2 yr: 3
active liver inflammation
mg/kg once daily. Max: 100
mg/day.
or 300 mg once daily.
INFANT under 1 month: 2
Lamivudine 150 J05AF05000T HIV infection in combination with
854 A/KK mg/kg twice daily. CHILD 3
mg Tablet 1002XX other antiretroviral agents
month or over: 4 mg/kg
twice daily. Maximum 300
mg daily
i) Adjunctive or monotherapy for
partial seizures and generalised
tonic-clonic seizures not
satisfactorily controlled with other i) Up to 200 mg daily in
Lamotrigine 100 N03AX09000
855 A antiepileptic drugs ii) Prevention of single or divided dosage ii)
mg Tablet T1002XX
mood episodes in adult 18 years 25- 200 mg daily
and above with bipolar disorder,
predominately by preventing
depressive episodes
Lamotrigine 25
mg N03AX09000 Add-on therapy in intractable 25 mg daily - 50 mg twice
856 A
Dispersible/Chew T2001XX partial seizures daily
able Tablet
190 / 371

a) Add-on therapy in
patients not taking
Valproate: week 1 and 2: 2
mg/kg/day twice daily, week
3 and 4: 5 mg/kg/day twice
daily. Maintenance: 5 - 15
mg/kg/day twice daily b)
Add-on therapy in patients
Lamotrigine 5 mg
N03AX09000 Management of seizures in children taking Valproate or other
857 Dispersible/Chew A
T2002XX aged 2 - 12 years anti-epileptic drugs, week 1
able Tablet
and 2: 0.2 mg/kg/day as a
single dose (children less
than 25 kg may take 5 mg
on alternate days), week 3
and 4: 0.5 mg/kg/day as a
single dose. Maintenance
dose: 1 -5 mg/kg/day once
daily or twice daily
i) Adjunctive or monotherapy for
partial seizures and generalised
tonic-clonic seizures not
satisfactorily controlled with other i) Up to 200 mg daily in
Lamotrigine 50 N03AX09000
858 A antiepileptic drugs ii) Prevention of single or divided dosage ii)
mg Tablet T1001XX
mood episodes in adult 18 years 25- 200 mg daily
and above with bipolar disorder,
predominately by preventing
depressive episodes
i) 30mg daily in the morning
for up to 4 weeks (duodenal
ulcer) or up to 8 weeks
(gastric ulcer). Maintenance:
15mg/day.ii) 30mg OD in
the morning for up to 8
weeks if not healed.
i) Peptic ulcer disease ii) Reflux Maintenance: 15mg OD. iii)
oesophagitis iii) Zollinger-Ellison Initially 60mg OM & adjust
Lansoprazole 30 A02BC03000
859 A* Syndrome iv) For eradication of as required. Daily doses
mg Tablet T1001XX
Helicobacter pylori in combination >120mg should be given in 2
with antibiotic divided doses. iv) 30 mg
twice daily in combination
with any of the 2 antibiotics
(clarithromycin 500 mg
twice daily , amoxicillin 1 g
twice daily or metronidazole
400 mg twice daily) for 1-2
weeks
191 / 371

Initial: 750 to 1500 mg/day
Phosphate binding agent for the in divided doses with meals
Lanthanum treatment of hyperphosphataemia then titrate in increments of
Carbonate V03AE03130 in dialysis patients with sustained 750 mg/day at intervals of 2
860 A*
1000mg T2004XX hypercalcaemia of more than three to 3 weeks. Maintenance:
Chewable Tablet months and secondary 1500-3000 mg/day in
hyperparathyroidism divided doses. Max: 3750
g/day
Hurler and Hurler-Scheie forms of
Mucopolysaccharidosis I (MPS I) 0.58 mg/kg of body weight
Laronidase 2.9 A16AB05000
861 A* and for patients with the Scheie administered once-weekly
mg/5ml Injection P3001XX
form who have moderate to severe as an intravenous infusion
symptoms
i) 5,000 iu/m2 for 10 days
during induction, 10,000
iu/m2 also used with high
L-Asparaginase dose methotrexate rescue in
L01XX02000P i) Acute lymphoblastic leukemia ii)
862 10,000 IU A* consolidation phase of acute
3001XX Non-hodgkin's lymphoma
Injection lymphoblastic leukemia ii)
CHILD: 5,000 - 25,000 iu/m2
per dose depending on
protocol
For reduction of Intraocular
Latanoprost Pressure (IOP) in patients with
0.005% and S01ED51990 Open-angle Glaucoma (OAG) and 1 drop in the affected eye(s)
863 A*
timolol maleate D2004XX Ocular Hypertension (OH) who are once daily
0.5% eye drops insufficiently responsive to topical
beta-blocker.
The recommended dosage is
one drop (1.5 µg) in the
affected eye(s) once daily in
Latanoprost Reduction of elevated intraocular
S01EE01000 the evening. If more than
864 0.005% Eye A* pressure in patients with open-
D2001XX one topical ophthalmic drug
Drops angle glaucoma
is being used, the drugs
should be administered at
least five (5) minutes apart
Loading dose: 100 mg once
Leflunomide 10 L04AA13000 i) Persistent active rheumatoid daily for 3 days.
865 A*
mg Tablet T1001XX arthritis ii) Active psoriatic arthritis Maintenance: 10-20 mg
once daily
Loading dose: 100 mg once
Leflunomide 20 L04AA13000 i) Persistent active rheumatoid daily for 3 days.
866 A*
mg Tablet T1002XX arthritis ii) Active psoriatic arthritis Maintenance: 10-20 mg
once daily.
192 / 371

Recommended starting
dose: 25 mg once daily on
days 1 to 21 of repeated 28
day cycle with
In combination with
dexamethasone 40 mg once
dexamethesone is indicated for the
Lenalidomide 10 L04AX04000 daily on days 1 to 4, 9 to 12
867 A* treatment of multiple myeloma
mg Capsule C1002XX and 17 to 20 of each 28 day
patients who have received at least
cycle for the first 4 cycles of
one prior therapy
therapy, thereafter
daily on day 1 to 4 every 28
day cycle
day cycle with
In combination with
one prior therapy
therapy, thereafter
day cycle
day cycle with
In combination with
one prior therapy
therapy, thereafter
day cycle
day cycle with
In combination with
one prior therapy
therapy, thereafter
day cycle
193 / 371
i) Treatment of hormone
responsive metastatic or locally
advance breast cancer after failure
of tamoxifen ii) Adjunct for node
positive postmenopausal women
Letrozole 2.5 mg L02BG04000
871 A* with early breast cancer (positive 2.5 mg once daily
Tablet T1001XX
or unknown oestrogen or positive
progesterone receptor status /
receptor status) who have received
5 years of adjuvant tamoxifen
therapy
Leucovorin
Calcium (Calcium V03AF03390 Treatment of folic acid antagonist 15 mg every 6 hours for the
872 A
Folinate) 15 mg T1001XX overdose next 48 - 72 hours
Tablet
i) 200mg/m2 by slow IV
injection over a minimum 3
minutes, followed by 5-
Fluorouracil or 20mg/m2 IV
followed by 5-Fluorouracil.
i) Biochemical modulator for 5- In both cases, treatment is
Leucovorin Fluorouracil in the treatment of repeated daily for 5 days;
Calcium (Calcium V03AF03237 colorectal cancer ii) As rescue for may repeat at 4-week
873 A
Folinate) 3 mg P3001XX high dose methotrexate iii) intervals for 2 courses then
Injection Megaloblastic anaemias due to 4- to 5-week intervals ii) 15
deficiency of folic acid mg (approximately
10mg/m2) every 6 hours for
10 doses, starting 24 hours
after the beginning of the
methotrexate infusion iii)
Up to 1 mg daily
i) 200mg/m2 by slow IV
injection over a minimum 3
minutes, followed by 5-
Fluorouracil or 20mg/m2 IV
followed by 5-Fluorouracil.
In both cases, treatment is
i) Biochemical modulator for 5- repeated daily for 5 days;
Leucovorin
Fluorouracil in the treatment of may repeat at 4-week
Calcium (Calcium V03AF03237
874 A colorectal cancer ii) As rescue for intervals for 2 courses then
Folinate) 50 mg P3002XX
high dose methotrexate iii) 4- to 5-week intervals ii) 15
Injection
Gestational trophoblastic disease mg (approximately
10mg/m2) every 6 hours for
10 doses, starting 24 hours
after the beginning of the
methotrexate infusion iii) 6 -
12 mg exactly 30 hours after
each dose of methotrexate.
194 / 371

In EMA-CO regime for high
risk gestational
trophoblastic disease, use
30 mg IM
Leuprolide i) Endometriosis ii) Hormonal
L02AE02122P
875 Acetate 11.25 mg A* therapy in advanced prostate 11.25 mg every 3 months
5002XX
Injection cancer
Leuprolide i) Endometriosis ii) Hormonal i) 3.75 mg monthly for 3 - 6
L02AE02122P
876 Acetate 3.75 mg A* therapy in advanced prostate months ii) 3.75 mg IM or SC
5001XX
Injection cancer injection monthly
i) ADULTS and ADOLESCENT
(from 16 years): Starting
dose: 250 mg twice daily,
Increase dose to 500 mg
twice daily after 2 week.
Dose can be further
increased by 250 mg twice
i) Monotherapy therapy in the daily every 2 weeks
treatment of partial onset seizures depending upon the clinical
with or without secondary response. Max: 1500 mg
generalization in patients from age twice daily. ii) ADULT more
16 years of age with newly than 18 years and
diagnosed epilepsy ii) Adjunctive ADOLESCENT (12 to 17
treatment in partial onset seizures years) more than or equal to
with or without secondary 50 kg: Initially 500 mg twice
Levetiracetam
N03AX14000 generalization in adults and daily may be increased up to
877 100 mg/ml A*
P3001XX children from 4 years of age with 1500 mg twice daily. Dose
Injection
epilepsy; juvenile myoclonic changes can be made in 500
epilepsy and idiopathic generalized mg twice daily increments
tonic clonic epilepsy from 12 years or decrements 2 to 4
of age. To be initiated when weekly. CHILD (4 to 11
conventional IV antiepileptic drugs years) and ADOLESCENT (12
failed to achieve control, or oral to 17 years) less than 50 kg :
form is temporarily not feasible in Initially 10 mg/kg twice
seizure emergencies daily, may be increased up
to 30 mg/kg twice daily.
Dose changes should not
exceed increments or
decrements of 10 mg/kg
twice daily every 2 weeks.
CHILD more than or equal to
50 kg: Adult dose
195 / 371

CHILD: 4-11 years and
adolescent (12-17 years)
As adjunctive therapy in the less than 50 kg: Initially 10
treatment of partial onset seizures mg/kg twice daily, may be
Levetiracetam
N03AX14000 with or without secondary increased up to 30 mg/kg
878 100 mg/ml Oral A*
L9901XX generalization in adults and twice daily. Dose changes
Solution
children from 4 years of age with should not exceed
epilepsy increments or decrements
of 10 mg/kg two times daily
twice weekly
i) Monotherapy ADULTS and
ADOLESCENT (from 16
years) : Starting dose: 250
mg twice daily, Increase
dose to 500 mg twice daily
after 2 week. Dose can be
further increased by 250 mg
twice daily every 2 week
depending upon the clinical
i) Monotherapy therapy in the response. Max: 1500 mg
treatment of partial onset seizures twice daily. ii) ADULT more
with or without secondary than 18 years and
generalization in patients from age ADOLESCENT (12-17 years)
16 years of age with newly more than or equal to 50 kg:
diagnosed epilepsy ii) Adjunctive Initially 500 mg twice daily
Levetiracetam N03AX14000 treatment in partial onset seizures may be increased up to
879 A*
250 mg Tablet T1001XX with or without secondary 1500 mg twice daily. Dose
generalization in adults and changes can be made in 500
children from 4 years of age with mg twice daily increments
epilepsy; juvenile myoclonic or decrements 2-4 weekly.
epilepsy and idiopathic generalized CHILD (4-11 years) and
tonic clonic epilepsy from 12 years ADOLESCENT (12-17 years)
of age less than 50 kg : Initially 10
mg/kg twice daily, may be
increased up to 30 mg/kg
twice daily. Dose changes
should not exceed
increments or decrements
of 10 mg/kg twice daily
every 2 weeks. CHILD more
than or equal to 50 kg: Adult
dose
196 / 371

i) Monotherapy ADULTS and
ADOLESCENT (from 16
years) : Starting dose: 250
mg twice daily, Increase
dose to 500 mg twice daily
after 2 week. Dose can be
further increased by 250 mg
twice daily every 2 week
depending upon the clinical
i) Monotherapy therapy in the response. Max: 1500 mg
treatment of partial onset seizures twice daily. ii) ADULT more
with or without secondary than 18 years and
generalization in patients from age ADOLESCENT (12-17 years)
16 years of age with newly more than or equal to 50 kg:
diagnosed epilepsy ii) Adjunctive Initially 500 mg twice daily
Levetiracetam N03AX14000 treatment in partial onset seizures may be increased up to
880 A*
500 mg Tablet T1002XX with or without secondary 1500 mg twice daily. Dose
generalization in adults and changes can be made in 500
children from 4 years of age with mg twice daily increments
epilepsy; juvenile myoclonic or decrements 2-4 weekly.
epilepsy and idiopathic generalized CHILD (4-11 years) and
tonic clonic epilepsy from 12 years ADOLESCENT (12-17 years)
of age less than 50 kg : Initially 10
mg/kg twice daily, may be
increased up to 30 mg/kg
twice daily. Dose changes
should not exceed
increments or decrements
of 10 mg/kg twice daily
every 2 weeks. CHILD more
than or equal to 50 kg: Adult
dose
Surgical anesthesia : Lumber
epidural : 10 - 20 ml (50 -
150 mg) , caesarean section
Production of local or regional : 15 - 30 ml (75 - 150 mg),
Levobupivacaine N01BB10110 anesthesia for surgery and intrathecal: 3 ml (15 mg),
881 A
5mg/ml Injection P3001XX obstetrics, and for postoperative peripheral nerve block : 1 -
pain management 40 ml,
ilioinguinal/iliohypogastric
block. CHILD : 0.25 - 0.5
ml/kg (1.25-2.5 mg/kg)
Symptomatic treatment of allergic Children above 6 years and
Levocetirizine
R06AE09110 rhinitis (including persistent allergic adults: 5 mg orally once
882 Dihydrochloride A*
T1001XX rhinitis) and chronic idopathic daily (Swallow whole, do not
5 mg Tablet
urticaria chew/crush).
197 / 371

Initially 1 cap tds. Max initial
dose: 6 caps/day. Patients
previously on immediate-
release
Levodopa 100 mg
Levodopa/Benserazide
and Benserazide
N04BA02977 preparations: Initially dose
883 25 mg A* Parkinson's Disease
T4001XX should substitute every
Dispersible
100mg of Levodopa with 1
Tablet
controlled-released cap,
given at same dosage
frequency as before.
Increase every 2-3 days.
Patients not receiving
Levodopa before, initially
100 - 125 mg 3 - 4 times
daily adjusted according to
Levodopa 100 mg response. Maintenance:
N04BA02000
884 and Carbidopa 25 B Parkinson's disease 0.75 - 2 g in divided doses.
T1001XX
mg Tablet In patients previously
treated with Levodopa the
dose should be about 20 -
25% of the dose previously
being taken
Initial: 100/25 mg 1-2
times/day, increase every 3-
4 days until therapeutic
effect, optimal dosage:
400/100 mg to 800/200
Levodopa 100
mg/day divided into 4-6
mg, Benserazide N04BA02977
885 B Parkinson's Disease doses. Dose: 200/50 mg
25 mg HBS C1001XX
used only when
capsule
maintenance therapy is
reached and not to exceed
levodopa 1000-1200
mg/benserazide 250-300 mg
per day
198 / 371

The optimum daily dosage
must be determined by
careful titration of levodopa
in each patient. The daily
dose should preferably be
optimised using 1 of the 4
available tablet strengths
(50/12.5/200mg,
100/25/200mg,
150/37.5/200mg or
200/50/200mg
levodopa/carbidopa/entaca
pone). Patients should be
instructed to take only 1
tablet/dose administration.
While the experience with
total daily dosage >200 mg
Levodopa 100
carbidopa is limited, the
mg, Carbidopa 25
N04BA03977 maximum recommended
886 mg and A* Idiopathic Parkinson's disease
T1002XX daily dose of entacapone is
Entacapone 200
2000 mg and therefore the
mg Tablet
maximum dose, for the
strengths of 50/12.5/200
mg, 100/25/200 mg and
150/37.5/200 mg, is 10
tablets/day. Ten (10) tablets
of the strength
150/37.5/200 mg equal to
carbidopa 375 mg/day.
Therefore, using a maximum
recommended daily dose of
carbidopa 375 mg, the
maximum daily dose of
200/50/200 mg is 7 tablets
per day. The maximum total
daily levodopa dose
administered should not
exceed 1500 mg.
199 / 371

(50/12.5/200mg,
100/25/200mg,
150/37.5/200mg or
200/50/200mg
Levodopa 150
mg, Carbidopa
887 37.5 mg and A* Idiopathic Parkinson's disease
Entacapone 200
mg Tablet
mg, 100/25/200 mg and
150/37.5/200 mg, is 10
of the strength
150/37.5/200 mg equal to
daily levodopa dose
exceed 1500 mg.
Initial: 100/25 mg 1-2
times/day, increase every 3-
4 days until therapeutic
effect, optimal dosage:
Levodopa 200
N04BA02977 400/100 mg to 800/200
888 mg, Benserazide B Parkinson's Disease
T1001XX mg/day divided into 4-6
50 mg Tablet
doses. Dose: 200/50 mg
used only when
maintenance therapy is
reached and not to exceed
200 / 371

levodopa 1000-1200
mg/benserazide 250-300 mg
per day
(50/12.5/200mg,
100/25/200mg,
150/37.5/200mg or
200/50/200mg
Levodopa 200
mg, Carbidopa 50
889 mg & A* Idiopathic Parkinson's disease
Entacapone 200
mg Tablet
mg, 100/25/200 mg and
150/37.5/200 mg, is 10
of the strength
150/37.5/200 mg equals
daily levodopa dose
exceed 1500 mg.
201 / 371

Patients not receiving
Levodopa before, initially
100 - 125 mg 3 - 4 times
Levodopa 250 mg response. Maintenance:
N04BA02000
890 and Carbidopa 25 B Parkinson's disease 0.75 - 2 g in divided doses.
T1002XX
mg Tablet In patients previously
treated with Levodopa the
dose should be about 20 -
25% of the dose previous
being taken
(50/12.5/200mg,
100/25/200mg,
150/37.5/200mg or
200/50/200mg
Levodopa 50 mg, total daily dosage >200 mg
Carbidopa 12.5 carbidopa is limited, the
N04BA03977
891 mg & A* Idiopathic Parkinson's disease maximum recommended
T1001XX
Entacapone 200 daily dose of entacapone is
mg Tablet 2000 mg and therefore the
mg, 100/25/200 mg and
150/37.5/200 mg, is 10
of the strength
150/37.5/200 mg equal to
daily levodopa dose
202 / 371

exceed 1500 mg.
Levofloxacin 250 J01MA12000
892 A* Community acquired pneumonia 500 mg daily for 7 - 14 days
mg Tablet T1001XX
893 A* Community Acquired Pneumonia 500 mg daily for 7 - 14 days
894 A* Community acquired pneumonia 500 mg daily for 7 - 14 days
mg Tablet T1002XX
Emergency contraception within 72 1.5 mg as a single dose as
hours of unprotected sexual soon as possible after coitus
Levonorgestrel G03AC03000
895 A* intercourse for the female victim of [preferably within 12 hours
1.5 mg Tablet T1001XX
sexual violence to prevent but no later than after 72
unwanted pregnancy hours]
Levonorgestrel
1 tablet daily for 21 days
150 mcg and G03AA07954
896 C+ Contraception from first day of the cycle,
Ethinyloestradiol T1001XX
followed by 7 tab free days
30 mcg Tablet
i) & ii):One unit intrauterine
device to be inserted into
the uterine cavity within 7
days of the onset of
menstruation or
Levonorgestrel immediately after first
i) Contraception (Initial release rate
52 mg G02BA03000 trimester abortion.
897 A* of 20 mcg/24 hours). ii) Idiopathic
Intrauterine P1001XX Postpartum insertion should
menorrhagia
System be postponed until 6 weeks
after delivery.Can be
inserted at any time of
amenorrheic woman. One
unit IUD is effective for 5
years
Start at low dose and
increase at 2-4 weeks
interval. Adult: Initially, 50-
100 mcg/day may increase
by 25-50 mcg at
approximately 3 to 4 weeks
intervals until the thyroid
Levothyroxine deficiency is corrected.
H03AA01520
898 Sodium 100 mcg B Hypothyroidism Maintenance: 100-200
T1001XX
Tablet mcg/day. CHILD; 0 - 3
months: 10 - 15
mcg/kg/day; 3 - 6 months: 8
- 10 mcg/kg/day; 6 - 12
months: 6 - 8 mcg/kg/day; 1
- 5 years: 5 - 6 mcg/kg/day;
6 - 12 years: 4 - 5
mcg/kg/day; more than 12
203 / 371

years: 2 -3 mcg/kg/day
interval. Usual
recommended dose for i)
Treatment of benign
euthyroid goitre: 75-
200mcg. ii) Prophylaxis of
relapse after surgery for
euthyroid goitre: 75-200mcg
iii) Substitution therapy in
hypothyroidism: ADULT
Levothyroxine
H03AA01152 Initially, 25-50mcg/day.
899 Sodium 25 mcg B Hypothyroidism
T1003XX Maintenance: 100-
Tablet
200mcg/day. CHILDREN
Initially 12.5-50mcg/day,
Maintenance: 100-
150mcg/m2 body surface
area iv) Concomitant
supplementation during
anti-thyroid drug treatment
of hyperthyroidism: 50-
100mcg v) Suppression
therapy in thyroid cancer:
150-300mcg
interval. Usual
recommended dose for i)
Treatment of benign
euthyroid goitre: 75-
200mcg. ii) Prophylaxis of
relapse after surgery for
euthyroid goitre: 75-200mcg
iii) Substitution therapy in
Levothyroxine hypothyroidism: ADULT
H03AA01520
900 Sodium 50 mcg B Hypothyroidism Initially, 25-50mcg/day.
T1002XX
Tablet Maintenance: 100-
200mcg/day. CHILDREN
Initially 12.5-50mcg/day,
Maintenance: 100-
150mcg/m2 body surface
area iv) Concomitant
supplementation during
anti-thyroid drug treatment
of hyperthyroidism: 50-
100mcg v) Suppression
therapy in thyroid cancer:
204 / 371

150-300mcg
Used for painless venepunctures,
radial artery cannulations before
extradural/spinal and other
Lidocaine 25mg Apply a thick layer under
N01BB52974 regional blocks in children above 1
901 and Prilocaine A occlusive dressing at least 1
G1001XX year old and adults. Also used in
25mg Cream hour before the procedure
chronic renal failure patients for
insertion of A-V fistulas and shunts
for haemodialysis.
Indicated for the symptomatic
relief of neuropathic pain 1 patch /day (Adults &
associated with previous herpes elderly. Cover the painful
zoster infection (post-herpetic area once daily for up to 12
Lidocaine
N01BB02110 neuralgia, PHN). Restrictions: i) For hr w/in 24-hr period.
902 Medicated A*
M6001XX elderly patients with Subsequent plaster-free
Plaster 5% w/w
polymedication status whom interval: At least 12 hr. Not
certain treatment was more than 3 plasters should
contraindicated or not tolerated. be used at the same time)
ii)Prescribed by pain specialist only.
For surface anaesthesia in dental
Lignocaine 10 % N01BB02110
903 B practice, in otorhinolaryngology Spray to affected part
w/w Spray A4001XX
and paracentesis
Lignocaine 2 %
By infiltration: 0.5 - 1 ml; not
with Adrenaline N01BB52974 For local anaesthesia including
904 B to exceed 7 mg/kg body
(1:80,000) P3001XX infiltration, nerve and plexus blocks
weight
Injection
Use for endotracheal tubes and
instruments, painful procedures in
the ear, nose and throat, burns,
Apply to affected area 10
Lignocaine 2% N01BB02110 wounds, abrasions, lacerations;
905 B mins before catheterization,
Jelly G4001XX catheterisation of the male and
etc
female urethra and for
symptomatic treatment of cystitis
and urethritis
As 2% soln: For pain: 300 mg
rinsed and ejected for
For post-tonsilectomy, sore throat,
mouth and throat pain; or
dumping syndrome, hiccough,
gargled and swallowed if
Lignocaine 2% N01BB02110 reflux vomiting, painful lesions of
906 A necessary for pharyngeal
Viscous Solution L5001XX the mouth, cardiospasm,
pain. Not to be used more
instrumentation of the respiratory
frequently than every 3 hr.
and digestive tract
Max (topical oral soln): 2.4
g/day.
205 / 371

Adult Male Instil 20 mL
slowly into the urethra until
it reaches external
sphincter, proximal to the
prostrate. Subsequently,
apply compression at the
corona for several mins. Fill
To provide local anaesthesia and the length of the urethra w/
lubrication during catheterization, the remaining gel. Sounding
Lignocaine 2%
exploration by sound and other procedure or
with N01BB52974
907 B endourethral operations and cytoscopy Instill 40 mL (in 3-
Chlorhexidine G3001XX
examinations, cytoscopy and 4 portions) into the
0.05% Gel
symptomatic treatment of painful insertion area then allow 5-
cystitis and urethritis 10 mins for anaesth to take
effect. Adult Female Prior to
urological procedure, instill
5-10 mL in small portions to
fill the whole urethra &
allow anaesth to take effect
in 3-5 mins.Childn <12 yr Up
to 6 mg/kg.
Bronchoscopy, 2 - 3 ml with
For anaesthesia of mucous suitable spray; biopsy in
Lignocaine 4 % N01BB02110 membranes of the oropharyngeal, mouth, 3 - 4 ml with suitable
908 B
Solution L5002XX tracheal and bronchial areas eg. in spray or swab (with
laryngoscopy and bronchoscopy adrenaline if necessary);
maximum 7.5 ml
50-100 mg IV as a bolus,
Lignocaine HCl Ventricular tachycardia and repeated after 5 minutes if
C01BB01110
909 (Lidocaine) 100 B ventricullar fibrillation. To be necessary. Maintenance : 1-
P3002XX
mg/ml Injection diluted before use 4 mg/min by IV infusion
under ECG monitoring
Local anesthesia : ADULT
Maximum: 100 mg; CHILD
Maximum: 3 mg/kg Cardiac
Local anesth by infiltration IV
arrhythmias : ADULT 50-100
regional anesthesia and nerve
Lignocaine HCl mg IV. Maximum: 200-300
N01BB02110 block. Emergency management of
910 (Lidocaine) 2% B mg/hour; CHILD Loading
P3001XX ventricular arrhythmias particularly
Injection dose: 0.5-1 mg/kg IV
after myocardial infarction and
repeated if necessary up to
cardiac surgery
3-5 mg/kg followed by a
mcg/kg/min
50-100 mg IV as a bolus,
Lignocaine HCl Ventricular tachycardia and repeated after 5 minutes if
C01BB01110
911 (Lidocaine) 20 B ventricullar fibrillation. To be necessary. Maintenance : 1-
P3001XX
mg/ml Injection diluted before use 4 mg/min by IV infusion
under ECG monitoring
206 / 371

According to patients weight
and nature of procedures,
maximum 200mg. For most
obstetric procedures, the
preparation is diluted to
Lignocaine HCl N01BB02110 Local or regional anaesthesia for
912 C+ 0.5%, which gives the
1% Injection P3002XX episiotomy repairs
maximum effect with the
least toxicity. [lignocaine
1%, 1 part and normal saline
or sterile distilled water, 1
part]
Preparation of nasal mucosa for
surgery (eg. Cautery to Little?s Adults and children over 12
area), aid the treatment of acute years : 5 squirts per nostril.
Lignocaine HCl
nose bleeds and removal of foreign Children: 8 to 12 years 3
5% and
N01BB02984 bodies from the nose, topical squirts per nostril, 4 to 8
913 Phenylephrine A*
A4101XX anaesthesia of the pharynx prior to years 2 squirts per nostril, 2
HCl 0.5% Nasal
direct or indirect laryngoscopy, to 4 years 1 squirt per
Spray
topical anaesthesia and local nostril. Doses are to be
vasoconstriction prior to administered once only.
endoscopy of the upper airways
Lignocaine,
Aluminium
Acetate, Zinc C05AX03931 Anorectal pain, pruritis, Apply once or twice daily.
914 A/KK
Oxide and G5001XX inflammation and irritation Not for prolonged use
Hydrocortisone
Ointment
Lignocaine,
Aluminium
1 suppository to be used
Acetate, Zinc C05AX03931 Anorectal pain, pruritis,
915 B once or twice daily. Not for
Oxide and S2001XX inflammation and irritation
prolonged use
Hydrocortisone
Suppository
Management of diabetes in
patients with renal failure where
metformin/sulphonylurea is Adults: 5 mg once daily.
contraindicated/untolerated and When linagliptin is added to
Linagliptin 5 mg A10BH05000 elderly with multiple co morbidities metformin, the dose of
916 A*
tablet T1001XX that always experience metformin should be
hypoglycemia with other maintained and linagliptin
antidiabetic. Not to be used in administered concomitantly.
diabetic patient whose HBA1c is
more than 9%.
MRSA patient with severe sepsis for 10 - 14 days. CHILD: 10
Linezolid 2 J01XX08000P
917 A* requiring intensive care and not mg/kg 3 times daily.
mg/ml Injection 3001XX
clinically responding to vancomycin PREMATURE NEONATES less
than 7 days: 10 mg/kg twice
207 / 371

daily
CHILD: 10 mg/kg 3 times
Linezolid 20 MRSA patients with severe sepsis
J01XX08000L daily. PREMATURE
918 mg/ml A* requiring intensive care and not
8001XX NEONATES less than 7 days:
Suspension clinically responding to vancomycin
10 mg/kg twice daily
ADULT: Above 12 years 600
MRSA patient with severe sepsis mg every 12 hours for 10-14
Linezolid 600 mg J01XX08000T requiring intensive care and not days. CHILD: 10 mg/kg 3
919 A*
Tablet 1001XX clinically responding to times daily. PREMATURE
vancomycin. NEONATES less than 7 days:
10 mg/kg twice daily
ADULT 10-30 ml daily at
night but should not be
A06AA01000
920 Liquid Paraffin C Constipation taken immediately before
L5001XX
going to bed. CHILD not
recommended
i) Prophylaxis and treatment of Dose depends on the
acute mania and hypomania preparation used. Doses
Lithium
N05AN01121 episodes ii)Prophylaxis of manic should be adjusted to
921 Carbonate 300 A
T1001XX depression in bipolar illness or produce a serum-lithium
mg Tablet
bipolar depression and recurrent concentration of 0.4-1
depression mmol/l.
Acute diarrhoea: ADULT: 4
mg stat, followed by 2 mg
after each unformed stool
Adjunct to rehydration in acute (up to 5 days). Usual 6- 8 mg
Loperamide 2 mg A07DA03110
922 B diarrhoea in adult also in chronic daily. Max: 16 mg daily.
Capsule C1001XX
diarrhoea in adult Chronic diarrhoea: Initially
4-8 mg daily in divided
doses, adjust according to
response. Max: 16 mg daily
Adult: (Therapy-naive
patients) 400/100 mg bd or
800/200 mg once daily;
(Therapy-experienced
Lopinavir 200 mg As second line protease inhibitor if patients): 400/100 mg bd.
J05AE06964T
923 and Ritonavir 50 A* intolerant to indinavir/ ritonavir as Concomitant therapy
1001XX
mg Tablet part of HAART regimen (efavirenz, nevirapine,
amprenavir, fosamprenavir
or nelfinavir) 400/100 mg
bd. Children >40 kg or w/
BSA >1.4 m2 as adult dose.
208 / 371

Tab Adult Therapy-naive
patients 400/100 mg bd or
800/200 mg once daily.
Therapy-experienced
patients 400/100 mg bd.
Concomitant therapy
(efavirenz, nevirapine,
amprenavir, fosamprenavir
Management of patients with or nelfinavir) 400/100 mg
Lopinavir/Ritona J05AE06964L asymptomatic and symptomatic bd. Can be used w/ no dose
924 A
vir Oral Solution 9901XX (early or advanced) HIV Infection adjustment. Childn >40 kg or
with CD4 cell counts <50 cubic mm w/ BSA >1.4 m2 Adult dose.
Oral Soln Childn 6 mth-12 yr,
15-40 kg 10/2.5 mg/kg bd; 7
to <15 kg 12/3 mg/kg bd.
Max: 5 mL bd in childn >40
kg. W/ efavirenz or
nevirapine 15-45 kg 11/2.75
mg/kg bd; 7 to <15 kg
13/3.25 mg/kg.
Allergic rhinitis, chronic urticaria
Loratadine 1 R06AX13000 years : 10 mg once daily.
925 A and other allergic dermatological
mg/ml Syrup L9001XX CHILD 2 - 6 years: 5 mg once
disorders
daily
Loratadine 10 mg R06AX13000 Allergic rhinitis and allergic years 10 mg once daily.
926 B
Tablet T1001XX dermatoses CHILD 2 - 6 years: 5 mg once
daily
Loratadine 5 mg
and
R01BA52988 For treatment of allergic rhinitis ADULT and CHILD over 12
927 Pseudoephedrine A/KK
T1001XX and allergic dermatoses years 1 tablet twice daily
Sulphate 120 mg
Tablet
i) 1 - 4 mg increase to 10 mg
Lorazepam 1 mg N05BA06000 ELDERLY (or delibitated) half
928 A/KK i) Severe anxiety ii) Insomnia
Tablet T1001XX adult dose ii) 1 - 2 mg at
bedtime Not recommended
in children
209 / 371

Hypertension: Usual starting
and maintenance dose: 50
mg once daily. Maximum
increasing the dose to 100
mg once daily. Patients with
Patients intolerant of ACE
intravascular volume-
inhibitors, only in the treatment of
depletion starting dose of 25
Losartan 50 mg C09CA01500 i) Hypertensive patient with left
929 A/KK mg once daily. Renal
Tablet T1001XX ventricular hypertrophy ii)
protection in Type 2 diabetic
Hypertension in diabetics with
patients with proteinuria
proteinuria or nephropathy
and hypertension, starting
dose: 50 mg once daily, may
be increased to 100 mg once
daily based on blood
pressure response
Fixed dose combination is
not indicated for initial
therapy. i. Usual starting &
maintenance dose: 1 tab of
losartan & HCTZ 50/12.5 mg
once daily. May be
increased to 2 tab of
or 1 tab of losartan & HCTZ
100/25mg once daily if
blood pressure remains
uncontrolled after about 3
Losartan Hypertension in patients who
weeks of combination
Potassium 100 cannot tolerate ACE inhibitors
C09DA01935 therapy with losartan &
930 mg & A* because of cough, hypertensive
T1004XX HCTZ 50/12.5mg. Max: 1 tab
Hydrochlorothiaz patient with left ventricular
of losartan & HCTZ
ide 25 mg Tablet hypertrophy
100/25mg once daily or 2
tab of Losartan & HCTZ
50/12.5 mg once daily. ii.
Usual starting dose: 50 mg
losartan once daily, may be
titrated with a combination
of losartan 50mg & HCTZ
12.5 mg, maybe substituted
with losartan 100mg & HCTZ
12.5mg, followed by
losartan 100 mg & HCTZ 25
mg once daily.
210 / 371

Fixed dose combination is
not indicated for initial
therapy. i. Usual starting &
maintenance dose: 1 tab of
once daily. May be
increased to 2 tab of
or 1 tab of losartan & HCTZ
100/25mg once daily if
blood pressure remains
Losartan uncontrolled after about 3
Hypertension in patients who
Potassium 100 weeks of combination
cannot tolerate ACE inhibitors
mg and C09DA01935 therapy with losartan &
931 A* because of cough, hypertensive
Hydrochlorothiaz T1003XX HCTZ 50/12.5mg. Max: 1 tab
patient with left ventricular
ide 12.5 mg of losartan & HCTZ
hypertrophy
Tablet 100/25mg once daily or 2
tab of Losartan & HCTZ
50/12.5 mg once daily. ii.
Usual starting dose: 50 mg
losartan once daily may be
titrated with a combination
of losartan 50mg & HCTZ
12.5 mg, maybe substituted
with losartan 100mg & HCTZ
12.5mg, followed by
losartan 100 mg & HCTZ 25
mg once daily.
Patients intolerant of ACE
inhibitors, only in the treatment of: Usual starting dose: 50 mg
Losartan
C09CA01500 i) Hypertensive patient with left once daily. May be
932 Potassium 100 A/KK
T1002XX ventricular hypertrophy increased to 100 mg once
mg Tablet
ii)Hypertension in diabetics with daily.
proteinuria or nephropathy
Losartan
Hypertension in patients who 1 tablet once daily, may
Potassium 50 mg
cannot tolerate ACE inhibitors increase to maximum dose
and C09DA01935
933 A/KK because of cough, hypertensive losartan 100 mg/
Hydrochlorothiaz T1001XX
patient with left ventricular hydrochlorothiazide 25 mg
ide 12.5 mg
hypertrophy once daily
Tablet
Magnesium
D11AX05183 Inflammatory skin conditions such
934 Sulphate 45% C Apply under dressing
G6001XX as boils and carbuncles
Paste
211 / 371

i) Mild hypomagnesemia
(ADULT): 1gm magnesium
sulphate (8mEq) IM every 6
hours for 4 doses. Severe
hypomagnesemia (ADULT):
0.25 g/kg IM over 4 hours.
Alternative dose of 5g may
be given by slow
i)Treatment and prophylaxis of intravenous infusion over 3
acute hypomagnesaemia ii) hours ii) Toxemia of
Magnesium Prevention and treatment of life- pregnancy: An initial
B05XA05183
935 Sulphate 50% C threatening seizures in the intravenous dose of 4gm of
P3001XX
Injection treatment of toxemias of magnesium sulphate is
pregnancy (pre-eclampsia and recommended. Followed by
eclampsia) an intramuscular dose of 4-
5gm into each buttock. This
may be followed by a dose
of 4-5gm into alternate
buttocks every 4 hours as
needed. Alternatively, the
initial dose IV dose may be
followed by an infusion of 1-
2gm/hr
Magnesium
A02AA10912 10-20 ml 3-4 times daily
936 Trisilicate C Heartburn, dyspepsia
L2101XX before meals
Mixture
ADULT 1-2 tablet to be
chewed up to 6 times a day
Magnesium A02AA10912
937 C Heartburn, dyspepsia before meals. CHILD over 6
Trisilicate Tablet T1001XX
years one tablet to be taken
3-4 times a day
As a buffering agent for
reconstituting didanosine powder
Magnesium, DDI should be mixed with
for oral administration so as to
Aluminium water and diluted with the
V07AB00900 prevent acid degradation of
938 Hydroxide and C appropriate dose of antacids
L8001XX didanosine which is used for the
Simethicone to a final concentration of
treatment of paediatric patients
Suspension 10 mg per ml
(more than 6 months old) with
symptomatic HIV infection
Wet hair, apply shampoo
and work up lather. Leave
Malathion 1 % P03AX03000
939 C+ Lice infestation for 15 minutes and rinse,
Shampoo L5201XX
comb. Repeat if necessary
after 7 - 9 days
212 / 371

0.25- 2 g/kg IV of a 15% to
Mannitol 10% 25% solution over 30-60
B05BC01000
940 Injection (10 A Cerebral oedema minutes. Safety and efficacy
P3001XX
g/100 ml) not established in children
under 12 years of age
0.25- 2 g/kg IV of a 15% to
Mannitol 20% 25% solution over 30-60
B05BC01000
941 Injection (20 A Cerebral oedema minutes. Safety and efficacy
P3002XX
g/100 ml) not established in children
under 12 years of age
The vaccine should be
reconstituted only with the
diluent supplied (sterile
water for injection) using a
For active immunization against
sterile syringe and needle.
measles and rubella in infants,
With gentle shaking the
children, adolescents and young
dried cake is easily
adults at risk. Immunization of
dissolved. After
Measles and susceptible non-pregnant
reconstitution the vaccines
Rubella Virus adolescent and adult females is
should be used immediately.
Vaccine Live, J07BD52963P indicated if certain precautions are
942 C A single dose of 0.5ml
Attenuated 4002XX observed. The vaccine can be safely
should be administered by
(Freeze-dried) 10 and effectively given
deep SC injection into the
doses/vial simultaneously with DTP, DT, TT,
anterolateral aspect of
Td, BCG, Polio Vaccine (OPV and
upper thigh in infants and
IPV), Haemophilus influenza type B,
upper arm in older children.
Hepatitis B, Yellow fever vaccine
If the vaccines are not used
and vitamin A supplementation.
immediately then it should
be stored in the dark at 20C
and 80C for no longer than 6
hours.
Measle's Vaccine Prophylaxis against measles and to By SC or IM injection, 0.5 ml
J07BD01000P
943 Injection (10 C+ prevent development of infection as a single dose at 12 - 15
4001XX
doses) (if given within 72 hours of contact) months of age
Measles, Mumps
and Rubella For immunisation of children Subcutaneous or by
J07BD52963P
944 (MMR) Vaccine C+ against measles, mumps and intramuscular injection, 0.5
4001XX
Injection (Single rubella ml
Dose)
Mebeverine HCl A03AA04110
945 B Irritable bowel syndrome 135 mg 3 times daily
Meclozine HCl 25
mg and R06AE55919 1 - 2 tablet 2 - 3 times daily
946 B Nausea and vomiting of pregnancy
Pyridoxine 50 mg T1001XX in severe cases
Tablet
213 / 371

1 tablet 3 times daily. The
Mecobalamin M09AX00000 dosage should be adjusted
947 B Peripheral neuropathies
500 mcg Tablet T1001XX according to age of patient
and severity of symptoms
i) 5-10 mg daily for 5-10
days started anytime during
cycle ii) 5-10 mg daily for 5-
Medroxyprogest i) Secondary amenorrhoea ii)
G03DA02122 10 days on day 16-21 of
948 erone Acetate 10 B Abnormal uterine bleeding due to
T1002XX menstrual cycle. Optimum
mg Tablet hormonal imbalance
secretory transformation 10
mg daily for 10 days from
day 16 of the cycle
Medroxyprogest
L02AB02122 Breast carcinoma, endometrial
949 erone Acetate A 200-500 mg orally daily
T1002XX carcinoma, renal carcinoma
100 mg Tablet
i) 5-10 mg daily for 5-10
days started anytime during
cycle ii) 5-10 mg daily for 5-
Medroxyprogest i) Secondary amenorrhoea ii)
G03DA02122 10 days on day 16-21 of
950 erone Acetate 5 B Abnormal uterine bleeding due to
T1001XX menstrual cycle. Optimum
mg Tablet hormonal imbalance
secretory transformation 10
mg daily for 10 days from
day 16 of the cycle
Medroxyprogest
G03AC06122 Prevention of pregnancy and to 150mg to be administered
951 erone Acetate 50 B
P3001XX provide long term contraception once every 3 month
mg/ml Injection
Medroxyprogest
L02AB02122 Breast carcinoma, endometrial
952 erone Acetate A 200-500 mg orally daily
T1001XX carcinoma, renal carcinoma
500 mg Tablet
ADULT: 250 - 500 mg 3
times daily after meals.
CHILD over 6 months: 6.5 -
Mefenamic Acid M01AG0100
953 B Mild to moderate pain 25 mg/kg daily 3 - 4 times
250 mg Capsule 0C1001XX
daily for not longer than 7
days except in juvenile
arthritis
ADULT: 250 - 500 mg 3
times daily after meals.
CHILD over 6 months: 6.5 -
Mefenamic Acid M01AG0100
954 B Mild to moderate pain 25 mg/kg daily 3 - 4 times
250 mg Tablet 0T1001XX
daily for not longer than 7
days except in juvenile
arthritis
214 / 371

Treatment of malaria:
ADULT and CHILD 25 mg/kg
usually given over 2-3 days.
Prophylaxis of malaria:
ADULT 250 mg once a week.
Mefloquine HCl P01BC02110 For multi-drug resistant cases of
955 A* CHILD over 5 kg : 5 mg/kg
250 mg Tablet T1001XX malaria only
once a week; prophylaxis
should start 1-3 weeks
before departure and
continue for 4 weeks after
last exposure
i) Initially 7.5 mg daily. May
be increased to 15 mg daily
Only for patients not responding to
ii) initially 15 mg daily. May
Meloxicam 7.5 M01AC06000 other NSAIDs in the treatment of i)
956 A/KK be reduced to 7.5 mg daily.
mg Tablet T1001XX painful osteoarthritis ii) rheumatoid
Maximum 15 mg daily. Child
arthritis
under 12 years not
recommended
i) 8 - 10 mg/m2 for 4 days
i) Multiple myeloma ii)
every 4 weeks ii) 10 - 35
Melphalan 2 mg L01AA03000 Neuroblastoma,
957 A mg/m2 once every month
Tablet T1001XX rhabdomyosarcoma iii) Recurrent
For dose regimes, refer to
neuroblastoma (palliative)
protocols
200 mg/ m2 IV infusions in
High dose conditioning therapy for divided doses for Day 1 to
Melphalan 50 mg L01AA03000
958 B stem cell transplantation in day 3 followed by IV
Injection P4001XX
multiple myeloma infusions of autologous
stem cells
Adult Initially 5 mg/day on
the 1st week, 5mg twice a
day on the 2nd week, then
As monotherapy or as adjunctive
15 mg/day (10mg in the
therapy with cholinesterase
morning and 5mg in the
Memantine HCI N06DX01110 inhibitors for the symptomatic
959 A* evening) on the 3rd week.
10 mg Tablet T1001XX treatment of patients with
From the 4th week on,
moderate to severe Alzheimer’s
continue treatment with
disease.
mg/day (10mg twice a day).
Max: 20 mg/day.
Adult Initially 5 mg/day on
the 1st week, 5mg twice a
As monotherapy or as adjunctive
day on the 2nd week, then
therapy with cholinesterase
15 mg/day (10mg in the
Memantine HCl N06DX01110 inhibitors for the symptomatic
960 A* morning and 5mg in the
20 mg Tablet T1002XX treatment of patients with
evening) on the 3rd week.
moderate to severe Alzheimer’s
From the 4th week on,
disease.
continue treatment with
215 / 371

mg/day (10mg twice a day).
Max: 20 mg/day.
Immunisation against
Meningococcal A,
J07AH04000 meningococcal diseases caused by Prophylaxis: 0.5 ml
961 C, Y, W 135 B
P4001XX Neisseria meningitis Group A, intramuscular injection.
Vaccine Injection
Group C, Group Y or Group W-135
Menotrophin 150
IU Injection Treatment of infertility where
(Follicle clomifene has fail or stimulation of
G03GA02954 SC or IM injection according
962 Stimulating A* follicle growth as part of an
P4002XX to patients response
Hormone 150 IU assisted reproductive technology
and Luteinizing (ART)
Hormone 150 IU)
Menotrophin 75
IU Injection Treatment of infertility where
(Follicle clomifene has fail or stimulation of
G03GA02954 SC or IM Injection according
963 Stimulating A* follicle growth as part of an
P4001XX to patient's response
Hormone 75 IU assisted reproductive technology
and Luteinizing (ART)
Hormone 75 IU)
The recommended initial
dose of MENOPUR is 75-150
IU daily. The subsequent
dosing should be adjusted
Menotrophin,
according to individual
Highly Purified 75 Anovulation in women who have
patient response.
IU Injection been unresponsive to treatment
Adjustments in dose should
(Follicle G03GA02954 with clomiphene citrate or
964 A* not be made more
Stimulating P4003XX stimulation of follicle growth as
frequently than every 7
Hormone 75 IU part of an assisted reproductive
days. The recommended
and Luteinizing technology (ART)
dose increment is 37.5 IU
Hormone 75 IU)
per adjustment and should
not exceed 75 IU. The
maximum daily dose should
not be higher than 225 IU.
Menthol 1.6% in
Industrial R01AX30000 Decongestion of the upper
965 C As directed for local use
Methylated Spirit A9901XX respiratory tract
Inhalation
Mepivacaine HCl Adult: Single site in the jaw:
2% with 36 mg (1.8ml). Entire oral
N01BB53974 For local anaesthesia including
966 Adrenaline B cavity: 180 mg (9 ml). Max:
P3001XX infiltration and nerve blocks
(1:100,000) 400 mg (20 ml) per single
Injection dental procedure
216 / 371

Adult: Single site in the jaw:
For dental local anaesthesia
54 mg (1.8 ml). Entire oral
Mepivacaine HCl N01BB03110 including infiltration and nerve
967 B cavity: 270 mg (9 ml). Max:
3% Injection P3001XX blocks on patients in whom
400 mg (13.3 ml) per single
adrenalin might be contraindicated
dental procedure
"Leukaemia adults:
2.5mg/kg or 80-00mg/m2
p.o per day, given as a single
dose. To be increased at the
end of 4 weeks, If necessary,
up to 5mg/kg p.o per day.
i) Langerhan's cell histocytosis ii)
Maintainance dosage is
Mercaptopurine L01BB02000T Acute lymphoblastic leukaemia iii)
968 A 1.5mg/kg -2.5mg/kg p.o per
50 mg Tablet 1001XX Acute promyelocytic leukaemia
day Children age 5 and
APML (maintenance)
older: Induction:
2.5mg/kg/day p.o once
daily. Maintanance dose:
1.5mg/kg -2.5mg.kg p.o
once daily or 70-100mg/m2
p.o once daily."
i. Emperical treatment for presume
infections in patients (adult and
ADULT: 0.5g - 1g 8 hourly
children) with febrile neutropenia,
CHILD: (aged 3 months and
Meropenem 1 g J01DH02000 used as monotherapy or in
969 A* over): 10-40mg/kg 8 hourly,
Injection P4002XX combination with anti-virals or
if body weight over 50kg,
antifungal agent ii. Septicaemia iii.
adult dosage should be used
Serious infections in renal impaired
patients
i. Emperical treatment for presume

infections in patients (adult and
ADULT: 0.5g - 1g 8 hourly
children) with febrile neutropenia,
CHILD: (aged 3 months and
Meropenem 500 J01DH02000 used as monotherapy or in
970 A* over): 10-40mg/kg 8 hourly,
mg Injection P4001XX combination with anti-virals or
if body weight over 50kg,
antifungal agent ii. Septicaemia iii.
adult dosage should be used
Serious infections in renal impaired
patients
217 / 371

Ulcerative colitis: 1 g
suppository insert rectally
once daily at bedtime. The
dose may be increased to
500 mg 3 times daily if the
response is inadequate after
2 weeks of therapy. To
Inflammatory bowel disease of
Mesalazine 1 g A07EC02259 achieve maximum benefit, it
971 A ulcerative colitis and Crohn's
Suppository S2002XX is recommended that the
disease.
suppository be retained in
the rectum for a minimum
of 1 to 3 hours or longer.
The usual course of therapy,
depending upon response,
may last from 3 to 6 weeks.
CHILD not recommended
Ulcerative colitis: 1 g
suppository insert rectally
once daily at bedtime. The
dose may be increased to
500 mg 3 times daily if the
response is inadequate after
2 weeks of therapy. To
Inflammatory bowel disease of
Mesalazine 250 A07EC02259 achieve maximum benefit, it
972 A ulcerative colitis and Crohn's
mg Suppository S2001XX is recommended that the
disease.
suppository be retained in
the rectum for a minimum
of 1 to 3 hours or longer.
The usual course of therapy,
depending upon response,
may last from 3 to 6 weeks.
CHILD not recommended
ADULT: 250 - 500 mg 3 - 4
Inflammatory bowel disease of times daily for 3 - 6 weeks.
Mesalazine A07EC02259
973 A ulcerative colitis and Crohn's CHILD up 2 years with
250mg MR Tablet T1001XX
disease. Crohn's disease: 20 - 30
mg/daily in divided doses
ADULT: 250 - 500 mg 3 - 4
Inflammatory bowel disease of times daily for 3 - 6 weeks.
Mesalazine A07EC02259
974 A ulcerative colitis and Crohn's CHILD up 2 years with
500mg MR Tablet T1002XX
disease. Crohn's disease: 20 - 30
mg/daily in divided doses
Mesalazine Inflammatory bowel disease of 60 ml (4g) at bedtime,
A07EC02259
975 6.67% w/w A ulcerative colitis and Crohn's retained overnight,
G2001XX
Enema disease. approximately 8 hours
218 / 371

IV injection at a dosage of
20% of the corresponding
oxazaphosphorine dose at
the times 0 hour
For prevention of urotoxic effects (concurrently with the
Mesna 100 V03AF01520
976 A of oxazaphosphorines e.g. oxazaphosphorine), 4 hours
ifosfamide and cyclophosphamide and 8 hours thereafter.
CHILD: Dose given at greater
frequency (e.g. 6 times) and
a shorter intervals (e.g. 3
hours)
Initial dose:1.25 mg/250 mg
ORALLY once daily; titrate in
As second-line therapy when diet,
increments of 1.25 mg/250
Metformin 500 exercise and initial treatment with
mg per day every 2
mg and A10BD02926 sulphonylurea or metformin do not
977 B weeks,2.5 mg/500 mg to 5
Glibenclamide T1001XX result in adequate glycemic control
mg/500 mg ORALLY twice
2.5 mg Tablet in patients with type 2 diabetes
daily; titrate in increments
mellitus
of 5 mg/500 mg up to MAX
20 mg/2000 mg once daily
Initial dose:1.25 mg/250 mg
ORALLY once daily; titrate in
As second-line therapy when diet,
increments of 1.25 mg/250
Metformin 500 exercise and initial treatment with
mg per day every 2
mg and A10BD02926 sulphonylurea or metformin do not
978 B weeks,2.5 mg/500 mg to 5
Glibenclamide 5 T1002XX result in adequate glycemic control
mg/500 mg ORALLY twice
mg Tablet in patients with type 2 diabetes
daily; titrate in increments
mellitus
of 5 mg/500 mg up to MAX
20 mg/2000 mg once daily
500 mg once daily.
Metformin HCl Diabetes mellitus who experienced
A10BA02110 Maximum dose 2000 mg
979 500 mg Extended A/KK gastrointestinal side effects with
T5001XX once daily with evening
Release Tablet normal metformin
meal
Initial: 500mg orally twice
daily with food.
Maintenance: Titrate in
Metformin HCl A10BA02110
980 B Diabetes mellitus 500mg increments weekly,
doses up to 2000 mg daily
may be divided into 2 equal
doses.
500 mg once daily.
Metformin HCl Diabetes mellitus who experienced
A10BA02110 Maximum dose 2000 mg
981 750 mg Extended A/KK gastrointestinal side effects with
T5003XX once daily with evening
Release Tablet normal metformin
meal
219 / 371

Initial 10-20mg per day,
increasing by 10-20mg per
Methadone N07BC02110 Detoxification treatment of day until there are no signs
982 A/KK
5mg/ml Syrup L9001XX narcotic addiction of withdrawal or
intoxication. Usual dose 40-
60mg/day
i) ADULT: 20 mg/m2 weekly.
CHILD: 20 - 30 mg/m2
weekly according to
protocol ii) Relapsed acute
lymphoblastic leukaemia
(ALL): 100 mg/m2/day for 5
days 6 weekly according to
protocol iii) Dose used by
i) Acute lymphoblastic leukaemia dermatologist: 5 - 25 mg
and acute promyelocytic leukemia weekly. Liver biopsy after
(maintenance) ii) Extensive plaque cumulative dose of 1.5 gram
Methotrexate 2.5 L01BA01000
983 A psoriasis, erythrodermic psoriasis, and repeat liver biopsy with
mg Tablet T1001XX
pustular psoriasis, Reiter's additional gram received.
syndrome, connective tissue Maximum cumulative dose
disease is 4 gram. Monitor full blood
count (FBC), renal and liver
function iv) Rheumatoid
arthritis, psoriatic
arthropathy: dose used by
rheumatologist: 2.5
mg/week orally starting
dose, increasing to 7.5 - 20
mg/weekly
i) 50 mg/m2 once every 2 - 3
weeks in combination with
other drugs ii) 50 mg IV Day
1, 3, 5, 9 every 3 weeks. For
high risk gestational
trophoblastic disease, use
100 mg/m2 as part of EMA-
i) Solid tumours ii) Gestational
CO regime iii) High dose
trophoblastic disease iii) Acute
regimes: 500 - 3000 mg/m2
Methotrexate 50 L01BA01520 leukaemia/lymphomas iv)
984 A per dose may be used,
mg Injection P3001XX Rheumatoid arthritis, psoriatic
employing the 500 mg
arthropathy, severe/erythrodermic
preparations. CHILD: Central
psoriasis
nervous system prophylaxis
for acute leukaemia 2
gm/m2 over 24 hours with
folinic acid rescue, 3 doses
for B-cell lineage. 4 doses
for T-lineage all every 3
weeks. Relapse acute
220 / 371

lymphoblastic leukaemia
(ALL): 1 gm/m2 over 36
hours with folinic acid
rescue every 3 weeks for 9
doses, maintenance: 50
mg/m2 every 2 weeks. B-cell
lymphoma: 3 gm/m2 over 3
hours with folinic acid
rescue for three doses.
Methotrexate level
monitoring recommended
when using high dose
regimens. The 500 mg
strength is not for
intrathecal (IT) use. Dosage
for intrathecal treatment
and prophylaxis in
leukaemia: less than 1 year:
5 mg, 1 - 2 years: 7.5 mg, 2 -
3 years: 10 mg, more than 3
years: 12.5 mg. IT
preparation must be clearly
stated/verified.
ENSURE THAT
FOR INTRATHECAL USE iv)
Dose used by
rheumatologist: 10 - 15 mg
IM injection or oral weekly.
Dose used by dermatologist:
10 - 25 mg IM injection
weekly
221 / 371

i) 50 mg/m2 once every 3
weeks in combination with
other drugs (for this dose,
use the 50 mg preparation)
ii) 50 mg IV Day 1, 3, 5, 9
every 3 weeks. For high risk
gestational trophoblastic
disease, use 100 mg/m2 as
part of EMA-CO regime iii)
High dose regimes: 500 -
3000 mg/m2 per dose may
be used, employing the 500
mg preparations. CHILD:
Central nervous system
prophylaxis for acute
leukaemia 2 gm/m2 over 24
Methotrexate i) Solid tumours ii) Gestational hours with folinic acid
L01BA01520
985 500 mg/20 ml A trophoblastic disease iii) Acute rescue, 3 doses for B-cell
P3002XX
Injection leukaemias, lymphomas lineage. 4 doses for T-
lineage all every 3 weeks.
Relapse acute lymphoblastic
leukaemia (ALL): 1 gm/m2
over 36 hours with folinic
acid rescue every 3 weeks
for 9 doses, maintenance:
50 mg/m2 every 2 weeks. B-
cell lymphoma: 3 gm/m2
over 3 hours with folinic
acid rescue for three doses.
Methotrexate level
monitoring recommended
when using high dose
regimens. THE 500 MG
STRENGTH IS NOT FOR
INTRATHECAL USE
Apply 0.1% lotion to area to
Repigmenting agent in vitiligo in be exposed to the UVA light
Methoxsalen 1% D05AD02000
986 A conjuction with controlled doses of ( need to dilute the 1%
Lotion L6001XX
UVA or sunlight lotion to 0.1% lotion,
otherwise the skin will burn)
0.2 - 0.6 mg/kg/body
weight. For repigmentation
Methoxsalen 10 D05BA02000 Protection before exposure to of larger lesions (greater
987 A
mg Capsule C1001XX sunlight, psoriasis and vitiligo than 6 cm sq): 20 mg/day 2
hours before exposure. Take
with food or milk
222 / 371

Treatment of anaemia associated
with chronic renal failure in the
Non Erythropoiesis
following circumstances: i) Patients
Stimulating Agent (ESA)-
who require 2 or more
treated patients: 0.6mcg/kg,
subcutaneous erythropoietin
once every two weeks (IV or
Methoxy injections per week and need to
SC). When the Hb is >11g/dl,
Polyethylene travel to obtain the injections. ii)
administration can be
Glycol-epoetin B03XA03000 Patients who are on high doses of
988 A* reduced to once monthly
Beta 100 mcg/0.3 P5001XX subcutaneous erythropoietin
using the dose equal to
ml Injection in injections eg. 6000 units or more
twice the previous two
Prefilled Syringe per time and require more than 1
weekly dose. ESA-treated
injection of conventional
patients: 120-360 mcg once
erythropoietin per time. iii)
monthly or 60-180 mcg
Patients who require 2 or more
every two weeks.
erythropoietin injections per week
and where compliance is an issue.
Non Erythropoiesis
every two weeks.
Non Erythropoiesis
patients : 120-360 mcg once
erythropoietin per time. iii)Patients
every two weeks
and where compliance is an issue
223 / 371

Non Erythropoiesis
Polyethylene travel to obtain the injections.
Glycol-epoetin B03XA03000 ii)Patients who are on high doses of
every two weeks.
Non Erythropoiesis
every two weeks
Non Erythropoiesis
erythropoietin per time. iii)Patients
every two weeks
and where compliance is an issue
224 / 371
Relief of minor aches and pains of

To be massage well to the
Methyl Salicylate M02AC00260 muscles and joints associated with
994 C+ affected area, 3 - 4 times
25% Ointment G5001XX simple backache, arthritis and
daily.
rheumatic conditions.
Methylcellulose To be used only for i) Post-
1% with 50 mg S01XA00990 operative cases with dry eye ii) 1 to 4 times daily depending
995 B
Vitamin C Eye D2001XX Unconscious patients in critical care on severity of cases
Drops unit (CCU) with exposure keratitis
Adult: 250 mg 2 - 3 times
daily, gradually increased at
intervals of 2 or more days,
maximum; 3 g/day. Elderly:
initially 125 mg twice daily,
increased gradually,
Methyldopa 250 C02AB01110
996 B Hypertension maximum; 2 g daily. Child:
mg Tablet T1001XX
Initially, 10 mg/kg or 300
mg/m2 daily in 2-4 divided
doses; increase as
necessary. Max: 65 mg/kg, 2
g/m2 or 3 g daily, whichever
is least.
Adult and children: 1 to 2
mg/kg (0.1 to 0.2 mL/kg of a
For treatment of idiopathic and
Methylene Blue V03AB17100 1% solution) IV very slowly
997 B drug-induced
1% Injection P3001XX over 5 minutes. This dosage
methaemoglobinemia
can be repeated if necessary
after one hour.
CHILD over 6 years, initially
5 mg 1 - 2 times daily,
increased if necessary at
weekly intervals by 5 - 10
mg daily to maximum of 60
Methylphenidate N06BA04110 Attention deficit hyperactivity mg daily in divided doses;
998 A
HCl 10 mg Tablet T1001XX disorder (ADHD) discontinue if no response
after 1 month, also suspend
periodically to assess child's
condition (usually finally
discontinued during or after
puberty)
225 / 371

CHILD over 6 years:
Individualize dosage, to be
taken once daily in the
morning. Dose may be
adjusted in increments to a
maximum of 54 mg/day, at
Methylphenidate
weekly interval. Patient new
HCl 18 mg N06BA04110 Attention deficit hyperactivity
999 A* to methylphenidate: starting
Extended-release T5002XX disorder (ADHD)
dose 18 mg once daily;
Tablet
adults 18mg or 36mg once
daily. Patient currently using
methylphenidate: 18 - 36
mg. Maximum 54 mg/day.
after 1 month
20 mg once daily to be
Methylphenidate taken in the morning.
N06BA04110 Attention deficit hyperactivity
1000 HCl 20 mg LA A* Dosage be adjusted in
C2003XX disorder (ADHD)
Capsule increments to a maximum
of 60 mg/day
CHILD over 6 years:
Individualize dosage, to be
taken once daily in the
morning. Dose may be
adjusted in increments to a
maximum of 54 mg/day, at
Methylphenidate
weekly interval. Patient new
HCl 36 mg N06BA04110 Attention deficit hyperactivity
1001 A* to methylphenidate: starting
Extended-release T5003XX disorder (ADHD)
dose 18 mg once daily;
Tablet
adults 18mg or 36mg once
daily. Patient currently using
methylphenidate: 18 - 36
mg. Maximum 54 mg/day.
after 1 month
20 mg once daily to be
Methylphenidate taken in the morning.
N06BA04110 Attention deficit hyperactivity
1002 HCl 40mg LA A* Dosage be adjusted in
C2002XX disorder (ADHD)
Capsule increments to a maximum
of 60 mg/day
226 / 371

i. Intramuscular route
a) Asthma: may be used in
i) Intramuscular administration: place of a short burst of oral
anti-inflammatory treatment, steroids in vomiting or non-
treatment of hematological and adherent patients. The
oncological disorders, endocrine recommended dose is 80-
disorders ii) Intrasynovial, 120mg intramuscularly as a
periarticular, intrabursal or soft one-dose b) Adrenogenital
tissue administration: Indicated as syndrome: 40mg every two
adjunctive therapy for short term weeks c) Rheumatoid
administration in : Synovitis of arthritis (maintenance): 40-
osteoarthritis, rheumatoid arthritis, 120mg weekly d)
acute and subacute bursitis, acute Dermatologic lesions (acute
Methylprednisol
H02AB04134 gouty arthritis, epicondylitis, acute severe dermatitis, chronic
1003 one Acetate A*
P3001XX nonspecific tenosynovitis, post- contact dermatitis,
40mg injection
traumatic osteoarthritis iii) seborrheic dermatitis): 40-
Intralesional use in alopecia areata, 120mg weekly for 1-4 weeks
discoid lupus erythematosus; ii. Intraarticular route
keloids, localized hypertrophic, Recommended dose is 4 to
infiltrated inflammatory lesions of 80 milligrams, depending
granuloma annulare, lichen planus, upon the size of the joint.
psoriatic plaques, lichen simplex Injections may be repeated
chronicus (neurodermatitis) at intervals of 1 to 5 or more
*Restricted to patients weeks in chronic cases
experiencing side effects with iii.Intralesional route 20 to
triamcinolone acetonide 60 milligrams
methylprednisolone acetate
injected into the lesion
Suppression of inflammatory and
Methylprednisol allergic disorders, cerebral oedema,
15 - 30 mg/kg daily. Large
one Sodium H02AB04520 immunosuppression treatment of
1004 A doses may be repeated 4 - 6
Succinate 0.5 g P4001XX haematological and oncological
hourly for up to 48 hours
Injection disorders, treatment of shock
states and endocrine disorders
Suppression of inflammatory and

Methylprednisol allergic disorders, cerebral oedema,
15 - 30 mg/kg daily. Large
one Sodium H02AB04520 immunosuppression treatment of
1005 A doses may be repeated 4 - 6
Succinate 1 g P4002XX haematological and oncological
hourly for up to 48 hours
Injection disorders, treatment of shock
states and endocrine disorders
227 / 371

i) CHILD over 5 years: 2.5 - 5
ml 3 times daily. 3 - 5 years
2 ml 2 - 3 times daily. 1 - 3
i) Dyspepsia, flatulence, hiatus
years: 1 ml 2 - 3 times daily.
hernia, peptic ulceration, reflux
Metoclopramide Under 1 year: 1 ml 2 times
A03FA01110 oesophagitis, gastritis, duodenitis,
1006 HCl 1 mg/ml B daily ii) Single dose given 10
L9001XX cholelithiasis, nausea, vomiting ii)
Syrup minutes before
Promote bowel transit during
examination. CHILD over 5
diagnostic procedures
years: 2.5 - 5 ml. Between 3
- 5 years: 2 ml. Under 1
year: 1 ml
i) ADULT over 20 years: 10
mg 3 times daily. ADULT
between 12 - 20 years: 5 mg
i) Dyspepsia, flatulence, hiatus 3 times daily. CHILD under
hernia, peptic ulceration, reflux 12 years: 0.12 mg/kg/dose 6
Metoclopramide A03FA01110 oesophagitis, gastritis, duodenitis, - 12 hourly ii) Single dose 5 -
1007 B
HCl 10 mg Tablet T1001XX cholelithiasis, nausea, vomiting ii) 10 minutes before
Promote bowel transit during examination; ADULT and
diagnostic procedures CHILD over 15 years: 10 - 20
mg; CHILD less than 15
years: 0.12 mg/kg/dose 6 -
12 hourly
i) ADULT over 20 years: 10
mg 3 times daily. ADULT
between 12 - 20 years: 5 mg
i) Dyspepsia, flatulence, hiatus 3 times daily. CHILD under
hernia, peptic ulceration, reflux 12 years: 0.12 mg/kg/dose 6
Metoclopramide
A03FA01110 oesophagitis, gastritis, duodenitis, - 12 hourly ii) Single dose 5 -
1008 HCl 5 mg/ml B
P3001XX cholelithiasis, nausea, vomiting ii) 10 minutes before
Injection
Promote bowel transit during examination; ADULT and
diagnostic procedures CHILD over 15 years: 10 - 20
mg; CHILD less than 15
years: 0.12 mg/kg/dose 6 -
12 hourly
Adult: 5-10 mg daily,
increased if necessary to 20
Oedema in congestive cardiac mg daily. Max: 80 mg in 24
Metolazone 2.5 C03BA08000
1009 A* failure, nephrotic syndrome and hr. Elderly: Initially, 2.5
mg Tablet T1002XX
impaired renal function mg/day or every other day.
Should be taken with food.
Take after breakfast.
228 / 371

Hypertension: Initially 100
mg to maximum 400 mg
daily, Angina: 50 mg - 100
Metoprolol
C07AB02123 Hypertension, angina, myocardial mg in 2 - 3 times daily.
T1002XX infarction, arrhythmias Myocardial infarction: 200
Tablet
Arrythmias: 50 mg - 300 mg
in 2 - 3 times daily
Hypertension: Initially 100
mg to maximum 400 mg
daily, Angina: 50 mg - 100
Metoprolol
C07AB02123 Hypertension, angina, myocardial mg in 2 - 3 times daily.
T1001XX infarction, arrhythmias Myocardial infarction: 200
Tablet
Arrythmias: 50 mg - 300 mg
in 2 - 3 times daily
Anaerobic infections Adult:
As a 1-g suppository 8 hrly
for 3 days, then 12 hrly.
Substitute oral therapy as
soon as possible. May be
unsuitable for initiating
therapy in severe infections.
Child: <1 yr: 125 mg; 1-5 yr:
Metronidazole P01AB01000 250 mg; 5-10 yr: 500 mg. All
1012 B Anaerobic infection
0.5 g Suppository S2001XX doses to be given 8 hrly for
3 days, then 12 hrly
thereafter. May be
unsuitable for initiating
therapy in severe infections.
Prophylaxis of postoperative
anaerobic bacterial
infections Adult: 1 g 8 hrly
starting 2 hr before surgery.
229 / 371

Anaerobic bacterial
infections Adult: Initially,
800 mg followed by 400 mg
8 hly for about 7 days. Other
recommended doses: 500
mg 8 hrly or 7.5 mg/kg 6
hrly (max: 4 g in 24 hr).
Child: 7.5 mg/kg 8 hrly.
Elderly: Use lower end of
adult dose
recommendations. Do not
admin as a single dose.
Prophylaxis of postoperative
anaerobic bacterial
Metronidazole P01AB01000
1013 B Anaerobic infection infections Adult: 400 mg by
mouth 8 hrly in the 24 hr
prior to surgery followed
postoperatively by IV or
rectal admin until oral
therapy is possible. Other
sources recommend that
oral doses be initiated only 2
hr prior to surgery and that
number of doses for all
admin routes be limited to a
total of 4. Elderly: Dose
reduction may be necessary.
Tab: Should be taken with
food.
Metronidazole
P01AB01000 CHILD: 7.5 mg/kg 3 times
1014 200 mg/5 ml B Anaerobic infection
L8001XX daily for 7 days
Suspension
ADULT: 500 mg IV infusion 8
hourly. CHILD: 7.5 mg/kg
body weight every 8 hours.
Metronidazole
J01XD01000P Neonates: 15mg/kg LD,
1015 500 mg/100 ml A Anaerobic infections
9901XX followed by 7.5mg/kg every
Injection
12 hourly. 1 month to 18
years: 7.5mg/kg (maximum
500mg) every 8 hours.
i) Fungal infections: Tinea pedis,
Tinea corporis, Tinea capitis and
Apply sparingly and rub
other dermatophyte infections
gently onto affected area 1-
Miconazole 2% D01AC02221 caused by Trichophyton and
1016 B 2 times daily continuing for
Cream G1001XX Epidermophyton species ii)
14 days after lesions have
Antifungal agent that has been in
healed
various candida infections including
vaginal candidiasis
230 / 371

Miconazole
D01AC02221 Skin infections caused by Dust powder over infected
1017 Nitrate 2% A
F2001XX dermatophytes or Candida area 1 - 2 times daily
Powder
Usual sedative range 2.5 -
7.5 mg (about 70 mcg/kg by
IV injection over 30
seconds). Premedication by
IM injection 70 - 100 mcg/kg
30 -60 minutes before
Pre-operative sedation, induction
surgery; ELDERLY: 1 - 1.5
Midazolam 5 N05CD08110 of general anaesthesia,
1018 A mg/kg. Induction: Induction
mg/5 ml Injection P3001XX premedication and sedation in ICU
by slow IV infusion 200 - 300
and sedation for minor procedures
mcg/kg (ELDERLY 100 - 200
mcg/kg. CHILD over 7 years
150 - 200 mcg/kg);
Maximum: 0.35mg/kg.
Sedation in ICU 0.03 - 0.2
mg/kg/hour
Usual sedative range 2.5 -
7.5 mg (about 70mcg/kg by
IV injection over 30
seconds). Premedication by
IM injection 70 - 100 mcg/kg
30 -60 minutes before
Pre-operative sedation, induction
surgery; ELDERLY: 1 - 1.5
Midazolam 5 N05CD08110 of general anaesthesia,
1019 A mg/kg. Induction: Induction
mg/ml Injection P3002XX premedication and sedation in ICU
by slow IV infusion 200 - 300
and sedation for minor procedures
mcg/kg (ELDERLY 100 - 200
mcg/kg. CHILD over 7 years
150 - 200 mcg/kg);
Maximum: 0.35mg/kg.
Sedation in ICU 0.03 - 0.2
mg/kg/hour
ADULT: Usually 7.5 - 15 mg
at bedtime; or for
premedication, 30 - 60
Midazolam 7.5 N05CD08253 minutes before the
1020 A/KK Pre and post-operative sedation
mg Tablet T1001XX procedure. For ELDERLY,
debilitated or impaired
liver/kidney function: 7.5
mg
Minocycline 100 J01AA08110C As second-line treatment for
1021 A* 100 mg daily 6 - 18 months
mg Capsule 1002XX leprosy only
Minocycline 50 J01AA08110C As second-line treatment for
1022 A* 100 mg daily 6 - 18 months
mg Capsule 1001XX leprosy only
231 / 371

ADULTS and CHILD above 12
years old: Initially 5 mg daily
in single or divided doses
(elderly 2.5 mg). May
Minoxidil 5 mg C02DC01000
1023 A* Severe hypertension increase by 5 - 10 mg daily
Tablet T1001XX
at intervals of 3 or more
days until optimum control
is achieved. Maximum 50
mg daily
Initially 15 mg daily at
bedtime increased
Mirtazapine 15 according to response up to
mg N06AX11000 45 mg daily as a single dose
Orodispersible T4001XX at bedtime or in 2 divided
Tablet doses. CHILD and
not recommended
Initially 15 mg daily at
bedtime increased
Mirtazapine 30 according to response up to
mg N06AX11000 45 mg daily as a single dose
Orodispersible T4002XX at bedtime or in 2 divided
Tablet doses. CHILD and
not recommended
Mitomycin C
S01AX00000 Pterygium, conjunctival tumour, 1 - 2 drops several times a
1026 0.002% Eye A
D2003XX glaucoma surgery day
Drops
Mitomycin C S01AX00000 Pterygium, conjunctival tumour, 1 - 2 drops several times a
1027 A
0.02% Eye Drops D2001XX glaucoma surgery day
Mitomycin C S01AX00000 Pterygium, conjunctival tumour, 1 - 2 drops several times a
1028 A
0.04% Eye Drops D2002XX glaucoma surgery day
i) 10 - 20 mg/m2 body
surface area (BSA) given as a
single dose through a
i) Gastrointestinal, lung, breast,
running IV infusion repeated
cervical cancers ii) Bladder tumours
every 6 - 8 weeks. The
iii) Opthalmological conditions:
whole schedule may be
conjunctival squamous neoplasia,
Mitomycin-C 10 L01DC03000 repeated depending on the
1029 A* squamous cell carcinoma of
mg Injection P4001XX bone marrow ii) 10 - 40 mg
conjunctiva, trabeculectomy
daily or every other day
chronic lymphocytic leukaemia,
(intravesical) iii) 0.4 mg
chronic myelogenous leukaemia.
topically as a single
Gastric, colorectal, lung cancer
application for
opthalmological conditions,
duration: 1 to 3 minutes
232 / 371

10 - 12 mg/m2 IV daily for 3
days, in combination with
other cytotoxic agents.
Refer to protocol. CHILD: 5 -
10 mg/m2 daily for 3 - 5
Acute leukaemia, elderly patients
days according to protocol.
Mitoxantrone 20 with acute myeloid leukaemia
L01DB07110 Treatment of acute
1030 mg/10ml A* (AML), relapsed/resistant acute
P3001XX leukaemia, ADULT: 8 - 12
Injection leukaemia, non-Hodgkin's
mg/m2/day once daily for 4
lymphoma (NHL)
- 5 days. CHILD more than 2
years: same as adult dose.
CHILD 2 years: 0.4
mg/kg/day once daily for 3 -
5 days
Mixed Gas-
Gangrene Prophylactic: 25,000 units
J06AA05000P
1031 Antitoxin 25,000 B Mixed gas-gangrene IM or IV. Therapeutic: Not
3001XX
units/5 ml less than 75,000 units IV
Injection
Initially 300 mg daily in
divided doses. Gradually to
Moclobemide N06AG02000
1032 A* Treatment of depressive syndrome in divided doses depending
on response. Usual range
150 - 600 mg daily. Not
recommended in children
For primary volume replacement in
hypovolaemia, peri-operative
Modified Fluid
B05AA06905 stabilization of the circulation, ADULT 500 - 1500 ml given
1033 Gelatin 4% B
P9901XX haemodilution, extracorporeal as IV infusion
Injection
circulation (haemodialysis and
heart-lung machine)
Administered by
intravenous infusion only.
For primary volume replacement in Total dosage and rate of
Modified hypovolaemia, peri-operative infusion depend upon the
Polypeptides B05AA10905 stabilization of the circulation, amount of blood loss and
1034 B
(Polygeline) 3.5% P9901XX haemodilution, extracorporeal hemodynamic parameters.
Injection circulation (haemodialysis and The usual dose is 500 to
heart-lung machine) 1000 milliliters (mL), with
total dosage not to exceed
2500 mL daily
i) As secondary prophylaxis and SC or IV 250 mcg/m2/day.
Molgramostim therapeutic use against Initiation: 24 to 72 hours
L03AA03000
1035 300 mcg A* chemotherapy induced leucopenia after chemotherapy.
P4002XX
Injection according to clinician's discretion ii) Duration: Until a clinically
Haemopoietic stem cell adequate neutrophil
233 / 371

transplantation (HSCT) recovery is achieved
Apply thin layer to the

affected skin areas once
Steroid responsive dermatosis and daily until the lesion heals or
Mometasone
D07AC13139 vitiligo. Used where a potent for duration of 3 weeks
1036 Furoate 0.1% A*
G1001XX steroid is required for short whichever is
Cream
duration not more than 6 weeks sooner.Massage gently and
thoroughly until the
medication disappears.
years: 100 mcg/day (2
sprays) to each nostril once
Mometasone daily. Maximum 200 mcg (4
Furoate 50 mcg R01AD09139 sprays) once daily. Reduce
1037 A* Allergic rhinitis
Aqueous Nasal A4101XX to 50 mcg (1 spray) once
Spray daily when control achieved.
CHILD 6 - 12 years old: 50
mcg (1 spray) to each nostril
once daily
45 ml diluted with half a
glass (120 ml) of water,
followed by one full glass
(240 ml) of water to be
taken depending on the
time of the procedure. For
morning procedure, 45 ml
dilute with half glass of
water should be taken at 7
Monobasic am and the second 45 ml at
Sodium Bowel cleansing prior to 7 pm on the day before the
A06AG01162
1038 Phosphate 48%, A colonoscopy, radiological procedure. For afternoon
L5001XX
Dibasic Sodium examination or bowel surgery procedure, the first dose
Phosphate 18% should be taken at 7 pm on
the day before and the
second dose at 7 am on the
day of the procedure. Solid
food must not be taken
during the preparation
period; clear fluids or water
can be taken liberally. Not
recommended for use in
children
Chronic treatment of asthma and
Montelukast CHILD more than 15 years
R03DC03520 relief of symptoms of seasonal
1039 Sodium 10 mg A/KK and ADULT: 10 mg daily at
T1001XX allergic rhinitis for children more
Tablet bedtime
than 15 years and adults
234 / 371
Asthmatics, not controlled on high

Montelukast dose inhaled corticosteroids more 12 months - 5 years: 1
R03DC03520
1040 Sodium 4 mg A* than 1600 mcg/day and with co- packet of 4mg oral granules
F1001XX
Oral Granules morbid allergic disorders. Chronic daily at bedtime
treatment of asthma
Asthmatics, not controlled on high
Montelukast dose inhaled corticosteroids more CHILD 6 - 14 years: One 5
R03DC03520
1041 Sodium 5 mg A* than 1600 mcg/day and with co- mg chewable tablet daily at
T2001XX
Tablet morbid allergic disorders. Chronic bedtime
treatment of asthma
For use in management of
5 - 20 mg or more regularly
Morphine HCl 10 N02AA01110 moderate to severe pain especially
1042 B every 4 hours in terminal
mg/5 ml Solution L9901XX that associated with neoplastic
pain
disease
10 - 60 mg 12 hourly
Prolonged relief of severe pain intervals, depend upon the
Morphine
associated with neoplastic disease; severity of the pain.
Sulphate 10 mg N02AA01183
1043 A assists in procuring sleep where Children (more than 1 year
Controlled T5001XX
sleeplessness is due to pain or of age) with severe cancer
Release Tablet
shock pain: 0.2 - 0.8mg/kg 12
hourly.
Morphine
5-10 mg every four hours.
Sulphate 10 mg N02AA01183 Relief of moderate to severe pain
1044 A* The dose may be increased
Immediate T6002XX (cancer patient)
according to needs
Release Tablet
Morphine
N02AA01183 Relief of severe chronic pain 15 - 30 mg regularly every 4
1045 Sulphate 10 mg A*
S2001XX (cancer patient) hours
Suppository
ADULT: 10 - 20 mg/kg or
more SC or IM every 4 hours
in terminal pain. CHILD: Up
Morphine For moderate to severe pain
N02AA01183 to 1 month: 0.15 mg/kg
1046 Sulphate 10 B especially that associated with
P3001XX body weight; 1 - 12 months:
mg/ml Injection neoplastic disease
0.2 mg/kg body weight; 1 - 5
years: 2.5 - 5 mg ; 6 - 12
years: 5 - 10 mg
Morphine
Suppository
Prolonged relief of severe pain
Morphine
associated with neoplastic disease; 10 - 60 mg 12 hourly
1048 A assists in procuring sleep where intervals, depend upon the
Controlled T5002XX
sleeplessness is due to pain or severity of the pain
Release Tablet
shock
Morphine
Suppository
235 / 371

Morphine
5-10 mg every four hours.
Sulphate 5 mg N02AA01183 Relief of moderate to severe pain
1050 A* The dose may be increased
Immediate T6001XX (cancer patient)
according to needs
Release Tablet
10 - 60 mg 12 hourly
Prolonged relief of severe pain intervals, depend upon the
Morphine
associated with neoplastic disease; severity of the pain.
1051 A assists in procuring sleep where Children (more than 1 year
Controlled T5003XX
sleeplessness is due to pain or of age) with severe cancer
Release Tablet
shock pain: 0.2 - 0.8mg/kg 12
hourly.
CHILD more than 1 year and
Moxifloxacin
S01AX22110 Treatment of conjunctivitis caused ADULT: 1 drop to affected
1052 0.5% Ophthalmic A*
D2001XX by susceptible organism eye(s) 3 times daily for 7
Solution
days
Second line therapy for Severe
Community Acquired Pneumonia
IV or Oral: 400 mg once
(CAP) patients with co-morbidity or
daily. The recommended
with recent antibiotic therapy,
Moxifloxacin 400 J01MA14110 total treatment duration for
1053 A* suspected infections of resistant
mg Injection P3001XX sequential administration
pathogens including Streptococcus
(intravenous followed by
pneumoniae, Haemophilus
oral therapy) is 7 to 14 days
influenzae & Mycoplasma
pneumoniae.
Second line therapy for Severe
Community Acquired Pneumonia
IV or Oral: 400 mg once
(CAP) patients with co-morbidity or
daily. The recommended
with recent antibiotic therapy,
Moxifloxacin J01MA14110 total treatment duration for
1054 A* suspected infections of resistant
400mg Tablet T1001XX sequential administration
pathogens including Streptococcus
(intravenous followed by
pneumoniae, Haemophilus
oral therapy) is 7 to 14 days
influenzae & Mycoplasma
pneumoniae.
Multivitamin A11BA00901 For prevention and treatment of INFANT less than 1 year: 1
1055 B
Drops D5001XX vitamin deficiencies ml daily
Initially 2 - 4 pairs IV 4 - 8
hourly, reduce to 1 pair IV
Multivitamin A11BA00901 For prevention and treatment of daily. For less serious cases,
1056 B
Injection P3001XX vitamin deficiencies 1 pair IV 1 - 2 times daily or
based on individual
requirements
Multivitamin A11BA00901 For prevention and treatment of CHILD 5 ml daily or based on
1057 C+
Syrup L9001XX vitamin deficiencies manufacturer
Multivitamin A11BA00901 For prevention and treatment of 1 - 2 tablets daily or based
1058 B
Tablet T1001XX vitamin deficiencies on individual requirements
236 / 371
Skin infection by Staphylococcus

Adults and child over 1 year,
Mupirocin 2% D06AX09000 aureus (including MRSA),
1059 A apply up to 3 times daily for
Cream G1001XX Staphylococcus epidermidis and
up to 10 days
beta-haemolytic streptococcus
ADULT and CHILD: Apply up
Mupirocin 2% D06AX09000
1060 A For MRSA infections only to three times daily for up to
Ointment G5001XX
10 days
i) Renal transplant rejection:
ADULT: 1 g twice daily.
CHILD (3 months and older):
i) Prophylaxis of acute organ 600 mg/m(2)/dose, twice
rejection in patients receiving daily; maximum daily dose,
allogenic renal, cardiac and hepatic 2 g/10 mL. Cardiac
Mycophenolate
L04AA06236 transplant ii) Used with steroids for transplant rejection: 1.5 g
1061 Mofetil 250 mg A*
C1001XX induction and maintenance of twice daily. Hepatic
Capsule
severe lupus nephritis resistant or transplant rejection: 1.5 g
intolerant to cyclophosphamide twice daily ii) Induction
therapy phase: 2 - 3 g/day for up to
6 months. Maintenance
phase: dose gradually tapers
to 1 g/day
i) Renal transplant rejection:
ADULT: 1 g twice daily.
CHILD (3 months and older):
i) Prophylaxis of acute organ 600 mg/m(2)/dose, twice
rejection in patients receiving daily; maximum daily dose,
allogenic renal, cardiac and hepatic 2 g/10 mL. Cardiac
Mycophenolate
L04AA06236 transplant ii) Used with steroids for transplant rejection: 1.5 g
1062 Mofetil 500 mg A*
T1002XX induction and maintenance of twice daily. Hepatic
tablet
severe lupus nephritis resistant or transplant rejection: 1.5 g
intolerant to cyclophosphamide twice daily ii) Induction
therapy phase: 2 - 3 g/day for up to
6 months. Maintenance
phase: dose gradually tapers
to 1 g/day
Prophylaxis of acute transplant
Mycophenolate rejection in adult patients receiving
L04AA06520
1063 Sodium 180mg A* allogenic renal transplant in 720 mg twice daily
T1001XX
Tablet combination with ciclosporin and
corticosteroids
Prophylaxis of acute transplant
Mycophenolate rejection in adult patients receiving
L04AA06520
1064 Sodium 360mg A* allogenic renal transplant in 720 mg twice daily
T1002XX
Tablet combination with ciclosporin and
corticosteroids
237 / 371

Nalbuphine HCl
N02AF02110 Perioperative analgesia, for relief of 10 - 20 mg SC, IM or IV
1065 10 mg/ml B
P3001XX moderate to severe pain every 3 - 6 hours
Injection
For the complete/partial reversal of
narcotic depression including 0.005 - 0.01 mg/kg body
Naloxone HCl respiratory depression induced by weight repeated at intervals
V03AB15110
1066 0.02 mg/ml B opioids such as natural and of 2 - 3 minutes according to
P3001XX
Injection synthetic narcotics. Diagnosis of the patient's needs by IM, IV
suspected acute opioids or SC
overdosage
For the complete/partial reversal of
narcotic depression including
Initially 0.4 - 2 mg IV
respiratory depression induced by
Naloxone HCl 0.4 V03AB15110 repeated at intervals of 2 - 3
1067 B opioids such as natural and
mg/ml Injection P3002XX minutes according to
synthetic narcotics. Diagnosis of
patient's needs
suspected acute opioids
overdosage
Initial 25 mg may be
increased to 50 mg.
Maintenance: 350 mg
Adjunct in relapse prevention weekly; administered as 50
Naltrexone HCl N07BB04110
1068 A treatment in detoxified formerly mg daily. Dosing interval
opioid-dependant patients may be lengthened to
improve compliance; 100
mg on alternate days or 150
mg every third day
ADULT: 25 - 50 mg every 3
Nandrolone
A14AB01135 weeks by IM. CHILD over 2
1069 Decanoate 25 A Anabolic therapy
P3001XX years: 25 - 50 mg every 3 to
mg/ml Injection
4 weeks
i) 0.5 - 1 g daily in 2 divided
i) Rheumatic arthritis, osteoarthritis
doses ii) 750 mg initially
Naproxen 250 M01AE02000 and ankylosing spondylitis ii) Acute
1070 A/KK then 250 mg 8 hourly iii) 500
mg Tablet T1001XX gout iii) Muscular skeletal disorder,
mg initially then 250 mg
dysmenorrhoea
every 6 - 8 hour as required
i) Rheumatic arthritis, osteoarthritis
Naproxen
M01AE02520 and alkylosing spondylitis ii) Acute 550 mg- 1100 mg in two
1071 Sodium 275 mg A
T1001XX gout iii) Muscular skeletal disorder divided doses
Tablet
and dysmenorrhoea
Neomycin 0.5% D06AX04256 Infections of the skin due to
1072 B area up to 3 times daily (For
Cream G1001XX susceptible organisms
short term use, 1 - 2 weeks)
238 / 371

Treatment of the following
conditions where bacterial
Neomycin 0.5%
infection is present or likely to Apply sparingly to affected
in
D07CC01947 occur: eczemas, prurigo nodularis, area 2 - 3 times daily. (May
1073 Betamethasone B
G1001XX psoriasis (excluding widespread cause sensitisation to
17-Valerate
plaque psoriasis), neomycin. Use with caution)
0.01% Cream
neurodermatoses, anal and genital
intertrigo
Neomycin 0.5% Apply sparingly to affected
infection is present or likely to
in area 2 to 3 times daily. (May
D07CC01947 occur: eczemas, prurigo nodularis,
1074 Betamethasone B cause sensitisation to
G5001XX psoriasis (excluding widespread
17-Valerate Neomycin. Use with
plaque psoriasis),
0.01% Ointment caution)
intertrigo
Neomycin 0.5%
in
D07CC01947 occur: eczemas, prurigo nodularis, area 2 - 3 times daily (May
1075 Betamethasone A
17-Valerate 0.1%
Cream
intertrigo
Neomycin 0.5%
in
D07CC01947 occur: eczemas, prurigo nodularis, area 2 to 3 times daily. (May
1076 Betamethasone A
17-Valerate 0.1%
Ointment
intertrigo
Neomycin 0.5% D06AX04256 Infections of the skin due to
1077 B area up to 3 times daily (For
Ointment G5001XX susceptible organisms
short term use, 1- 2 weeks)
Neomycin with
1 - 2 drops in the affected
Polymyxin B
S01AA30990 Eye infections that require a broad eye 2 - 4 times daily. In
1078 Sulphate and A
D2001XX spectrum antibiotic severe infections : 1 - 2
Gramicidin Eye
drops every 15 - 30 minutes
Drops
239 / 371

i) ADULT: 1 - 2.5 mg at
suitable intervals by SC, IM
or IV. Usual total daily dose
5 - 20 mg. CHILD: 200 - 500
Neostigmine mcg at suitable intervals
i) Myasthenia gravis ii) Reversal of
Methylsulphate N07AA01183 throughout the day.
1079 B non-depolarising neuromuscular
2.5 mg/ml P3002XX NEONATE: 50 - 250 mcg
blockade
Injection every 4 hours ii) By IV
injection over 1 minute, 50 -
70 mcg/kg (maximum 5 mg)
after or with atropine
sulphate 0.6 - 1.2 mg
ADULT: 4 - 6.5 mg/kg/day
IM or IV in 2 - 3 equally
divided doses for 7 - 14
Netilmicin days. Maximum: 7.5
J01GB07183P
1080 Sulphate 100 A Systemic infections mg/kg/day. CHILD: 5 - 7.5
3002XX
mg/2 ml Injection mg/kg/day 8 - 12 hourly
depending on gestation and
age. Maximum: 7.5
mg/kg/day
J01GB07183P
3003XX
age. Maximum: 7.5
mg/kg/day
J01GB07183P
3001XX
age. Maximum: 7.5
mg/kg/day
Combined with other
antiretrovirals: 200 mg once
daily for the 1st 14 days; up
Treatment of HIV-1 infection in to 200 mg twice daily if rash
Nevirapine 200 J05AG01000T
1083 A/KK combination with other does not develop. Re-
mg Tablet 1001XX
antiretroviral agents introduce at a lower dose
for the 1st 14 days if
treatment is interrupted for
>7 days,necessitate
240 / 371

reintroduction at a lower
dose for the first 14 days.
Adult over 18 years old: 15

mg patch on waking (usually
in the morning) and remove
16 hours later (usually at
For the treatment of tobacco bedtime) for 8 weeks, then
Nicotine 10 mg/
dependence by relieving nicotine 10 mg patch daily for 2
16 hour N07BA01000
1084 A/KK withdrawal symptoms, thereby weeks followed by one 5 mg
Transdermal M7005XX
facilitating smoking cessation in patch daily for another 2
Patch
smokers motivated to quit. weeks. Apply to dry non-
hairy skin site. Application
limited to 16 hours in a 24-
hr period in each case.
Review at 3 months.
For the treatment of tobacco
Nicotine
dependence by relieving nicotine Apply 1 patch daily for 24
14mg/24 hour N07BA01000
1085 A/KK withdrawal symptoms, thereby hours as in the product
Transdermal M7002XX
facilitating smoking cessation in leaflet
Patch
smokers motivated to quit.
Nicotine 15 mg/
16 hour N07BA01000
Transdermal M7006XX
Patch
Review at 3 months.
For the treatment of tobacco Smokes ≤ 20 sticks/day,
dependence by relieving nicotine chew 2mg gum. Smokes ≥
Nicotine 2 mg N07BA01000
1087 A/KK withdrawal symptoms, thereby 20 sticks/day,chew 4 mg
Gum M9901XX
facilitating smoking cessation in gum. (MAX 24 pieces /day
smokers motivated to quit. for up to 12 week.)
241 / 371

Nicotine
21mg/24 hour N07BA01000
Transdermal M7003XX
facilitating smoking cessation in leaflet.
Patch
For the treatment of tobacco Smokes ≤ 20 sticks/day,
dependence by relieving nicotine chew 2mg gum. Smokes ≥
Nicotine 4 mg N07BA01000
1089 A/KK withdrawal symptoms, thereby 20 sticks/day,chew 4 mg
Gum M9902XX
facilitating smoking cessation in gum. (MAX 24 pieces /day
smokers motivated to quit. for up to 12 week.)
Nicotine 5 mg/
16 hour N07BA01000
Transdermal M7004XX
Patch
Review at 3 months.
Nicotine 7mg/24
hour N07BA01000
Transdermal M7001XX
facilitating smoking cessation in leaflet.
Patch
Prophylactic: 15 - 30 mg
daily. Therapeutic: 50 - 250
Nicotinic Acid 50 A11HA01000 For prophylaxis and treatment of
1092 B mg daily. Maximum single
mg Tablet T1001XX Vitamin B3 deficiency
dose: 200 mg. Maximum
dose in 24 hours: 800 mg
100 - 200 mg 3 times daily,
gradually increased over 2 -
4 weeks to 1 - 2 g 3 times
daily with or after meals.
Nicotinic Acid C10AD02000 CHILD: 100 - 250 mg/day in
1093 B Hyperlipidaemia
500 mg Tablet T1001XX 3 divided doses with meals
increase 100 mg/day weekly
or 250 mg/day every 2 - 3
weeks as tolerated.
Maximum: 10 mg/kg/day
10 - 30 mg 3 times daily.
Nifedipine 10 mg C08CA05000
1094 B Hypertension Maximum: 120 - 180 mg per
Capsule C1001XX
day
242 / 371

Initial dose of 10 mg twice
daily. Usual range 10 - 30
Nifedipine 10 mg C08CA05000 mg 3 times daily. Maximum:
1095 B Hypertension
Tablet T1001XX 120 - 180 mg per day.
Elderly: Dose reduction may
be necessary.
For the treatment of adult patients 300mg twice daily. Dose
with newly diagnosed Philadelphia adjustments or
Nilotinib 150mg L01XE08110T
1096 A* chromosome positive chronic modifications:For
capsule 1001XX
myelogenous leukemia in the neutropenia &
chronic phase (CP). thrombocytopenia
Treatment of chronic phase and

accelerated phase Philadelphia
chromosome positive chronic
myelogenous leukaemia (CML) in
400 mg twice daily, 12 hours
adults who: i) Failed imatinib ie no
Nilotinib 200 mg L01XE08110C apart. No food should be
1097 A* cytogenic response and no
Capsule 1001XX taken two hours before and
haematological response by 12
1 hour after taking the dose
months ii) Have molecular
resistance to Imatinib as shown by
molecular mutation studies iii) Are
intolerant to Imatinib
IV infusion of 1 mg/hour for

Prophylaxis & treatment of a period of 2 hours (about
Nimodipine 10 ischaemic neurological deficits 15 mcg/kg/hour). IV therapy
C08CA06000
1098 mg/50 ml A* caused by cerebral vasospasm should be started no later
P9901XX
Infusion Solution following subarachnoid than 4 days after
haemorrhage of aneurysmal origin haemorrhage & continue for
up to 10 - 14 days
Prophylaxis & treatment of
ischaemic neurological deficits
Nimodipine 30 C08CA06000 360 mg daily in divided
1099 A* caused by cerebral vasospasm
mg Tablet T1001XX doses for 7 days
following subarachnoid
haemorrhage of aneurysmal origin
5 - 10 mg at bedtime.
ELDERLY or debilitated 2.5 -
Nitrazepam 5 mg N05CD02000 5 mg. CHILD not
1100 B Epilepsy (infantile spasms)
Tablet T1001XX recommended. Increasing
slowly according to
response
243 / 371

Acute uncomplicated
urinary tract infections
Adult: 50-100 mg 4 times
daily for 7 days. Dual-
release preparation: 100 mg
bid. Child: >3 mth and older
Nitrofurantoin J01XE01000T Uncomplicated lower urinary tract
1101 B children: 3 mg/kg daily in 4
100 mg Tablet 1002XX infections
divided doses. Prophylaxis
of uncomplicated urinary
tract infections Adult: 50-
100 mg at bedtime. Child:
>3 mth and older children: 1
mg/kg once daily.
Number of factor IX units
required = body weight (kg)
x desired factor IX increase
(% or units/dL) x reciprocal
Treatment and prophylaxis of of observed recovery
Nonacog alfa B02BD09000 bleeding in patients with (units/kg per units/dL).
1102 A*
1000 IU injection P4003XX haemophilia B (congenital factor IX Average dose for secondary
deficiency) prophylaxis for previously
treated adult patients (PTP)
was 40 units/kg (range 13 to
78 units/kg) at intervals of 3
to 4 days
Nonacog alfa B02BD09000 bleeding in patients with (units/kg per units/dL).
1103 A*
2000 IU injection P4004XX haemophilia B (congenital factor IX Average dose for secondary
to 4 days
Treatment and prophylaxis of
of observed recovery
Nonacog alfa 250 B02BD09000 bleeding in patients with
1104 A* (units/kg per units/dL).
IU injection P4001XX haemophilia B (congenital factor IX
Average dose for secondary
deficiency)
prophylaxis for previously
244 / 371

to 4 days.

Nonacog alfa 500 B02BD09000 bleeding in patients with (units/kg per units/dL).
1105 A*
IU injection P4002XX haemophilia B (congenital factor IX Average dose for secondary
to 4 days
Noradrenaline
Acid Tartrate Septic shock and shock where Infuse and titrate to desired
C01CA03123
1106 (Norepinephrine A peripheral vascular resistance is pressure response. Range:
P3001XX
Bitartrate) 1 low 0.05 - 0.5 mcg/kg/minute
mg/ml Injection
1 tablet daily starting on the
Norethisterone G03AC01000
1107 C+ Contraception first day of the menstrual
0.35 mg Tablet T1001XX
bleeding
By deep IM injection only.
First injection is within first
Norethisterone 5 days of the cycle. The next
G03AC01257
1108 Enanthate 200 B Contraception 3 injections are given at 8
P3001XX
mg/ml Injection weeks interval after which
the injection interval should
be extended to 12 weeks
1 year: 1-2 drops 4 times
Superficial infections of the eye
Norfloxacin 0.3% S01AX12000 daily. First day : 1 - 2 drops
1109 A* (Pseudomonas aeruginosa and
Eye Drops D2001XX two hourly during waking
MRSA) and its adnexae
hours (depending on
severity)
Apply liberally to affected
area twice daily or as
required. After lesion has
disappeared continue
Prevention and treatment of
Nystatin 100,000 D01AA01000 treatment for 10 days to
1110 C cutaneous infections caused by
units/g Cream G1001XX prevent relapses. Nail
Candida albicans
infection: Cut nails as short
as possible. Apply cream
once daily until growth of
new nail has set in
245 / 371

Apply liberally to affected
area twice daily or as
required. After lesion has
Prevention and treatment of disappeared continue
Nystatin 100,000 D01AA01000 cutaneous or mucocutaneous treatment for 10 days to
1111 C
units/g Ointment G5001XX infections caused by Candida prevent relapses. Nail
albicans infection: Cut nails as short
as possible. Apply cream
once daily until growth of
new nail has set in
Prevention and treatment of NEWBORN: 50,000-100,000
candidiasis of the skin and mucous units daily. CHILD up to 5
Nystatin 100,000 membranes, protection against years: 100,000 -500,000
A07AA02000
1112 units/ml B candidas overgrowth during units 6 hourly. CHILD up to
L8001XX
Suspension antimicrobial /corticosteroid 6-12 years and ADULT:
therapy and as selective 500,000-1,000,000 units 3 to
decontamination regimens 4 times daily

candidiasis of the skin and mucous ADULT: 500,000 -1,000,000
membranes, protection against units 6 hourly, according to
Nystatin 500,000 A07AA02000
1113 B candidas overgrowth during severity of infections. CHILD:
units Tablet T1001XX
antimicrobial /corticosteroid 100,000-500,000 units 6
therapy and as selective hourly
decontamination regimens
i) Acromegaly ii) Treatment of
patients with symptoms associated
i, ii and iii) Initially 0.005 -
with gastro-entero-pancreatic
0.1 mg SC 1 - 2 times daily,
endocrine tumours iii) Carcinoid
increase gradually up to 0.1
tumours with features of the
- 0.2 mg 3 times daily iv) 0.1
carcinoid syndrome, VIPomas,
mg 3 times daily for 7
Octreotide 0.05 H01CB02122 glucagonomas,
1114 A consecutive days, starting
mg/ml Injection P3002XX gastrinomas/Zollinger-Ellison
on the day of operation, at
syndrome, GRFomas, insulinomas
least 1 hour before
iv) Prevention of complications
laparotomy v) 25 mcg/hour
following pancreatic surgery v)
for 5 days by continous IV
Emergency management of
infusion
bleeding gastro-eosophageal
varices in patients with cirrhosis
246 / 371

i) Acromegaly ii) Treatment of
patients with symptoms associated
i, ii and iii) Initially 0.005 -
with gastro-entero-pancreatic
0.1 mg SC 1 - 2 times daily,
endocrine tumours iii) Carcinoid
increase gradually up to 0.1
tumours with features of the
- 0.2 mg 3 times daily iv) 0.1
carcinoid syndrome, VIPomas,
mg 3 times daily for 7
Octreotide 0.1 H01CB02122 glucagonomas,
1115 A consecutive days, starting
mg/ml Injection P3001XX gastrinomas/Zollinger-Ellison
on the day of operation, at
syndrome, GRFomas, insulinomas
least 1 hour before
iv) Prevention of complications
laparotomy v) 25 mcg/hour
following pancreatic surgery v)
for 5 days by continous IV
Emergency management of
infusion
bleeding gastro-eosophageal
varices in patients with cirrhosis
i) Adjunctive treatment for active
acromegaly (second/third line
therapy in whom surgery or
radiotherapy is inappropriate or
ineffective- based on level of
growth hormone and high IGF-1
and residual pituitary tumor). ii)
Treatment of symptoms associated
Octreotide
H01CB02122 with functional gastro-entero- 10 - 30 mg every 4 weeks as
P2001XX pancreatic endocrine tumours. iii) deep intragluteal injection
Injection
Carcinoid tumours with features of
the carcinoid syndrome, VIPomas,
Glucagonomas,
Gastrinomas/Zollinger-Ellison
syndrome, Insulinomas, for pre-
operative control of hypoglycemia
and for maintenance therapy,
GRFomas.
247 / 371

i) Adjunctive treatment for active
acromegaly (second/third line
therapy in whom surgery or
radiotherapy is inappropriate or
ineffective- based on level of
growth hormone and high IGF-1
and residual pituitary tumor). ii)
Treatment of symptoms associated
Octreotide
H01CB02122 with functional gastro-entero- 10 - 30 mg every 4 weeks as
P2002XX pancreatic endocrine tumours. iii) deep intragluteal injection
Injection
Carcinoid tumours with features of
the carcinoid syndrome, VIPomas,
Glucagonomas,
Gastrinomas/Zollinger-Ellison
syndrome, Insulinomas, for pre-
operative control of hypoglycemia
and for maintenance therapy,
GRFomas.
CHILD: 1 - 12 years: 5 drops
Acute otitis media with
twice daily for 10 days.
tympanostomy tubes, chronic
Ofloxacin 0.3% S02AA00000 ADULT and CHILD over 12
1118 A/KK suppurative otitis media with
Otic Solution D1001XX years: 6 - 10 drops twice
perforated tympanic membranes
daily and remain in the ear
and otitis externa
about 10 minutes
i) As second-line treatment of
leprosy ii) As second-line treatment
i) 400 mg/day ii) 400 mg
Ofloxacin 100 mg J01MA01000 for tuberculosis and multidrug
1119 A twice daily iii) 200 mg twice
Tablet T1001XX resistant tuberculosis (MDR-TB) iii)
daily
Sequential therapy for UTI and
pyelonephritis
200 mg IV twice daily for 3 -
5 days followed with 200 mg
Ofloxacin 200 mg J01MA01000 Sequential therapy for UTI and
1120 A tablet twice daily for 3 - 5
Injection P4001XX pyelonephritis
days as maintenance dose
(if necessary)
i) 5 - 10 mg once daily,
increase to 10 mg once daily
i) Acute and maintenance within 5 - 7 days, adjust by 5
treatment of schizophrenia and - 10 mg/day at 1 week
Olanzapine 10 other psychoses where positive and intervals, maximum 20
N05AH03000
1121 mg Disintegrating A* or negative symptoms are mg/day ii) 10 - 15 mg once
T4002XX
Tablet prominent ii) Short-term use for daily, increase by 5 mg/day
acute mania episodes associated at intervals of not less than
with Bipolar 1 disorder 24 hours. Maintenance 5 -
20 mg/day; maximum 20
mg/day
248 / 371

other psychoses where positive and intervals, maximum 20
Olanzapine 10 N05AH03000
1122 A* or negative symptoms are mg/day ii) 10 - 15 mg once
mg Tablet T1002XX
prominent ii) Short-term use for daily, increase by 5 mg/day
mg/day
other psychoses where positive and intervals, maximum 20
Olanzapine 5 mg N05AH03000
1123 A* or negative symptoms are mg/day ii) 10 - 15 mg once
Tablet T1001XX
prominent ii) Short-term use for daily, increase by 5 mg/day
mg/day
Olanzapine 5mg other psychoses where positive and intervals, maximum 20
N05AH03000
1124 Disintegrating A* or negative symptoms are mg/day ii) 10 - 15 mg once
T4001XX
Tablet prominent ii) Short-term use for daily, increase by 5 mg/day
mg/day
Olive Oil Ear S02DC00000 3 - 4 drops 3 - 4 or as
1125 C Impacted wax softener
Drops D1001XX directed
Olopatadine
hydrochloride S01GX09110 Temporary prevention of ocular One drop in each affected
1126 A*
ophthalmic D2002XX itching due to allergic conjunctivitis eye once a day
solution 0.2%
249 / 371

i) Adult & adolescent ≥12 yr,
150-375 mg SC every 2-4
wk, according to body wt &
baseline serum total IgE
level.. For subcutaneous
administration only. Do not
administer by the
i) For adults and adolescents (≥12
intravenous or
years), for severe persistent allergic
intramuscular route. ii)
asthma whose symptoms are
Appropriate dose and
inadequately controlled with
dosing frequency of
inhaled corticosetroids ii) For
omalizumab is determined
Children (6 to <12 years of age): As
by baseline IgE (IU/ml),
add-on therapy to improve asthma
measured before the start
Omalizumab 150 control with severe persistent
of treatment, and body
mg (powder and R03DX05000 allergic asthma who have positive
1127 A* weight (kg). Prior to initial
solvent for P3001XX skin test or in vitro reactivity to a
dosing, patients should have
solution) perennial aero allergen and
their IgE level determined
frequent daytime symptoms or
for their dose assignment.
night-time awakenings and who
Based on these
have had multiple documented
measurements 150-375mg
severe asthma exacerbations
in 1 -3 injections may be
despite daily high-dose inhaled
needed for each
corticosteroids, plus a long-acting
administration. Patients
inhaled beta 2 agonist
whose baseline IgE levels or
body weight in kilograms
are outside the limits of the
dosing table should not be
given omalizumab. For
subcutaneous
administration only.
i) 20 - 80 mg 1 - 2 times daily
up to 8 - 12 weeks ii) 20 mg
Only for : i)Reflux oesophagitis (clarithromycin 500 mg
ii)For eradication of Helicobacter twice daily, amoxicillin 1 g
Omeprazole 10 A02BC01000 pylori infection iii)Benign peptic twice daily or metronidazole
1128 A/KK
mg Capsule C1001XX ulcer not responding to 400 mg twice daily) for 1 - 2
conventional therapy iv)Zollinger- weeks iii) 20 mg once daily
Ellison Syndrome for 4 - 6 weeks iv) ADULT: 20
- 120 mg once daily adjusted
according to the patient's
response. CHILD 0.4 - 0.8
mg/kg/day
250 / 371

i) 20 - 80 mg 1 - 2 times daily
up to 8 - 12 weeks ii) 20 mg
Only for : i)Reflux oesophagitis (clarithromycin 500 mg
ii)For eradication of Helicobacter twice daily, amoxicillin 1 g
Omeprazole 20 A02BC01000 pylori infection iii)Benign peptic twice daily or metronidazole
1129 A/KK
mg Capsule C1002XX ulcer not responding to 400 mg twice daily) for 1 - 2
conventional therapy iv)Zollinger- weeks iii) 20 mg once daily
Ellison Syndrome for 4 - 6 weeks iv) ADULT: 20
- 120 mg once daily adjusted
according to the patient's
response. CHILD 0.4 - 0.8
mg/kg/day
i) Reflux oesophagitis, eradication
of H. Pylori infection, benign peptic i) 40 mg IV once daily when
Omeprazole 40 A02BC01000 ulcer not responding to oral therapy is inappropriate
1130 A*
mg Injection P4001XX conventional therapy, Zollinger- ii) 40- 160 mg by IV in single
Ellison Syndrome ii) Endoscopically or divided doses
confirmed peptic ulcer
i)8 mg given by IV infusion
over 15 minutes or by IM
immediately before
treatment followed by 8 mg
orally every 12 hours for up
to 5 days. CHILD 5 mg/m2
body surface IV over 15
minutes immediately before
chemotherapy followed by 4
i)Prevention of nausea and
mg orally every 12 hours for
Ondansetron 2 A04AA01110 vomiting induced by chemotherapy
1131 A up to 5 days ii)Prevention : 4
mg/ml Injection P3001XX and radiotherapy ii)Postoperative
mg given by IV at induction
nausea and vomiting
of anaesthesia. CHILD over 2
years, 100mcg/kg (max
4mg) by slow IV before,
during or after induction of
anaesthesia. Treatment of
postoperative: 4 mg by IM
or slow. CHILD over 2 years
100 mcg/kg (maximum 4mg)
by slow IV
251 / 371

i)8 mg 1 - 2 hours before
treatment then 8 mg every
CHILD, treatment by
infusion followed by 4 mg by
i)Prevention of nausea and mouth every 12 hours for up
Ondansetron 4 A04AA01110 vomiting induced by chemotherapy to 5 days ii)Prevention of
1132 A
mg Tablet T1001XX and radiotherapy ii) Postoperative postoperative nausea and
nausea and vomiting vomiting, 16 mg 1 hour
before anaesthesia or 8 mg
1 hour before anaesthesia
followed by 8 mg at
intervals of 8 hours for a
further 2 doses
i)8 mg 1 - 2 hours before
treatment then 8 mg every
CHILD, treatment by
infusion followed by 4 mg by
i)Prevention of nausea and mouth every 12 hours for up
Ondansetron 8 A04AA01110 vomiting induced by chemotherapy to 5 days ii)Prevention of
1133 A
mg Tablet T1002XX and radiotherapy ii) Postoperative postoperative nausea and
nausea and vomiting vomiting, 16 mg 1 hour
before anaesthesia or 8 mg
1 hour before anaesthesia
followed by 8 mg at
intervals of 8 hours for a
further 2 doses
i)8 mg given by IV infusion
over 15 minutes or by IM
immediately before
treatment followed by 8 mg
orally every 12 hours for up
to 5 days. CHILD 5 mg/m2
body surface IV over 15
minutes immediately before
i)Prevention of nausea and chemotherapy followed by 4
Ondansetron 8 A04AA01110 vomiting induced by chemotherapy mg orally every 12 hours for
1134 A
mg/4ml Injection P3002XX and radiotherapy ii)Postoperative up to 5 days ii)Prevention : 4
nausea and vomiting mg given by IV at induction
of anaesthesia. CHILD over 2
years, 100mcg/kg (max
4mg) by slow IV before,
during or after induction of
anaesthesia. Treatment of
postoperative: 4 mg by IM
or slow. CHILD over 2 years
100 mcg/kg (maximum 4mg)
252 / 371

by slow IV
ADULT: 200 - 400 ml (1 - 2
sachets) for every loose
motion. CHILD: 200 ml (1
sachet) for every loose
Oral Rehydration A07CA00905 Replacement of fluid and motion. In severe
1135 C
Salt F2101XX electrolytes loss in diarrhoea dehydration 100 ml/kg for 3
- 4 hours. INFANT: 1 - 1.5
times their usual feed
volume (50 ml per stool for
small infant)
Initially 150 mg daily in
Orphenadrine M03BC01110
1136 A Painful muscle spasm divided doses. Maximum:
400 mg daily
Manual reprocessing, at
least 12 minute immersion
time at room temperature
Ortho- High level disinfectant for sensitive (20 degree celcius) is
V07AV00000
1137 phthalaldehyde A endoscopes or semi-critical required. Automatic
L9909XX
0.55% Solution reusable medical devices endoscope reprocessor, at
least 5 minute immersion
time at a minimum of 25
degree celcius is required
disease despite 5-fluorouracil
Oxaliplatin 50 mg L01XA03000 85 mg/m2 IV repeated every
1138 A* chemotherapy for advanced
Injection P4001XX 2 weeks
disease iii) good performance
status (WHO of 2 or less). The
oncologist
ADULT: Initially 5 mg 2 - 3
times daily increased if
necessary to maximum 5 mg
For the relief of symptoms of
4 times daily. ELDERLY:
bladder instability associated with
Initially 2.5 - 3 mg twice
Oxybutynin voiding in patients with uninhibited
G04BD04110 daily, increased to 5 mg
1139 Chloride 5 mg A* neurogenic or reflex neurogenic
T1001XX twice daily according to
Tablet bladder (ie urgency, frequency,
response and tolerance.
urinary leakage, urge incontinence,
CHILD over 5 years,
dysuria)
neurogenic bladder
instability: 2.5 - 3 mg twice
daily increased to 5 mg
253 / 371

twice daily to maximum 3
times daily.
i)As a second line drug in the

management of opioid responsive, Initially 5 mg every 4 to 6
moderate to severe chronic cancer hours, increased if
Oxycodone HCl pain ii)As a step-down analgesic necessary according to
N02AA05110
1140 10 mg Immediate A* drug in post-operative procedures severity of pain, usual max.
C1002XX
Release Capsules (Initiated by palliative medicine 400 mg daily, but some
physicians, oncologists, patients may require higher
anaesthesiologists, haematologists doses
and pain specialists only)
ADULT, ELDERLY and
Management of moderate to CHILDREN more than 18
severe chronic cancer pain non- years, opioid-naive patients:
Oxycodone HCl responsive to morphine (in 10 mg 12 hourly. Renal or
N02AA05110
1141 10 mg Prolonged A* accordance with WHO step-wise hepatic impairment: 5 mg
T5001XX
Release Tablet ladder of chronic pain 12 hourly. Titrate dose
management) [Initiated by Chronic carefully, as frequently as
Pain Specialist only] once a day if necessary, to
achieve pain relief
Oxycodone HCl pain ii)As a step-down analgesic necessary according to
N02AA05110
1142 20 mg Immediate A* drug in post-operative procedures severity of pain, usual max.
C1003XX
ADULT, ELDERLY and
Management of moderate to CHILDREN more than 18
severe chronic cancer pain non- years, opioid-naïve patients:
Oxycodone HCl responsive to morphine (in 10 mg 12 hourly. Renal or
N02AA05110
1143 20 mg Prolonged A* accordance with WHO step-wise hepatic impairment: 5 mg
T5002XX
Release Tablet ladder of chronic pain 12 hourly. Titrate dose
management) [Initiated by Chronic carefully, as frequently as
Pain Specialist only] once a day if necessary, to
achieve pain relief
Management of moderate to Initially, 10 mg every 12
severe chronic cancer pain non- hours, increased if
Oxycodone HCl responsive to morphine (Initiated necessary according to
N02AA05110
1144 40 mg Prolonged A* by palliative medicine physicians, severity of pain, usual max.
T5003XX
Release Tablet oncologists, anaesthesiologists, 200 mg every 12 hours, but
haematologists and pain specialists some patients may require
only) higher doses
254 / 371

Oxycodone HCl 5 pain ii)As a step-down analgesic necessary according to
N02AA05110
1145 mg Immediate A* drug in post-operative procedures severity of pain, usual max.
C1001XX
Adults over 18 years: The
following starting doses are
recommended. A gradual
increase in dose may be
required if analgesia is
inadequate or if pain
severity increases. IV Bolus:
Dilute to 1 mg/ml in 0.9%
saline, 5% dextrose or water
for injections. Administer a
bolus dose of 1 to 10 mg
slowly over 1-2 minutes.
Doses should not be
administered more
frequently than every 4
hours. IV Infusion: Dilute to
1 mg/ml in 0.9% saline, 5%
For the treatment of moderate to
dextrose or water for
Oxycodone severe pain in patients with cancer
N02AA05110 injections. A starting dose of
1146 Hydrochloride 10 A* and post-operative pain. For the
P3001XX 2 mg/hour is recommended.
mg/ml Injection treatment of severe pain requiring
IV PCA: Dilute to 1 mg/ml in
the use of a strong opioid.
0.9% saline, 5% dextrose or
water for injections. Bolus
doses of 0.03 mg/kg should
be administered with a
minimum lock-out time of 5
minutes. SC Bolus: Use as 10
mg/ml concentration. A
starting dose of 5 mg is
recommended, repeated at
4-hourly intervals as
required. SC Infusion: Dilute
in 0.9% saline, 5% dextrose
or water for injections if
required. A starting dose of
7.5 mg/day is recommended
in opioid naïve patients,
titrating gradually according
255 / 371

to symptom control. Cancer
patients transferring from
oral oxycodone may require
much higher doses (see
below). Transferring
patients between oral and
parenteral oxycodone: The
dose should be based on the
following ratio: 2 mg of oral
oxycodone is equivalent to 1
mg of parenteral
oxycodone. It must be
emphasised that this is a
guide to the dose
required.Inter-patient
variability requires that each
patient is carefully titrated
to the appropriate dose.
Adults and paediatric
patients from 18 years of
age: The usual starting dose
for opioid-naïve patients or
patients presenting with
moderate to severe chronic
The management of moderate to
Oxycodone pain uncontrolled by weaker
severe chronic pain unresponsive
Hydrochloride opioids is one tablet
to non-narcotic analgesics. The
10mg and 10mg/5mg at 12 hourly
N02AA55900 opioid antagonist naloxone in the
1147 Naloxone A* intervals, or one tablet
T1002XX fixed combination is added to
Hydrochloride 5mg/2.5mg 12-hourly for
counteract and/or prevent opioid-
Dihydrate 5mg patients with mild hepatic
induced constipatio. For pain
Tablet impairment and patients
specialist only
with renal impairment. The
dose should then be
cautiously titrated, as
frequently as every 1-2 days
if necessary, to achieve pain
relief.
256 / 371

Adults, elderly and children
over 12 years: Usual starting
dose for opioid-naive
patients or patients
presenting with moderate
to severe pain uncontrolled
by weaker opioids
(especially if they are
receiving concurrent
Management of moderate to sedatives, muscle relaxants
severe chronic cancer pain non- or other CNS medicines) is
responsive to morphine in 10mg 12 hourly. The dose
Oxycodone accordance with WHO step-wise should then be carefully
Hydrochloride N02AA05110 ladder of chronic pain titrated with longitudinal
1148 A*
10mg Controlled T5301XX management. (Initiated by patient monitoring,
Release Tablet palliative medicine physicians, assessing whether the pain
oncologists, anaesthesiologists, is opioid responsive and
haematologists and pain specialists providing the patient
only) significant pain relief.
Patients with renal or
hepatic impairment: The
recommended adult starting
dose should be reduced by
1/3 to 1/2, and each patient
adequate pain control
according to their clinical
situation.
induced constipatio. For pain
specialist only
dose should then be
relief.
257 / 371

by weaker opioids
Management of moderate to sedatives, muscle relaxants
severe chronic cancer pain non- or other CNS medicines) is
responsive to morphine in 10mg 12 hourly. The dose
Oxycodone accordance with WHO step-wise should then be carefully
Hydrochloride N02AA05110 ladder of chronic pain titrated with longitudinal
1150 A*
20mg Controlled T5302XX management. (Initiated by patient monitoring,
Release Tablet palliative medicine physicians, assessing whether the pain
oncologists, anaesthesiologists, is opioid responsive and
haematologists and pain specialists providing the patient
only) significant pain relief.
situation.
induced constipation. For pain
specialist only
dose should then be
relief.
258 / 371

by weaker opioids
sedatives, muscle relaxants
Management of moderate to
or other CNS medicines) is
severe chronic cancer pain non-
10mg 12 hourly. The dose
responsive to morphine in
Oxycodone should then be carefully
accordance with WHO step-wise
Hydrochloride N02AA05110 titrated with longitudinal
1152 A* ladder of chronic pain management
40mg Controlled T5303XX patient monitoring,
(Initiated by palliative medicine
Release Tablet assessing whether the pain
physicians, oncologists,
is opioid responsive and
anaesthesiologists, haematologists
providing the patient
significant pain relief.
situation.
pain uncontrolled by weaker
Oxycodone severe chronic pain unresponsive
opioids is one tablet
Hydrochloride 5 to non-narcotic analgesics. The
10mg/5mg at 12 hourly
mg and Naloxone N02AA55900 opioid antagonist naloxone in the
1153 A* intervals, or one tablet
Hydrochloride T1001XX fixed combination is added to
5mg/2.5mg 12-hourly for
Dihydrate 2.5mg counteract and/or prevent opioid-
patients with mild hepatic
Tablet induced constipation. For pain
impairment and patients
specialist only
dose should then be
relief.
259 / 371

Newborn (up to 4 weeks): 1
Oxymetazoline
R01AA05110 Acute cold, paranasal sinusitis, drop. Infant (1 - 12 month):
1154 HCI 0.01% Nasal A*
D6003XX syringitis, otitis media. 1 - 2 drop. Doses to be given
Drops
twice or three times daily
Oxymetazoline
1 - 2 drops twice daily in
HCl 0.025% R01AA05110 Acute colds, paranasal sinusitis and
1155 A/KK each nostril for child more
(Paediatric) Nasal D6001XX otitis media
than 1 year
Drops
Oxymetazoline
2 - 3 sprays into each nostril
HCl 0.025% R01AA05110 Acute colds, paranasal sinusitis and
1156 A twice daily for child more
(Paediatric) Nasal A4101XX otitis media
than 1 year
Spray
Oxymetazoline
R01AA05110 Acute colds, paranasal sinusitis and 1 - 2 drops twice daily in
1157 HCl 0.05% (Adult) A/KK
D6002XX otitis media each nostril
Nasal Drops
Oxymetazoline 2 - 3 sprays into each nostril
R01AA05110 Acute colds, paranasal sinusitis and
1158 HCl 0.05% (Adult) A twice daily, maximum 6
A4102XX otitis media
Nasal Spray sprays per nostril/day
ADULT and CHILD: 1 - 5
mg/kg daily in one daily
Anaemias caused by the
dose. Usual effective dose 1
Oxymetholone A14AA05000 administration of myelotoxic drugs,
1159 A - 2 mg/kg/day, given for a
50 mg Tablet T1001XX treatment of AIDS-wasting
minimum trial of 3 - 6
syndrome
months because response
may be delayed
Oxytetracycline Conjunctivitis, dacryocystitis,
with Polymyxin B S01AA30947 blepharoconjunctivitis, keratitis, Apply into the conjunctival
1160 B
Sulphate Eye G5101XX trachoma, blepharitis, pre-op sac 4 times daily
Ointment prophylaxis against infection
IV: 0.5 - 1 milliunits/minute;
gradually increase dose in
increments of 1 - 2
milliunits/minute until
Oxytocin 10 desired contraction pattern
H01BB02000
1161 units/ml B Induction of labour is established; dose may be
P3001XX
Injection decreased after desired
frequency of contractions is
reached and labor has
progressed to 5 - 6 cm
dilation
i) 1 ml IM may be repeated
after 2 hours. Should not
Oxytocin 5 units i) Prevention and treatment of post
exceed 3 ml within 24 hours
& Ergometrine G02AC01900 partum haemorrhage ii)
1162 C+ ii) For routine management
Maleate 0.5 P3001XX Management of third stage of
of third stage of labour, 1 ml
mg/ml Injection labour
IM following delivery of the
anterior shoulder or
260 / 371

immediately after delivery
of the child
i) Treatment of recurrent breast i) 175 mg/m2 IV over 3
cancer, after failure of hours every 3 weeks ii) 175
anthracycline-based chemotherapy mg/m2 IV over 3 hour
ii) Primary adjuvant therapy in followed by cisplatin 75
Paclitaxel 100 advanced ovarian cancer in mg/m2 in every 3 weeks or
L01CD01000
1163 mg/16.6 ml A* combination with cisplatin iii) 135 mg/m2 IV over 24 hours
P3002XX
Injection Treatment of locally advanced or followed by cisplatin 75
metastatic non-small cell lung mg/m2 every 3 weeks iii)
cancer (NSCLC) in chemonaive 135 mg/m2 IV over 24 hours
patients in combination with followed by cisplatin 75
platinum compounds mg/m2 every 3 weeks
i) Treatment of recurrent breast i) 175 mg/m2 IV over 3
cancer, after failure of hours every 3 weeks ii) 175
anthracycline-based chemotherapy mg/m2 IV over 3 hour
ii) Primary adjuvant therapy in followed by cisplatin 75
advanced ovarian cancer in mg/m2 in every 3 weeks or
Paclitaxel 30 L01CD01000
1164 A* combination with cisplatin iii) 135 mg/m2 IV over 24 hours
mg/5 ml Injection P3001XX
Treatment of locally advanced or followed by cisplatin 75
metastatic non-small cell lung mg/m2 every 3 weeks iii)
cancer (NSCLC) in chemonaive 135 mg/m2 IV over 24 hours
patients in combination with followed by cisplatin 75
platinum compounds mg/m2 every 3 weeks
Initiation: Deltoid IM 150 mg
eq on Day1, followed by
deltoid IM 100 mg eq on
one week later.
Maintenance: Monthly dose
Paliperidone 100 Second or third line treatment of of 75 mg eq (this can be
N05AX13000
1165 mg Prolonged A* acute and maintenance treatment increased or decreased
P2004XX
Release Injection of schizophrenia in adults based on individual patient’s
tolerability and/or efficacy).
These monthly maintenace
dose can be administered in
either the deltoid or gluteal
muscle
one week later.
Paliperidone 150 Second or third line treatment of Maintenance: Monthly dose
N05AX13000
1166 mg Prolonged A* acute and maintenance treatment of 75 mg eq (this can be
P2005XX
Release Injection of schizophrenia in adults increased or decreased
based on individual patient’s
261 / 371

muscle
ADULT 6 mg once daily in
the morning, adjusted if
necessary; usual range 3 -12
Paliperidone 3 mg daily. Renal impairment
N05AX13000 Second or third line treatment of
1167 mg Extended A* (creatinine clearance
T5001XX schizophrenia
Released Tablet between 10-50 mL/min) 3
mg once daily. Avoid if
creatinine clearance less
than 10mL/min
one week later.
N05AX13000
P2002XX
muscle
than 10mL/min
one week later.
N05AX13000
P2003XX
muscle
262 / 371

than 10mL/min
For the prevention of serious lower
respiratory tract disease caused by
Palivizumab J06BB16000P 15 mg/kg IM once a month
1172 A* respiratory syncytial virus (RSV) in
100mg Injection 3001XX during season of RSV risk
paediatric patients at high risk of
RSV disease
Dose depends on the initial
Pamidronate
M05BA03520 Hypercalcaemia of malignancy serum calcium levels. Doses
1173 Disodium 30 mg A*
P3001XX (tumour -induced hypercalcaemia) range from a single infusion
Injection
of 30 - 90 mg
Dose depends on the initial
Pamidronate
M05BA03520 Hypercalcaemia of malignancy serum calcium levels. Doses
P3002XX (tumour -induced hypercalcaemia) range from a single infusion
Injection
of 30 - 90 mg
Treatment of pancreatic exocrine
insufficiency due to conditions such Initially 1 - 2 capsules with
Pancreatin 150 A09AA02000
1175 A/KK as cystic fibrosis, chronic each meal. May increase to
mg Capsule C1001XX
pancreatitis and non-pancreatic 5 - 15 capsules daily
diseases
ADULT: Initially 50 - 100
mcg/kg IV, then 10 - 20
mcg/kg as required. CHILD >
Pancuronium
M03AC01320 Muscle relaxant as an adjunct to 2 YEARS: Initially 60 - 100
1176 Bromide 2 mg / B
P3001XX general anaesthesia mcg/kg then 10 - 20 mcg/kg.
ml lnjection
Intensive care, by IV, 60
mcg/kg every 60 - 90
minutes
40 mg twice daily until oral
Pantoprazole 40 A02BC02000 Bleeding peptic ulcer and acute administration can be
1177 A*
mg Injection P3001XX stress ulceration resumed. CHILD not
recommended
263 / 371

i) 40 mg twice daily in
combination with any of the
2 antibiotics (Clarithromycin
500 mg twice daily,
i) Helicobacter pylori eradication ii) Amoxicillin 1 g twice daily or
Peptic ulcer disease iii) Erosive and Metronidazole 400 mg twice
Pantoprazole 40 A02BC02000 non-erosive reflux oesophagitis daily) for 1-2 weeks ii) 40 mg
1178 A*
mg Tablet T1001XX (GERD and NERD) iv) Zollinger- daily for 2 - 4 weeks iii) 20 -
Ellison Syndrome v) Prevention of 40 mg daily on morning for
NSAID induced gastropathy 4 weeks iv) Initially 80 mg
daily, dose can be titrated
up or down as needed. v) 20
mg daily. CHILD not
recommended
Relief of cerebral and peripheral ADULT: 30 - 120 mg may be
Papaverine HCl
A03AD01110 ischaemia associated with arterial repeated every 3 hours as
1179 120 mg/10ml A
P3002XX spasm and myocardial ischaemia necessary. CHILD: 6 mg/kg
Injection
complicated by arrhythmias daily in 4 divided doses
Body Weight (BW) ≤ 10kg:
7.5mg/kg, max: 30mg/kg
BW >10kg to ≤ 33kg:
15mg/kg, max 60mg/kg not
Paracetamol exceeding 2g BW >33kg to ≤
10mg/ml in N02BE01000 50kg: 15mg/kg, max
1180 A Mild to moderate pain and pyrexia
100ml Solution P3101XX 60mg/kg not exceeding 3g
for IV Infusion BW >50kg (with risk of
hepatotoxicity): 1g, max 3g
BW >50kg (without risk of
hepatotoxicity): 1g, max 4g
OR as in the product leaflet
CHILD: up to 1 year: 60 - 120
mg. 1 - 5 years: 120 - 240
mg. 6 - 12 years: 240 - 480
Paracetamol 120 N02BE01000
1181 C+ Mild to moderate pain and pyrexia mg per dose. Repeat every 4
mg/5 ml Syrup L9001XX
- 6 hours when necessary.
Maximum of 4 doses in 24
hours
CHILD 1 - 5 years: 125 - 250
mg; 6 - 12 years: 250 - 500
mg; 3 - 11 months: 80 mg
inserted every 4 - 6 hours if
Symptomatic relief of fever and necessary, maximum 4
1182 C+ post operative pain for paediatric doses in 24 hours. INFANTS
cases under 3 months should not
be given Paracetamol unless
advised by doctor; a dose of
10 mg/kg (5 mg/kg if
jaundiced) is suitable
264 / 371

CHILD 1 - 5 years : 125 - 250
mg; 6 - 12 years : 250 - 500
mg; 3 - 11 months : 80 mg
inserted every 4 - 6 hours if
Symptomatic relief of fever and necessary, maximum 4
1183 B post operative pain for paediatric doses in 24 hours. INFANTS
cases under 3 months should not
be given Paracetamol unless
advised by doctor; a dose of
10 mg/kg (5 mg/kg if
jaundiced) is suitable
1184 C+ Mild to moderate pain and pyrexia 4 - 6 hours, maximum of 4 g
mg Tablet T1001XX
daily
Paradichlorobenz
ene, Turpentine Occlusion or partial occlusion of the
S02DA30900
1185 Oil and B external auditory meatus by soft Instill 5 drops into the ears
D1001XX
Chlorbutol Ear wax or wax plug
Drops
Paraffin Mole
D02AC00000
1186 Alba (White Soft C Xerosis and ichthyosis Apply to the affected area
G5001XX
Paraffin)
Paraffin Mole D02AC00000
1187 C Xerosis and ichthyosis Apply to the affected area
Flava G5002XX
The usual intramuscular
dose of paraldehyde for
status epilepticus is 0.15 to
0.3 milliliter/kilogram, a
moderate additional dose
Paraldehyde N05CC05000
1188 C Status epilepticus (0.05 milliliter/kilogram)
Injection P3001XX
may be necessary. The dose
may be repeated in 2 to 6
hours and no more than 5
milliliters should be
administered in one site
40 mg followed by 20 or 40
mg every 6 to 12 hours, as
Parecoxib Management of post operative required. Use limited to two
M01AH0452
1189 Sodium 40mg A* pain in the immediate post days only with a maximum
0P3001XX
Injection operative setting only dose of 80 mg/day. Reduce
the initial dose by 50% in
elderly less than 50 kg
Recommended dose is 800
mg ORALLY once daily.
Pazopanib For treatment of advanced and/or
L01XE11110T Should be taken without
1190 Hydrochloride A* metastatic renal cell carcinoma
1001XX food (at least one hour
200 mg Tablet (RCC)
before or two hours after
meal). The dose should not
265 / 371

exceed 800 mg.
Recommended dose is 800

mg ORALLY once daily.
Pazopanib For treatment of advanced and/or Should be taken without
L01XE11110T
1191 Hydrochloride A* metastatic renal cell carcinoma food (at least one hour
1002XX
400 mg Tablet (RCC) before or two hours after
meal). The dose should not
exceed 800 mg.
Administered as a slow (one
hour) intravenous perfusion,
Pefloxacin 400 J01MA03196 Infections due to gram-positive and after diluting the contents of
1192 A
mg Injection P3001XX gram-negative pathogens the 400 mg in 250 ml 5%
glucose (two perfusions
daily, morning and evening)
i) Infections due to gram-positive
Pefloxacin 400 J01MA03000 and gram-negative pathogens ii) ADULT i) 800 mg/day in 2
1193 A
mg Tablet T1001XX Uncomplicated UTI, chancroid divided doses ii) 800 mg stat
gonococcal urethritis
Adults (≥18 years): One 6
mg dose (a single pre-filled
syringe) of pegfilgrastim for
each chemotherapy cycle,
administered as a
subcutaneous injection
approximately 24 hours
following cytotoxic
Reduction in the duration of
chemotherapy. Renal
neutropenia, the incidence of
impairment:
febrile neutropenia and the
Pharmacokinetics of
Pegfilgrastim Pre- incidence of infection as
pegfilgrastim is not
filled Syringe 6 L03AA13000 manifested by febrile neutropenia
1194 A* expected to be affected by
mg/0.6 ml (10 P5001XX in patients treated with cytotoxic
renal impairment. Hepatic
mg/ml) chemotherapy for malignancy (with
impairment:
the exception of chronic myeloid
Pharmacokinetics of
leukaemia and myelodysplastic
pegfilgrastim is not
syndromes)
expected to be affected by
hepatic impairment.
Paediatric population:
Insufficient data to
recommend the use of
pegfilgrastim in children and
adolescents under 18 years
of age.
266 / 371

i) Combination therapy with
Ribavirin: ADULT: SC 1.5
mcg/kg/week CHILD and
ADOLESCENT (3-17 yr): SC
Peginterferon
L03AB10000 Treatment of: i) Chronic Hepatitis C 60 mcg/m2/week for 24-48
1195 Alfa-2b 80 mcg A*
P5002XX ii) Chronic Hepatitis B weeks Monotherapy:
Injection
ADULT: SC 1 mcg/kg/week
for 24 weeks to 1 year ii) SC
1.0 - 1.5 mcg/kg once
weekly for 52 weeks
i) Chronic hepatitis C usually in
i) 180 mcg weekly SC with
combination with ribavirin
ribavirin 800 mg daily for 24
(Important to establish hepatitis C
weeks in patients in
virus (HCV) genotype and viral load
genotype 2 and 3 and 180
where combination treatment is
mcg weekly SC with ribavirin
Peginterferon advocated) ii) For the treatment of
(1000 - 1200 mg) for 48
Alpha-2a 135 L03AB11000 both HbeAg-positive and HbeAg-
1196 A* weeks for those with
mcg Prefilled P5002XX negative chronic hepatitis B with
genotype 1 and 4. 135 mg
Syringe compensated liver disease and
dose may be used for
evidence of viral replication who
patients who cannot
are not responding or tolerating
tolerate the 180 mcg dose ii)
oral antiviral therapy (Initiated by
180 mcg weekly SC for 48
Hepatologist and
weeks
Gasteroenterologist only)
i) Chronic hepatitis C usually in
i) 180 mcg weekly with
combination with ribavirin
ribavirin 800 mg daily for 24
(Important to establish hepatitis C
weeks in patients in
virus (HCV) genotype and viral load
genotype 2 and 3 and 180
where combination treatment is
mcg weekly with ribavirin
Peginterferon advocated) ii) For the treatment of
(1000 - 1200 mg) for 48
Alpha-2a 180 L03AB11000 both HbeAg-positive and HbeAg-
1197 A* weeks for those with
mcg Prefilled P5001XX negative chronic hepatitis B with
genotype 1 and 4. 135 mg
Syringe compensated liver disease and
dose may be used for
evidence of viral replication who
patients who cannot
are not responding or tolerating
tolerate the 180 mcg dose ii)
oral antiviral therapy (Initiated by
180 mcg subcutaneously
Hepatologist and
once a week for 48 weeks
Gasteroenterologist only)
i) Monotherapy: SC at a
dose of 0.5 or 1 mcg/kg
once weekly for at least 6
Pegylated
months. Combination
Interferon Alpha- L03AB10000 Treatment of: i) Chronic Hepatitis C
1198 A* therapy: 1.5mcg/kg/week SC
2b 100 mcg P5003XX ii) Chronic Hepatitis B
in combination with
Injection
ribavirin capsules. ii) 1-1.5
mcg/kg once weekly for at
least 24 weeks and up to 52
267 / 371

weeks.
Pegylated months. Combination
Interferon Alpha- L03AB10000 Treatment of: i) Chronic Hepatitis C therapy: 1.5mcg/kg/week SC
1199 A*
2b 120 mcg P5004XX ii) Chronic Hepatitis B in combination with
Injection ribavirin capsules. ii) 1-1.5
weeks.
1200 A*
weeks.
1201 A*
weeks.
268 / 371

50 mg/m2 IV every 4 weeks
for as long as the disease
does not progress & patient
continues to tolerate
treatment.For doses <90
mg: dilute in 250 ml
Dextrose 5 % in Water. For
i) For patients with platinum- doses >90 mg: dilute in 500
resistant ovarian cancer where the ml Dextrose 5 % in Water.
disease relapses within 6 months To minimize the risk of
after completion of the initial infusion reactions, the initial
platinum-based chemotherapy ii) dose is administered at a
Pegylated For patients with platinum- rate no greater than 1
Liposomal L01DB01110 sensitive ovarian cancer where the mg/minute. Renal
1202 A*
Doxorubicin HCl P3003XX disease responds to first-line impairment: No dose
20 mg/vial platinum-based therapy but adjustment required in
relapses 12 months or more after patients with creatinine
completion of the initial platinum clearance 30-156 ml/min, no
based chemotherapy. As third line pharmacokinetic data are
therapy for very selected patients. available in patients with
(Gyne Oncology Specialist only) creatinine clearance of less
than 30 ml/min. Hepatic
impairment: At initiation of
therapy: Bilirubin 1.2 - 3.0
mg/dl, the first dose is
reduced by 25 %, Bilirubin >
3.0 mg/dl, the first dose is
reduced by 50 %.
Initial therapy 500 mg/m(2)
IV over 10 minutes on day 1,
In combination with Cisplatin for followed 30 minutes later by
the 2nd line treatment of patients cisplatin 75 mg/m(2) infused
Pemetrexed
L01BA04016 with locally advanced or metastatic IV over 2 hours; repeat cycle
P3002XX non small cell lung cancer (NSCLC) every 21-days. Prior
Injection
other than predominantly chemotherapy : 500
squamous cell histology mg/m(2) IV, as a single-
agent, over 10 minutes on
day 1 of each 21-day cycle
Initial therapy 500 mg/m (2)
IV over 10 minutes on day 1,
In combination with Cisplatin for followed 30 minutes later by
the 2nd line treatment of patients cisplatin 75 mg/m(2) infused
Pemetrexed
L01BA04016 with locally advanced or metastatic IV over 2 hours; repeat cycle
P3001XX non small cell lung cancer (NSCLC) every 21-days. Prior
Injection
other than predominantly chemotherapy : 500
squamous cell histology mg/m(2) IV, as a single-
agent, over 10 minutes on
day 1 of each 21-day cycle
269 / 371

Pentamidine Only for the treatment of 4 mg/kg once daily by slow
P01CX01198
1205 Isethionate 300 A* pneumonia due to Pneumocytosis IV infusion for at least 14
P3001XX
mg Injection carinii days
Pentoxifylline C04AD03000
1206 A/KK Peripheral vascular disease 400 mg 2 - 3 times daily
Peracetic Acid Immersion time based on
V07AV00000 High level disinfectant or sterilant
1207 and Hydrogen A manufacturer
L9906XX for heat labile endoscopes
Peroxide recommendation
Essential hypertension, for patients
Perindopril 4 mg One tablet daily, preferably
C09BA04900 whose blood pressure is
1208 and Indapamide A/KK taken in the morning and
T1001XX insufficiently controlled by
1.25 mg Tablet before a meal.
perindopril alone.
i) 4 mg as single dose, may
be increased to a single 8
mg dose. ELDERLY: Start
treatment with 2 mg dose.
In renal insufficiency, dose
should be adapted
according to creatinine
clearance ii) Single starting
i) Hypertension ii) Congestive heart oral dose of 2 mg should be
Perindopril 4 mg C09AA04000
1209 B failure iii) Stable coronary artery increased to a single 4 mg
Tablet T1001XX
disease once BP acceptability has
been demonstrated iii) 4 mg
once daily for 2 weeks, may
daily. ELDERLY: 2 mg once
daily for 1 week, then 4 mg
once daily for the following
week, may be increased up
to 8 mg once daily
i) 4 mg as single dose, may
be increased to a single 8
mg dose. ELDERLY: Start
treatment with 2 mg dose.
In renal insufficiency, dose
should be adapted
according to creatinine
i) Hypertension ii) Congestive heart clearance ii) Single starting
Perindopril 8 mg C09AA04000
1210 B failure iii) Stable coronary artery oral dose of 2 mg should be
Tablet T1002XX
disease increased to a single 4 mg
once BP acceptability has
been demonstrated iii) 4 mg
once daily for 2 weeks, may
daily. ELDERLY: 2 mg once
daily for 1 week, then 4 mg
once daily for the following
270 / 371

week, may be increased up
to 8 mg once daily
Peritoneal
Dialysis Solution B05DB00908 For chronic renal disease requiring Dose depending on clinical
1211 B
(1.5% Dextrose 5 H2001XX dialysis and for acute renal failure cases
Litres)
Peritoneal
Dialysis Solution B05DB00908 For chronic renal disease requiring Dose depending on clinical
1212 B
(4.25% Dextrose, H2002XX dialysis and for acute renal failure cases
2 Litres)
As a once replacement for a single
Administered as a single
glucose exchange as part of a
daily exchange for the long
continuous ambulatory peritoneal
Peritoneal dwell in continuous
dialysis (CAPD) or automated
Dialysis with B05DB00908 ambulatory peritoneal
1213 A* peritoneal dialysis (APD) regimen
7.5% Icodextrin H2003XX dialysis or automated
for the treatment of chronic renal
Solution peritoneal dialysis. The
failure, particularly for patients
recommended dwell time is
who have lost ultra filtration on
8 to 16 hours
glucose solutions
Apply thoroughly to all body
parts. Leave on for 8 - 14
Permethrin 5% P03AC04000
1214 A* Treatment of scabies hours. Not recommended
w/v Lotion L6001XX
for children less than 2 years
old
ADULT: Initially 4 mg 3 times
Perphenazine 4 N05AB03000 response, maximum 24 mg
1215 B Schizophrenia and other psychoses
mg Tablet T1001XX daily. ELDERLY: 1/4 to 1/2
adult dose. CHILD not
recommended
ADULT: 0.5 - 2 mg/kg SC or
IM every 3 - 4 hours if
For relief of moderate to severe
Pethidine HCl necessary. CHILD: by IM 0.5
N02AB02110 pain (medical and surgical), pre-
1216 100 mg/2 ml B - 2 mg/kg. Up to 1 year : 1- 2
P3002XX anaesthetic medication and
Injection mg/kg weight IM, 1 - 5 years
obstetrical analgesia
: 12.5 - 25 mg IM, 6 - 12
years: 25 - 50 mg IM
ADULT: 0.5 - 2 mg/kg SC or
IM every 3 - 4 hours if
For relief of moderate to severe
necessary. CHILD: by IM 0.5
Pethidine HCl 50 N02AB02110 pain (medical and surgical), pre-
1217 B - 2 mg/kg. Up to 1 year : 1- 2
mg/ml Injection P3001XX anaesthetic medication and
mg/kg weight IM, 1 - 5 years
obstetrical analgesia
: 12.5 - 25 mg IM, 6 - 12
years: 25 - 50 mg IM
Phenobarbitone N03AA02000 ADULT: 60 - 180 mg daily on.
1218 B Epilepsy
30 mg Tablet T1002XX CHILD: Up to 8 mg/kg daily
271 / 371

ADULT: 10 mg/kg IV at a
rate of not faster than 100
mg/minute. Initial maximum
dose does not exceeding 1
Phenobarbitone gm. Daily maintenance of 1 -
N03AA02520
1219 Sodium 200 B Status Epilepticus 4 mg/kg/day. CHILD: 10 - 20
P3001XX
mg/ml Injection mg/kg/dose loading dose,
followed by repeated doses
at 10 mg/kg/dose (strictly in
ICU setting). Maintenance 5
- 8 mg/kg/day
Phenol 80% w/w D08AE03000
1220 C As disinfectant Use in various dilutions
Liquid L5001XX
Phenoxybenzami 1 mg/kg daily over at least 2
C04AX02110 Hypertensive episodes associated
1221 ne HCl 100 mg/2 A* hours into large vein. Do not
P3001XX with phaeochromocytoma
ml Injection repeat within 24 hours.
i) ADULT: 500 - 750 mg 6
hourly.CHILD; up to 1 year:
62.5 mg, 1 - 5 years: 125 mg,
i) Treatment or prophylaxis of
Phenoxymethyl 6 - 12 years: 250 mg 6
J01CE02500T infections caused by susceptible
1222 Penicillin 125 mg C hourly ii) ADULT: 125 - 250
1001XX organisms ii) Prophylactic,
Tablet mg twice daily. CHILD: 25 -
rheumatic fever
50 mg/kg in divided doses
every 6 - 8 hours. Maximum:
3 g/day
CHILD: Up to 1 year: 62.5 mg
Phenoxymethyl Treatment or prophylaxis of
J01CE02500F 6 hourly; 1 - 5 years: 125 mg
1223 Penicillin 125 C infections caused by susceptible
2101XX 6 hourly; 6 - 12 years: 250
mg/5 ml Syrup organisms
mg 6 hourly
i) ADULT: 500 - 750 mg 6
hourly.CHILD; up to 1 year:
62.5 mg, 1 - 5 years: 125 mg,
i) Treatment or prophylaxis of
Phenoxymethyl 6 - 12 years: 250 mg 6
J01CE02500T infections caused by susceptible
1224 Penicillin 250 mg C hourly ii) ADULT: 125 - 250
1002XX organisms ii) Prophylactic,
Tablet mg twice daily. CHILD: 25 -
rheumatic fever
50 mg/kg in divided doses
every 6 - 8 hours. Maximum:
3 g/day
272 / 371

Mydriasis and
vasoconstriction: 1 drop of
2.5% or 10% solution,
repeated in one hour if
necessary. Chronic
mydriasis: 1 drop of a 2.5%
or 10% solution 2 - 3 times a
For pupillary dilation in uveitis, for day. Uveitis with posterior
Phenylephrine
S01FB01110 refraction without cyclopegic. For synechiae (treatment) or
1225 HCI 2.5% Eye B
D2001XX fundoscopy and other diagnostic synechiae, posterior
Drops
procedures (prophylaxis): 1 drop of a
necessary, not to exceed
three times a day.
Treatment may be
continued the following day,
if necessary
Mydriasis and
vasoconstriction: 1 drop of
necessary. Chronic
mydriasis: 1 drop of a 2.5%
or 10% solution 2 - 3 times a
For pupillary dilation in uveitis, for day. Uveitis with posterior
Phenylephrine
S01FB01110 refraction without cyclopegic. For synechiae (treatment) or
1226 HCl 10% Eye B
D2002XX fundoscopy and other diagnostic synechiae, posterior
Drops
procedures (prophylaxis): 1 drop of a
necessary, not to exceed
three times a day.
Treatment may be
continued the following day,
if necessary
6 years: 300-400 mg/day in
3 - 4 divided doses before
Phenytoin meals. Maximum: 600
N03AB02520
1227 Sodium 100 mg B Epilepsy mg/day. CHILD: Initially 5
C1002XX
Capsule mg/kg/day in 2 - 3 divided
doses. Maintenance: 4 - 8
mg/kg/day. Maximum: 300
mg/day
273 / 371

ADULT: Patients with no
previous treatment may be
started on 1 teaspoonful or
5 mL (125 milligrams) 3
times daily. It is then
individualized to the patient.
An increase to 5
Phenytoin
teaspoonfuls (625
Sodium 125 N03AB02520
1228 B Epilepsy milligrams) may be made if
mg/5ml L8001XX
necessary. CHILD: Initially 5
Suspension
mg/kg/day in 2 - 3 divided
mg/day. Children over 6
years and adolescents may
require the minimum adult
dose (300mg/day).
6 years: 300-400 mg/day in
3 - 4 divided doses before
Phenytoin meals. Maximum: 600
N03AB02520
1229 Sodium 30 mg B Epilepsy mg/day. CHILD: Initially 5
C1001XX
Capsule mg/kg/day in 2 - 3 divided
mg/day
i) Status epilepticus: ADULT
10 - 15 mg/kg by slow IV.
Maximum 50 mg/minute.
Maintenance: 100 mg
Phenytoin orally/IV every 6 - 8 hours.
N03AB02520
1230 Sodium 50mg/ml B Status epilepticus CHILD 15 - 20 mg/kg by slow
P3001XX
lnjection IV. Maximum: 1 - 3
mg/kg/minute ii)
Neurosurgery 100 - 200 mg
IM approximately at 4
hourly interval
Phosphate
Solution
For supplemental ionic phosphorus
containing B05XA09902 According to the needs of
1231 A for correction of
Sodium Acid L5001XX the patient
hypophosphataemia
Phosphate 1.936
g /15 ml
Phyllanthus 2 capsules to be taken
HA05BA5999
1232 Niruri Extract 250 A/KK Liver tonic orally, 3 times a day, before
C1001XX
mg Capsule or after meals
Pilocarpine 1% S01EB01110 Miotics in chronic open-angle
1233 B 1 drop 1 - 4 times a day
Eye Drops D2001XX glaucoma
274 / 371

Adult and children more
than 12 years: 4.5g 6 hourly,
Piperacillin 4 g & Febrile neutropenia, lower
J01CR05961P for neutropenia adult and
1236 Tazobactam 500 A* respiratory tract infection and
3001XX children more than 50kg:
mg Injection severe sepsis
4.5g 6 hourly. Children less
than 50kg: 90mg/kg 6 hourly
ADULT: 100 - 150 mg/kg
IM/IV in divided doses.
Increase to 200 - 300 mg/kg
in severe infections & at
Piperacillin
J01CA12520P Infections due to Pseudomonas least 16 g in life-threatening
1237 Sodium 4 g A
4002XX aeruginosa infections. Single dose over
Injection
2 g: IV route only.
Maximum: 24 g/day. CHILD:
50-75 mg/kg/dose every 6 -
8 hourly
30 - 160 mg/kg/day orally or
Piracetam 1 g N06BX03000 Treatment of cerebral functional parenterally 2 times daily or
1238 A*
Injection P3001XX impairment 3 to 4 times daily.
Maximum: 24 g/day
Initially 7.2 g daily in 2 - 3
Mild cognitive impairment, post
according to response by 4.8
Piracetam 1.2 g N06BX03000 concussional head syndrome, head
1239 A* g daily every 3 - 4 days to
Tablet T1001XX injury disorder, chronic vertigo and
maximum of 20 g daily.
myoclonus
CHILD under 16 years not
recommended
30 - 160 mg/kg/day orally.
Children with learning disability,
Piracetam 20% N06BX03000 To be given 2 times daily or
1240 A* progressive myoclonic epilepsy and
Solution L5001XX 3 - 4 times daily. Maximum
hypoxia
24 g/day
As monotherapy: 150 - 250
mg as 3 - 5 divided doses
Piribedil 50 mg N04BC08000 daily. As combination with L-
1241 A* Parkinson disease
Tablet T5001XX dopa therapy: 50 - 150 mg
daily (50 mg per 250 mg of
L-dopa)
i) 20 mg daily, maintenance
i) Rheumatoid arthritis,
10 - 30 mg daily, in single or
osteoarthritis, ankylosing
Piroxicam 10 mg M01AC01000 divided doses ii) 40 mg daily
1242 A/KK spondylitis ii) Acute
Capsule C1001XX in single or divided doses for
musculoskeletal disorders iii) Acute
2 days, then 20 mg daily for
gout
7 - 14 days iii) 40 mg
275 / 371

initially, then 40 mg daily in
single or divided doses for 4
- 6 days
Starting with 0.5mg daily,
the dosage should be
progressively increased. The
average maintenance
dosage is 1.5mg daily in
Pizotifen 0.5 mg N02CX01253 Prophylactic treatment of vascular
1243 B divided doses or as a single
Tablet T1001XX headache
dose at night. Max dose: 4.5
mg/day and 3 mg/dose.
Child: >2 yr: Up to 1.5 mg
daily in divided doses. Max
dose: 1 mg/dose.
Primary injection: 1 single
injection (0.5 ml) only.
Prevention of pneumococcal
Booster: Must not be given
Pneumococcal infections in high risk subjects from
J07AL01000P within 5 years except in very
1244 Vaccine A the age of 2 years including patient
3001XX high risk patient who
(Polyvalent) with a history of splenectomy or
received the vaccine while
scheduled splenectomy
under immunosuppressive
treatment
Apply 2 - 3 drops carefully to
lesion after protecting
surrounding area with
Podophyllum 10 - D06BB04000
1245 B External anogenital warts vaseline. Wash off after 6
20% Paint L7001XX
hours or if feel burning
sensation and repeat 2 - 3
times weekly or once weekly
Local treatment of cervical and
vaginal inflammation and tissue
For cauterization, undiluted
damage eg. discharge due to
Policresulen 360 once or twice weekly whilst
G01AX03900 bacterial, trichomonal and fungal
1246 mg/g A for vaginal douches, to be
L9901XX infections, protrusions of
Concentrate diluted 1 part concentrate
endocervical mucosa (erosion),
to 5 parts of water
haemostasis following biopsy or
excision of uterine polyps
Two drops (0.1 ml). Primary
Poliomyelitis Oral immunization: 1 oral dose at
J07BF02000D
1247 Live Vaccine (10 C+ Immunisation against poliomyelitis 3,4 & 5 month of age.
5001XX
Doses) Booster doses at 1-4 years &
7 years.
276 / 371

The usual dose of potassium
citrate is 30 - 60 mEq/day
orally in 3 or 4 doses with
meals or within 30 minutes
A12BA02955 For treatment of calcium and uric
1248 Polycitra Syrup C after meals. ADULT: 15 ml 3
L9001XX acid stones
times daily well diluted with
water. CHILD 5-15 ml 3
times daily, after meals and
at bedtime.
1 sachet dissolved in 1 L of
water. 2-3 L of oral solution
are required. When morning
surgery is planned, the oral
Bowel cleansing prior to
solution is given in the late
Polyethylene colonoscopy, radiological
A06AD15000 afternoon the day prior. If
1249 Glycol /Macrogol A examination or colonic surgery.
F2101XX surgery is scheduled in
4000 Powder Suitable for patients with heart
afternoon, the oral solution
failure or renal failure
should be given on the same
day for ingestion to be
completed three hours
before surgery
3 drops 3 - 4 times daily.
Polymyxin B
External auditory meatus
Sulphate 10,000
and canal to be thoroughly
U, Neomycin Treatment of bacterial infection
S02CA03991 cleansed and dried before
1250 Sulphate 5 mg B and inflammation of the external
D1001XX each application but soap
and auditory meatus
should not be used as the
Hydrocortisone
antibiotics may be
10 mg Ear Drops
inactivated by it
Prophylaxis of invasive
Prophylaxis of invasive fungal fungal infections: 200mg
infections in the following adult (5ml) three times a day. The
patients: i. Patient receiving duration of therapy is based
remission-induction chemotherapy on recovery from
for acute myelogenous leukemia neutropenia or
(AML) or myelodysplastic immunosuppression. For
syndrome (MDS) expected to result patients with acute
Posaconazole in prolonged neutropenia and who myelogenous leukemia or
J02AC04000L
1251 40mg/ml Oral A* are at high risk of developing myelodysplastic syndromes,
8001XX
Suspension invasive fungal infections. ii. prophylaxis with
Haematopoietic stem cell posaconazole should start
transplant (HSCT) recipients who several days before the
are undergoing high-dose anticipated onset of
immunosuppressive therapy for neutropenia and continue 7
graft versus host disease and who days after the neutrophil
are at high risk of developing count rises above
invasive fungal infections. 500cell/mm3. Increasing the
total daily dose above
277 / 371

800mg does not further
enhance the exposure to
posaconazole.
Dosage depends on the age,
weight, clinical and
Potassium biological (acid-base
Chloride 0.15% Prevention and treatment of balance) conditions of the
A06AD10921
1252 w/v & Sodium B potassium, sodium and chloride patient and concomitant
L9902XX
Chloride 0.9% depletion therapy. Maximum
w/v Injection recommended dose of
potassium is 2 to 3
mmol/kg/24hr
By slow IV infusion
depending on the deficit or
For the correction of severe
Potassium the daily maintenance
B05XA01100 hypokalaemia and when sufficient
1253 Chloride 1 g/10 B requirements. 1 g diluted in
P3001XX potassium cannot be taken by
ml Injection 500 ml normal saline or
mouth
glucose and given slowly
over 2 - 3 hours
Potassium
A12BA01100 1 g once or twice daily until
1254 Chloride 1 g/15 C Potassium depletion
L2101XX serum potassium is restored
ml Mixture
ADULT: 2 - 3 tablets daily.
Potassium
A12BA01100 For the treatment and specific Severe deficiency: 9 - 12
1255 Chloride 600 mg B
T5001XX prevention of hypokalaemia tablets daily or according to
SR Tablet
the needs of the patient
ADULT: 15-30 ml well
diluted with water. CHILD up
Potassium Citrate to 1 year: 2.5 ml 3 times
3 g/10 ml and A12BA02955 daily; 1 - 5 years: 5 ml 3
1256 C For systemic or urine alkalinization
Citric Acid L2101XX times daily; 6 - 12 years: 10
Mixture ml 3 times daily. To be taken
well diluted with water,
after meals and at bedtime.
Potassium
Dihydrogen B05XA06170 For treatment of Up to 10mmol phosphate
1257 A
Phosphate P3001XX hypophosphataemia administered over 12 hours
Injection
Potassium Iodide H03CA00200 Pre-operative management of ADULT and CHILD: 50 - 250
1258 B
Mixture L2101XX hyperthyroidism and thyrotoxicosis mg 3 times daily
Potassium Cleansing and deodorising
D08AX06362 As soaks or wet dressing 1 -
1259 Permanganate C+ suppurative eczematous reactions
L9901XX 3 times daily or as required
1:10,000 Solution and wounds
Potassium Cleansing and deodorising
D08AX06362 As a bath once to twice daily
1260 Permanganate C suppurative eczematous reactions
L9902XX or as required
1:20,000 Solution and wounds
278 / 371
Povidone Iodine Skin operation prior to surgery, in To be applied undiluted in

10% (equivalent D08AG02000 cleansing open wounds, as an pre-operative skin
1261 B
to 1% iodine) L9902XX antiseptic for operative wounds disinfection and general
Solution infections antisepsis.
Spread 5 ml over both hands
and rub thoroughly for
about 5 minutes. Rinse
Povidone Iodine thoroughly. Repeat if
7.5% (equivalent D08AG02000 As preoperative scrub for hands desired. Pre-operative use
1262 B
to 0.75% iodine) L9901XX and skin on patient: Apply scrub and
Scrub rub thoroughly for about 5
minutes. Rinse off using a
sterile gauze saturated with
water
Adult: Used in combination
with atropine. Admin
atropine via IM/IV inj and
repeat as needed until
patient shows signs of
atropine toxicity. Maintain
atropinisation for at least 48
hr. As soon as the effects of
atropine are observed, 1-2 g
of pralidoxime (chloride,
iodide or mesilate) may be
given via IM/IV inj. Repeat
Antidote in the treatment of dose after 1 hr, then every
organophosphorus insecticide 8-12 hr, if necessary. In
Pralidoxime 25 V03AB04000 poisoning and in the control of severe poisoning,
1263 B
mg/ml Injection P3002XX overdosage by anticholinergic continuous infusion of 200-
drugs used in the treatment of 500 mg/hr may be given,
myasthenia gravis titrated according to
response. Alternatively,
pralidoxime chloride may be
given at an initial dose of 30
mg/kg via IV infusion over
20 minutes or IV inj over 5
minutes, followed by IV
infusion at 8 mg/kg/hr. Max:
12 g/24 hr. Child: As
mesilate: 20-60 mg/kg.
Renal impairment: Dose
adjustment may be
required.
279 / 371

Dose escalation: 0.125 mg 3
times daily on week 1 then
0.25 mg 3 times daily week
2 then 0.5 mg 3 times daily
on week 3. Increase by 0.75
mg at weekly intervals if
Treatment for signs and symptoms needed up to maximum of
Pramipexole of advanced idiopathic Parkinson's 4.5 mg/day. Patient on
N04BC05110
1264 Dihydrochloride A* disease. It may be used as levodopa: Reduce dose.
T1001XX
0.125 mg Tablet monotherapy or in combination Renal impairment: In patient
with levodopa with creatinine clearance <
20ml/min, the daily dose of
pramipexole should be
started at 0.125 mg daily
instead of 0.25mg and the
maximum dose should not >
1.5 mg daily
Dose escalation: 0.125 mg 3
times daily on week 1 then
0.25 mg 3 times daily week
2 then 0.5 mg 3 times daily
on week 3. Increase by 0.75
mg at weekly intervals if
Treatment for signs and symptoms needed up to maximum of
Pramipexole of advanced idiopathic Parkinson's 4.5 mg/day. Patient on
N04BC05110
1265 Dihydrochloride A* disease. It may be used as levodopa: Reduced dose.
T1002XX
1 mg Tablet monotherapy or in combination Renal impairment: In patient
with levodopa with creatinine clearance <
20ml/min, the daily dose of
pramipexole should be
started at 0.125 mg daily
instead of 0.25mg and the
maximum dose should not >
1.5 mg daily
Dose escalation: 0.375
mg/day on week 1, 0.75
mg/day on week 3. Increase
by 0.75 mg at weekly
Treatment for signs and symptoms
Pramipexole intervals if needed up to a
of advanced idiopathic Parkinson's
Dihydrochloride N04BC05110 max of 4.5 mg/day. Patient
1266 A disease. It may be used as
Extended Release T5001XX on l-dopa: reduce dose.
monotherapy or in combination
0.375mg Tablet Renal Impairment: CrCl 30-
with levodopa
50 mL/min Initially 0.375 mg
every other day. May be
increased by 0.375 mg at
weekly intervals to max 2.25
mg/day
280 / 371

Dose escalation: 0.375
mg/day on week 3. Increase
by 0.75 mg at weekly
Treatment for signs and symptoms
Pramipexole intervals if needed up to a
of advanced idiopathic Parkinson's
Dihydrochloride N04BC05110 max of 4.5 mg/day. Patient
1267 A disease. It may be used as
Extended Release T5003XX on l-dopa: reduce dose.
monotherapy or in combination
1.5mg Tablet Renal Impairment: CrCl 30-
with levodopa
50 mL/min Initially 0.375 mg
every other day. May be
increased by 0.375 mg at
weekly intervals to max 2.25
mg/day
Co-administered with aspirin, is
indicated to reduce the rate of
thrombotic cardiovascular (CV)
events (including stent thrombosis)
in patients with acute coronary
Initiate treatment with a
syndromes who are to be managed
single 60mg oral loading
with percutaneous coronary
dose. Continue at
Prasugrel HCl 10 B01AC22110 intervention (PCI) as follows: STEMI
1268 A* 10mg/5mg once daily with
mg Tablet T1002XX with or without diabetes, UA and
or without food. Patients
NSTEMI with diabetes, age <75yrs
should also take aspirin (75
old, weight >60kg, without history
mg - 325 mg) daily.
of TIA stroke and clinically
suspected clopidogrel resistance
subset. (Only to be used in
Cardiology Centre as third line
treatment/ adjunctive therapy).
coronary heart disease intolerant
Pravastatin
C10AA03520 or not responsive to other forms of 10 - 20 mg once daily.
1269 Sodium 20 mg A/KK
T1001XX therapy. In health clinics, Maximum: 40 mg daily
Tablet
Pravastatin is restricted to HIV
patients on HAART.
Initially 0.5 mg 2 - 3 times
daily, the initial dose on
retiring to bed at night;
Prazosin HCl 1 C02CA01110 increased to 1 mg 2 - 3
1270 B Hypertension
mg Tablet T1001XX times daily after 3 - 7 days:
further increased if
necessary to maximum 20
mg daily
281 / 371

1271 B Hypertension
mg daily
1272 B Hypertension
mg daily
Pre/Post Natal Vitamin and mineral supplement
A11AA03903 1 capsule daily or based on
1273 Vitamin & C+ for use during pregnancy and
C1001XX individual requirements
Mineral Capsule lactation
Pre/Post Natal Vitamin and mineral supplement
A11AA03903 1 tablet daily or based on
1274 Vitamin & C+ for use during pregnancy and
T1001XX individual requirements
Mineral Tablet lactation
i) 5 - 25 mg daily in divided
doses ii) 10 - 20 mg/m2
i) Replacement therapy for primary body surface daily in divided
Prednisolone 3 H02AB06000 and secondary adrenocortical doses iii) ADULT: 5 - 60 mg
1275 B
mg/5 ml Syrup L9001XX insufficiency ii) Adrenogenital daily. CHILD: 0.5 - 2
syndrome iii) Other therapy mg/kg/day in divided doses
every 6 - 8 hours or as a
single daily
i) 5 - 25 mg daily in divided
doses ii) 10 - 20 mg/m2
i) Replacement therapy for primary body surface daily in divided
Prednisolone 5 H02AB06000 and secondary adrenocortical doses iii) ADULT: 5 - 60 mg
1276 B
mg Tablet T1001XX insufficiency ii) Adrenogenital daily. CHILD: 0.5 - 2
syndrome iii) Other therapy mg/kg/day in divided doses
every 6 - 8 hours or as a
single daily
i) Initially, 75 mg twice daily.
May be increased to 150 mg
twice daily after 3-7 days.
i) Second line treatment of Max: 600 mg/day after an
Pregabalin 150 N03AX16000 neuropathic pain in patients who additional 7-day interval ii)
1277 A*
mg Capsules C1002XX do not response to first line drugs Initially, 75 mg twice daily.
ii) Fibromyalgia May be increased to 150 mg
twice daily within 1 week or
225 mg twice daily. Max:
450 mg/day
282 / 371

i) Initially, 75 mg twice daily.
twice daily after 3-7 days.
i) Second line treatment of Max: 600 mg/day after an
Pregabalin 75 mg N03AX16000 neuropathic pain in patients who additional 7-day interval ii)
1278 A*
Capsule C1001XX do not response to first line drugs Initially, 75 mg twice daily.
ii) Fibromyalgia May be increased to 150 mg
twice daily within 1 week or
225 mg twice daily. Max:
450 mg/day
i) 15 mg daily for 14 days,
increased to higher doses or
longer course if resistance in
P.vivax occurs. ii) ADULT: 30
i) Treatment of malaria ii)
Primaquine 7.5 P01BA03162 mg once weekly. CHILD: 0.5
1279 B Prophylaxis together with a
mg base Tablet T1001XX mg once weekly Child:
schizonticide such as chloroquine
250mcg/kg daily for 14 days.
Should be taken with food.
Take with meals to avoid GI
discomfort.
ADULT: Initially 1 tablet
daily in the evening,
increasing by 1 tablet every
Primidone 250 N03AA03000 4 - 7 days to 3 - 4 tablets
1280 B Epilepsy
mg Tablet T1001XX daily. Maximum dosage: 1.5
g daily in divided doses.
CHILD: 6 - 8 years: Up to 1/2
adult dose
Hyperuricemia associated with
gout and gouty arthritis (for cases
Probenecid 500 M04AB01000 500 mg to 1000 mg twice
1281 A allergic to allopurinol or serum uric
mg Tablet T1001XX daily
acid not controlled by allopurinol
alone)
ADULT: 300,000 - 900,000
Procaine
units (300 - 900 mg) IM
Benzylpenicillin
J01CE09702P Treatment of infections due to daily. CHILD: Up to 1 year:
1282 Aqueous 3 mega B
4001XX Penicillin G-sensitive organisms 150 mg IM daily. 1 - 5 years:
units (3 g)
300 mg IM daily. 6 - 12
Injection
years: 600 mg IM daily
ADULT: 300,000 - 900,000
Procaine units (300 - 900 mg) IM
Penicillin J01CE09702P Treatment of infections due to daily. CHILD: Up to 1 year:
1283 B
Fortified 4 MU 4002XX Penicillin G-sensitive organisms 150 mg IM daily. 1 - 5 years:
Injection 300 mg IM daily. 6 - 12
years: 600 mg IM daily
283 / 371

Adult: Monotherapy:
Initially, 50 mg/day,
increased by 50 mg daily to
250-300 mg daily in divided
doses. Continue doses until
max response is achieved or
appearance of signs of
toxicity. Maintenance: 50-
Procarbazine HCl L01XB01110
1284 A Lymphomas 150 mg/day or 1-2 mg/kg
50 mg Capsule C1001XX
daily until a cumulative dose
of at least 6 g. Combination
Therapy: 100 mg/m2 on
days 1-14 of each 4- or 6-wk
cycle. Child: Initially, 50
mg/m2 daily, up to 100
mg/m2 adjust according to
response.
Nausea and vomiting Adult:
As maleate or mesilate: 20
mg, further doses are given
if needed. Recommended
buccal dose: As maleate: 3-6
Prochlorperazine mg bid. Vertigo Adult: As
N05AB04253 i) Severe nausea and vomiting ii)
1285 Maleate 5mg B maleate or mesilate: 15-30
T1002XX Vertigo/labyrinthine disorders
Tablet mg daily, given in divided
doses. May reduce gradually
to 5-10 mg daily.
Recommended buccal dose:
3-6 mg bid. May be taken
with or without food.
Deep IM injection, 12.5 mg
Prochlorperazine repeated if necessary after 6
N05AB04253 i) Severe nausea and vomiting ii)
1286 Mesylate 12.5 B hours and then followed by
P3001XX Vertigo/labyrinthine disorders
mg/ml Injection an oral dose. Not
i) Initial dose 2.5mg TDS,
increasing by 2.5-5mg/day
at intervals of 2 or 3 days
i) All forms of Parkinson's disease
until the optimum clinical
(idiopathic paralysis agitants), post-
response is achieved. Usual
encephalitis and arteriosclerosis ii)
Procyclidine HCl maintenance dose: 15-
N04AA04110 To control troublesome
1287 5 mg/ ml B 30mg/day. Max: 60mg/day
P3001XX extrapyramidal symptoms induced
Injection ii) Initial dose 2.5mg TDS,
by neuroleptic drugs including
increasing by 2.5mg daily
pseudo-parkinsonism, acute
until symptoms are relieved.
dystonic reactions and akathisia
Usual maintenance dose:
10-30mg/day. IV
Emergency: 5-10 mg. IM
284 / 371

Emergency: 5-10 mg as a
single dose, may repeat
after 20 mins if needed.
Max: 20 mg/day.
200-300mg daily orally. For
supplementation of the
Progesterone G03DA04000 Supplementation of the luteal luteal phase during in IVF,
1288 A*
100 mg capsule C1001XX phase 400-600mg per day in 2-3
divided doses to be inserted
vaginally.
90 mg intravaginally daily
Progesterone 8% G03DA04000 Treatment of infertility due to
1289 A* from day of egg retrieval till
Vaginal Gel G3001XX inadequate luteal phase
pregnancy established
Oedema and inflammation in
M09AB00000
1290 Prolase Tablet B conjunction with other physical or 2 tablet 4 times daily
T1001XX
chemotherapeutic measures
By deep IM: ADULT: 25 - 50
mg, maximum 100 mg.
Promethazine CHILD: 5 - 10 years : 6.25 -
R06AD02110
1291 HCl 25 mg/ml B Allergic conditions 12.5 mg. By slow IV: 25 - 50
P3001XX
Injection mg in a solution of 2.5
mg/ml in water for injection.
Maximum 100 mg
Promethazine CHILD 2 - 5 years: 5 - 15 mg
R06AD02110
1292 HCl 5 mg/5 ml B Allergic conditions daily, 5 - 10 years : 10 - 25
L9001XX
Syrup mg daily
Deep anaesthesia:1 or 2
drops in the (eyes) every 5
to 10 minutes for 3 to 5
doses. For minor surgical
Proparacaine HCI
S01HA04110 Topical anaesthesia in ophthalmic procedures: instill 1 to 2
1293 0.5% Ophthalmic B
D2001XX procedures drops every 5 to 10 minutes
Drops
for 1 to 3 doses. Tonometry
and/or tonography
procedure: 1 to 2 drops in
each eye before procedure.
ADULT: 15 mg twice daily to
Treatment of urinary incontinence,
3 times daily, increase to 4
urgency and frequency in
times daily if required. Max
Propiverine HCl G04BD06110 neurogenic detrusor overactivity
1294 A* dose: 60 mg daily. CHILD
15 mg Tablet T1001XX (detrusor hyperreflexia) and in
more than 5 years: 0.2 to
idiopathic detrusor overactivity
0.4 mg/kg per day in 2
(overactive bladder)
divided doses
285 / 371

Adult: Induction: 20- 40 mg
by injection or infusion
every 10 sec. Usual dose:
1.5-2.5 mg/kg.
Maintenance: 4-12
mg/kg/hr or intermittent
bolus inj of 20-50 mg. Child:
>8 yr: Induction dose of 2.5
mg/kg. Maintenance dose:
9-15 mg/kg/hr by IV infusion
Propofol Induction & maintenance of or intermittent bolus inj.
N01AX10000
1295 10mg/ml (1%) A* general anaesthesia. Sedation of Elderly: Including
P9901XX
Injection ventilated ICU patients neurosurgical and
debilitated patients: Infuse
at a rate of 20 mg every 10
sec. Maintenance: 3-6
mg/kg/hr. Usual dose
needed: 1-1.5 mg/kg.
Duration of use: Can be
administered for a
maximum period of 7 days.
Sedation: 0.3 - 4
mg/kg/hour up to 3 days
Adult: IV Induction and
maintenance of general
anesth Induction: 40 mg
every 10 sec. Maintenance:
4-12 mg/kg/hr or
intermittent boluses of 20-
Propofol
50 mg. Sedation In
20mg/ml (2%) Induction & maintenance of
N01AX10000 diagnostic and surgical
1296 emulsion for A* general anaesthesia. Sedation of
P9902XX procedures: Initial: 6-9
injection of ventilated ICU patients
mg/kg/hr by infusion.
infusion
Maintenance: 1.5-4.5
mg/kg/hr. For ventilated
patients: 0.3-4 mg/kg/hr.
Monitor lipid concentrations
if duration of sedation >3
days.
Slow IV injection in a dose of
1 mg over 1 minute,
repeated if necessary every
2 minutes until a maximum
Propranolol HCl 1 C07AA05110 Arrhythmias and thyrotoxicosis
1297 A of 10 mg has been given in
mg/ml Injection P3001XX crisis
conscious patients and 5 mg
in patients under
anaesthesia. CHILD: 25 - 50
mcg/kg slow IV with
286 / 371

appropriate monitoring
Dysrythmias, tachycardia,
Propranolol HCl C07AA05110 hypertrophic obstructive
1298 B 10 - 40 mg 3 - 4 times daily
10 mg Tablet T1001XX cardiomyopathy (For cardiologist
only)
i) Initially 80 mg twice daily
increased as required to a
usual range of 160 - 320 mg
daily. CHILD: Initial doses of
1 mg/kg in divided doses,
can be increased to 2 - 4
mg/kg/day in divided doses
ii) Initial dose of 40 mg 2 - 3
times daily. Maintenance
120 - 240 mg daily iii) 40mg
4 times daily for 2 - 3 days
then 80 mg twice daily,
i) Hypertension ii) Angina iii)
beginning 5 - 21 days after
Propranolol HCl C07AA05110 Myocardial infarct iv) Cardiac
1299 B infarction iv) 10 - 40 mg 3 - 4
40 mg Tablet T1002XX arrhythmia v) Portal hypertension
times daily v) Initially 40 mg
vi) Migraine vii) Thyrotoxicosis
twice daily. The dose may
be increased as required up
to 160 mg twice daily vi)
Initial prophylaxis dose: 40
mg 2 - 3 times daily. The
dose may be increased at
weekly intervals up to 160
mg daily vii) Adjunct: 10 - 40
mg 3 - 4 times daily. CHILD:
Arrythmias, thyrotoxicosis:
0.25 - 0.5 mg/kg 3 - 4 times
daily as required
ADULT Initially 300-450mg
in 8 hourly intervals (can be
given up to 600-
900mg/daily) until
symptoms are controlled in
1-2 months. Maintenance
Propylthiouracil H03BA02000
1300 B Hyperthyroidism 50-150mg daily for at least
12-18 months. CHILDREN 6-
10 years: 50-150mg.
CHILDREN > 10 years: 150-
300mg daily. All doses are to
be given in 3 divided doses
daily. Taken with food.
287 / 371

5 ml slow IV injected over 10
minutes. If administered
within 15 minutes of
heparin dose, 1 mg will
neutralise approximately
100 units of heparin. If
Heparin overdose and following
longer time has elapsed, less
cardiac or arterial surgery or
Protamine protamine is required. Not
V03AB14183 dialysis procedures when required
1301 Sulphate 10 B more than 50 mg should be
P3001XX to neutralize the effects of heparin
mg/ml Injection injected at any one time.
administered during extracorporeal
The dose is dependent on
circulation
the amount and type of
heparin to be neutralised,
its route of administration
and the time elapsed since it
was last given and blood
coagulation studies.
Trophic lesions in patients with
arterial occlusive disease and with
Protein Free
D03AX00000 chronic venous insufficiency, burn
1302 Haemodialysate A Apply 3 - 5 times daily
G4001XX injuries, impaired wound healing,
10% Jelly
decubitus ulcers and skin ulcer
caused by irradiation
Eyes disorders e.g. burns, scalds,
Protein Free
S01XA20000 ulcers, prevention and treatment of
1303 Haemodialysate A Instill 1 drop 3 - 4 times daily
G3001XX radiation dermatitis, traumatic and
20% Eye Gel
ischaemic wound
Trophic lesions in patients with
arterial occlusive disease and with
Protein Free
D03AX00000 chronic venous insufficiency, burn
1304 Haemodialysate A Apply 3 - 5 times daily
G5001XX injuries, impaired wound healing,
5% Ointment
decubitus ulcers and skin ulcer
caused by irradiation
Painful and inflammatory affliction

Protein Free
on the oral mucosa, gums and lips,
Haemodialysate D03AX00000 Apply to lesions 3 - 5 times
1305 A teething pain, denture pressure
Dental Adhesive G6001XX daily
sores, oral and maxillofacial surgery
Paste
and dressing after scaling
ADULT and CHILD: 2 years
Pyrantel
P02CC01127 and older - single dose
1306 Pamoate 125 mg C Intestinal nematodes
T1001XX 10mg/kg body weight once.
Tablet
Maximum 1 g
Pyrantel ADULT and CHILD: 2 years
P02CC01127
1307 Pamoate 250 mg C Intestinal nematodes and older - single dose
T1002XX
Tablet 10mg/kg body weight once.
288 / 371

Maximum 1 g
Pyrazinamide J04AK01000T biweekly (max 2000mg).
1308 B Tuberculosis
500 mg Tablet 1001XX Children: 20-30mg/kg daily
or 30-40mg/kg thrice
weekly.
ADULT: 30 - 120 mg at
suitable intervals
throughout the day, total
Pyridostigmine
N07AA02320 daily dose 0.3 - 1.2 g. CHILD
1309 Bromide 60 mg B Myasthenia gravis
T1001XX up to 6 years initially 30 mg,
Tablet
6 - 12 years initially 60 mg,
usual total daily dose 30 -
360 mg
i) INFANT 4 mg/kg daily for
i)Pyridoxine-dependent convulsions
short periods ii) 100 - 400
in infant ii)Sideroblastic anaemia
mg daily in divided doses iii)
iii)B6-deficient anaemia in adult iv)
Pyridoxine HCl 10 A11HA02110 ADULT 20 - 50 mg up to 3
1310 C+ Prophylaxis to peripheral neuritis in
mg Tablet T1001XX times daily iv) Prophylaxis
isoniazid therapy v) Nausea and
10 mg daily, therapeutic 50
vomiting of pregnancy and
mg 3 times daily v) 20 - 100
irradiation sickness
mg daily
i) Pyridoxine-dependent i) INFANT 4 mg/kg daily for
convulsions in infancy ii) short periods ii) 100 - 400
Sideroblastic anaemia iii) B6- mg daily in divided doses iii)
Pyridoxine HCl 50 A11HA02110 deficient anaemia in adult iv) ADULT 20 - 50 mg up to 3
1311 B
mg/2 ml Injection P3001XX Prophylaxis to peripheral neuritis in times daily iv) Prophylaxis
isoniazid therapy v) Nausea and 10 mg daily, therapeutic 50
vomiting of pregnancy and mg 3 times daily v) 20 - 100
irradiation sickness mg daily
289 / 371

i) Initial titration schedule
over 4 days: 25 mg twice
daily on Day 1, increase in
steps of 25 - 50 mg 2 to 3
times daily on Days 2 and 3
to reach target dose of 300 -
400 mg daily by Day 4, given
Institute further dose
adjustments, if indicated, at
intervals of 2 days or more,
in steps of 25 - 50 mg twice
daily ii) 100 mg (Day 1), 200
mg (Day 2), 300 mg (Day 3)
& 400 mg (Day 4). Further
i) Schizophrenia ii) Short term
dosage adjustments up to
treatment of acute manic episodes
Quetiapine 800 mg/day by Day 6 should
associated with bipolar I disorder,
Fumarate 100 mg N05AH04138 be in increments of not
1312 A* either monotherapy or adjunct to
Immediate T1002XX more than 200 mg/day.
lithium or divalproex iii) Treatment
Release Tablet Adjust dose within the range
of depressive episodes associated
of 200 - 800 mg/day
with bipolar disorder
depending on clinical
response and tolerability of
the patient. Usual effective
dose range: 400 - 800
mg/day iii) 50 mg ORALLY
once a day on Day 1, then
100 mg once daily on Day 2,
then 200 mg once daily on
Day 3, then 300 mg once
daily on Day 4 (all doses
given at bedtime); patients
requiring higher doses
should receive 400 mg on
Day 5, increased to 600 mg
on Day 8 (week 1)
i) & ii) 300 mg once daily on
Day 1 then 600 mg on Day 2.
Maintenance dose: 400 to
800 mg once daily.
Quetiapine i)Schizophrenia ii) Moderate to Maximum dose: 800 mg
Fumarate 200 mg N05AH04138 severe manic episodes in bipolar daily iii) 50 mg on Day 1, 100
1313 A*
Extended Release T5002XX disorder iii) Major depressive mg on Day 2, 200 mg on Day
Tablet episodes in bipolar disorder 3 and 300 mg on Day 4.
300 mg. May be titrated up
to 600 mg daily. In elderly or
hepatic impairment:Start
290 / 371

with 50mg/ day, may be
increased in increments of
50mg /day to an effective
dose.
i) Initial titration schedule
over 4 days: 25 mg twice
daily on Day 1, increase in
steps of 25 - 50 mg 2 to 3
times daily on Days 2 and 3
to reach target dose of 300 -
400 mg daily by Day 4, given
Institute further dose
adjustments, if indicated, at
intervals of 2 days or more,
in steps of 25 - 50 mg twice
daily ii) 100 mg (Day 1), 200
mg (Day 2), 300 mg (Day 3)
& 400 mg (Day 4). Further
i) Schizophrenia ii) Short term
dosage adjustments up to
treatment of acute manic episodes
Quetiapine 800 mg/day by Day 6 should
associated with bipolar I disorder,
Fumarate 200 mg N05AH04138 be in increments of not
1314 A* either monotherapy or adjunct to
Immediate T1004XX more than 200 mg/day.
lithium or divalproex iii) Treatment
Release Tablet Adjust dose within the range
of depressive episodes associated
of 200 - 800 mg/day
with bipolar disorder
depending on clinical
response and tolerability of
the patient. Usual effective
dose range: 400 - 800
mg/day iii) 50 mg ORALLY
once a day on Day 1, then
100 mg once daily on Day 2,
then 200 mg once daily on
Day 3, then 300 mg once
daily on Day 4 (all doses
given at bedtime); patients
requiring higher doses
should receive 400 mg on
Day 5, increased to 600 mg
on Day 8 (week 1)
Day 1 and 600 mg on Day 2.
Quetiapine i) Schizophrenia ii) Moderate to Maintenance dose: 400 -
Fumarate 300 mg N05AH04138 severe manic episodes in bipolar 800 mg once daily.
1315 A*
Extended Release T5003XX disorder iii) Major depressive Maximum dose: 800 mg
Tablet episodes in bipolar disorder daily iii) 50 mg on Day 1, 100
mg on Day 2, 200 mg on Day
3 and 300 mg on Day 4.
291 / 371

to 600 mg daily
Day 1 and 600 mg on Day 2.
Maintenance dose 400 -
800mg once daily.
Quetiapine i) Schizophrenia ii) Moderate to
Maximum dose: 800 mg
Fumarate 400 mg N05AH04138 severe manic episodes in bipolar
1316 A* daily iii) 50 mg on Day 1, 100
Extended Release T5004XX disorder iii) Major depressive
mg on Day 2, 200 mg on Day
Tablet episodes in bipolar disorder
3 and 300 mg on Day 4.
to 600 mg daily
Day 1 then 600 mg on Day 2.
Maintenance dose: 400 to
800 mg once daily.
Maximum dose: 800 mg
daily. iii)50 mg on Day 1, 100
Quetiapine i)Schizophrenia ii)Moderate to mg on Day 2, 200 mg on Day
Fumarate 50 mg N05AH04138 severe manic episodes in bipolar 3 and 300 mg on Day 4.
1317 A*
Extended Release T5001XX disorder iii)Major depressive Recommended daily dose is
Tablet episodes in bipolar disorder 300 mg. May be titrated up
to 600 mg daily. In elderly or
hepatic impairment: Start
with 50mg/ day, may be
increased in increments of
50mg /day to an effective
dose.
By slow intravenous infusion
(over 4 hours). ADULT: 20
mg/kg followed by 10 mg/kg
every 8 hours. CHILD : 20
Quinine
mg/kg followed by 10 mg/kg
Dihydrochloride P01BC01110
1318 B Severe and complicated malaria every 12 hours, initial dose
600 mg/2 ml P3001XX
should be half in patients
Injection
who have received quinine,
quinidine or mefloquine
during the previous 12 or 24
hours
292 / 371

300 - 600 mg daily.
Treatment: 1.2 - 2 g daily in
divided doses. CHILDS less
than 1 year : 100 - 200 mg
Quinine Sulphate P01BC01183 daily, 1 - 3 years : 200 - 300
1319 B Severe and complicated malaria
300 mg Tablet T1001XX mg daily, 4 - 6 years: up to
500 mg daily, more than 7
years : up to 1 g daily. All
above doses are given for 7
days in 2 - 3 divided doses
i) Treatment and maintenance of i) 10-20 mg daily for 4-8
Rabeprazole
A02BC04520 erosive or ulcerative weeks, maintenance 10-20
1320 Sodium 20 mg A*
T1001XX gastroesophageal reflux disease mg daily ii) 20 mg daily at
Tablet
(GERD) ii) Duodenal ulcers morning for up to 4-8 weeks
Prophylaxis: 3 dose (1 ml
each) schedule on D0, D7
and D28. Booster dose after
Rabies Human every 2 - 3 years. Post
Diploid Cell exposure prophylaxis: use
J07BG01000P Pre-exposure and post-exposure
1321 Vaccine B after attack of a potential
4001XX vaccination against rabies
(Lyophilised) rabid animal: 1 dose on D0,
Injection D3, D7, D14 and D28. In
previously vaccinated
individuals 2 doses on D0
and D3
Raloxifene HCl 60 G03XC01110 Prevention and treatment of post
1322 A* 1 tablet daily
mg Tablet T1001XX menopausal osteoporosis
Raltgeravir combination with other
antiretroviral agents is indicated for 400mg administered orally,
the treatment of HIV-1 infection in twice daily with or without
Raltegravir 400 J05AX08500T
1323 A* patients who are contraindicated food, to be given
mg tablet 1001XX
to boosted Protease Inhibitor or combination with other
who are intolerant to boosted antiretroviral agent.
Protease Inhibitor.
i) Hypertension: Initially 2.5
mg once daily, increased at
intervals of 1 - 2 weeks to
i) Hypertension and congestive
maximum 10 mg once daily;
heart failure ii) Post-myocardial
Congestive heart
infarction iii) Reducing risk of
Ramipril 2.5 mg C09AA05000 failure:Initially 1.25 mg once
1324 A myocardial infarction, stroke or
Tablet T1001XX daily. Max: 10 mg/day ii)
cardiovascular death in diabetics or
Initially 2.5 mg twice daily
patients with increased
for 2 days then increased to
cardiovascular risks
maximum 5 mg twice daily
iii) Initially 1.25 - 2.5 mg
once daily, increased to 5
293 / 371

mg once daily after 1 week,
maximum dose: 10 mg once
daily after 3 weeks
i) Hypertension: Initially 2.5
mg once daily, increased at
intervals of 1 - 2 weeks to
maximum 10 mg once daily;
i) Hypertension and congestive Congestive heart
heart failure ii) Post-myocardial failure:Initially 1.25 mg once
infarction iii) Reducing risk of daily. Max: 10 mg/day ii)
Ramipril 5 mg C09AA05000
1325 A myocardial infarction, stroke or Initially 2.5 mg twice daily
Tablet T1002XX
cardiovascular death in diabetics or for 2 days then increased to
patients with increased maximum 5 mg twice daily
cardiovascular risks iii) Initially 1.25 - 2.5 mg
once daily, increased to 5
mg once daily after 1 week,
maximum dose: 10 mg once
daily after 3 weeks
0.5 mg (0.05ml) as a single
i) Treatment of Neovascular (wet)
intravitreal Injection.Interval
Age-Related Macular Degeneration
between 2 doses should not
(ARMD) ii) Treatment of visual
be shorter than 1 month,
impairment due to diabetic
then monitor for visual
macular edema (DME) iii)
Ranibizumab 10 S01LA04000P acuity monthly. Treatment is
1326 A* Treatment of visual impairment
mg/ ml Injection 3001XX given monthly & continued
due to macular edema secondary
until max visual acuity is
to retinal vein occlusion (RVO)
achieved, confirmed by
Note: Indication ii) and iii)
stable visual acuity for 3
approved to be used by retinal
consecutive monthly
specialist only (PFUKKM 1/2015)
assessments.
i) 150 mg twice daily (at
morning and night) or 300
mg on night for 4-8 weeks.
i) Benign gastric and duodenal ulcer Maintenance: 150-300 mg
Ranitidine 150 A02BA02110 ii) Reflux oesophagitis iii) Non-ulcer on night ii) 150 mg twice
1327 B
mg Tablet T1001XX dyspepsia iv) Zollinger-Ellison daily or 300 mg on night for
Syndrome 8-12 weeks iii) 150 mg daily
or twice daily iv) 150 mg and
may be increased as
necessary to 6 g/day
CHILD 2-4 mg/kg 2 times
Ranitidine 150 A02BA02110
1328 B Peptic ulcer disease daily. Maximum 300 mg
daily
294 / 371

i) ADULT: Slow IV injection
of 50 mg diluted to 20 ml
and given over at least 2
minutes. May be repeated
every 6-8 hours or IV
i) Benign gastric/ duodenal
infusion at rate of 25
ulceration, reflux oesophagitis,
Ranitidine 25 A02BA02110 mg/hour for 2 hours, may
1329 B Zollinger Ellison Syndrome ii) Stress
mg/ml Injection P3001XX be repeated at 6-8 hours
ulcer prophylaxis in post-operative
intervals or IM. CHILD: 1
and high risk patients
mg/kg/dose 6-8 hourly. ii)
Initial slow IV injection of 50
mg, then continuous
infusion of 125-250
mcg/kg/hour
i) 150 mg twice daily (at
morning and night) or 300
mg on night for 4-8 weeks.
i) Benign gastric and duodenal ulcer Maintenance: 150-300 mg
Ranitidine 300 A02BA02110 ii) Reflux oesophagitis iii) Non-ulcer on night ii) 150 mg twice
1330 B
mg Tablet T1002XX dyspepsia iv) Zollinger-Ellison daily or 300 mg on night for
Syndrome 8-12 weeks iii) 150 mg daily
or twice daily iv) 150 mg and
may be increased as
necessary to 6 g/day
295 / 371

For IV use only. ADULT:
Induction:Bolus infusion:
1µg/kg over 30-60 seconds;
Continuous infusion: 0.5-
1µg/kg/min; Maintenance:
Continuous infusion: 0.025
to 2 µg/kg/min. CHILD (1-12
years of age): Induction:
Insufficient data; Neonates:
IV infusion 0.4-1.0
mcg/kg/minute depending
on the anaesthetic method
and adjust according to
i) As an analgesic agent for use
patient response,
during induction and/or
supplemental IV inj of 1
maintenance of general
mcg/kg dose may be given.
anaesthesia during surgical
1-12 yr: initially 0.1-1
procedures including cardiac
mcg/kg by IV inj over at
surgery. ii)Continuation of
Remifentanil 5 N01AH06110 least 30 seconds (excluded if
1331 A* analgesia into the immediate post-
mg Injection P4001XX not needed), followed by IV
operative period under close
infusion 0.05-1.3
supervision, during transition to
longer acting analgesia. iii)Provision
on the anaesthetic method
of analgesia and sedation in
and adjust according to
mechanically ventilated intensive
patient response,
care patients.
supplemental IV bolus inj
may be admin during
infusion. 12-18 yr: 0.1-1
mcg/kg IV inj over at least
30 seconds (excluded if not
needed), followed by IV
infusion of 0.05-2
on anaesthetic method and
adjust according to patient
response, supplemental IV
bolus inj may be admin
during infusion.
296 / 371

OHA naïve patient: Start
dose with 0.5mg per meal
Patients transferred from
another oral hypoglycaemic
agent: Start dose with 0.5-
1mg per meal In
combination with
Type 2 diabetes mellitus (as
metformin: Start dose as
Repaglinide 2 mg A10BX02000 monotherapy or in combination
1332 A* 0.5mg per meal Titrate
Tablet T1001XX with metformin when metformin
every 1-2weeks according to
alone is inadequate)
blood glucose response.
Max single dose: 4mg
before each main meal. Max
total daily dose: 16mg.
Doses to be taken within 30
minutes of meals, 2-4 meals
a day
ADULT (more than 18 years
old): 50mg/kg/day
Recommended: Body
weight: ≤ 75kg should
receive 1000mg daily as two
200mg capsules in the
morning and three 200mg
capsules in the evening
Body weight: >75kg should
For the treatment of chronic
Ribavirin 200 mg J05AB04000C receive 1200mg as three
1333 A* hepatitis C (in combination with
Capsule 1001XX 200mg capsules in the
interferon alfa-2a/2b)
morning and three 200mg
capsules in the evening
Genotype 1,4: 48 weeks
Genotype: 24 weeks
duration should be
individualized in accordance
with the baseline
characteristics of the
disease.
CHILD: 2.5-10 mg/day in
Riboflavine 3 mg A11HA04000 For prevention and treatment of
1334 C divided doses. ADULT: 5-30
Tablet T1001XX riboflavine deficiency
mg/day in divided doses
CHILD: 20 mg/kg body
Rifampicin 100 J04AB02000L weight daily in 1 - 2 doses.
1335 A Tuberculosis and leprosy
mg/5 ml Syrup 9001XX Up to 1 year: 10 mg/kg body
weight in a single daily dose
297 / 371

i) ADULT: 450 - 600 mg as a
single morning dose. CHILD:
i) Tuberculosis ii) Leprosy iii) daily in 1 - 2 doses. Directly
Rifampicin 150 J04AB02000C
1336 B Prophylaxis for meningococcal observed therapy (DOT): 10
mg Capsule 1001XX
meningitis mg/kg twice weekly or 3
times/week. Maximum: 600
mg ii) 600 mg/day iii) 600
mg twice daily for 2 days
Patient more than or 71 kg:
Rifampicin 150
5 tab/day, 55 -70 kg: 4
mg, Isoniazid 75
J04AM05000 Initial phase (2 months) of tab/day, 38-54 kg: 3
1337 mg & B
T1001XX tuberculosis treatment tab/day, 30-37 kg: 2
Pyrazinamide
tab/day. To be taken as a
400 mg Tablet
single dose
Rifampicin 150
mg, Isoniazid 75 ADULT: 30 - 37 kg: 2 tablets
mg, Treatment of both pulmonary and daily, 38 - 54 kg: 3 tablets
J04AM06000
1338 Pyrazinamide B extrapulmonary tuberculosis, in the daily, 55 - 70 kg: 4 tablets
T1001XX
400 mg & intensive treatment phase daily, more than 70 kg: 5
Ethambutol HCl tablets daily
275 mg Tablet
30-37kg: 2 tablets once
Rifampicin For pulmonary tuberculosis in
daily, 38-54kg: 3 tablets
150mg + J04AM02000 which organisms are susceptible in
1339 B once daily, 55-70kg: 4
Isoniazid 75mg T1001XX continuation phase treatment for 4
tablets once daily, Above
tablet months
70kg: 5 tabs once daily
i) Tuberculosis ADULT: Daily
doses: 10mg/kg/day Body
weight doses: 10-15/kg/day
CHILD: 10 - 20 mg/kg body
weight daily in 1 - 2 doses.
Maximum daily dose :
600mg Directly observed
therapy (DOT): 10 mg/kg
i) Tuberculosis ii) Leprosy iii) twice weekly or 3
Rifampicin 300 J04AB02000C
1340 B Prophylaxis for meningococcal times/week. Maximum: 600
mg Capsule 1002XX
meningitis mg ii) Leprosy: ADULT: 600
mg/day CHILDREN: 10mg/kg
iii) Prophylaxis for
meningococcal meningitis:
for 2 days CHILDREN:
10mg/kg twice daily for 2
days INFANT: 5mg/kg twice
daily for 2 days"
298 / 371

Rifampicin: 600 mg once
monthly, Dapsone: 100 mg
Rifampicin,
J04AM02961 For the treatment of leprosy and daily, Clofazimine: 300 mg
1341 Dapsone & B
T9901XX tuberculosis once monthly and 50 mg
Clofazimine
daily (or 100 mg on
alternate days)
Ringers Solution
(contained
As a source of electrolytes and
sodium chloride, B05XA30905 According to the needs of
1342 B water for hydration/replenishing of
potassium P6001XX the patient
chloride
chloride and
calcium chloride)
ADULT : 2 mg in 1 - 2 divided
doses on first day then 4 mg
in 1 - 2 divided doses on 2nd
day then 6 mg in 1 - 2
divided doses on 3rd day
(slower titration appropriate
in some patients); usual
range 4 - 8 mg daily; dose
Risperidone 1 mg N05AX08000 above 10 mg daily only if
1343 B Psychoses and schizophrenia
Tablet T1001XX benefit outweigh risk
(maximum 16 mg daily).
Elderly (or in hepatic or
renal impairment): initially
0.5 mg twice daily increased
in steps of 0.5 mg twice
daily to 1 - 2 mg twice daily.
Not recommended in
children under 15 years
ADULT: 2 mg in 1 - 2 divided
doses on 1st day then 4 mg
Risperidone 1
N05AX08000 above 10 mg daily only if
1344 mg/ml Oral A Psychoses and schizophrenia
L5001XX benefit outweighs risk
Solution
daily to 1-2 mg twice daily.
Not recommended in
299 / 371

ADULT : 2 mg in 1 - 2 divided
doses on first day then 4 mg
Risperidone 2 mg N05AX08000 above 10 mg daily only if
1345 B Psychoses and schizophrenia
Tablet T1002XX benefit outweigh risk
daily to 1 - 2 mg twice daily.
Not recommended in
Treatment of acute and chronic
25 mg IM every 2 weeks.
schizophrenic psychosis and other
Dose increments (if
Risperidone 25 psychotic conditions, in which
N05AX08000 required) to 37.5 mg or 50
1346 mg Injection A* positive and negative symptoms
P3001XX mg can be considered after
(Long Acting) are prominent. It also alleviates
a minimum of 4 weeks on
affective symptoms associated with
each dosage
schizophrenia
Dose increments (if
Risperidone 37.5 psychotic conditions, in which
each dosage
schizophrenia
Dose increments (if
Risperidone 50 psychotic conditions, in which
each dosage
schizophrenia
IV 0.05 mg/min to be
gradually increased by 0.05
mg/min every 10-15
Ritodrine HCl 50 G02CA01110
1349 A Prevention of preterm labour minutes. IM injection: 10 mg
mg/5 ml Injection P3001XX
4-6 hourly. Continue
treatment for 12-48 hours
after ceased contraction
300 / 371

ADULT: (Single PI) initially
Progressive or advanced HIV 300 mg twice daily, increase
infection in combination with other by 100 mg twice daily
Ritonavir 100 mg J05AE03000C antiretroviral agents. Criteria for increments to 600 mg twice
1350 A*
Capsule 1001XX use: a) Clinical AIDS b) CD4 less daily. (Dual PI) Initially
than 350 cells or c) Viral load more 200mg BD, then increase by
than 10,000 copies/ml 100mg BD & reaching
400mg BD within 2 wk.
ADULT: 400 - 600 mg twice
Progressive or advanced HIV daily. CHILD: >1 month,
infection in combination with other initiate at dise of 25mg/m2
Ritonavir 80 J05AE03000L antiretroviral agents. Criteria for twice daily, titrate dose
1351 A*
mg/ml Solution 9901XX use: a) Clinical AIDS b) CD4 less upward every 2-3 days by
than 350 cells or c) Viral load more 50mg/m2 twice daily
than 10,000 copies/ml (maximum dose 600mg
twice daily)
i) 375 mg/m2 BSA
administered as an IV
infusion through a
i) Treatment of patients with dedicated line once weekly
relapsed or chemo-resistant low for 4 weeks ii) Combination
grade or follicular B-cell Non- with CHOP
Hodgkin's lymphoma ii) Adjunctive (cyclophosphamide,
therapy with combination doxorubicin, prednisone and
chemoagents for aggressive Non- vincristine) as 375 mg/m2
Hodgkin Lymphoma iii) Severe BSA on day 1 of each
active rheumatoid arthritis with chemotherapy cycle for 8
Rituximab 10 L01XC02000P
1352 A* inadequate response or intolerance cycles after IV
mg/ml Injection 3001XX
to other disease-modifying anti- administration of the
rheumatic drugs (DMARDs) glucocorticoid component
including one or more tumour of CHOP. iii) 1000 mg IV
necrosis factor (TNF) inhibitor infusion followed by a
therapies iv) Maintenance in second 1000 mg IV infusion
relapsed/ refractory follicular two weeks later iv)
lymphoma after response to 375mg/m2 BSA once every 3
induction therapy months until disease
progression or for a
maximum period of two
years.
10 mg once daily. Initial
dose should be taken 6 to
Prevention of venous 10 hour post-surgery
Rivaroxaban 10 B01AX06000 thromboembolism in patients provided that haemostasis
1353 A*
mg Tablet T1001XX undergoing elective hip or knee has been established.
replacement surgery Duration of treatment:
Major hip surgery 5 weeks.
Major knee surgery 2 weeks
301 / 371

i)Prevention of stroke and systemic
embolism in adult patients with
non-valvular atrial fibrillation with
one or more risk factors, such as
Congestive heart failure (CHF),
hypertension, age ≥ 75 yrs, i)20mg once daily or 15mg
diabetes mellitus, prior stroke or once daily (for patients with
transient ischaemic attack. moderate renal impairment
Rivaroxaban 15 B01AX06000
1354 A* ii)Treatment of deep vein (creatinine clearance 30-49
mg Tablet T1002XX
thrombosis (DVT), and prevention ml/min) Dosage: ii) & (iii)
of recurrent DVT and pulmonary 15mg BD for 21 days,
embolism (PE) following an acute followed by 20mg OD.
DVT in adults. iii) Treatment of
Pulmonary Embolism (PE), and
prevention of recurrent DVT and
pulmonary embolism (PE) following
an acute PE in adults.
i)Prevention of stroke and systemic
embolism in adult patients with
non-valvular atrial fibrillation with
one or more risk factors, such as
Congestive heart failure (CHF),
hypertension, age ≥ 75 yrs, i)20mg once daily or 15mg
diabetes mellitus, prior stroke or once daily (for patients with
transient ischaemic attack. moderate renal impairment
Rivaroxaban 20 B01AX06000
1355 A* ii)Treatment of deep vein (creatinine clearance 30-49
mg Tablet T1003XX
thrombosis (DVT), and prevention ml/min) Dosage (ii) &
of recurrent DVT and pulmonary (iii)15mg BD for 21 days,
embolism (PE) following an acute followed by 20mg OD.
DVT in adults. iii) Treatment of
Pulmonary Embolism (PE), and
prevention of recurrent DVT and
pulmonary embolism (PE) following
an acute PE in adults.
Initial dose 1.5 mg 2 times
daily, may increase by 1.5
For psychiatrists and neurologists mg 2 times daily every 2
Rivastigmine 1.5 N06DA03123 only. Mild to moderately severe weeks to maximum of 6 mg
1356 A*
mg Capsule C1001XX dementia associated with 2 times daily. If treatment is
Alzheimer's or Parkinson's disease interrupted for several days,
should be reinitiated at the
lowest daily dose
302 / 371

daily. May be increased
after a minimum of 2 weeks
of treatment to 3 mg 2
For psychiatrists and neurologists
Rivastigmine 2 times daily. Subsequently to
N06DA03123 only. Mild to moderately severe
1357 mg/ml Oral A* 4.5 mg 2 times daily, up to
L9901XX dementia associated with
Solution maximum of 6 mg 2 times
Alzheimer's or Parkinson's disease
daily. If treatment is
interrupted for several days,
lowest daily dose
Rivastigmine 3 N06DA03123 only. Mild to moderately severe weeks to maximum of 6 mg
1358 A*
lowest daily dose
Rivastigmine 4.5 N06DA03123 only. Mild to moderately severe weeks to maximum of 6 mg
1359 A*
lowest daily dose
Initial, 4.6 mg/24 hr patch
Rivastigmine TOPICALLY once daily; after
Mild to moderately severe
4.6mg/24hr N06DA03123 a minimum of 4 weeks and
1360 A* dementia associated with
Transdermal M7001XX good tolerability, increase
Patch the dose to 9.5 mg/24 hr
patch once daily
Rivastigmine 6 N06DA03123 only. Mild to moderately severe weeks to maximum of 6 mg
1361 A*
lowest daily dose
Initial, 4.6 mg/24 hr patch
Rivastigmine 9.5 TOPICALLY once daily; after
Mild to moderately severe
mg/24hr N06DA03123 a minimum of 4 weeks and
1362 A* dementia associated with
Transdermal M7002XX good tolerability, increase
Patch the dose to 9.5 mg/24 hour
patch once daily
303 / 371

Initial, 4.6mg/24 hours
patch TOPICALLY once daily,
after a minimum of 4 weeks
of treatment and if well
Rivastigmine
Mild to moderately severe tolerated, this increased to
Transdermal N03DA03123
1363 A* dementia associated with 9.5mg/24 hours or
Patch 13.3mg/24 M7003XX
Alzheimer's or Parkinson's disease 13.3mg/24 hours (individual
hours
responses to rivastigmine
may vary and some patients
may derive additional
benefit from higher doses)
Adult: Initially, 600mcg/kg
by inj. Higher doses of 1
mg/kg may be used for
intubation during rapid
sequence induction of
anaesthesia. Maintenance:
150 mcg/kg by inj (may
reduce to 75-100 mcg/kg if
inhalational anaesthesia is
used) or by infusion at a rate
of 300-600 mcg/kg/hr.
Doses should be based on
lean body weight for obese
patients weighing >30%
As an adjunct to general
above the ideal body
anaesthesia to facilitate
weight. Child: Infants and
Rocuronium endotracheal intubation, to provide
M03AC09320 children >1 mth: Initially,
1364 Bromide 10 A* skeletal muscle relaxation during
P3001XX 600 mcg/kg by inj.
mg/ml Injection surgery and to facilitate mechanical
Maintenance: 150 mcg/kg
ventilation in adults, children and
by inj or by infusion at a rate
infants from 3 months of age
of 300-600 mcg/kg/hr,
maintenance doses may be
required more frequently
than in adult patients.
Elderly: Reduced
maintenance doses: 75-100
mcg/kg. Renal impairment:
Initially, 600mcg/kg by inj.
Maintenance: 75-
100mcg/kg. Hepatic
impairment: or biliary tract
disease: Initially, 600mcg/kg
by inj. Maintenance: 75-100
mcg/kg.
304 / 371

ADULT: Initially 2 mg once
daily for the 1st week. May
be increased by 2 mg at ≥1
week intervals. Max: 24
mg/day. Switching from
ropinirole immediate-
realease to prolonged-
release tablet; dose of
Treatment of idiopathic
Ropinirole HCI 2 ropinirole prolonged release
N04BC04110 Parkinson?s disease. It may be used
1365 mg Extended A* tablet should be based on
T5003XX as monotherapy or in combination
Release Tablet the total daily dose of
with levodopa
release tab the patient was
taking. Tablets should be
taken at a similar time each
day with or without food,
must be swallowed whole
and must not be chewed,
crushed or divided.
ADULT: Initially 2 mg once
daily for the 1st week. May
be increased by 2 mg at ≥1
week intervals. Max: 24
mg/day. Switching from
realease to prolonged-
release tablet; dose of
Treatment of idiopathic
Ropinirole HCI 4 ropinirole prolonged release
N04BC04110 Parkinson?s disease. It may be used
1366 mg Extended A* tablet should be based on
T5004XX as monotherapy or in combination
Release Tablet the total daily dose of
with levodopa
release tab the patient was
taking. Tablets should be
taken at a similar time each
day with or without food,
must be swallowed whole
and must not be chewed,
crushed or divided.
0.25 mg 3 times daily
Parkinson disease in younger gradually increasing till
Ropinirole HCl N04BCO4110 patients and patients with adequate response obtained
1367 A*
0.25 mg Tablet T1001XX dyskinesias, especially peak dose up to a maximum of 24
dyskinesias mg/day. Most patients need
3-9 mg/day
Parkinson disease in younger 0.25 mg 3 times daily
Ropinirole HCl 1 N04BCO4110 patients and patients with gradually increasing till
1368 A*
mg Tablet T1002XX dyskinesias, especially peak dose adequate response obtained
dyskinesias up to a maximum of 24
305 / 371

mg/day. Most patients need
3-9 mg/day
Dose adjusted according to

patient physical status and
nature of procedure. i)
Lumbar epidural: 15-25 ml
of 7.5 mg/ml solution;
Caesarean section, 15-20 ml
of 7.5 mg/ml solution in
i) Surgical anaesthaesia including
Ropivacaine HCl N01BB09110 incremental doses ( max .
1369 A* obstetrics ii) Acute pain
2 mg/ml Injection P3001XX total dose 150 mg). ii)
management
lumbar epidural: 10-20 ml of
2mg/ml solution followed by
10-15 ml of 2 mg/ml
solution at interval at of
least 30 minutes. Labour
pain 6-10 ml/hour of
2mg/ml solution
Dose adjusted according to
patient physical status and
nature of procedure. i)
Lumbar epidural: 15-25 ml
of 7.5 mg/ml solution;
Caesarean section, 15-20 ml
of 7.5 mg/ml solution in
Ropivacaine HCl i) Surgical anaesthaesia including
N01BB09110 incremental doses (max .
1370 7.5 mg/ml A* obstetrics ii) Acute pain
P3002XX total dose 150 mg). ii)
Injection management
lumbar epidural: 10-20 ml of
2mg/ml solution followed by
10-15 ml of 2 mg/ml
solution at interval at of
least 30 minutes. Labour
pain 6-10 ml/hour of
2mg/ml solution
306 / 371
Type 2 diabetes with insulin

resistant features. Prescribed to
new patients only if inadequate
glycaemic control with all other
combination of oral antidiabetic
medications (such as
sulphonylureas, metformin,
acarbose or DPPIV inhibitors) and is
the only suitable alternative. Use of
rosiglitazone in combination with
4 mg once daily or in 2
insulin (for new patients) is not
Rosiglitazone 4 A10BG02000 divided doses, may be
1371 A* recommended. Combined use with
mg Tablet T1002XX increased to 8 mg/day in 1-2
insulin should be limited to existing
divided doses after 12 week
cases with stable glycaemic control
and requires close monitoring in
view of increased risk of fluid
retention, weight gain and
hypoglycaemia. In cases of existing
use in patients with optimal
glycaemic control, rosiglitazone
should be continued with close
monitoring of cardiovascular,
osteoporosis and fracture risk.
Initially 5-10 mg once daily
intervals of at least 4 weeks
to 20 mg once daily,
increased after further 4
weeks to 40 mg daily ONLY
in severe
hypercholesterolemia with
Dyslipidaemia not responsive to high cardiovascular risk.
Rosuvastatin 10 C10AA07390
1372 A* atorvastatin 40 mg or equivalent Patient of Asian origin,
mg Tablet T1002XX
doses of other statins patients on concomitant
ciclosporin/fibrate and
patients with risk factors for
myopathy/rhabdomyolysis
(including personal/family
history of muscular
disorders/toxicity), the
maximum dose should be 20
mg daily
307 / 371

Initially 5-10 mg once daily
intervals of at least 4 weeks
to 20 mg once daily,
increased after further 4
weeks to 40 mg daily ONLY
in severe
hypercholesterolemia with
Dyslipidaemia not responsive to high cardiovascular risk.
Rosuvastatin 20 C10AA07390
1373 A* atorvastatin 40 mg or equivalent Patient of Asian origin,
mg Tablet T1003XX
doses of other statins patients on concomitant
ciclosporin/fibrate and
patients with risk factors for
myopathy/rhabdomyolysis
(including personal/family
history of muscular
disorders/toxicity), the
maximum dose should be 20
mg daily
A single daily dose should be
initiated at 4mg/24 h and
Rotigotine 2 mg
then increased in weekly
per 24 hour N04BC09000 For stage IV Parkinson Disease with
1374 A* increments of 2mg/24 h to
Transdermal M7001XX peak dyskinesia
an effective dose up to a
Patch
maximal dose of 16mg/24
hr.
Rotigotine 4 mg
Patch
hr.
Rotigotine 6 mg
Patch
hr.
Rotigotine 8 mg
Patch
hr.
308 / 371

Rubella Virus
J07BJ01000P Immunization against rubella
1378 Vaccine Injection C 0.5 ml SC as a a single dose
3001XX (German measles)
(Single injection)
The recommended starting
dose is 15 mg twice daily for
patients with a platelet
count between
For the treatment of disease- 100,000/mm3 and
related splenomegaly or symptoms 200,000/mm3 and 20 mg
in adult patients with primary twice daily for patients with
myelofibrosis (also known as a platelet count of
chronic idiopathic myelofibrosis), >200,000/mm3. There is
Ruxolitinib 15mg L01XE18162T post-polycythemia vera limited information to
1379 A*
tablet 1002XX myelofibrosis or post-essential recommend a starting dose
thrombocythemia myelofibrosis. for patients with platelet
Place in therapy: To be used as 3rd counts between
line after hydroxyurea and other 50,000/mm3 and
best available treatment such as <100,000/mm3. The
danazol and S.C. Interferon maximum recommended
starting dose in these
patients is 5 mg twice daily
and the patients should be
titrated cautiously.
count between
1380 A*
309 / 371

count between
1381 A*
2 ml may be inhaled up to 4
times daily over a period of
Salbutamol 0.5 % Asthma and other conditions
R03AC02183 3 minutes per inhalation
1382 Inhalation B associated with reversible airways
A3001XX (0.5 ml diluted in 2.5 ml of
Solution obstruction
normal saline by inhalation
over 5 to 15 minutes)
500 mcg by SC/IM injection
4 hourly or 250 mcg by slow
IV. If required, by IV
Asthma and other conditions
Salbutamol 0.5 R03CC02183 infusion, initially 5 mcg/min
1383 A associated with reversible airways
mg/ml Injection P3001XX adjusted according to
obstruction
response and heart rate,
usually in the range 3 - 20
mcg/min
ADULT : 100 - 200 mcg up to
Salbutamol 100 Asthma and other conditions
R03AC02183 3 - 4 times daily. CHILD : 100
1384 mcg/dose B associated with reversible airways
A1001XX mcg increased to 200 mcg if
Inhalation obstruction
necessary
CHILD 2 - 6 years : 1 - 2 mg 3
Asthma and other conditions - 4 times daily, 6 - 12 years :
Salbutamol 2 mg R03CC02183
1385 B associated with reversible airways 2 mg 3 - 4 times daily. CHILD
Tablet T1001XX
obstruction over 12 years and ADULT : 2
- 4 mg 3 - 4 times daily
Asthma and other conditions CHILD 2 - 6 years : 1 - 2 mg 3
Salbutamol 2 R03CC02183
1386 B associated with reversible airways - 4 times daily, 6 - 12 years :
obstruction 2 mg 3 -4 times daily
310 / 371

CHILD : 100 - 200 mcg.
Maintenance : 100 - 200
Salbutamol Asthma and other conditions
R03AC02183 mcg 2 - 4 times daily. ADULT
1387 200mcg/dose B associated with reversible airways
A2001XX : 100 - 400 mcg. Maitenance
Inhaler obstruction
: 100 - 400 mcg 2 - 4 times
daily
Infusions containing 5 mg in
500ml (10 mcg/ml) at the
rate of 10 - 45 mcg/min
minutes until evidence of
patient response as shown
Salbutamol 5 R03CC02183 Prevention of uncomplicated
1388 A* by reduction of strength,
mg/5 ml Injection P3002XX premature labour only
frequency or duration of
contractions; maintain rate
for 1 hour after contractions
have stopped, then
gradually reduce by 50%
every 6 hours
i) ADULT, acute attack 1-2 g
4 times daily until remission
occurs (if necessary
corticosteroids may also be
given), reducing to a
mg 4 times daily, CHILD over
2 years, acute attack 40-60
Salicylazosulphap i) Treatment of inflammatory mg/kg daily, maintenance
yridine A07EC01000 bowel disease of ulcerative colitis dose 20-30 mg/kg daily ii)
1389 A/KK
(Sulfasalazine) T1001XX and Crohn's disease ii) Rheumatoid ADULT, initially; 0.5-1 g/day,
500 mg Tablet arthritis increase weekly to
g/day in 2 divided doses,
maximun 3 g/day. CHILD
over 6 years, juvenile
rheumatoid arthritis: 30-50
doses up to a maximum of 2
g/day
Salicylic Acid 1 -
2% in D07XA01952 Apply sparingly to affected
1390 B Seborrhoeic capitis
Hydrocortisone G5001XX areas 1-2 times daily
1% Ointment
Seborrhoeic dermatitis, scalp
Salicylic Acid 2 - D01AE12000 Apply sparingly to the
1391 C psoriasis and hyperkeratotic skin
10% Cream G1001XX affected area 2-3 times daily
conditions
Salicylic Acid 2 - D01AE12000 Seborrhoeic dermatitis, scalp, Apply sparingly to the
1392 C
10% Ointment G5001XX psoriasis and hyperkeratotic skin affected area 2-3 times daily
311 / 371

disorders
Apply sparingly to the

Seborrhoeic dermatitis, scalp,
Salicylic Acid 2 % D01AE12000 affected area 2-3 times
1393 B psoriasis and hyperkeratotic skin
Lotion L6001XX daily. Wash with cleanser 2 -
conditions
3 times per day
Apply daily and protect
surrounding skin (eg with
Salicylic Acid 20% D01AE12000
1394 C Plantar warts soft paraffin or specially
Ointment G5002XX
designed plaster) ,may need
to continue up to 3 months
Salicylic Acid, Apply the paste liberally and
D01AE12952
1395 Starch, Zinc C Use as a protective or base carefully to the lesions twice
G6001XX
Oxide Paste daily
Salmeterol 25
mcg and Regular treatment of reversible
R03AK06989 12 years : 1 - 2 puff twice
1396 Fluticasone A* obstructive airway diseases
A2102XX daily. CHILD over 4 years : 1
Propionate 125 including asthma.
puff twice daily
mcg Inhalation
Regular treatment of reversible ADULT and CHILD more than
Salmeterol
obstructive airway diseases 12 years : 2 puff twice daily.
25mcg and
R03AK06989 including asthma in children, where CHILD over 4 years : 2 puff
1397 Fluticasone A*
A2104XX use of lower dose of a combination twice daily No data on use
Propionate
(bronchodilator and inhaled for children aged under 4
50mcg Inhalation
corticosteroids) is appropriate. years.
i) Regular treatment of reversible
Salmeterol 50 obstructive airways diseases i) ADULT and CHILD more
mcg and including asthma ii) For the regular than 12 years : 1 puff twice
R03AK06989
1398 Fluticasone A/KK treatment of chronic obstructive daily. ii) For COPD: Dose is
A2101XX
Propionate 250 pulmonary disease (COPD) one inhalation 50/250mcg
mcg Inhalation including chronic bronchitis and to 50/500mcg twice daily.
emphysema
i) Regular treatment of reversible
Salmeterol 50
obstructive airways diseases i) ADULT and CHILD more
mcg and
R03AK06989 including asthma ii) Chronic than 12 years : 1 puff twice
1399 Fluticasone A*
A2106XX obstructive pulmonary disease daily ii) ADULT 1 puff twice
Propionate 500
including chronic bronchitis and daily
mcg Inhalation
emphysema
312 / 371
i) As add on therapy in type 2

diabetes patients inadequately
controlled on metformin
monotherapy and high risk of
hypoglycaemia, especially elderly
Recommended starting dose
patients with co-morbidities. ii) As
and maintenance dose in
add on therapy in type 2 diabetes
patients with normal renal
patients inadequately controlled
function and mild renal
with a sulphonylure and
insufficiency (CrCl more
Saxagliptin 2.5 A10BH03000 intolerant/contraindicated for
1400 A/KK than 50 ml/min) is 5 mg
mg Tablet T1001XX metformin therapy iii) As add on
once daily. For patients with
therapy in type 2 diabetes patients
moderate to severe renal
inadequately controlled on
insufficiency (CrCl less than
metformin and sulphonylurea
or equal to 50 ml/min) dose
combination therapy iv) In patients
is 2.5 mg once daily
with renal failure where metformin
contraindicated Not to be used in
patients with HbA1c > 8% on
single/combination OAD, as insulin
initiation is preferred.

dose of in patients who
need 5mg of saxagliptin and
who are not currently
treated with metformin is
5mg saxagliptin/500 mg
metformin extended-release
once daily with gradual dose
escalation to reduce the
gastrointestinal side effects
due to metformin. In
Indicated as an adjunct to diet and
Saxagliptin 2.5mg patients treated with
exercise to improve glycemic
and Metformin metformin, the dose of
A10BD10926 control in adults with type 2
1401 HCl 1000mg A should provide metformin at
T1001XX diabetes mellitus when treatment
Extended- the dose already being
with both saxagliptin and
Release Tablet taken, or the nearest
metformin is appropriate.
therapeutically appropriate
dose. Patients who need
2.5mg saxagliptin in
combination with
may be treated with
2.5mg/1000mg. Patients
who need 2.5mg saxagliptin
who are either metformin
naive or who require a dose
of metformin higher than
313 / 371

1000mg should use the
individual components. Max
daily recommended dose is
5mg/2000mg.
i) As add on therapy in type 2

controlled on metformin
monotherapy and high risk of
hypoglycaemia, especially elderly
patients with co-morbidities. ii) As
add on therapy in type 2 diabetes
patients inadequately controlled
2.5-5mg once daily. Patients
with a sulphonylure and
with CrCl < 50ml/min, and
Saxagliptin 5 mg A10BH03000 intolerant/contraindicated for
1402 A/KK when coadministered with
Tablet T1002XX metformin therapy iii) As add on
strong CYP450 3A4/5
inhibitors: 2.5mg OD
inadequately controlled on
metformin and sulphonylurea
combination therapy iv) In patients
with renal failure where metformin
contraindicated Not to be used in
patients with HbA1c > 8% on
single/combination OAD, as insulin
initiation is preferred.
314 / 371

patients treated with
metformin, the dose of
Saxagliptin 5mg should provide metformin at
and Metformin the dose already being
1403 HCl 1000mg A taken, or the nearest
Extended- therapeutically appropriate
Release Tablet dose. Patients who need
combination with
may be treated with
5mg/2000mg.
315 / 371

patients treated with
metformin, the dose of
Saxagliptin 5mg should provide metformin at
and Metformin the dose already being
1404 HCl 500 mg A taken, or the nearest
Extended- therapeutically appropriate
Release Tablet dose. Patients who need
combination with
may be treated with
5mg/2000mg.
For treatment of shock due to
burns, crushing injuries, abdominal
emergencies and where there is a
predominant loss of plasma fluids ADULT 12.5-25 g (250-500
Selected Plasma
B05AA02000 and red blood cells, emergency ml) by IV. CHILD usual dose
1405 Protein 5 g/100 B
P3001XX treatment of shock due to 33 ml/kg body weight at
ml Injection
haemorrhage and in infants and rate of 5-10 ml/min
small children in the initial therapy
of shock due to dehydration and
infection
Only for treatment of late stage 5 mg twice daily at breakfast
Selegiline HCl 5 N04BD01110
1406 A* Parkinsonism with on and off and lunch. Maximum 10
mg Tablet T1001XX
phenomenon mg/day
316 / 371

Dandruff: apply 5-10 mL
topically twice weekly for 2
weeks, then 1-4 times per
month, as needed, leave on
for 2-3 min, then rinse
Selenium
D11AC03180 Dandruff, seborrheic dermatitis of thoroughly. Seborrheic
1407 Sulphide 2.5% A/KK
L5201XX scalp dermatitis of scalp: apply 5-
Shampoo
10 mL topically twice weekly
for 2 weeks, then 1-4 times
per month, as needed, leave
on for 2-3 min, then rinse
thoroughly
Depression, obsessive-
compulsive disorder: 50
mg/day, may increase in
steps of 50mg at weekly
interval, max:200mg/day.
Major depression, obsessive-
Sertraline HCI 50 N06AB06110 Panic disorder: Initially 25
1408 B compulsive disorder (OCD), panic
mg Tablet T1001XX mg/day. After 1 week,
disorder
increase dose to 50 mg/day.
All dose changes should be
made at intervals of more
than 1 week, max: 200
mg/day
Control of hyperphosphatemia in
adult patients receiving
haemodialysis and peritoneal Starting dose is one or two
dialysis. Restriction: Sevelamer 800mg tablets three times
carbonate 800mg tablet should be per day with meals. Adjust
Sevelamer V03AE02121 used in context of multiple by one tablet per meal in
1409 A*
800mg Tablet T1001XX therapeutic approach which two weeks interval as
include calcium supplement, 1, 25- needed to obtain serum
hydroxy Vitamin D3 or one of its phosphorus target (1.13 to
analogues to control the 1.78mmol/L).
development of renal bone
disease.
i) Adult: Given via a
calibrated vaporiser: Up to
5% v/v with oxygen or a
mixture of oxygen and
nitrous oxide. Child: Given
Sevoflurane N01AB08000 To be used only for i) induction and
1410 A* via a calibrated vaporiser:
Liquid L5001XX ii) maintenance of anaesthesia
Up to 7% v/v. ii) Adult: 0.5-
3% v/v with or without
nitrous oxide. Child: 0.5-3%
v/v with or without nitrous
oxide.
317 / 371

ADULTS ≥ 18 years: The
recommended dose is 20mg
three times a day. Tablets
should be taken
approximately 6 to 8 hours
apart with or without food.
ELDERLY (≥65 years): Dosage
adjustments are not
required in elderly patients.
Clinical efficacy as measured
by 6-minute walk distance
could be less in elderly
patients. IMPAIRED RENAL
FUNCTION: Initial dose
Treatment of adult patients with adjustments are not
pulmonary arterial hypertension required in patients with
classified as WHO functional class II renal impairment, including
Sildenafil Citrate and III, to improve exercise severe renal impairment
G04BE03136
1411 20 mg Film- A* capacity. Efficacy has been shown (creatinine clearance
T1004XX
coated Tablet in primary pulmonary hypertension <30ml/min). A downward
and pulmonary hypertension dose adjustment to 20 mg
associated with connective tissue twice daily should be
disease. considered after a careful
benefit-risk assessment only
if therapy is not well-
tolerated. IMPAIRED
HEPATIC FUNCTION: Initial
dose adjustments are not
required in patients with
hepatic impairment (Child-
Pugh class A and B). A
downward dose adjustment
to 20mg twice daily should
be considered after a careful
benefit-risk assessment only
if therapy is not well-
tolerated.
Silver Nitrate D08AL01221 Apply undiluted to affected
1412 B Use as antiseptic
0.5% Lotion L6001XX area for a limited period
infections in severe burns, leg Burns: Apply 3 mm thick
Silver
D06BA01199 ulcers where infections may layer twice daily with sterile
1413 Sulfadiazine 1% B
G1001XX prevent healing and for the applicator. Leg ulcer: apply
Cream
prophylaxis of infections in skin at least 3 times a week
grafting
318 / 371

Simvastatin 10 C10AA01000 coronary heart disease intolerant 10 - 20 mg once daily.
1414 B
therapy
1415 B
therapy
1416 B
therapy
metformin/sulphonylurea is ADULT over 18 years, 100
contraindicated/untolerated and mg once daily: 100mg once
Sitagliptin 100 A10BH01000 elderly with multiple co morbidities daily CrCl ≥ 30 to <
1417 A*
mg Tablet T1003XX that always experience 50ml/min: 50mg once daily
hypoglycemia with other CrCl < 30 ml/min: 25mg
antidiabetic. Not to be used in once daily
diabetic patient whose HbA1c is
more than 9%
Sitagliptin 25 mg A10BH01000 elderly with multiple co morbidities daily CrCl ≥ 30 to <
1418 A*
Tablet T1001XX that always experience 50ml/min: 50mg once daily
more than 9%
i)Type 2 diabetes patients,
especially the elderly, with multiple
co-morbidities that always
experience hypoglycaemia with
other antidiabetics who are
inadequately controlled on 50 mg/500 mg twice daily.
Sitagliptin 50 mg
metformin or sitagliptin alone or The recommended
and Metformin A10BD07926
1419 A* already being treated with the maximum daily dose is 100
HCl 1000 mg T1003XX
combination of sitagliptin and mg sitagliptin plus 2000 mg
Tablet
metformin ii)Newly diagnosed type metformin
2 diabetes patients with high
baseline HbA1c and multiple co-
morbidities who may experience
hypoglycaemia with other
antidiabetics
319 / 371

Sitagliptin 50 mg
HCl 500 mg T1001XX
Tablet
antidiabetics
Sitagliptin 50 mg
HCl 850 mg T1002XX
Tablet
antidiabetics
Sitagliptin 50 mg A10BH01000 elderly with multiple co morbidities daily CrCl ≥ 30 to <
1422 A*
Tablet T1002XX that always experience 50ml/min: 50mg once daily
more than 9%
Treatment of symptoms of gastro-
Sodium Alginate oesophageal reflux eg. acid
1000 mg/10 ml & regurgitation, heartburn,
Potassium A02BX13915 indigestion due to the reflux of Adult, elderly & children ≥12
1423 A*
Bicarbonate 200 L8001XX stomach contents not responding year: 5-10 mL.
mg/10 ml to conventional antacids or as an
Suspension addition to PPI when PPI alone fails
to control the symptoms
320 / 371

Sodium and Depend on the type of
Meglumine V08AA01993 procedure and the degree
1424 B For IV pyelography
Diatrizoate 58- P3002XX and extent of contrast
60% Injection required
i) 3 g in every 2 hours until
Sodium i) Relief of discomfort in mild
A02AH00131 urinary pH exceeds 7 ii)
1425 Bicarbonate 1 B urinary tract ii) Alkalinisation of
L2102XX Maintenance of alkaline
g/15 ml Mixture urine
urine 5-10 g daily
For acceleration of excretion in
Sodium IV infusion of 2 - 5 mmol/kg
drug intoxication (where excretion
Bicarbonate 4.2% B05XA02131 body weight over a period
1426 B of the drug into the urine is
(0.5 mmol/ml) P3001XX of 4 - 8 hours or according
accelerated by elevated urine pH)
Injection to the needs of the patients
and for acidosis
Sodium
S02DC00131
1427 Bicarbonate 5% C To soften the impacted ear wax 2-3 drops 3-4 times daily
D1001XX
w/v Ear Drops
For acceleration of excretion in
Sodium According to the needs of
drug intoxication (where excretion
Bicarbonate 8.4% B05XA02131 the patient. In severe shock
1428 B of the drug into the urine is
(1 mmol/ml) P3002XX due to cardiac arrest: 50 ml
accelerated by elevated urine pH)
Injection by IV
and for acidosis
Sodium
CHILD up to 1 year 5 ml; up
Bicarbonate A02AH00131 Heartburn for rapid relief of
1429 C to 1-5 years 10 ml in 4 to 6
Mixture L2101XX dyspepsia
divided doses
(Paediatric)
For relieving of discomfort in mild
Sodium urinary tract infection,
Bicarbonate, symptomatic relief of dysuria to 4 - 8 g (1- 2 sachets)
Citric Acid, B05CB10955 enchance the action to certain dissolved in a glass of cold
1430 B
Sodium Citrate M4001XX antibiotics especially some water 4 times daily as
and Tartaric Acid sulphonamides. In gout as urinary prescribed
- 4 g per sachet alkalinizers to prevent cystallisation
of urates
Sodium
Bicarbonate,
Magnesium
Carbonate, A02AH00912 Heartburn, for rapid relief of ADULT 10-20 ml 3 times
1431 C
Tincture L2101XX dyspepsia daily
Cardamom
Compound
Mixture
Bowel cleansing before colonic
Sodium
surgery, colonoscopy or ADULT 133 ml (1 bottle)
Biphosphate
A06AG01162 radiological examination to ensure administered rectally. CHILD
1432 16%, Sodium A
G2001XX the bowel is free of solid contents. more than 2 years half the
Phosphate 6%
It is not to be used for treatment of adult dose (66.6ml)
Rectal Solution
constipation
321 / 371

45 ml diluted with half a
glass (120 mL) of water,
followed by one full glass
(240 mL) of water. Timing of
doses is dependent on the
time of the procedure. For
morning procedure, first
dose should be taken at 7
Bowel cleansing before colonic a.m. and second at 7 p.m.
Sodium
surgery, colonoscopy or on day before the
Biphosphate
A06AG01162 radiological examination to ensure procedure. For afternoon
1433 16%, Sodium A
L9901XX the bowel is free of solid contents. procedure, first dose should
Phosphate 6%
It is not to be used for treatment of be taken at 7 p.m. on day
Solution
constipation before and second dose at 7
a.m. on day of the
procedure. Solid food
should not be taken during
the bowel preparation
period. However clear fluids
or water can be taken
liberally. CHILD under 12
years not recommended
Sodium Chloride For replenishing fluid and energy
0.18% with B05XA03904 and for restoring or maintaining According to the needs of
1434 B
Dextrose 10% P6001XX the concentration of sodium and the patient
Injection chloride ions
1435 B
Dextrose 4.23% P6004XX the concentration of sodium and the patient
For replenishing fluid and for
100 - 1000 ml by IV or
Sodium Chloride B05XA03100 restoring / maintaining the
1436 B according to the needs of
0.45% Injection P6001XX concentration of sodium and
the patient
chloride ions
1437 B
1438 B
Sodium Chloride S01XA03000
1439 C Irrigation of conjunctival sac 1 - 2 drops every 3 - 4 hours
322 / 371
For replenishing fluid and for

100 - 1000 ml by IV or
Sodium Chloride B05XA03100 restoring/maintaining the
1440 C+ according to the needs of
0.9% Injection P6002XX concentration of sodium and
the patient
chloride ions
1441 C+
Addition of sodium electrolyte in
Sodium Chloride B05XA03100 parenteral nutrition bags especially According to the needs of
1442 B
20% Injection P9902XX in paediatrics or neonates with the patient
restricted fluid allowance
Sodium Chloride B05XA03100 According to the needs of
1443 B Acute dilutional hyponatraemia
3% Injection P9901XX the patient
Sodium
Labelling of erythrocytes for the Usual dose range : 10 - 200
Chromate V09GX00143
1444 A* investigation of haemotological microcuries IV by IV
(Chromium-51) L9901XX
disorders injection
Solution
Dose depending on clinical
cases. Usually, 30 ml given
Prophylaxis for aspiration
Sodium Citrate B05CB02136 10- 60 minutes before
1445 B pneumonitis (use as an oral
0.3 M Solution L9901XX anaesthesia prior to elective
solution)
cesarean surgery is an
effective antacid
Sodium Citrate B05CB02136 Sterile solution for irrigation or Dose depending on clinical
1446 B
3.8% Solution H3001XX washout of infected bladder cases
Citrates and citric acid solutions are
used to correct the acidosis of
certain renal tubular disorders to ADULT 10 - 20 ml. CHILD up
Sodium Citrate,
treat metabolic acidosis for long- to 1 year 2.5 ml tds; 1-5 year
Citric Acid B05CB02136
1447 B term urine alkalinization for 5 ml tds; 6-12 years 10 ml
Mixture 3 g/10 L2101XX
prevention and treatment of uric tds. To be taken well diluted
ml
acid and calcium kidney stones and with water
as nonparticulate neutralizing
buffers
Sodium allergic conjunctivitis including
S01GX01520
1448 Cromoglycate 2% A/KK seasonal and perennial allergic 1 or 2 drops 4 times daily
D2001XX
Eye Drops conjunctivitis and vernal
keratoconjunctivitis
Sodium
V07AV00000
1449 Dichloroisocyanu C Low and medium level disinfectant 50 - 10,000 ppm av chlorine
T1001XX
rate 2.5 g Tablet
Sodium
V07AV00000
1450 Dichloroisocyanu C Low and medium level disinfectant 50 - 10,000 ppm av chlorine
T1002XX
rate 5 g Tablet
323 / 371
Skin infections caused by

staphylococci, streptococci,
Sodium Fusidate D06AX01520 Apply to affected area 2 - 3
1451 A corynebacterium minutissumun
2% Ointment G5001XX times daily
and other sodium fusidate-
sensitive organisms
Adults: The recommended
dosage is individual. The
recommended daily dosage
of phosphate during
intravenous nutrition would
normally be 10-20mmol.
This can be met by using 10-
Sodium
20ml of sodium
glycerophosphat Indicated in adult patients and
glycerophosphate to the
e for addition B05XA14171 infants as a supplement in
1452 A infusion solution or to the
into infusion P3001XX intravenous nutrition to meet the
admixture for which
solution, 20ml requirement of phosphate.
compatibility has been
vial
proved. Infants: The
recommended dosage is
individual. The
recommended dose for
infants and neonates is 1.0-
1.5 mmol/kg
bodyweight/day.
Sodium
V07AV00000 Low-level disinfectant and Antiseptic: less than 0.5%.
1453 Hypochlorite C
L9903XX antiseptic Disinfectant: 5%
Solution
Sodium Iodide
V09FX03200 Used in the determination of
1454 (Iodide-131) A* 5 - 50 millicuries
P3001XX various thyroid functions
Injection
Sodium Iodide
V09FX03200 Determination of various thyroid 5 - 10 milicuries (5 mCi for
1455 (Iodine-131) A*
C1001XX functions whole body scan)
Capsule
Sodium Iodide
(Iodine-131) V10XA01200 i) Thyrotoxicosis ii) Thyroid i) 2 - 30 millicuries ii) 80 -
1456 A*
Capsule C1001XX carcinoma 300 millicuries
(Therapeutic)
Sodium Iodide
V10XA01200 i) Thyrotoxicosis ii) Thyroid i) 5-25 millicuries ii) 30-150
1457 (Iodine-131) A*
L9901XX carcinoma millicuries
Solution
324 / 371

Adult: 300 mg sodium nitrite
IV over 3 minutes followed
after 5 minutes with 12.5g
sodium thiosulphate IV
administered over 10
minutes. CHILD: 4 - 10
mg/kg of sodium nitrite
(max: 300 mg) followed by
400 mg/kg of sodium
Sodium Nitrite 30 V03AB08220
1458 B For cyanide poisoning thiosulfate, as a 25 or 50%
solution (max: 12.5 g).
Methaemoglobin
concentration should not
exceed 30-40%. If symptoms
of cyanide toxicity recur, the
doses of nitrite and
thiosulfate may be repeated
after 30 min at half the
initial doses.
i) By IV infusion, initially 0.5-
1.5 mcg/kg/min, then
adjusted before
increasement of 0.5
mcg/kg/min every 5 mins
within range 0.5-8
i) Hypertensive crisis ii) Controlled
Sodium mcg/kg/min (lower doses in
C02DD01520 hypotension during anaesthesia in
1459 Nitroprusside 10 A patients already receiving
P3001XX order to reduce bleeding in surgical
mg/ml Injection other antihypertensives);
procedures
stop if marked response not
obtained with max dose in
10 minutes. Use only in
infusion with 5 % Dextrose
IV. ii) By IV infusion, max:
1.5 mcg/kg/min
Initially 5 millicuries, follow
Sodium Polycythemia vera, chronic myeloid
if necessary by a dose of not
Phosphate V10XX01162 and chronic lymphocytic leukaemia
1460 A* more than 3 or 4 millicurie
(Phosphorus-32) P3001XX and palliative treatment of bone
at intervals of not less than
Injection metastases
2 months
ADULT: Oral: 15 g 1 -
4times/day. Rectal: 30 g in
Treatment and prevention of 100 ml 2% methylcellulose
Sodium
hyperkalaemia associated with and 100 ml water as a daily
Polystyrene V03AE01520
1461 A anuria or severe oliguria, in dialysis retention enema. Retain for
Sulphonate F2101XX
patients or those on prolonged 9 hours followed by non-
Powder
peritoneal dialysis sodium cleansing enema.
CHILD: 1 g/kg in 1 - 4 doses
in acute hyperkalemia.
325 / 371

Maintenance : 0.5 g/kg/daily
0.5-2 mL into the

submucosal layer at the
Sodium base of the oesophageal
Sclerotherapy of oesophageal
Tetradecyl C05BB04183 varix or the haemorrhoid;
1462 A* varices, haemorrhoids and varicose
Sulphate 1 % P3001XX several injections may be
veins
Injection given at different sites, max.
total injected 10-15 mL of
1% per treatment
0.5-2 mL into the
submucosal layer at the
Sodium base of the oesophageal
Sclerotherapy of oesophageal
Tetradecyl C05BB04183 varix or the haemorrhoid,
1463 A* varices, haemorrhoids and varicose
Sulphate 3 % P3002XX several injections may be
veins
Injection given at different sites, max.
total injected 10-15 mL of
1% per treatment
Apply to all affected parts of
Sodium the body and face with a
D01AE00181 Fungicides. For the treatment of
1464 Thiosulphate 10- C brush after a bath once daily
L9901XX pityriasis versicolor
20% Solution or twice daily or 3 times
daily
Adult: To be given after 300
mg of sodium nitrite has
been admin over 5-20 min:
12.5 g of sodium thiosulfate
(50 ml of a 25% solution or
25 ml of a 50% solution)
given over 10 min.
Methaemoglobin
Sodium doses of nitrite and
V03AB06181
1465 Thiosulphate 500 B For cyanide poisoning thiosulfate may be repeated
P3001XX
mg/ml Injection after 30 min at half the
initial doses. Child: To be
given after 4-10 mg/kg of
sodium nitrite (max: 300
mg) has been admin: 400
mg/kg of sodium
thiosulfate, as a 25 or 50%
solution (max: 12.5 g).
Methaemoglobin
326 / 371

doses of nitrite and
thiosulfate may be repeated
after 30 min at half the
initial doses.
ADULT: Initially 600 mg/day
in 2 - 3 divided doses; dose
may be increased by 200 mg
at 3-day intervals to max 2.5
g/day. Usual maintenance
dose: 1-2 g/day (20-30
mg/kg/day). CHILD: More
than 20 kg. Initially 400
Sodium mg/day with spaced
N03AG01520
1466 Valproate 200 B Epilepsy increases until control is
T1001XX
mg Tablet achieved (usually 20-30
mg/kg/day), dose may be
increased to 35 mg/kg/day.
Less than 20 kg 20
mg/kg/day, in severe cases
the dose may be increased
provided plasma
concentration can be
monitored
ADULT: Initially 600 mg/day;
dose may be increased by
200 mg at 3-day intervals to
max 2500 mg/day. Usual
maintenance dose: 1000-
2000 mg/day (20-30
mg/kg/day). CHILD: More
Sodium
N03AG01520 than 20 kg. Initially 400
1467 Valproate 200 B Epilepsy
L9001XX mg/day with spaced
mg/5 ml Syrup
increases until control is
achieved (usually 20-30
mg/kg/day), dose may be
increased to 35 mg/kg/day.
Less than 20 kg, 20
mg/kg/day. Severe cases: 50
mg/kg daily
ADULT and CHILD above 10
years: 10 to 15 mg/kg/day
IV, may increase 5 to 10
Sodium
N03AG01520 mg/kg/week to achieve
1468 Valproate 400 B Status epilepticus
P4001XX optimal clinical response
mg Injection
(Maximum 60 mg/kg/day or
less with a therapeutic
range of 50 to 100 mcg/mL)
327 / 371
Symptomatic treatment of urge

Solifenacin incontinence and/or increased 5mg od. Dose can be
G04BD08000
1469 Succinate 5 mg A* urinary frequency and urgency as increased to 10mg if
T1001XX
Tablet may occur in patients with necessary.
overactive bladder syndrome.
i) Growth failure due to inadequate
i) 0.7-1 mg/m2/day or
endogenous growth hormone. ii)
0.025-0.035 mg/kg/day
Somatropin 10 Growth failure in girls due to
H01AC01000 SC/IM. ii) 1.4 mg/m2/day or
1470 mg (30IU) A* gonadal dysgenesis (Turner
P5002XX 0.045-0.05 mg/kg/day SC. iii)
Injection syndrome). iii) Growth failure in
0.035 mg/kg/day or 1
short children born small
mg/m2/day SC
gestational age (SGA)
i) Growth failure due to inadequate
i) 0.7-1 mg/m2/day or
endogenous growth hormone ii)
0.025-0.035 mg/kg/day
Somatropin 12 Growth failure in girls due to
H01AC01000 SC/IM ii) 1.4 mg/m2/day or
1471 mg (36IU) A* gonadal dysgenesis (Turner
P3002XX 0.045-0.05 mg/kg/day SC iii)
Injection syndrome) iii) Growth failure in
0.035 mg/kg/day or 1
short children born small
mg/m2/day SC
gestational age (SGA)
i) Growth failure due to growth i) 0.7-1 mg/m2/day or
hormone insufficiency ii)Growth 0.025-0.035 mg/kg/day
Somatropin 5mg H01AC01000 failure in girls due to gonadal SC/IM ii) 1.4 mg/m2/day or
1472 A*
(15IU) Injection P3004XX dysgenesis (Turner syndrome) 0.045-0.05 mg/kg/day SC iii)
iii)Growth failure in short children 0.035 mg/kg/day or 1
born small gestational age(SGA) mg/m2/day SC
i) Growth failure due to growth i) 0.7-1 mg/m2/day or

hormone insufficiency ii)Growth 0.025-0.035 mg/kg/day
Somatropin 8 mg H01AC01000 failure in girls due to gonadal SC/IM ii) 1.4 mg/m2/day or
1473 A*
(24IU) Injection P3003XX dysgenesis (Turner syndrome) 0.045-0.05 mg/kg/day SC iii)
iii)Growth failure in short children 0.035 mg/kg/day or 1
born small gestational age(SGA) mg/m2/day SC
Supraventricular and
ventricular arrhythmias
Adult: Initially, 80 mg/day as
single or in 2 divided doses,
increased gradually every 2-
3 days. Usual dose: 160-320
mg/day in 2 divided doses.
Sotalol HCl 160 C07AA07110
1474 A* Ventricular tachyarrythmias Life-threatening ventricular
mg Tablet T1002XX
arrhythmias Adult: Initially,
80 mg bid, increased
gradually every 3 days to
240-320 mg/day in divided
doses if needed.
Maintenance: 160-320
mg/day in divided doses.
328 / 371

Max: 480-640 mg in divided
doses.
Supraventricular and
ventricular arrhythmias
Adult: Initially, 80 mg/day as
single or in 2 divided doses,
increased gradually every 2-
3 days. Usual dose: 160-320
mg/day in 2 divided doses.
Life-threatening ventricular
Sotalol HCl 80 mg C07AA07110
1475 A* Ventricular tachyarrythmias arrhythmias Adult: Initially,
Tablet T1001XX
80 mg bid, increased
gradually every 3 days to
240-320 mg/day in divided
doses if needed.
Maintenance: 160-320
mg/day in divided doses.
Max: 480-640 mg in divided
doses.
ADULT: 100 - 200 mg daily in
divided doses. Increase to
Spironolactone C03DA01000 Oedema and ascites in cirrhosis of
1476 B 400 mg if required. CHILD:
25 mg Tablet T1001XX the liver, congestive heart failure
initially 3 mg/kg daily in
divided doses
Infant: 0 - 13 days old: 0.5
mg/kg/dose twice daily.
Infant 14 days and older and
Stavudine 1 J05AF04000L HIV infection, in combination with
1477 A* weighing less than 30 kg: 1
mg/ml Solution 5001XX other antiretrovirals
mg/kg twice daily; more
than 30 kg and <60kg: 30 mg
twice daily
ADULT more than 60 kg: 40
mg twice daily; less than 60
Stavudine 30 mg J05AF04000C HIV infection, in combination with
1478 A/KK kg: 30 mg twice daily. CHILD
Capsule 1001XX other antiretrovirals
<30kg: 1mg/kg twice daly;
>30kg refer to adult dosage
Fixed dose triple therapy for
treatment of HIV infection in adults
Stavudine 30 mg,
once patients have been stabilized SLN 30: 30-60 kg 1 tablet
Lamivudine 150 J05AR07964T
1479 A/KK on the maintenance regimen of twice daily. SLN 40 ≥60 kg 1
mg & Nevirapine 1001XX
nevirapine 200 mg twice daily and tablet twice daily
200 mg Tablet
have demonstrated adequate
tolerability to nevirapine
329 / 371

ADULT more than 60 kg: 40
mg twice daily; less than 60
Stavudine 40 mg J05AF04000C HIV infection, in combination with
1480 A* kg: 30 mg twice daily. CHILD
Capsule 1002XX other antiretrovirals
<30kg: 1mg/kg twice daly;
>30kg refer to adult dosage
Fixed dose triple therapy for
treatment of HIV infection in adults
Stavudine 40 mg,
once patients have been stabilized SLN 30: 30-60 kg 1 tablet
Lamivudine 150 J05AR07964T
1481 A* on the maintenance regimen of twice daily. SLN 40 ≥60 kg 1
mg & Nevirapine 1002XX
nevirapine 200 mg twice daily and tablet twice daily
200 mg Tablet
have demonstrated adequate
tolerability to nevirapine
Myocardial infarction:
1,500,000 units over 30 - 60
minutes. Pulmonary
Streptokinase embolism: 250,000 units by
B01AD01000 Acute myocardial infarction, acute
1482 1,500,000 IU A* IV infusion over 30 minutes,
P4001XX pulmonary embolism
Injection then 100,000 units every
hour for up to 12-72 hours
with monitoring of clotting
factors
ADULT: 15 mg/kg daily; max:
1 g daily. Reduce max daily
dose to 500-750 mg in
patients >40 yr. As part of
an intermittent therapy: 25-
30 mg/kg/day 2-3 times/wk;
Streptomycin
J01GA01183 max: 1.5 g/dose. Not >120 g
1483 Sulphate 1 g B Tuberculosis
P4001XX over the course of
Injection
treatment should be given
unless there are no other
treatment options. Child:
20-40 mg/kg (max: 1 g) daily
or 25-30 mg/kg (max: 1.5 g)
2-3 times wkly.
Treatment of postmenopausal
Strontium osteoporosis to reduce risk of
M05BX03000
1484 Ranelate 2 g A* vertebral and hip fractures when 2 g sachet once daily
F1001XX
Granules biphosphonates are
contraindicated or not tolerated
Succindialdehyde
High level disinfection for Immersion time is based on
11% & V07AV00000
1485 A endoscopes, ultrasonicprobes, manufacturers
Dimethoxytetrah L9907XX
anaesthesia equipment etc recommendation
ydrofuran 3%
330 / 371

i) 2 g twice daily or 1 g 4
times daily for 4-6 weeks or
i) Benign gastric and duodenal in resistant cases up to 12
Sucralfate 1 g A02BX02000
1486 A ulceration ii) Stress ulcer weeks (maximum 8 g daily)
Tablet T1001XX
prophylaxis ii) 1 g 6 times daily
(maximum 8 g daily). CHILD
not recommended
2 mg/kg sugammadex is
recommended, if
spontaneous recovery has
occurred up to at least the
Indicated for reversal of reappearance of second
neuromuscular blockade induced twitch tension of the train-
by rocuronium and vecuronium in of-four (T2). 4 mg/kg
Sugammadex
V03AB35000 selective patient group: obese, sugammadex is
1487 100 mg/ml A*
P3001XX elderly, underlying cardiovascular recommended if recovery
Injection
disease. For pediatric population, has reached at least 1- 2
sugammadex is recommended for post-tetanic counts (PTC).
routine reversal For immediate reversal
following administration of
rocuronium a dose of 16
mg/kg sugammadex is
recommended
Chloroquine resistant
falciparum malaria acute
attack Adult: Per tab
contains pyrimethamine 25
mg and sulfadoxine 500 mg:
2-3 tabs as a single dose. Do
not repeat for at least 7
days. Child: Pyrimethamine
Treatment of Plasmodium 25mg + Sulfadoxine 500mg
falciparum malaria in patients in (Tablet): <2 yr (5-10 kg): ?
Sulfadoxine 500
whom chloroquine resistance is tab as a single dose; 2-5 yr
mg and P01BD51981
1488 B suspected and malaria prophylaxis (>10-20 kg): 1 tab as a single
Pyrimethamine T1001XX
for travellers to areas where dose; 5-10 yr (< 20-30 kg):
25 mg Tablet
chloroquine-resistant malaria is 1? tab as a single dose; 10-
endemic 14 yr (> 30-45 kg): 2 tab as a
single dose. Do not repeat
for at least 7 days. Renal
impairment: Dose reduction
may be needed. Severe:
contra-indicated. Hepatic
impairment: Dose reduction
may be needed. Severe:
contra-indicated.
331 / 371

Mild to moderate infections:
Sulphamethoxaz more than 2months: 8 -
ole 200 mg & 12mg Trimethoprim/kg/day
J01EE01961L Infections caused by susceptible
1489 Trimethoprim 40 B divided every 12hours.
8001XX pathogens
mg/5ml Serious Infections: 15-20mg
Suspension Trimethoprim/kg/day
divided every 6 hours.
i) ADULT: 960 mg twice daily
increased to 1.44 g twice
daily in severe infections.
CHILD: 36 mg/kg daily in 2
divided doses increased to
54 mg/kg/day in severe
infections ii) Treatment:
ADULT & CHILD over 4
i) Severe or complicated infections weeks: 120 mg/kg/day
Sulphamethoxaz when oral therapy is not feasible ii) PO/IV infusion in 2 - 4
ole 400 mg & J01EE01961P Treatment and prophylaxis of divided doses for 14 days.
1490 A
Trimethoprim 80 3001XX pneumocystis carinii pneumonia Prophylaxis: ADULT: 960 mg
mg Injection (PCP) in immunocompromised once daily or 960 mg on
patients alternate days (3 times a
week) or 960 mg twice daily
on alternate days (3 times a
week). CHILD 6 weeks - 5
months: 120 mg twice daily
on 3 consecutive days or 7
days per week; 6 months - 5
years: 240 mg; 6 - 12 years:
480 mg
i) ADULT: 1 - 3 tablets twice
daily ii) Treatment: ADULT &
CHILD over 4 weeks: 120
mg/kg/day in 2 - 4 divided
doses for 14 days.
i) Severe or complicated infections Prophylaxis: ADULT: 960 mg
Sulphamethoxaz due to susceptible infection ii) once daily or 960 mg on
ole 400 mg & J01EE01961T Treatment and prophylaxis of alternate days (3 times a
1491 B
Trimethoprim 80 1001XX pneumocystis carinii pneumonia week) or 960 mg twice daily
mg Tablet (PCP) in immunocompromised on alternate days (3 times a
patients week). CHILD; 6 weeks - 5
months: 120 mg twice daily
on 3 consecutive days or 7
days per week; 6 months - 5
years: 240 mg; 6 - 12 years:
480 mg
332 / 371

When used in scalp
disorders, a small amount of
cream should be rubbed
gently into the roots of the
Sulphur 2% & hair. When used in skin
D10AB02951 Acne vulgaris and seborrhoeic
1492 Salicylic Acid 2% C disorders, the cream should
G1001XX dermatitis
Cream be applied sparingly to the
affected area. Apply once
daily or until noticeable
improvement, then once or
twice a week
200-400 mg twice daily; 800
mg daily in predominantly
negative symptoms and 2.4
g daily in mainly positive
Sulpiride 200 mg N05AL01000 Acute and chronic schizophrenia,
1493 B symptoms. Elderly, lower
Tablet T1001XX chronic delusional psychoses
initial dose; increased
gradually according to
response. Child under 14
years not recommended
Sumatriptan 100 N02CC01000 Treatment of acute migraine 50 mg per attack and not
1494 A/KK
mg Tablet T1002XX attacks more than 300 mg daily
Sumatriptan 50
mg Fast N02CC01000 Treatment of acute migraine 50 mg per attack and not
1495 A
Disintegrating T5001XX attacks more than 300 mg daily
Tablet
Sumatriptan 50 N02CC01000 Treatment of acute migraine 50 mg per attack and not
1496 A/KK
mg Tablet T1001XX attacks more than 300 mg daily
6 mg given by SC as soon as
possible after onset. Dose
Sumatriptan 6 may be repeated once after
N02CC01000 Treament of acute migraine attacks
1497 mg/0.5 ml A not less than 1 hour if
P5001XX and cluster headache
Injection needed. Max. 12 mg in 24
hours. Child not
recommended
Apply to exposed areas at
least 30 minutes prior to
solar exposure; reapply after
Sunscreen 5 - D02BA02000
1498 B Photodermatitis swimming, prolonged
20% w/w Cream G1001XX
perspiration and after 2
hours of continuos sun
exposure
333 / 371

Intravenous: Muscle
relaxant in general
anaesthesia Adult: As
chloride: single dose of 0.3-
1.1 mg/kg injected;
supplementary doses of 50-
100% of the initial dose may
be given at 5-10 min
intervals. Max dose
Suxamethonium (repeated IV injection or
M03AB01100 Muscle relaxant as an adjunct to
1499 Chloride 50 B continuous infusion): 500
P3001XX anaesthesia
mg/ml lnj mg/hr Child: As chloride: <1
yr: 2 mg/kg; 1-12 yr: 1
mg/kg. Intramuscular:
Muscle relaxant in general
anaesthesia Adult: As
chloride: 3-4 mg/kg. Max
total dose: 150 mg Child: As
chloride: <1 yr: Up to 4-5
mg/kg; ≥1 yr: Up to 4 mg/kg.
Max dose: 150 mg.
Diagnostic test for
investigation of
adrenocortical insufficiency
Adult: As plain preparation:
Measure plasma cortisol
concentration immediately
before and exactly 30 min
after IM/IV inj of 250 mcg.
Post-inj rise in plasma
cortisol concentration ≥200
nmol/l (70 mcg/l) if normal
adrenocortical function. As
Synthetic ACTH Diagnostic test to differentiate
depot preparation (if
(Tetracosactrin H01AA02000 primary adrenal from secondary
1500 A inconclusive results with
Acetate) 250 P3001XX (pituitary) adrenocortical
plain preparation): Measure
mcg/ml Injection insufficiency
plasma cortisol
concentration before and
exactly 30 min, 1, 2, 3, 4 and
5 hr after an IM inj of 1 mg
tetracosactide acetate
depot. Adrenocortical
function normal if the post-
inj rise in plasma cortisol
concentration increases 2-
fold in 1st hr, and continues
to rise steadily. Expected
levels in 1st hr: 600-1,250
334 / 371

nmol/l, increasing slowly up
to 1000-1800 nmol/l by 5th
hr. Child: IV 250 mcg/1.73
m2 BSA. Intramuscular
Adult ≥16 years: Apply
For short-term and intermittent 0.03% or 0.1% to the
long-term therapy in the treatment affected skin twice daily and
of patients with moderate to rub in gently and
severe atopic dermatitis in whom completely. Children ≥ 2
the use of alternative, conventional years: Apply 0.03% ointment
Tacrolimus 0.03% D11AH01000
1501 A* therapies are deemed inadvisable thinly to the affected skin bd
Ointment G5002XX
because of potential risks, or in the and rub in gently and
treatment of patients who are not completely. Treatment
adequately responsive to or are should be continued for 1
intolerant of alternative, week after clearing of signs
conventional therapies & symptoms of atopic
dermatitis.
Adult ≥16 years: Apply
For short-term and intermittent 0.03% or 0.1% to the
long-term therapy in the treatment affected skin twice daily and
of patients with moderate to rub in gently and
severe atopic dermatitis in whom completely. Children ≥ 2
the use of alternative, conventional years: Apply 0.03% ointment
Tacrolimus 0.1% D11AH01000
1502 A* therapies are deemed inadvisable thinly to the affected skin bd
Ointment G5001XX
because of potential risks, or in the and rub in gently and
treatment of patients who are not completely. Treatment
adequately responsive to or are should be continued for 1
intolerant of alternative, week after clearing of signs
conventional therapies & symptoms of atopic
dermatitis.
i) Primary immunosuppressant
i) 0.2 mg/kg/day in 2 divided
Tacrolimus 0.5 L04AD02000 agent for all solid organ
1503 A* doses ii) 0.3 mg/kg/day in 2
mg Capsule C1003XX transplantation ii) Rescue therapy
divided doses
for rejection
Tacrolimus 1 mg L04AD02000 agent for all solid organ
Capsule C1001XX transplantation ii) Rescue therapy
divided doses
for rejection
Tacrolimus 5 mg L04AD02000 agent for all solid organ
Capsule C1002XX transplantation ii) Rescue therapy
divided doses
for rejection
Tacrolimus L04AD02000 agent for all solid organ
5mg/ml Injection P3001XX transplantation ii) Rescue therapy
divided doses
for rejection
335 / 371

Tamoxifen
L02BA01136 20 mg in 1-2 divided doses.
1507 Citrate 20 mg A Breast cancer
T1001XX Max: 40 mg/day
Tablet
Second line treatment of functional
Tamsulosin HCl symptoms of benign prostatic
400 mcg G04CA02110 hyperplasia (BPH) in patients who
1508 A* 400 mcg once daily
Extended Release T5001XX do not tolerate first line drugs or
Tablet when first line drugs are
inappropriate or contraindicated
Tar, Coal Tar and Massage into wet hair, rinse
D05AA00952 Dandruff, seborrhoeic dermatitis
1509 Oleyl Alcohol A/KK and repeat. Use once or
L5001XX and atopic dermatitis
Liquid twice weekly
Technetium-99m as
pertechnetate is obtained
by elution with a sterile
solution of Sodium Chloride
0.9%. The dosage depend on
type of scan i) Thyroid
scintigraphy: 18.5-80 MBq
(0.5-2.2 mCi) Scintigraphy
performed 20 minutes after
intravenous injection ii)
Salivary gland scintigraphy:
40 MBq (1.1 mCi)
Scintigraphy performed
immediately after
intravenous injection and at
Sodium pertechnetate is used for
regular intervals up to 15
scintigraphy or nuclear scan
minutes iii) Meckel?s
Technetium-99m V09CA01000 particularly of the brain and thyroid
1510 A* diverticulum scintigraphy:
Sterile Generator P3001XX to prepare various technetium-99m
400 MBq (10.8 mCi)
labelled injections for selective
Scintigraphy performed
organ imaging
immediately after
intravenous injection and at
regular interval up to 30
minutes iv) Brain
scintigraphy: 370-800 MBq
(10-22 mCi) Rapid
sequential images are taken
immediately within the first
minute after intravenous
administration, static
images 1 to 4 hours later.
Thyroid and coriod plexus
should be blocked to avoid
non-specific 99mTc uptake
v) Cardiac and vascular
336 / 371

scintigraphy: 740-925 MBq
(20-25 mCi) Red cells are
labeled in vivo or in vitro by
pretreating with a reducing
agent. Dynamic images are
taken in the first minute
after intravenous
administration, followed by
regular images over 30
minutes vi) Gastrointestinal
bleeding: 740-925 MBq (20-
25 mCi) Red cells are labeled
in vivo or in vitro by
pretreating with a reducing
agent. Dynamic images are
taken in the first minutes
after intravenous
administration, followed by
regular images at
appropriate intervals for up
to 24 hours vii) Lacrimal
duct scintigraphy: 2-4 MBq
each eye (50-100 mCi) Drops
are instilled into eye and
dynamic images are taken
over 2 minutes, followed by
static images at appropriate
intervals over 20 minutes
Tegafur 100 mg
L01BC53980 300-600 mg daily in 2-3
1511 & uracil 224 mg A* Non small cell lung cancer
C1001XX divided doses
Capsule
years: 600 mg once daily.
Treatment of chronic hepatitis B in Renal Dose Adjustment:
Telbivudine 600 J05AF11000T patients with evidence of viral 600mg every 48hours (30-
1512 A*
mg Tablet 1001XX replication and active liver 49ml/min), 600 mg every
inflammation 72hours. (<30ml/min; not
requiring dialysis); 600mg
every 96 days (ESRD)
Hypertension in patients who
Telmisartan 40 C09CA07000
1513 A/KK cannot tolerate ACE inhibitors 40mg - 80mg once daily
mg Tablet T1001XX
because of cough
Telmisartan 80
mg & Hypertension in patients who
C09DA07000
T1001XX
Tablet
337 / 371

hypertension in adults: i)
Replacement therapy:Patients
receiving telmisartan and
Single-pill combination
amlodipine from separate tablets
should be taken once daily.
may instead receive one tablet
Initiate with telmisartan
Telmisartan 80 containing the same component
80mg/amlodipine 5mg one
mg and C09DB04935 doses ii) Add on therapy: Patients
1515 A/KK tablet per day. The
Amlodipine 10 T1002XX who blood pressure is not
maximum recommendation
mg Tablet adequately controlled on
dose is telmisartan
telmisartan or amlodipine
monotherapy iii) Initial therapy:
tablet per day.
May also be used as initial therapy
in patients who are likely to need
multiple drugs to achieve their
blood pressure goals
hypertension in adults: i)
Replacement therapy:Patients
receiving telmisartan and
Single-pill combination
amlodipine from separate tablets
should be taken once daily.
may instead receive one tablet
Initiate with telmisartan
Telmisartan 80 containing the same component
mg and C10BX03935 doses ii) Add on therapy: Patients
1516 A/KK tablet per day. The
Amlodipine 5 mg T1008XX who blood pressure is not
maximum recommendation
Tablet adequately controlled on
dose is telmisartan
telmisartan or amlodipine
monotherapy iii) Initial therapy:
tablet per day.
May also be used as initial therapy
in patients who are likely to need
multiple drugs to achieve their
blood pressure goals
i)Hypertension in patients who
cannot tolerate ACE inhibitors
because of cough ii)Reduction of
the risk of myocardial infarction,
Telmisartan 80 C09CA07000 stroke, or death from i) 40mg - 80mg once daily ii)
1517 A/KK
mg Tablet T1002XX cardiovascular causes in patients 55 80mg once daily
years or older at high risk of
developing major cardiovascular
events who are unable to take ACE
inhibitors
338 / 371

Concomitant phase:
75mg/m2 daily with
radiotherapy for 42 days,
followed by 6 cycle of
In patients with glioblastoma
adjuvant treatment.
multiforme who fulfill all the
Adjuvant phase: Additional
Temozolomide L01AX03000 following criteria : i. Total /near
1518 A* 6 cycles of adjuvant phase.
100 mg Capsule C1003XX total resection ii. ECOG/WHO
Cycle 1- 150mg/m2 once
performance status 0-2 iii. Age less
daily for 5 days followed by
than 60 years
23 days without treatment.
Cycle 2-6 : 200mg/m2 once
daily for 5 days per 28-day
cycle
Concomitant phase:
75mg/m2 daily with
radiotherapy for 42 days,
followed by 6 cycle of
In patients with glioblastoma
adjuvant treatment.
multiforme who fulfill all the
Adjuvant phase: Additional
Temozolomide L01AX03000 following criteria : i. total /near
1519 A* 6 cycles of adjuvant phase.
20 mg Capsule C1001XX total resection ii. ECOG/WHO
Cycle 1- 150mg/m2 once
performance status 0-2 iii. Age less
daily for 5 days followed by
than 60 years
23 days without treatment.
Cycle 2-6 : 200mg/m2 once
daily for 5 days per 28-day
cycle
Acute myocardial reinfarction
Less than 60 kg: 30 mg, 60 -
where streptokinase is
69 kg: 35 mg, 70 - 79 kg: 40
Tenecteplase contraindicated due to previous
B01AD11000 mg; 80 -90 kg: 45 mg, 90 kg
1520 10,000 unit (50 A* streptokinase induced antibodies.
P4001XX or above: 50 mg. Administer
mg) Injection [Indicated when antibodies was
single IV bolus over 5-10
given more than 5 days and less
seconds
than 12 months]
Tenofovir Treatment of HIV-1 infection in
Disoproxil adults in combination with other
J05AR03964T
1521 Fumarate 300 mg A/KK antiretroviral agents (such as non- 1 tablet once daily.
1001XX
& Emricitabine nucleoside reverse transcriptase
200 mg Tablet inhibitors or protease inhibitors).
i)Treatment of HIV-1 infected
adults in combination with other 300mg once daily. Renal
antiretroviral agents. ii)Use as first Dose Adjustment: 300mg
Tenofovir
line monotherapy for chronic every 48hours (30-
Disoproxil J05AF07138T
1522 A* hepatitis B or as a rescue therapy 49ml/min); 300mg every
Fumarate 300 mg 1001XX
for patients with drug resistance 72hours (10-29ml/min);
Tablet
hepatitis B virus (according to 300mg every 7 days after
resistant profile or treatment dialysis (Hemodialysis)
guidelines).
339 / 371

Initially 1 mg at night,
Only for treatment of Benign
Terazosin HCl 1 G04CA03110 increased in a stepwise
1523 A/KK Prostatic Hyperplasia. Not to be
mg Tablet T1001XX fashion to 2 mg, 5 mg or 10
used for treatment of hypertension
mg once daily
i) Initially 1 mg at night,
increased in a stepwise
fashion to 2 mg, 5 mg or 10
mg once daily. ii)Initial: 1mg
Terazosin HCl 2 G04CA03110 i) Treatment of Benign Prostatic
1524 A/KK once daily at bedtime,
mg Tablet T1002XX Hyperplasia. ii)Hypertension
Maintenance: 1-5mg once
(morning or evening) or
twice daily. Max: 20-
40mg/day
i) Initially 1 mg at night,
increased in a stepwise
fashion to 2 mg, 5 mg or 10
mg once daily. ii) Initial: 1mg
Terazosin HCl 5 G04CA03110 i) Treatment of Benign Prostatic
1525 A/KK once daily at bedtime,
mg Tablet T1003XX Hyperplasia. ii)Hypertension
Maintenance: 1-5mg once
(morning or evening) or
twice daily. Max: 20-
40mg/day
Fungal infections especially 250 mg once daily for 6
Terbinafine HCl D01BA02110
1526 A/KK onchomycosis caused by weeks for fingernails: 12
dermatophytes weeks for toenails
12 years: 1 inhalation 6
hourly. Severe cases: Single
dose may be increased to 3
Bronchial asthma, chronic
Terbutaline inhalations. Maximum 12
R03AC03183 bronchitis, emphysema and other
1527 0.5mg/dose B inhalation/24 hour. CHILD 3-
A2001XX lung diseases where bronchospasm
Inhaler 12 year: 1 inhalation 6
is a complicating factor
hourly. Severe cases: Single
dose may be increased to 2
inhalations. Maximum 8
inhalation/24 hour
CHILD less than 7 years : 75
Terbutaline Asthma and other conditions
R03CC03183 mcg/kg 3 times daily, 7 - 15
1528 Sulphate 0.3 B associated with reversible airways
L9001XX years : 2.5 mg 2 - 3 times
mg/ml Syrup obstruction
daily
SC, IM or slow IV: 250-500
mcg up to 4 times daily.
Bronchial asthma, chronic
CHILD 2 - 15 years 10mcg/kg
Terbutaline bronchitis, emphysema and other
R03CC03183 to a maximum of 300 mcg.
1529 Sulphate 0.5 B lung diseases where
P3001XX Continuous IV infusion, as a
mg/ml Injection broncoconstriction is a
solution containing 3 - 5
complicating factor
mcg/ml, 1.5 - 5 mcg/minute
for 8 - 10 hours; reduce
340 / 371

dose for children
ADULT : 5 - 10 mg 2 -4 times
daily, additional doses may
Terbutaline
Asthma and other conditions be necessary in severe acute
Sulphate 10 R03AC03183
1530 B associated with reversible airways asthma. CHILD up to 3 years
mg/ml Nebulizer A3001XX
obstruction : 2 mg, 3 - 6 years : 3 mg, 6 -
Solution
8 years : 4 mg, over 8 years :
5 mg 2 - 4 times daily
ADULT: Initially 2.5 mg 3
times daily for 1 - 2 week,
Terbutaline Asthma and other conditions then up to 5 mg 3 times
R03CC03183
1531 Sulphate 2.5 mg B associated with reversible airways daily. CHILD less than 7
T1001XX
Tablet obstruction years: 75 mcg/kg 3 times
daily, 7 - 15 years: 2.5 mg 2 -
3 times daily
2 mg IV bolus over 1 minute.
Maintenance: 1 - 2 mg IV
Terlipressin bolus 4 - 6 hourly until
H01BA04000 Acute oesophageal variceal
1532 1mg/5mg A* bleeding is controlled, up to
P4001XX bleeding
Injection 24 - 36 hours. The maximum
daily dosage is 120-150
mcg/kg body weight.
By IM only. Hypogonadism
250 mg every 2-3 weeks. To
maintain an adequate
Only for treatment of male
androgenic effect 250 mg
infertility, protein deficiency during
every 3-6 weeks. Potency
Testosterone 250 G03BA03000 convalescence after surgery and
1533 A* disorders 250 mg every 4
mg/ml Injection P3001XX wasting disorder. In women,
weeks. Male climateric
supplementary therapy of
disorders: 250 mg every 3-4
progressive mammary carcinoma
weeks. Repeated 6-8 weeks
courses at 2-3 months
interval
2 doses of 0.5 mL IM at an
interval of 4-8 wk, followed
Tetanus Toxoid J07AM01000 Immunization against tetanus
1534 C+ by the 3rd dose 6-12 mth
Injection P3001XX infection
later. Booster: 0.5 mL IM
every 10 yr.
"Adult: 250-500 mg 6 hrly.
Tetracycline HCl J01AA07110C Infections caused by susceptible
1535 B Max: 4 g/day. Child: ≥12 yr
250 mg Capsule 1001XX pathogens
Max: 2 g daily"
"Adult: 250-500 mg 6 hrly.
Tetracycline HCl J01AA07110T Infections caused by susceptible
1536 B Max: 4 g/day. Child: ≥12 yr
250 mg Tablet 1001XX pathogens
Max: 2 g daily"
341 / 371

First line induction therapy in newly
diagnosed multiple myeloma,
salvage therapy in relapsed
multiple myeloma and
Thalidomide 50 L04AX02000 maintenance therapy in multiple
1537 A* 50 mg to 200 mg daily
mg Capsule C1001XX myeloma (contraindicated for
pregnant women; pregnancy test
for females in reproductive age
group before starting treatment
should be done).
Used in myocardial perfusion
scintigraphy, acute myocardial
infarction and post-surgical
Thallous Chloride
V09GX01100 assessment of coronary artery
1538 (Thallium-201) A* As IV infusion
P3001XX bypass graft patency, muscle
Injection
perfusion scintigraphy, visualisation
of brain and thyroid tumours and
metastases
ADULT: 125 mg 3 - 4 times
daily after food, increased to
Theophylline 125 R03DA04000 Reversible airways obstruction, 250 mg if required. CHILD: 1
1539 B
mg Tablet T1001XX acute severe asthma - 15 years : 5 mg/kg/dose
(up to 600 mg/ day) every 3
- 4 times daily
Theophylline 250
R03DA04000 Reversible airways obstruction and daily. CHILD under 12 years :
1540 mg Long Acting B
T5001XX acute severe asthma Up to 10 mg/kg body weight
Tablet
2 times daily
ADULT : 125 mg 3 - 4 times
daily after food, increased to
Theophylline 80 R03DA04000 Reversible airways obstruction and 250 mg if required. CHILD 1 -
1541 B
mg/15 ml Syrup L9001XX acute severe asthma 15 years : 5 mg/kg/dose (up
to 600 mg/day) every 3 - 4
times per day
i) Mild to chronic deficiency:
i) For the prevention or treatment 10-25 mg daily. Severe
of Vitamin B1 deficiency syndromes deficiency: 200- 300 mg
Thiamine HCl 100 A11DA01110
1542 B including beri-beri and peripheral daily ii) 500 mg every 8
neuritis associated with pellagra ii) hours for 2 days, followed
Wernicke-Korsakoff Syndrome by 100 mg 2 times daily until
patient can take oral dose
Thiamine of Vitamin B1 deficiency syndromes deficiency: 200- 300 mg
A11DA01221
1543 Mononitrate 10 C including beri-beri and peripheral daily ii) 500 mg every 8
T1002XX
mg Tablet neuritis associated with pellagra ii) hours for 2 days, followed
342 / 371

Thiamine of Vitamin B1 deficiency syndromes deficiency: 200 - 300 mg
A11DA01221
1544 Mononitrate 3 C including beri-beri and peripheral daily ii) 500 mg every 8
T1001XX
mg Tablet neuritis associated with pellagra ii) hours for 2 days, followed
Refer to specific protocols.
Usually 100 mg/m2 for 5 - 7
days (acute myeloid
leukaemia) or up to 2 weeks
Thioguanine 40 L01BB03000T For acute leukaemia and chronic
1545 A (chronic myeloid leukaemia
mg Tablet 1001XX granulocytic leukaemia
for accelerated/ advanced
disease). CHILD: 40 - 60
g/m2 daily according to
protocol
i) ADULT : For induction 200
- 400 mg. For repeat
injection 3 - 5 mg/kg over 10
- 15 seconds until desired
i) General anaesthesia, induction ii)
Thiopental depth of anaesthesia is
N05CA19520 Anticonvulsant for cases resistant
1546 Sodium 500 mg B obtained. Not FDA approved
P3001XX to conventional anticonvulsants in
Injection for use in pediatric patients
the ICU
ii) 75 - 125 mg IV single
dose; for local-anaesthetic
induced convulsion: 125 -
250 mg IV over 10 minutes
Thymol
A01AD11985 For sore throat and minor mouth
1547 Compound C To be gargled 3-4 times daily
M2001XX inflammation
Gargle
343 / 371

A two-injection regimen is
recommended for
thyrotropin
administration.The two-
injection regimen is
thyrotropin 0.9 mg
intramuscularly (IM),
followed by a second 0.9 mg
IM injection 24 hours later.
After reconstitution with 1.2
Thyrogen (thyrotropin alfa) is
mL Sterile Water for
indicated for use as an adjunctive
Injection, 1.0 mL solution
treatment for radioiodine ablation
(0.9 mg thyrotropin alfa) is
of thyroid tissue remnants in
Thyrotropin alfa administered by
H01AB01000 patients who have undergone a
1548 0.9mg/ml A* intramuscular injection to
P3002XX near-total or total thyroidectomy
Injection the buttock. For radioiodine
for well-differentiated thyroid
imaging or treatment,
cancer and who do not have
radioiodine administration
evidence of distant metastatic
should be given 24 hours
thyroid cancer.
following the final Thyrogen
injection. Diagnostic
scanning should be
performed 48 hours after
radioiodine administration,
whereas post-therapy
scanning may be delayed
additional days to allow
background activity to
decline.
Treatment of complaints resulting
from the natural or surgical
Tibolone 2.5 mg G03CX01000 menopause & in cases at high risk
1549 A* 2.5mg daily
Tablet T1001XX for breast carcinomas where
general hormone replacement
therapy is contraindicated
a)Patient who failed clopidogrel
readmitted to hospital with
recurrent atherothrombotic event
while patients are on clopidogrel.
b) ACS patients with:i) STEMI - Initially, 180mg as single
Ticagrelor 90 mg B01AC24000 going for invasive (PCI), ii) dose followed by 90mg bd
1550 A*
Tablet T1001XX NSTEMI/UA - intermediate to high with maintenance dose of
risk (based on TIMI score). iii) Other ASA 75-150 mg daily.
complicated ACS cases treated
either medically or invasively via
PCI or CABG (risk of Stent
thrombosis, 3VD etc.)
344 / 371

i) Prevention of thrombotic stroke
for patients who are sensitive
/intolerant to Acetysalicylic Acid ii)
Ticlopidine HCl B01AC05110 Maintenance of coronary bypass 250 mg twice daily taken
1551 A/KK
250 mg Tablet T1001XX surgery or angioplasty iii) with food
Maintenance of patency of access
in patients on chronic
haemodialysis
Initially, 1 drop of 0.25% 2
Timolol Maleate S01ED01253 Elevated intraocular pressure, times daily, if clinical
1552 A
0.5% Eye Drops D2002XX chronic open angle glaucoma response is not adequate, 1
drop of 0.5% 2 times daily
i) ADULT : 2 g as a single
dose for 2 - 3 days. CHILD 3
years and older : 50 mg/kg
daily for 3 days ii) ADULT : 2
g as a single dose (repeated
Tinidazole 500 P01AB02000 i) Amoebiasis ii) Urogenital
1553 B once if necessary). Sexual
mg Tablet T1001XX trichomoniasis and giardiasis
partners should be treated
concomitantly with the
same dose. CHILD 6 years
and older : single dose of 1
gram
i)Treatment of DVT and PE,
in conjunction with
warfarin: 175 anti-Factor Xa
IU/kg SC once daily for at
least 6 days.
ii)Thromboprophylaxis in
patients with:Moderate risk
i)Treatment of deep vein
Tinzaparin of thrombosis (general
thrombosis (DVT) and pulmonary
sodium 10,000 surgery):3,500 anti-Factor
embolism (PE), not amounting to
anti-Factor Xa B01AB10520 Xa IU SC 2 hrs before
1554 A* hemodynamic instability.
IU/ml Injection in P5001XX surgery and postoperatively,
ii)Prevention of post-operative DVT
Prefilled 3,500 anti-Factor Xa IU once
in patients undergoing general and
syringe/cartridge daily for 7-10 days. High risk
orthopaedic surgery.
of thrombosis (eg. total hip
replacement):4,500 anti-
Factor Xa IU SC or 50 anti-
Factor Xa IU/kg body weight
SC 2 hrs before surgery and
then once daily until the
patients has been mobilized.
345 / 371

i)Treatment of DVT and PE,
in conjunction with
warfarin: 175 anti-Factor Xa
IU/kg SC once daily for at
least 6 days.
ii)Thromboprophylaxis in
patients with:Moderate risk
i)Treatment of deep vein
Tinzaparin of thrombosis (general
thrombosis (DVT) and pulmonary
sodium 20,000 surgery):3,500 anti-Factor
embolism (PE), not amounting to
anti-Factor Xa B01AB10520 Xa IU SC 2 hrs before
1555 A* hemodynamic instability.
IU/ml Injection in P5002XX surgery and postoperatively,
ii)Prevention of post-operative DVT
Prefilled 3,500 anti-Factor Xa IU once
in patients undergoing general and
syringe/cartridge daily for 7-10 days. High risk
orthopaedic surgery.
of thrombosis (eg. total hip
replacement):4,500 anti-
Factor Xa IU SC or 50 anti-
Factor Xa IU/kg body weight
SC 2 hrs before surgery and
then once daily until the
patients has been mobilized.
Skin fungal infections resistant to Gently massage into the
Tioconazole 1% D01AC07000
1556 A antifungal drugs such as affected and surrounding
Cream G1001XX
miconazole and clotrimazole area 1-2 times daily
Tioconazole 100 Adult & Child > 12yr: Insert
G01AF08000
1557 mg Vaginal A Vulvovaginal candidiasis nightly on retiring for 3-6 or
S1001XX
Tablet 14 days
Apply 4.6 g intravaginally
Tioconazole 6.5% G01AF08000 prior to bedtime as a single
1558 A Vulvaginal candidiasis
Vaginal Ointment G5001XX dose therapy, therapy may
extend to 7 days
Maintenance bronchodilator
Tiotropium treatment to relieve symptoms of
2.5mcg/puff R03BB04320 patients with chronic obstructive 5 mcg (2 puff) once daily, at
1559 A/KK
solution for A3001XX pulmonary disease (COPD) in which the same time of the day
inhalation the diagnosis of COPD is confirmed
by spirometry.
Long term maintenance treatment
Tiotropium of bronchospasm and dypsnoea Contents of one capsule is
Bromide 18 mcg R03BB04320 associated with COPD. Tiotropium inhaled once daily with the
1560 A/KK
Inhalation C9901XX has usually been added to standard Handihaler inhalation device
Capsules therapy (e.g. inhaled steroids, at the same time of the day.
theophylline, albuterol rescue)
346 / 371

Unstable angina or non-ST segment
elevation myocardial infarction By IV infusion, 0.4
Tirofiban HCl with the following: elevated cardiac mcg/kg/min for 30 minutes,
B01AC17110
1561 0.25 mg/ml A* markers, refractory chest pain, ST- then 0.1 mcg/kg/min for at
P9901XX
Injection segment changes and thrombolysis least 48 hours, maximum
in myocardial infarction (TIMI) risk 108 hours
score 4
Recommended dose for
Indicated for the treatment of
rheumatoid arthritis of
moderate to severe active
tocilizumab for adult
rheumatoid arthritis (RA) in adult
patients is 8mg/kg given
patients: i) with inadequate
once every 4 weeks as a
respond or intolerance to
single-drip IV infusion over 1
conventional disease- modifying
hour. It should be diluted to
antirheumatic drugs (DMARDS) ii)
Tocilizumab 20 L04AC07000 100 ml by a healthcare
1562 A* who has failed antitumour necrosis
mg/ml Injection P3001XX professional with sterile
factors (antiTNFs) iii) where TNF is
0.9% w/v sodium chloride
contraindicated (patients with
solution over 1 hour. For
history of pulmonary tuberculosis
patients whose body weight
[PTB]) It also can be used as
is more than 100kg, doses
monotherapy or with combination
exceeding 800mg per
with methotrexate (MTX) and/ or
infusion are not
other DMARDS.
recommended
4 mg once daily. May
Tolterodine Treatment of overactive bladder
G04BD07123 decrease to 2 mg once daily
1563 Tartrate ER 4 mg A* with symptoms of urinary,
C2002XX depending on response and
Capsule frequency or urge incontinence
tolerability
ADULT: Initially 25-50mg
nightly for 1 week.
Subsequently at wkly or bi-
wkly intervals, increase dose
by 25-50 to 100mg/day in 2
divided doses. CHILD aged 2
and above: Approx 5-9
Topiramate 100 N03AX11000 Add-on therapy for intractable mg/kg/day in 2 divided
1564 A*
mg Tablet T1003XX partial epilepsy doses. Titrate at 25mg (or
less, based on a range of 1-
3mg/kg/day) nightly for the
1st week. Subsequently at 1
or 2 wkly intervals, with
increments of 1-3
dose.
347 / 371

nightly for 1 week.
Topiramate 15
N03AX11000 Add-on therapy for intractable mg/kg/day in 2 divided
1565 mg Capsule A*
C1001XX partial epilepsy doses. Titrate at 25mg (or
Sprinkle
increments of 1-3
dose.
nightly for 1 week.
Topiramate 25
N03AX11000 Add-on therapy for intractable mg/kg/day in 2 divided
1566 mg Capsule A*
C1002XX partial epilepsy doses. Titrate at 25mg (or
Sprinkle
increments of 1-3
dose.
nightly for 1 week.
1567 A*
increments of 1-3
dose.
348 / 371

nightly for 1 week.
1568 A*
increments of 1-3
dose.
Trace Elements Only to be used to cover daily loss
B05XA30905 10 ml added to 500-1000 ml
1569 and Electrolytes A* of electrolyte and trace elements
P3001XX solution, given by IV infusion
(Adult) Solution for patient on parenteral nutrition
According to the needs of
the patient. INFANT and
CHILD weighing 15 kg or
less: Basal requirements of
the included trace elements
are covered by 1 ml/kg/day
Trace Elements
Only to be used to cover daily loss to a maximum dose of 15
and Electrolytes B05XA30905
1570 A* of electrolyte and trace elements ml. CHILD weighing 15 kg or
(Paediatric) P3002XX
for patient on parenteral nutrition more, a daily dose of 15 ml,
Solution
should meet basic trace
element requirements.
However, for patients
weighing more than 40 kg
the adult preparation trace
element should be used
Post-operative pain, chronic cancer
Tramadol HCl
N02AX02110 pain, analgesia/pain relief for
1571 100 mg A 100mg rectally up to qds
S2001XX patients with impaired renal
Suppository
function
Post-operative pain, chronic cancer
50 - 100 mg every 4 hours.
Tramadol HCl N02AX02110 pain, analgesia/pain relief for
1572 A Max : 400 mg daily. Not
100 mg/ml Drops D5001XX patients with impaired renal
function.
ADULT: 50mg initially, can
Moderate to severe acute or
take another 50mg after 30
chronic pain (eg. Post-operative
Tramadol HCl 50 N02AX02110 - 60 min if pain not relieved.
1573 A/KK pain, chronic cancer pain and
mg Capsule C1001XX Max 400 mg daily. CHILD:
analgesia/pain relief for patients
1mg/kg/dose repeated
with impaired renal function)
every 6 hours (Max:
349 / 371

2mg/kg/dose and
100mg/dose)
ADULT: IV/IM/SC 50 -
Moderate to severe acute or 100mg. (IV inj over 2-3 min
chronic pain (eg. Post-operative or IV infusion). Initially 100
Tramadol HCl 50 N02AX02110
1574 A pain, chronic cancer pain and mg then 50 - 100 mg every 4
analgesia/pain relief for patients - 6 hours. . Max: 400 mg
with impaired renal function) daily. CHILD (1 year and
above): 1 - 2mg/kg/dose
ADULT: Slow IV 0.5-1 g (10 -
15 mg/kg) 3 times daily.
Tranexamic Acid
B02AA02000 Haemorrhage associated with Continuous infusion at a
1575 100 mg/ml B
P3001XX excessive fibrinolysis rate of 25 - 50 mg/kg daily.
Injection
CHILD: slow IV 10
mg/kg/day 2-3 times daily
ADULT: 1-1.5 g (15-25
mg/kg) 2-4 times daily.
CHILD: 25 mg/kg/day 2-3
Tranexamic Acid B02AA02000 Haemorrhage associated with times daily. Menorrhagia
1576 B
250 mg Capsule C1001XX excessive fibrinolysis (initiated when
menstruation has started), 1
g 3 times daily for up to 4
days; maximum 4 g daily
Used only in adjuvant setting for Initial loading dose is 4
patients with HER2 over-expressed mg/kg administered as a 90
breast cancer, that is HER2 3+ by minutes IV infusion.
Trastuzumab 440 L01XC03000P
1577 A* immunohistochemistry and over- Subsequent doses is 2
mg Injection 4001XX
expressed by FISH (Fluorescence in mg/kg administered as 30
situ hybridization) and high risk minutes IV infusion weekly
group for 51 weeks
To decrease intraocular pressure
Travoprost (IOP) in patients with open-angle
S01ED51990 1 drop in the affected eye(s)
1578 0.004% & Timolol A* glaucoma or ocular hypertension
D2003XX once daily
0.5% Eye Drops who are insufficiently responsive to
other topical anti glaucomas
Apply thinly to the affected
area once daily or twice
daily. Avoid exposure to
Tretinoin 0.01% D10AD01000 Acne vulgaris, recalcitrant cases of
1579 A/KK sunlight. Duration of
Gel G3001XX acne (comedonal type)
treatment: 8-12 weeks is
required before any
noticeable response
350 / 371

Tretinoin 0.05% D10AD01000 Acne vulgaris and recalcitrant cases
1580 A/KK sunlight. Duration of
Cream G1001XX of acne (comedonal type)
treatment: 8 - 12 weeks is
required before any
noticeable response
Tretinoin 0.1% D10AD01000 Acne vulgaris and recalcitrant cases
1581 A sunlight. Duration of
Cream G1002XX of acne (comedonal type)
treatment: 8 - 12 weeks is
required before any
noticeable response
Triamcinolone
A01AC01351 Apply a thin layer to
1582 Acetonide 0.1% B Oral and perioral lesions
G3101XX affected area 2-4 times daily
Oral Paste
Smaller joints: 2.5 - 5 mg
Triamcinolone and larger joints: 5 - 15 mg.
H02AB08351 Inflammation of joints, bursae and
1583 Acetonide 10 A Treatment should be limited
P3001XX tendon sheaths
mg/ml Injection to 1 mg/injection site to
prevent cutaneous atrophy
Triamcinolone Allergies, dermatoses, rheumatoid
H02AB08351 40-80 mg deep into the
1584 Acetonide 40 A/KK arthritis and inflammatory
P3002XX gluteal muscle
mg/ml Injection opthalmic diseases
ADULT: Initially 5 mg twice
daily, increase by 5 mg after
1 week, then at 3-day
intervals. Maximum 40
Trifluoperazine N05AB06110
1585 B Psychotic disorder mg/day. CHILD up to 12
HCI 5 mg Tablet T1001XX
years: Initially up to 5 mg
daily in divided doses
adjusted to response, age
and body weight
Trimetazidine 20 C01EB15110 Prophylactic treatment of episodes
1586 B 20 mg 3 times daily
mg Tablet T1001XX of angina pectoris
35 mg twice daily in the
Trimetazidine 35 C01EB15110 Prophylactic treatment of episodes
1587 B morning and evening with
mg MR Tablet T5001XX of angina pectoris
meals
ADULT: 200 mg daily in 1 or
2 divided doses or 300 mg
daily as a single dose. Acute
Treatment of urinary tract
Trimethoprim J01EA01000T infection: 200 mg twice
1588 B infections due to susceptible
100 mg Tablet 1001XX daily. CHILD: 6-8 mg/kg/day
pathogens
in 2 divided doses. 6 - 12
years: 100 mg twice daily; 6
months - 5 years: 50 mg
351 / 371

twice daily. 6 weeks - 5
months: 25mg twice daily
ADULT: 200 mg daily in 1 or

2 divided doses or 300 mg
daily as a single dose. Acute
Treatment of urinary tract infection: 200 mg twice
Trimethoprim J01EA01000T
1589 B infections due to susceptible daily. CHILD: 6 - 12 years:
pathogens 100 mg twice daily; 6
months - 5 years: 50 mg
twice daily. 6 weeks - 5
months: 25mg twice daily
5 - 10 mg daily, 2 - 4 hours
before exposure to sunlight.
Trioxsalen 5 mg D05BA01000
1590 A Vitiligo To increase pigmentation:
Tablet T1001XX
10 mg daily, 2 hours prior to
UV irradiation
Decongestion of the upper
Triprolidine HCl
respiratory tract in common cold, ADULT and CHILD more than
1.25 mg and
R01BA52110 hay fever, allergic and vasomotor 12 year : 10 ml. CHILD 6 - 12
1591 Pseudoephedrine B
L9001XX rhinitis and sinusitis. Doses to be years : 5 ml, 2 - 5 years : 2.5
HCl 30 mg per 5
taken twice daily or three times ml
ml Syrup
daily
ADULT 2.5 mg every 4 - 6
hours; maximum dose 10
mg/day. CHILD 6 - 12 years :
1.25 mg every 4 - 6 hours;
Triprolidine HCl Decongestion of the upper
maximum dose 5 mg/day, 2
2.5 mg and R01BA52988 respiratory tract in common cold,
1592 B - 4 years : 0.625 mg every 4 -
Pseudoephedrine T1002XX hay fever, allergic and vasomotor
6 hours; maximum dose 2.5
HCl 60 mg Tablet rhinitis and aerotitis
mg/day, 4 - 6 years : 0.938
mg every 4 - 6 hours;
maximum dose 3.744
mg/day
1 intramuscular injection
i) Treatment of confirmed central every 4 weeks. The
precocious puberty (preterm sexual treatment must be started
development) in girls under 9 in the first 5 days of the
years, boys under 10 years of age ii) menstrual cycle. The
Genital and extragenital duration of treatment
Triptorelin 3.75 L02AE04000P endometriosis (stage I to stage IV). depends on the initial
1593 A
mg Injection 2001XX Treatment should not be severity of the
administered for more than 6 endometriosis and the
months. It is not recommended to changes observed in the
start a second treatment course clinical features. In principle,
with triptorelin or another GnRH the treatment should be
analogue. administered for at least 4
months and for at most 6
352 / 371

months. It is not
recommended to start a
second treatment course
with triptorelin or another
GnRH analogue.
Tropicamide 1% S01FA06000 Topical use to produce cycloplegic 1 - 2 drops several times a

1594 A/KK
Eye Drops D2002XX refraction for diagnostic purposes day
Symptomatic treatment for urge
incontinence and/or increased
1 tablet twice daily. Tablet
urinary frequency and urgency as
should be swallowed whole
may occur in patients with
with a glass of water before
Trospium overactive bladder (eg. Idiopathic
G04BD09100 meals on empty stomach.
1595 Chloride 20mg A* or neurologic detrusor overactivity)
C1001XX Severe renal impairment
coated tablet Place in therapy: As first line
(CrCl between 10 & 30
treatment for overactive bladder in
mL/min/1.73 m2): 1 tab
patients with Parkinsonism,
daily or every 2nd day
Alzheimer?s or other cognitive
disease
Tuberculine PPD V04CF01000 For routine Mantoux (tuberculin 10 units is injected
1596 B
Injection P3001XX sensitivity) test intradermally
Active immunization against ADULT and CHILD 6 years of
Typhoid Vaccine J07AP01000C
1597 B typhoid fever in adult and child 6 age or older, 1 capsule on
Capsule 1001XX
years of age or older days 1, 3 and 5
0.5 ml single IM injection
Typhoid Vaccine Active immunization against into the deltoid or vastus
J07AP02000P
1598 Injection (20 B typhoid fever in adult and child lateralis, may reimmunize
3001XX
doses) more than 2 years with 0.5 ml IM every 3 years
if needed.
Dosage is one tablet to be
taken orally as soon as
Emergency contraception within 4-
possible, but no later than
Ulipristal Acetate G03AD02122 5 days of unprotected sexual
1599 A 120 hours (5 days) after
30mg Tablet T1001XX intercourse for sexual assault
unprotected sexual
victim.
intercourse or contraceptive
failure.
To be individualized. 75 IU-
Urofollitropin 150 IU daily and maybe
G03GA04000 Stimulation of follicular growth in
1600 (FSH) 150 IU A* increased or decreased by
P3002XX infertile women
Injection up to 75 IU/day at 7 or 14
day intervals if necessary
To be individualized. 75 IU-
Urofollitropin 150 IU daily and maybe
G03GA04000 Stimulation of follicular growth in
1601 (FSH) 75 IU A* increased or decreased by
P3001XX infertile women
Injection up to 75 IU/day at 7 or 14
day intervals if necessary
353 / 371

ADULT: Acute pulmonary
embolism: IV loading dose
4400 iu/kg over 10 mins,
maintenance 4400
iu/kg/hour for 12 hours.
Peripheral vascular
Treatment of thromboembolic occlusion: infuse 2500 iu/ml
disease such as mycocardial into clot at a rate of 4000
Urokinase 6000 B01AD04000 infarction, peripheral artery iu/min for 2 hours. This may
1602 A
IU Injection P4001XX occlusion, pulmonary embolism, be repeated up to 4 times.
retinal artery thrombosis and other Hyphaema: 5000 IU in 2 ml
ophthalmologic use saline solution is injected
and withdrawn repeatedly
over the iris. If residual clot
remains, leave 0.3ml in the
anterior chambers for 24-48
hours to facilitate futher
dissolution
10-15 mg/kg daily in 2 to 4
divided doses usually for 3
Ursodeoxycholic Cholestatic liver diseases (eg. months to 2 years. If there is
A05AA02000
1603 Acid 250 mg A primary biliary cirrhosis, primary no decrease in stone size
C1001XX
Capsule cholangitis etc) after 18 months, further
treatment seems not to be
useful
Body weight less than
Treatment of moderate to severe 100kg: Initial dose of 45 mg
plaque psoriasis in adults who SC, followed by 45 mg 4
failed to, or who have weeks later, then every 12
Ustekinumab 90 L04AC05000 contraindication to, or are weeks thereafter. Body
1604 A*
mg/ml Injection P3002XX intolerant to conventional systemic weight more than 100 kg:
therapies including ciclosporin, initial dose 90 mg SC,
methotrexate and followed by 90 mg 4 weeks
photochemotherapy (PUVA). later, & then every 12 weeks
thereafter.
For adult patients who have
received other than kidney
transplant, the
recommended dose is 900
For the prevention of mg (two 450 mg tablets)
cytomegalovirus (CMV) disease in once a day starting within
Valganciclovir J05AB14110T
1605 A* CMV-negative patients who have 10 days of transplantation
received a solid organ transplant until 100 days post-
from a CMV-positive donor transplantation. For adult
patients who have received
a kidney transplant, the
recommended dose is 900
mg (two 450 mg tablets)
354 / 371

once a day starting within
10 days of transplantation
until 200 days post-
transplantation.
i) Adults: Dosage should
start at 500mg daily
increasing by 200mg at
three-day intervals until
control is achieved. This is
i) In the treatment of generalized
generally within the dosage
or partial epilepsy, particularly with
range 1000mg to 2000mg
the following patterns of
per day. Children: >20KG:
seizures:absence, myoclonic, tonic-
Valproic Acid and 500mg/day (irrespective of
clonic, atonic-mixed as well as, for
Sodium N03AG01520 weight) with spaced
1606 B partial epilepsy:simple or complex
Valproate (ER) T5001XX increases until control is
seizures, secondary generalized
500mg Tablet achieved. ii) Initial dose of
seizures, specific syndrome (West,
1000mg/day, to be increase
Lennox-Gastatut). ii) Treatment
rapidly as possible to
and prevention of mania associated
achieve lowest therapeutic
with bipolar disorders.
dose, which produce desired
clinical effects. Recommend
initial dose is 1000mg &
2000mg daily. Max dose
3000mg daily.
Valsartan 160 mg
and
C09DA03935 Treatment of essential
1607 Hydrochlorothiaz A/KK 1 tablet once daily
T1005XX hypertension
ide 12.5 mg
Tablet
i) 80 or 160 mg once daily.
once daily. ii) 40 mg twice
Patients who cannot tolerate ACE
daily. Uptitration to 80 mg
Valsartan 160 mg C09CA03000 inhibitors because of cough, in i)
1608 A/KK and 160 mg twice daily.
Tablet T1002XX Hypertension ii) Heart failure iii)
Max: 320 mg in divided
Post myocardial infarction
doses. iii) 20 mg twice daily.
Uptitration to max of 160
mg twice daily.
Valsartan 80 mg
and Hypertension in patients who
C09DA03935
1609 Hydrochlorothiaz A/KK cannot tolerate ACE inhibitors 1 tablet once daily
T1001XX
Tablet
355 / 371

i) 80 or 160 mg once daily.
once daily. ii) 40 mg twice
Patients who cannot tolerate ACE daily. Uptitration to 80 mg
Valsartan 80 mg C09CA03000 inhibitors because of cough, in i) and 160mg twice daily. Max:
1610 A/KK
Tablet T1001XX Hypertension ii) Heart failure iii) 320 mg in divided doses. iii)
Post myocardial infarction 20 mg twice daily increased
over several weeks to
160mg twice daily if
tolerated.
Slow IV infusion, ADULT: 500
mg over at least 60 minutes
every 6 hours or 1 g over at
least 100 minutes every 12
hours. NEONATE up to 1
Vancomycin HCl J01XA01110P Only for the treatment of MRSA week, 15 mg/kg initially,
1611 A*
500 mg Injection 4001XX and CAPD peritonitis then 10 mg/kg every 12
hours. INFANT 1 - 4 weeks,
15 mg/kg initially then 10
mg/kg every 8 hours. CHILD
over 1 month, 10 mg/kg
every 6 hours
0.5 mg once daily for Day 1-
Varenicline 3, then 0.5 mg twice daily
N07BA03123
1612 Tartrate 0.5 mg A/KK Smoking cessation treatment for Day 4-7, then 1 mg twice
T1001XX
and 1 mg Tablet daily; duration of treatment
is 12 weeks
0.5 mg once daily for Day 1-
Varenicline 3, then 0.5 mg twice daily
N07BA03123
1613 Tartrate 1 mg A/KK Smoking cessation treatment for Day 4-7, then 1 mg twice
T1002XX
Tablet daily; duration of treatment
is 12 weeks
i) Health staff working with
children, pregnant women,
transplant, cancer and
immunocompromised patients who
are at high risk of contacting
varicella and transmitting it to at ADULT and CHILD 13 years
Varicella Virus risk patients ii) Transplant patients or more: 2 doses of 0.5 ml
Vaccine Live J07BK01000P or candidates who are: a) SC injection separated by 4 -
1614 A*
Attenuated 4001XX Immunocompetent and not 8 weeks apart. CHILD 12
Injection receiving immunosuppressant months - 12 years: 0.5ml SC
drugs, do not have graft versus as a single dose
host disease 2 years or more after
transplant b) Susceptible to
Varicella-Zoster virus at least 3
weeks before grafting iii) Children:
a) with impaired humoral immunity
356 / 371

b) HIV-infected children more than
12 months of age, in CDC class N1
(asymptomatic) or A1 (mildly
symptomatic) with age specific CD4
more than 25% c) with conditions
that require systemic steroid
therapy less than 2 mg/kg body
weight or a total of 20 mg/day of
prednisolone or its equivalent.
[Those receiving high doses of
systemic steroids at 2 mg/kg body
weight or more of prednisolone for
more than 2 weeks may be
vaccinated after steroid therapy
has been discontinued for at least
three months] iv) Acute
lymphoblastic leukemia (ALL)
patients with negative history of
varicella who:- a) are 12 months to
17 years of age b) have leukemia in
remission for at least 12 months c)
have a peripheral blood
lymphocyte count 700 cells/ mm3
or more. [If platelet count of
greater 100,000/mm3 within 24
hours of vaccination are not being
submitted to radiotherapy.
Chemotherapy should be withheld
for seven days before and after
immunisation] v) Susceptible
subjects in clinical trials who will be
submitted for chemotherapy vi)
Children and susceptible patients
on chronic dialysis
i) 5 - 20 units SC or IM every
4 hours ii) 20 units in 100 -
Vasopressin 20 200 ml 5% dextrose saline
H01BA01000 i) Pituitary diabetes insipidus ii)
1615 units/ml A over 15 minutes as infusion
P3001XX Oesophageal variceal bleeding
Injection which may be repeated
after at intervals of 1 - 2
hours. Maximum: 4 doses
357 / 371

ADULT & NEONATES > 5
MONTHS Initial: 80-100
mcg/kg as inj. Maintenance:
20-30 mcg/kg, adjust
Vecuronium
Alternatively, as continuous
Bromide 10 M03AC03320 As an adjunct in anaesthesia to
1616 A* infusion at 0.8-1.4
mg/10 ml P3001XX produce skeletal muscle relaxation
mcg/kg/min after initial IV
Injection
dose of 40-100 mcg/kg.
NEONATE and INFANT up to
4 months: Initially 10 - 20
mcg/kg, then incremental
dose to achieve response
ADULT & NEONATES > 5
MONTHS Initial: 80-100
mcg/kg as inj. Maintenance:
20-30 mcg/kg, adjust
Vecuronium Alternatively, as continuous
M03AC03320 As an adjunct in anaesthesia to
1617 Bromide 4 mg/ml A* infusion at 0.8-1.4
P3002XX produce skeletal muscle relaxation
Injection mcg/kg/min after initial IV
dose of 40-100 mcg/kg.
NEONATE and INFANT up to
4 months: Initially 10 - 20
mcg/kg, then incremental
dose to achieve response.
i), ii) & iii) ADULT: 75 mg
once daily. May increase
dose by 75 mg/day every 4
days to a maximum dose of
225 mg/day, (severe
Venlafaxine HCl i) Depression ii) Generalized anxiety depression: max:
N06AX16110
1618 150 mg Extended A* disorder iii) Social anxiety disorder 375mg/day) iv) 37.5 mg/day
C2002XX
Release Capsule (social phobia) iv) Panic disorder for the first 4-7 days after
which the dose should be
increased to 75 mg once
daily. CHILD and
not recommended.
358 / 371

i), ii) & iii) ADULT: 75 mg
once daily. May increase
dose by 75 mg/day every 4
days to a maximum dose of
225 mg/day, (severe
Venlafaxine HCl i) Depression ii) Generalized anxiety depression: max:
N06AX16110
1619 75 mg Extended A* disorder iii) Social anxiety disorder 375mg/day) iv) 37.5 mg/day
C2001XX
Release Capsule (social phobia) iv) Panic disorder for the first 4-7 days after
which the dose should be
increased to 75 mg once
daily. CHILD and
not recommended
Initially 5-10mg given by
slow IV over at least 2
Verapamil HCl minutes. The dose can be
C08DA01110
1620 2.5 mg/ml A/KK Supraventricular tachycardia repeated 10mg 30 minutes
P3001XX
Injection after the first dose if the
initial response is not
adequate.
i) Supraventricular ADULT: 40 - 80 mg 3-4 times
Verapamil HCl 40 C08DA01110
1621 B tachyarrhythmias (SVT) prophylaxis daily. In oral long term
mg Tablet T1001XX
ii) angina therapy, max: 480 mg daily
Treatment of type 2 diabetes
mellitus patients who are unable to
50 mg/850 mg or 50
Vildagliptin 50 achieve sufficient glycaemic control
mg/1000 mg twice daily.
mg and A10BD08926 at their maximally tolerated dose of
1622 A* Maximum daily dose is 100
Metformin HCl T1002XX oral metformin alone or who are
mg vildagliptin plus 2000 mg
1000 mg Tablet already treated with the
metformin hydrochloride.
combination of vildagliptin and
metformin as separate tablets.

50/500mg or 50/850mg or
50/1000mg twice daily.
1623 A* Maximum daily dose is
100mg vildagliptin and
2000mg metformin.
359 / 371

50 mg/850 mg or 50
mg/1000 mg twice daily.
1624 A* Maximum daily dose is 100
mg vildagliptin plus 2000 mg
metformin hydrochloride.
i) As second line therapy in type 2

controlled on maximal tolerated
dose of metformin monotherapy
and high risk of hypoglycaemia. ii)
As second line therapy in type 2
controlled on maximal tolerated
dose of sulphonylurea and
intolerant/contraindicated for
metformin therapy. iii) As third line
inadequately controlled with dual
OAD combination therapy with ADULT over 18 years: 50mg
Vildagliptin 50 A10BH02000 sulphonylurea and metformin iv) As bd when combine with
1625 A*
mg Tablet T1001XX a monotherapy in type 2 diabetes metformin, 50 mg od when
mellitus patients inadequately combine with sulphonylurea
controlled by diet and exercise
alone and for whom metformin is
inappropriate due to
contraindications or intolerance.
v)An adjunct to diet and exercise to
improve glycaemic control in
patients with type 2 diabetes
mellitus: As a dual therapy in
combination with insulin in patients
with insufficient glycaemic control.
Insulin dose and regimen should be
optimized before addition of
vildagliptin.
360 / 371

Adult: Initially, 3.7 mg/m2,
increase dose weekly based
on WBC counts in
increments of about 1.8
mg/m2 until leukocyte
count decreases to about
3000/mm3, or maximum
weekly dose of 18.5 mg/m2
reached. Usual dose: 5.5-7.4
mg/m2 per week. Do not
administer next dose, even
though 7 days have lapsed
unless the leukocyte count
has returned to at least
4000/mm3. Child: Initial 2.5
Hodgkin's disease, choriocarcinoma
mg/m2 of BSA, increased
Vinblastine resistant to other
L01CA01183 dose at weekly intervals in
1626 Sulphate 10 mg A chemotherapeutic agents, non-
P3002XX increments of about 1.25
Injection small cell lung cancer, Langerhans
mg/m2 until leukocyte
cell histiocytosis
count decreases to about
3000/ mm3, or maximum
weekly dose of 12.5 mg/m2
reached. Do not increase
dose once leukocyte count
reaches approximately 3000
cells/mm3, instead, a dose
of 1 increment smaller to be
admin at wkly intervals for
maintenance. Do not
administer next dose, even
though 7 days have lapsed
unless the leukocyte count
has returned to at least
4000/mm3.
i) ADULT: 1.4 mg/m2 weekly
(maximum 2 mg weekly) ii)
Refer to protocol iii) 1.4
i) Solid tumours ii) Gestational mg/m2 weekly (maximum 2
Vincristine trophoblastic disease iii) Non- mg weekly) iv) 0.4 mg/m2 IV
L01CA02183
1627 Sulphate 1 mg A Hodgkin's lymphoma iv) Multiple continuous infusion on days
P3001XX
Injection myeloma v) Acute lymphoblastic 1 - 4 v) Refer to protocol.
leukemia CHILD: 1 mg/m2 to 2 mg/m2
weekly according to
protocol (0.05 mg/kg for
infants less than 10kg)
361 / 371

i) Single agent: Adult
30mg/m2 IV administered
over 6-10 minutes once
weekly Combination with
cisplatin : 30mg/m2 IV
administered over 6-
10mintes once weekly
combination with cisplatin
IV on days and 29 and then
every 6 weeks or
i) First line treatment in non-small Vinolrebine administered at
Vinorelbine 10 L01CA04000 cell lung cancer in combination a dose of 25mg/m2 IV
1628 A*
mg Injection P4001XX with cisplatin/ifosfomide ii) weekly in combination with
Metastatic breast cancer cisplatin given every 4
weeks at a dose of
100mg/m2 ii) 25 - 30 mg/m2
diluted in saline solution,
infused over 6 - 10 minutes,
administered weekly or
vinolrebine maybe given as
an 8mg/m2 IV BOLUS
followed by 8mg/m2 as a
96-hour intravenous
infusion
i) Single agent: Adult
30mg/m2 IV administered
over 6-10 minutes once
weekly Combination with
cisplatin : 30mg/m2 IV
administered over 6-
10mintes once weekly
combination with cisplatin
IV on days and 29 and then
every 6 weeks or
i) First line treatment in non-small Vinolrebine administered at
Vinorelbine 50 L01CA04000 cell lung cancer in combination a dose of 25mg/m2 IV
1629 A*
mg Injection P4002XX with cisplatin/ifosfomide ii) weekly in combination with
Metastatic breast cancer cisplatin given every 4
weeks at a dose of
100mg/m2 ii) 25 - 30 mg/m2
diluted in saline solution,
infused over 6 - 10 minutes,
administered weekly or
vinolrebine maybe given as
an 8mg/m2 IV BOLUS
followed by 8mg/m2 as a
96-hour intravenous
infusion.
362 / 371

Not more than 10 ml daily,
Vitamin A & D A11CB00901 allowance being made for
1630 C Prevention of ricketts
(Cod Liver Oil) L5001XX Vitamin D obtained from
other sources
0.06 - 0.6ml (2,500-25,000
Vitamin A & D
IU of Vitamin A and 250-
Concentrate
A11CB00901 2,500 IU of D) daily,
1631 25,000 B Prevention of ricketts
L5002XX allowance being made for A
units/0.6ml
and D obtained from other
Liquid
sources
Children with measles malnutrition i) 0-5 months, 50,000 IU ii)
Vitamin A 50,000 A11CA01000 and serious infections. Category C 6-11 months, 100,000 IU iii)
1632 C
IU Capsule C1001XX can use this drug for Orang Asli and 1-5 years, 200,000 IU.
in Sabah Frequency twice daily
Vitamin B
A11EX00901 Prophylaxis and treatment of
1633 Complex 10 ml B 1-2 ml daily by IM
P3001XX vitamin B deficiency
Injection
Vitamin B A11EA00901 Prophylaxis and treatment of
1634 C+ 1-2 tablets daily
Complex Tablet T1001XX vitamin B deficiency
Mild cases: 1 ampoule given
Vitamin B1, B6, A11DB00901 For deficiency or raised by IM 2-3 times weekly.
1635 B
B12 Injection P3001XX requirement of Vitamin B1, B6, B12 Severe cases: 1 ampoule
daily
Vitamin B1, B6, A11DB00901 For deficiency or raised 1 - 3 tablets 3 times daily
1636 B
B12 Tablet T1001XX requirement of Vitamin B1, B6, B12 swallowed unchewed.
For all types of severe chemical
Vitamin C 10% S01XA15000 1 to 4 times daily depending
1637 B corneal burns especially acid and
Eye Drops D2001XX on severity of case
alkali burns
To improve appetite and growth.
Vitamin E, B12, Neurasthenia, nausea and vomiting
A11E000901
1638 B6, Nicotinamide A in pregnancy, radiation sickness 1 - 2 tablet daily
T1001XX
Tablet and neuritis due to isoniazid
therapy and alcoholism
Prophylaxis of vitamin K
deficiency bleeding in
neonates Child: Neonate:
0.5-1 mg, given as a single
dose via IM inj.
Alternatively, 2 mg may be
Vitamin K1 1 B02BA01000
1639 C+ Vitamin K deficiency in neonates given orally, followed by a
2nd dose of 2 mg after 4-7
days. Intravenous Vitamin K
deficiency bleeding in
neonates Child: Infant: 1 mg
by IV/IM/SC inj, further
doses may be given if
363 / 371

necessary
Haemorrhage associated with 0.5 - 20 mg by very slow IV

Vitamin K1 10 B02BA01000
1640 B hypoprothrombinaemia caused by at a rate not exceeding 1 mg
overdose of anticoagulants per minute
Healthy neonate 2 mg orally
at birth or soon after
followed by 2 mg at 4 - 7
days. Exclusively breastfed
baby, in addition, 2 mg
orally at monthly intervals
Vitamin K1 Mixed
B02BA01000 until end of breastfeeding
1641 Micelle 2 mg/0.2 B Prevention of bleeding in neonates
P3004XX period. Neonate at special
ml Injection
risk, 1 mg IM/IV at birth or
soon after if oral route is not
suitable. Treatment: 1 mg IV
initially. Further doses
depend on clinical picture
and coagulation status
Adult and Children 12 years
i) Treatment of
and greater: Loading dose: 6
mg/kg 12 hourly for first 24
with progressive, possibly life-
hours. Maintenance: i) 4
threatening infections such as
mg/kg 12 hourly ii) 3 mg/kg
invasive aspergillosis, fluconazole-
12 hourly. Dose may be
Voriconazole 200 J02AC03000P resistant serious invasive
1642 A* increased to 4 mg/kg 12
mg Injection 3001XX candidiasis, serious fungal
hourly if response is
infections caused by Scedosporium
inadequate. Children aged
species and Fusarium species
2years to <12years with
ii)Prevention of breakthrough
normal hepatic and renal
fungal infections in febrile high-risk
function: No loading dose
neutropenic patients
needed; 7mg/kg 12hourly
Adult and Children 12 years
i) Treatment of
and greater and over 40 kg:
Loading dose: 400 mg 12
hourly for first 24 hours.
Maintenance: 200 - 300 mg
12 hourly. Less than 40 kg:
resistant serious invasive
Voriconazole 200 J02AC03000T Loading dose: 200 mg 12
1643 A* candidiasis, candidiasis of the
mg Tablet 1002XX hourly for first 24 hours.
oesophagus, serious fungal
12 hourly. Children aged
species and Fusarium species ii)
2years to <12years with
Prevention of breakthrough fungal
normal hepatic and renal
infections in febrile high-risk
function: No loading dose
needed; 200mg 12hourly
364 / 371

i) Treatment of
ADULT and CHILDREN 12
years and greater and over
40 kg: Loading dose: 400 mg
12 hourly for first 24 hours.
resistant serious invasive
Voriconazole 50 J02AC03000T Maintenance: 200 - 300 mg
1644 A* candidiasis, candidiasis of the
mg Tablet 1001XX 12 hourly. Less than 40 kg:
oesophagus, serious fungal
Loading dose: 200 mg 12
hourly for first 24 hours.
species and Fusarium species ii)
Prevention of breakthrough fungal
12 hourly
infections in febrile high-risk
Initially 10 mg daily for 2
days. Maintenance dose, 3-9
Warfarin Sodium B01AA03520 Treatment and prophylaxis of
1645 B mg daily according to the
1 mg Tablet T1001XX thromboembolic disorders
INR (taken at the same time
each day)
days. Maintenance dose, 3-9
1646 B mg daily according to the
each day)
days. Maintenance dose, 3-
1647 B 10 mg daily according to the
each day)
days. Maintenance dose, 3-
1648 B 10 mg daily according to the
each day)
Water for V07AB00000 As a diluent and vehicle for the According to the needs of
1649 C+
Injection P3001XX administration of medications the patient
White Petroleum
Anhydrous Liquid S01XA20900 Keeping the eye lubricated and Apply a small amount into
1650 A
Landin, Mineral G5101XX comfortable during the night the eye
Oil Eye Ointment
365 / 371

i) Prophylaxis of maternal-
foetal HIV transmission
during labour and delivery
Adult: Loading dose: 2
mg/kg, followed by
continuous infusion of 1
mg/kg/hr until umbilical
cord is clamped. If
caesarean section is
planned, start the IV
infusion 4 hr before the
operation. Renal and
Hepatic impairment: Dose
reduction may be needed.
HIV infection (to be discuss:
not in indication) Adult: 1-2
To reduce the rate of maternal-
mg/kg every 4 hr, given as 2-
foetal transmission of HIV in: i) HIV-
Zidovudine 1% J05AF01000P 4 mg/ml infusion over 1 hr.
1651 A positive pregnant women over 14
Injection 3001XX Child: As continuous
weeks of gestation ii) Their
infusion: 20 mg/m2/hr.
newborn infants
Alternatively, as
intermittent infusion: 120
mg/m2 every 6 hr. Renal
impairment: Haemodialysis
or peritoneal dialysis: 1
mg/kg every 6-8 hr. ii)
Prophylaxis of HIV infection
in neonates Child: Neonates:
1.5 mg/kg every 6 hr. Start
treatment within 12 hr after
birth and continue for 1st 6
wk of life. Dose to be given
via IV infusion over 30
minutes. Renal impairment:
Dose adjustment may be
needed.
366 / 371

i) HIV infection Adult: 600
mg daily in divided doses, in
antiretroviral agents. Child:
6 wk - 12 yr: 160 mg/m2
every 8 hr. Max: 200 mg
every 8 hr. May be used in
i) Management of patients with
asymptomatic and symptomatic
Zidovudine 10 J05AF01000L anti-retrovirals. Renal and
1652 A* (early or advanced) HIV infections
mg/ml Syrup 9001XX Hepatic impairment: Dose
with CD4 cell counts less than 500
reduction may be needed. ii)
cu. mm. ii) Neonatal prophylaxis
2 mg/kg every 6 hr for 1st 6
wk of life, starting within 12
hr after birth. Renal and
hepatic impairment: Dose
adjustment may be needed.
i) HIV infection Adult: 600
mg daily in divided doses, in
6 wk - 12 yr: 160 mg/m2
i) Management of patients with
asymptomatic and symptomatic
Zidovudine 100 J05AF01000C anti-retrovirals. Renal and
1653 A/KK (early or advanced) HIV infections
mg Capsule 1001XX Hepatic impairment: Dose
with CD4 cell counts less than 500
reduction may be needed. ii)
cu. mm ii) Neonatal prophylaxis
2 mg/kg every 6 hr for 1st 6
wk of life, starting within 12
hr after birth. Renal and
hepatic impairment: Dose
adjustment may be needed.
Zidovudine 300 HIV infection in combination with
J05AR01964T ADULT and CHILD over 12
1654 mg & Lamivudine A/KK at least one other antiretroviral
1001XX years: 1 tablet twice daily
150 mg Tablet drug
367 / 371

HIV infection Adult: 600 mg
daily in divided doses, in
6 wk - 12 yr: 160 mg/m2
i) Management of patients with combination with other
asymptomatic and symptomatic anti-retrovirals.
Zidovudine 300 J05AF01000T
1655 A* (early or advanced) HIV infections ii)Prophylaxis of maternal-
mg Tablet 1001XX
with CD4 cell counts < 500 cu. mm foetal HIV transmission
ii) HIV positive pregnant mothers Adult: 100 mg 5 times daily
or 200 mg tid or 300 mg bid.
Start treatment after 14th
wk of gestation until the
start of labour.
Haemodialysis or peritoneal
dialysis (CrCl <10 ml/min:
100 mg every 6-8 hr.
Skin protective in various skin
D02AB00000 Apply 3 times daily or as
1656 Zinc Oxide Cream C+ conditions such as nappy rash,
G1001XX required
eczema and problem skin
Skin protective in various skin
Zinc Oxide D02AB00240 Apply 3 times daily or as
1657 C conditions such as nappy rash and
Ointment G5001XX required
eczema
Insert 1 suppository night
zinc oxide, benzyl For relief of pruritus, burning and and morning after bowel
benzoate and C05AX04931 soreness in patients with movements; does not use
1658 C
balsam peru S1001XX haemorrhoids and perianal for longer than 7 days OR
suppository conditions please refer to the product
insert.
ADULT: Initially 10 mg
(every 2 hour) or 20 mg
Ziprasidone 20 N05AE04110 (every 4 hour). Maximum:
1659 A* Acute agitation in schizophrenia
mg/ml Injection P3001XX 40 mg/day. IM
administration more than 3
days has not been studied
i) Treatment of hypercalcaemia of
4 mg reconstituted and
malignancy ii) Prevention of
Zoledronic Acid 4 M05BA08000 should be given as a 15
1660 A* skeletal related events in patients
mg Injection P3001XX minutes IV infusion every 3-
with multiple myeloma involving
4 weeks
multiple bone lesions
368 / 371

10-mg tablet daily. Stilnox
should always be taken just
before going to bed. In
Zolpidem
N05CF02123 elderly patients or patients
1661 Tartrate 10 mg A For treatment of insomnia
T1001XX with hepatic insufficiency:
Tablet
Dosage should be halved ie,
5 mg. Dosage must never
exceed 10 mg/day.
For adults, usually 100 to
200mg of zonisomide is to
As adjunctive therapy in the
be administered orally 1 to 3
treatment of partial seizures in
times a day initially. The
adults with epilepsy. Restrictions:
Zonisamide N03AX15000 dose is gradually increased
1662 A* As adjunctive therapy in the
100mg tablet T1001XX at every one to two weeks
treatment of partial seizures in
up to 200-400mg daily, in 1
adults with epilepsy when 1st line
to 3 divided doses. The
and 2nd line therapy failed.
maximum daily dose should
not exceed 600mg per day.
Acute Schizophrenia and
Other Acute Psychoses;
Severe Acute States of
Agitation; Mania: Oral
treatment: Usually 10-50
Zuclopenthixol N05AF05000 Only for psychoses with insight or
1663 A* mg/day. In moderate to
20 mg/ml Drops D5001XX compliance
severe cases initially 20
mg/day increased, if
necessary, by 10-20 mg/day
every 2-3 days to ≥75 mg
daily.
369 / 371

Clopixol-Acuphase: Clopixol-
Acuphase is administered by
IM injection. The dosage
range should normally be
50-150 mg (1-3 mL) IM
repeated if necessary,
preferably with a time
interval of 2-3 days. In a few
patients, an additional
injection may be needed 24-
48 hrs following the 1st
injection. In the
maintenance therapy,
Only for treatment of agitated and treatment should be
Zuclopenthixol violent patients suffering from continued with oral Clopixol
N05AF05122
1664 Acetate 100 A* schizophrenia who are not or Clopixol Depot IM after
P3002XX
mg/2 ml Injection responding to the available the following guidelines:
standard drugs Change to Oral Clopixol: 2-3
days after the last injection
of Clopixol-Acuphase, a
patient who has been
treated with 100 mg
Clopixol-Acuphase, oral
treatment should be started
at a dosage of about 40 mg
daily, possibly in divided
dosages. If necessary, the
dose can be further
increased by 10-20 mg every
2-3 days up to 75 mg or
more.
370 / 371

Clopixol-Acuphase: Clopixol-
Acuphase is administered by
IM injection. The dosage
range should normally be
50-150 mg (1-3 mL) IM
repeated if necessary,
preferably with a time
interval of 2-3 days. In a few
patients, an additional
injection may be needed 24-
48 hrs following the 1st
injection. In the
maintenance therapy,
Only for treatment of agitated and treatment should be
Zuclopenthixol violent patients suffering from continued with oral Clopixol
N05AF05122
1665 Acetate 50 A* schizophrenia who are not or Clopixol Depot IM after
P3001XX
mg/ml Injection responding to the available the following guidelines:
standard drugs Change to Oral Clopixol: 2-3
days after the last injection
of Clopixol-Acuphase, a
patient who has been
treated with 100 mg
Clopixol-Acuphase, oral
treatment should be started
at a dosage of about 40 mg
daily, possibly in divided
dosages. If necessary, the
dose can be further
increased by 10-20 mg every
2-3 days up to 75 mg or
more.
By deep IM injection test
dose 100 mg followed after
Only for treatment of agitated and 7 - 28 days by 100 - 200 mg
Zuclopenthixol violent patients suffering from or more followed by 200 -
N05AF05135
1666 Decanoate 200 A* schizophrenia who are not 400 mg at intervals of 2 - 4
P2001XX
mg/ml Injection responding to the available weeks adjusted according to
standard drugs response. Maximum 600 mg
weekly. Child not
recommended
371 / 371

Malaysia Pharmaceutical

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Malaysia Pharmaceutical

Uploaded by

Copyright:

Available Formats

MINISTRY OF HEALTH MEDICINES FORMULARY - 2/2015

No. Generic Name MDC Category Indication(s) Dosage

Antiretroviral combination therapy

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

i) ADULT: initially 400 mg 5

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

i) ADULT: initially 400 mg 5

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

i) Treatment of chronic HBeAg

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

Used as a 30 seconds gargle

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

Once weekly transdermal

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage

No. Generic Name MDC Category Indication(s) Dosage